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ABSTRACT 
Proliferative vitreoretinopathy (PVR) is the most common cause of late anatomical 
failure of retinal detachment surgery. Efforts to modify this vitreoretinal scarring 
response have so far proved clinically unsuccessful, with surgical and visual outcomes 
remaining poor. This work is aimed at identifying strategies to improve outcomes in 
eyes at high risk of PVR development following open globe trauma (OGT), and those 
with established PVR disease.   
 
Two prospective clinical trials investigating the benefit of adjunctive corticosteroids in 
these two populations were conducted in a total of one hundred and eighty patients. 
Clinical and imaging data were collected over the course of approximately 3500 
hospital attendances. 
 
The Adjunct in Ocular Trauma (AOT) Trial was a two year, pilot, single-centre 
prospective, participant and surgeon-masked randomized-controlled-clinical trial 
(RCT). Forty patients requiring vitrectomy surgery following OGT were randomized to 
either standard (control) or study treatment (adjuncts) in a 1:1 allocation ratio. Peri-
operatively, the adjunct group received intravitreal and subtenons triamcinolone 
acetonide, oral flurbiprofen and guttae prednisolone acetate 1%. The control group 
received standard care. 
Primary outcome was anatomical success at 6 months and showed similar results in 
anatomical success with 50% (10/20) in the adjunct group, compared to 47% (9/19) in 
the standard group (Odds Ratio 1.11, 95% Confidence Interval 0.316-3.904).   
Secondary outcomes included final visual acuity, occurrence of PVR, intraocular 
pressure (IOP) rise, number of operations and recruitment rate. Final median visual 
acuity was 31 ETDRS letters in the adjunct group compared to 25 ETDRS letters in the 
standard group. Other secondary outcomes were similar between the two groups.  
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The hypothesis that an adjunctive slow-release dexamethasone implant (Ozurdex ®) 
could improve the outcomes of vitreoretinal surgery for established PVR was tested in 
the Ozurdex® in PVR Study. In this two year, single-centre prospective, participant 
and surgeon-masked RCT, 140 patients requiring vitrectomy surgery with silicone oil 
for retinal detachment with established PVR (Grade C) were randomized to either 
standard (control) or study treatment (adjunct) in a 1:1 allocation ratio. 
Intraoperatively, the adjunct group received an injection of 0.7mg of slow-release 
dexamethasone (Ozurdex) at the time of (a) vitrectomy surgery and (b) at silicone oil 
removal.  The control group received standard care. 
Primary outcome measure was the proportion of patients with a stable retinal 
reattachment with removal of silicone oil without additional vitreoretinal surgical 
intervention at 6 months.  Secondary outcomes included i) final visual acuity (median 
and ETDRS of 55 letters or better), ii) cystoid macular edema (CMO), foveal thickness 
and macular volume iii) development of overt PVR recurrence, iv) complete and 
posterior retinal reattachment, vi) tractional retinal detachment, vii) hypotony/raised 
IOP, viii) macula pucker/epiretinal membrane, ix) cataract, x) quality of life 
All 140 patients were recruited within 25 months of study commencement; 138 
patients had primary outcome data.  Primary outcome assessment showed similar 
results in anatomical success between the two groups (49.3% vs 46.3%, adjunct vs 
control, (Odds Ratio 0.89, 95% Confidence interval 0.46 – 1.74, p= 0.733).  Mean 
visual acuity at 6 months was 38.3 ETDRS letters and 40.2 letters in the adjunct and 
control group respectively. Secondary anatomical outcomes (complete/posterior 
reattachment rates and PVR recurrence) were comparable between the two groups.   
Exploratory analysis suggested that the proportion of patients with cystoid macular 
oedema (CMO) or a foveal thickness of >300µm was lower in steroid-treated eyes 
compared to controls (42.7% and 47.6% vs 67.2% and 67.7%, respectively p= 0.004, p= 
0.023).   
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Cystoid macular oedema is a secondary cause of visual loss.  At 6 months following 
successful surgery for PVR, eyes with evidence of external limiting membrane (ELM) 
disruption on Spectral Domain-Optical Coherence Tomography  achieve a worse visual 
outcome than eyes where the ELM appears preserved (p=0.006).  
 
Provisional work using retinectomy specimens retrieved at the time of surgery in 
sixteen patients were studied aiming to isolate a population of Müller glia with stem 
cell characteristics (hMSC). This suggested that it is feasible to isolate a cell population 
of appropriate morphology of hMSCs, from eyes with advanced PVR.  These cells 
survived up to ten weeks in culture but eventually terminally differentiate.  
 
The work in this thesis has shown that corticosteroids do not modify the vitreoretinal 
scarring response sufficiently to improve anatomical outcomes at 6 months. Further 
work is required to improve the outcome in eyes with PVR. Adopting visual acuity as a 
primary outcome, may be a plausible design in future vitreoretinal trials.  
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SmPC    Summary of Product Characteristics 
SPC    Summary of Product Characteristics 
SRF   Subretinal Fluid 
SRM   Subretinal Membrane 
SSA    Site Specific Assessment 
SSAR    Suspected Serious Adverse Reaction 
SUN   Standardisation of Uveitis Nomenclature 
SUSAR   Suspected Unexpected Serious Adverse Reaction 
TA   Triamcinolone Acetonide 
Tfr-rRA   Transferrin ricin-A 
TGF   Tissue Growth Factor 
TIA   Texture Intensity Adjusted 
TIMPS    Tissue Inhibitors of Metalloproteinases 
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TMF    Trial Master File  
TMG    Trial Management Group 
TNF   Tumour Necrosis Factor 
TRD    Tractional Retinal Detachment 
TRITC   Tetramethylrhodamine 
TSC    Trial Steering Committee 
VA   Visual Acuity 
VEGF    Vascular Endothelial Growth Factor 
VFQ   Visual Functioning Questionnaire  
VITAN   Vitreous Analysis 
WMA   World Medical Authority 
5-FU    5 – Fluorouracil 
5-FUR    5-Fluorourudine  
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1 Introduction 
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1.1 Ocular Anatomy 
 
The eye is a highly specialised organ of photoreception. Photoreception is the process 
by which light energy induces changes in the retina which result in action potentials 
relayed via the optic nerve to the brain where the information is processed and 
consciously appreciated as vision.  All other ocular structures are secondary to this 
process and either facilitate the focussing of external light onto the retina or provide 
nourishment for the supporting tissues in the eye. [1]   
The eye is an approximate sphere with a diameter of 25mm. It can be considered as 
parts of two spheres; a smaller anterior part of greater curvature than the larger 
posterior part.  The eye consists of three layers or tunics; the tough outer layer 
consists of the transparent cornea anteriorly and the white sclera posteriorly; the 
middle vascular uveal layer is composed of the iris, ciliary body and choroid; and the 
inner neural layer is the retina. The coats surround the transparent intraocular media 
(aqueous and vitreous humor) divided respectively into anterior and posterior 
segments by the crystalline lens.  
Figure 1.1:  Schematic Diagram of Eye 
Figure 1.1 Ocular anatomy:  three tunics consisting of cornea and sclera; 
vascular uvea (iris, ciliary body and choroid); retina (adapted from [2]) 
Posterior segment anatomy will be discussed in greater detail due to its relevance to 
this thesis. 
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 Vitreous  1.1.1
 
The vitreous constitutes eighty per cent of the ocular volume and is usually about 4 
mls in the average eye. It is an almost completely acellular transparent viscous fluid 
consisting of almost 99% water. The remainder consists of hyaluronic acid and 
predominantly type II collagen (although types IX and a V/XI hybrid exist in smaller 
quantities) and these molecular constituents are mainly concentrated in the cortical 
(outer) vitreous.  The cortical vitreous exhibits condensations of fine collagen fibrils at 
its external boundaries known as the anterior and posterior hyaloid membranes. 
 
The posterior hyaloid membrane is adherent to the internal limiting membrane (ILM) 
of the retina most strongly at the fovea and the optic disc. The 3-4 mm annular zone of 
adhesion which straddles the ora serrata is known as the vitreous base [3]. The 
posterior border of the vitreous base is of clinical importance and will be discussed 
further in this chapter (section 1.2.2).  
 
 Retina and Retinal Pigment Epithelium 1.1.2
 
The retina is a laminated structure consisting of the inner neurosensory retina and the 
outer retinal pigment epithelium. These structures are derived embryologically from 
two layers of ectoderm following optic cup invagination. The potential space between 
these layers is equivalent to the subretinal space in neurosensory retinal detachment.   
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 Neurosensory retina 1.1.2.1
 
The neurosensory retina is a thin (150 to 400µm) transparent structure which consists 
mainly of neural tissue. It is comprised of photoreceptors (rods and cones), integrating 
cells (bipolar, horizontal, amacrine and ganglion cells) and supporting cells (Muller 
cells).  The arrangement of these cells can be further divided into six cell layers, two 
layers of neuronal connections and two limiting membranes [3].  
Figure 1.2:  Schematic Diagram of Neurosensory Retina 
Figure 1.2. schematic representation of retinal structure demonstrating 
layered arrangement of neurosensory retina and attachment to retinal 
pigment epithelium [4] 
 
 Retinal Pigment Epithelium 1.1.2.2
 
The retinal pigment epithelium (RPE) is a continuous hexagonal monolayer of epithelial 
cells which extends from the margins of the optic nerve head anteriorly to the ora 
serrata. Here it is continuous with the pigmented epithelium of the pars plana.  It has 
multiple properties and functions which from a crucial role in visual function. Its apices 
form microvilli which envelop the outer segments of the photoreceptor and adjacent 
RPE cells are joined by tight junctions which constitute the outer blood –retinal barrier.  
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1.2 Retinal Detachment 
 
 Categorisation 1.2.1
 
Retinal detachment (RD) is the pathological separation of the neurosensory retina 
from the under lying retinal pigment epithelium. It is conventionally divided into four 
categories depending on the primary causative pathology. The commonest is a 
rhegmatogenous detachment, where there is a full thickness breach in the 
neuroepithelium. Tractional RDs are caused by mechanical forces pulling the 
neurosensory retina away from the RPE. Combined tractional rhegmatogenous RDs are 
a combination of mechanical traction resulting in a full thickness neurosensory breach. 
Finally, exudative retinal detachments result from accumulation of subretinal fluid with 
an intact overlying neurosensory epithelium.[5] 
 
Further expansion regarding the pathogenesis of rhegmatogenous retinal detachment 
will be discussed herein. 
 
 Pathogenesis of Rhegmatogenous Retinal Detachment 1.2.2
 
Rhegmatogenous retinal detachment occurs following a full thickness breach in the 
neuroepithelium allowing egress of liquid from the vitreous cavity into the subretinal 
space and subsequent separation of the neurosensory retina from the RPE. This breach 
can either be caused by dynamic vitreous traction during posterior vitreous 
detachment (i.e. retinal tear) or secondary to localised retinal atrophy (retinal hole). 
The former is more common and will be discussed in greater detail [6] . 
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As the eye ages the vitreous liquefies, the concentration of hyaluronic acid in the 
vitreous decreases[7] , thereby, allowing the collagen fibres to aggregate. [8, 9] The 
resultant lack of structural support causes the vitreous gel to collapse, with secondary 
separation of the posterior hyaloid membrane from the internal limiting membrane. 
This physiological ‘event’ occurs without adverse effect in the majority of eyes, as 63% 
of patients in their eighth decade have evidence of posterior vitreous detachment [10].  
However, the force generated by ocular saccades is transmitted to the posterior gel 
and exerts dynamic traction on the retina causing it to tear in some eyes.  This is 
usually at an area of abnormal vitreoretinal adhesion at the posterior aspect of the 
vitreous base.  The combination of i) ongoing dynamic vitreous traction at the apex of 
the tear, ii) the generation of fluid currents from ocular saccadic movements and iii) 
gravitational force, result in recruitment of fluid from the vitreous cavity into the sub 
retinal space and propagation of the neurosensory detachment.   
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1.3 Proliferative Vitreoretinopathy (PVR) 
Proliferative vitreoretinopathy (PVR) is the commonest cause of late anatomic failure 
in retinal detachment surgery and has a reported incidence of 5-11% of all 
rhegmatogenous retinal detachments [11-13].  PVR is an inflammatory process that 
can be considered as an exaggerated and maladapted wound healing response of the 
retina.  It results in the formation of complex fibrocellular membranes on both 
surfaces of the retina, the posterior hyaloid face and in the basal vitreous. The 
contraction of these membranes distorts the normal retinal architecture with resultant 
visually detrimental sequelae. Membrane contraction can cause tractional retinal 
detachment, the reopening of pre-existing breaks or the formation of new ones, which 
may ultimately result in recurrent rhegmatogenous detachment.  
Historically, based on the premise that the primary pathology was centred in the 
vitreous, PVR was previously referred to as massive vitreous retraction syndrome 
(MVR) or massive preretinal retraction syndrome (MPR). However, in order to 
acknowledge the role of periretinal membrane formation and pigment epithelial cell 
proliferation, it later became known as massive periretinal proliferation (MPP)[15].  
A unifying classification system was published in 1983 by the Retina Society 
Terminology Committee [12] coining the phrase proliferative vitreoretinopathy (PVR), 
which was later updated in 1991 to the current classification system in clinical practice 
today [16].  
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 Classification of PVR 1.3.1
 
The current classification system divides the clinical appearance into three grades of 
increasing severity. Grades A and B are frequently referred to as ‘early’ PVR. Grade A 
primarily consists of eyes post retinal detachment with pigment clumps in the vitreous 
or on the surface of the retina. Where the mobility of the vitreous and detached retina 
is reduced and/or the edges of the retinal break appear irregular and folded, the eye 
demonstrates feature of PVR Grade B. 
 
Table 1.1:  Updated Proliferative Vitreoretinopathy Grade Classification  
 
Grade Features 
A Vitreous haze, vitreous pigment clumps, pigment clusters on inferior retina  
B Wrinkling of inner retinal surface, retinal stiffness, vessel tortuosity, rolled and 
irregular edge of retinal break, decreased mobility of vitreous  
CP 1-12 Posterior to equator; focal, diffuse or circumferential full-thickness folds, 
subretinal strands 
CA 1-12 Anterior to equator; focal, diffuse or circumferential full-thickness folds, 
subretinal strands, anterior displacement, condensed vitreous strands 
 
Table 1.1 is adapted from the ‘Updated classification of retinal detachment 
with proliferative vitreoretinopathy’ publication by Machemer et al  [16]  
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Figure 1.3:  Proliferative Vitreoretinopathy Grades A and B 
 
Figure 1.3 (A) Oblique slit-lamp bio-microscopic image of Grade A 
proliferative vitreoretinopathy (PVR). White arrow indicates clump of 
pigment within the vitreous cavity (B) Colour fundus photograph of retinal 
detachment caused by a giant retinal tear. Black arrow demonstrates rolled 
edge (PVR Grade B) of the retinal break    
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In established PVR (Grade C) formed membranes are visible on or below the retinal 
surface and there are diffuse or circumferential retinal folds of full-thickness. Grade C 
PVR is categorised into anterior and/or posterior in relation to the equator of the 
globe. Its extent is expressed in terms of clock hours.  
Furthermore, the subdivision of Grade C PVR can be described in terms of the 
contraction type (Table 1.2). Focal posterior traction denotes a single starfold, which 
may become diffuse with confluence. Subretinal proliferations may be anterior or 
posterior and can appear as annular folds, linear bands and moth-eaten sheets. 
Circumferential contraction of membranes occurs along the posterior edge of the 
vitreous base thereby displacing the retina centrally and stretching the peripheral 
retina. Finally, there may be anterior displacement of the vitreous base with stretching 
or detachment of the ciliary body from anterior tractional membrane.    
 
Table 1.2:  Updated Proliferative Vitreoretinopathy Contraction Classification  
Type Location (in relation 
to equator) 
Features 
Focal Posterior Starfold posterior to vitreous base 
Diffuse Posterior Confluent starfolds posterior to vitreous base; 
optic disc may not be visible 
Subretinal Posterior/Anterior Proliferation under retina; annular strands near 
disc; linear strands; moth eaten-sheets 
Circumferential Anterior Contraction along posterior edge of vitreous 
base with central displacement of retina; 
peripheral retina stretched; posterior retina in 
radial folds 
Anterior Anterior Vitreous base pulled anteriorly by proliferative 
tissue; peripheral retinal trough; displacement 
ciliary processes may be stretched ,may be 
covered by membrane; iris may be retracted 
Table 1.2 is adapted from the ‘Updated classification of retinal detachment 
with proliferative vitreoretinopathy’ publication by Machemer et al [16] 
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The grading of established PVR (Grade C) from fundus photographic images may be 
limited by the field of exposure and not accurately represent their clinical appearance. 
Examples of retinal detachments with their corresponding sub-classification will follow.    
Figure 1.4:  Proliferative Vitreoretinopathy Grade C 
 
Figure 1.4 Composite figure of widefield images of retinal detachments with 
Grade C PVR (A) Focal posterior starfold (white arrows)of Grade CP 3 (B) 
Example of full thickness retinal fold (blue arrow) caused by focal starfold 
(C) a total retinal detachment with posterior and macular membrane and 
diffuse anterior membranes (white arrows), also note the rolled edge at the 
posterior extent of the large retinal break (black arrow), (D) extensive 
diffuse posterior epiretinal and subretinal membrane distorted normal 
retinal architecture and vasculature 
 
Although the current classification system has served to standardize PVR terminology 
in clinical practice and research, it remains limited. The number, location and size of 
retinal breaks are not included, and many clinicians feel that grading the extent of PVR 
membranes in terms of clock hours limits their description to one circumferential 
meridian, e.g. when distinguishing linear subretinal bands from confluent sheets [17]. 
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 Pathophysiology of PVR 1.3.2
 
The pathophysiology of PVR is a complex sequence of events which remains 
incompletely understood. Rhegmatogenous retinal detachment (RRD) is considered 
the starting point for PVR development. Vitreoretinal scarring can be considered the 
result of the following components: a) blood retinal barrier (BRB) breakdown; b) 
cellular accumulation and proliferation; c) extracellular matrix (ECM) and collagen 
production with fibrin deposition; d) formed membrane contraction. Growth factors 
may be involved in various components of the process. 
 
 Blood retinal barrier breakdown 1.3.2.1
 
The retinal vascular endothelium and the tight junctions of the RPE comprise the blood 
barrier. A retinal tear results in the dispersion of retinal pigment epithelial (RPE) cells 
into the vitreous cavity, in addition to allowing egress of vitreous fluid into the 
subretinal space. The blood- retinal-barrier (BRB) breakdown which follows retinal 
detachment appears to have a central role in the dispersion of cells and production of 
growth factors which promote the further evolution of PVR [18]. 
 
 Cellular accumulation and proliferation 1.3.2.2
Analysis of excised tissue and animal models have identified four main categories of 
cells in PVR membranes [19] ; i) retinal pigment epithelial cells (RPE) [20-29], ii) glial 
cells [20, 25-33], iii) fibroblasts [20-23, 34-38] and  iv) inflammatory cells (macrophages 
[22, 24, 36, 37, 39, 40] and lymphocytes [41-43]).  
Experimental and clinical studies have described the importance of RPE cell 
chemotaxis, proliferation and subsequent metaplastic differentiation.  They appear to 
adopt a fibroblast morphology under the effect of local growth factors, although the 
precise trigger initiating the process in not understood.  
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[44] Studies have demonstrated a central role of retinal glial cell activation and 
extension into both epiretinal and subretinal membranes [45, 46]. The intraretinal glial 
response following retinal detachment without PVR has been widely described[47]. 
Whilst it may have  a protective role in the process of neurite remodelling through 
growth factor production [48] , a switch in equilibrium towards  glial scar formation  is 
a key component in the pathological process of PVR development. There is growing 
evidence that more importance should be attributed to this intraretinal Müller cell 
response [49] .  
 
Macrophages and lymphocytes may play a role in membrane formation and 
contraction as they migrate into the vitreous cavity and subretinal space following 
blood retinal barrier breakdown [48]  and have been found in higher concentrations in 
the vitreous of eyes with PVR compared to those without. Their role is likely to involve 
the production of fibrogenic growth factors.  
 
 Extracellular matrix production and fibrin deposition 1.3.2.3
 
Collagen (predominantly types I and III) and the cell attachment protein, fibronectin 
are key components in PVR membrane formation [24, 25, 50].  Both proteins are 
thought to be derived from RPE and glial cells. ECM turnover and remodelling is 
regulated by a group of proteolytic enzymes known as matrix metalloproteinases 
(MMPs) and their natural inhibitors, tissue inhibitors of metalloproteinases (TIMPs). 
MMPs 1,2,3 and 9 and TIMPs 1,2 and 3 have been demonstrated to be present in PVR 
membranes and may play an important role in membrane formation [51].  
Fibrin deposition in the early phase of BRB breakdown, may add to the  scaffold for 
complex fibrocellular membrane formation in PVR  [52]. 
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 Contraction of formed membranes 1.3.2.4
It is the contraction of the aforementioned complex periretinal and vitreous 
membranes which are responsible for the clinical picture of PVR. Membrane 
shortening may be mediated by intrinsic fibroblastic cells, some of which have been 
demonstrated to contain myofilaments [21, 23, 35]. Alternative explanations suggest 
an RPE-collagen interaction via fibronectin bridges[53].  
 
 Growth Factors 1.3.2.5
 
Growth factors (or cytokines) may mediate the aforementioned processes of cellular 
activation, proliferation and contractile membrane formation. Various cytokines have 
been shown to be present in excised PVR epiretinal membranes and in the vitreous of 
eyes with PVR [54, 55]. Among them, platelet derived growth factor (PDGF), acid and 
basic fibroblast growth factor (FGF), transforming growth factor alpha and beta (TGF α 
and TGF-β), granulocyte colony stimulating factor (G-CSF) and insulin-like growth 
factor 1 (IGF-1) may be the most important. Some of these growth factors (i.e. PDGF, 
FGF and TGF) have fibrogenic activity.  
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 Clinical Management of Eyes with Retinal Detachment and PVR 1.3.3
 
The principles of retinal detachment surgery with PVR share the same basic principles 
of managing RDs without PVR. These include the closure or sealing of retinal breaks 
and the complete release of pre-retinal traction. Achieving these endpoints in eyes 
with PVR is challenging.  The addition of prevention of re-proliferation may be added 
as a third factor in PVR cases.  
Successful repair necessitates adequate vitreous clearance with particular attention to 
the basal vitreous. This serves to both remove the activated cellular components as 
well as reduce the scaffold for subsequent contractile membrane formation. To 
achieve adequate anterior vitreous dissection lens removal may be required.  
In established PVR (Grade C), membrane peeling is performed in order to relive 
traction exerted on the retinal break. This may sometimes be difficult to achieve in 
anterior PVR both due to access, and due to the continuity of glial cells between the 
retina and the fibrocellular PVR membrane [16]. With residual anterior traction, a 
relieving retinotomy and anterior retinectomy is necessary.  
The Silicone Study Reports [56]demonstrated  comparable efficacy of silicone oil and 
perfluoropropane  gas (C3F8)  as an intraocular tamponade in the management of 
established PVR. Whilst individual surgeon preference may favour one agent over the 
other, most cases of established PVR are managed with silicone oil [54].   
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1.4 Modifying the PVR Response 
 
Although the pathophysiology of the PVR process remains incompletely understood, 
clinical observation and laboratory investigation have identified potential therapeutic 
targets for pharmacological adjuncts to act upon.   
A variety of agents have been identified as potential adjuncts to modify the 
vitreoretinal scarring response, with corticosteroids offering the advantage of activity 
against multiple stages in the PVR process.  Triamcinolone acetonide and 
dexamethasone have been the most widely studied corticosteroid agents in the 
management of PVR. A more detailed description of these preparations will be 
included in Chapters 2 and 3, respectively, where they have been adopted as the 
primary investigational medicinal products of two randomised controlled clinical trials.  
 
The remainder of this section of this chapter will broadly outline the mechanisms of 
action of corticosteroids and both pre-clinical and clinical evidence supporting their 
use in eyes with PVR. Thereafter, a short summary outlining other therapeutic agents 
which have been investigated in the pharmacotherapy of PVR will follow.  
 
 
 
 
 
 
 
 
44 
 
 
 
 Corticosteroids   1.4.1
 
Corticosteroids (or glucocorticoids) are among the most widely used therapeutic 
agents and their mode of administration varies depending on their target tissue. They 
are effective in many inflammatory and immune-mediated conditions. Developments 
in the understanding of the mechanisms of gene transcription and cell signalling in 
inflammation has helped to explain how they are able to modify the inflammatory 
pathway with resultant therapeutic effect. [57] 
 
 Mode of action 1.4.1.1
 
Corticosteroids (or glucocorticoids) are produced endogenously in the zona fasiculata 
of the adrenal cortex and effect a wide variety of metabolic, immunosuppressant, anti-
proliferative and anti-inflammatory activities. An overview of these actions is not 
included in this thesis, although an explanation of the proposed mechanism of action 
of exogenous corticosteroid administration will be discussed herein. 
In 1950, the Nobel Prize for Medicine and Physiology was awarded to Kendall and 
Reichstein, and Philip Hensch. The former partnership had successfully synthesised 
cortisol and then adrenocorticotrophin hormone (ACTH), and Hensch had described its 
dramatic efficacy in rheumatoid arthritis patients. [58] A short time later, this 
beneficial effect was extended to asthma sufferers initially via oral administration, and 
eventually in 1972 as inhaled corticosteroid. [59]  
Relatively recent developments in the understanding of the mechanisms of gene 
transcription and cellular signalling in inflammation have served to explain how 
corticosteroids are able to attenuate the inflammatory response. [57] [60] The 
predominant effect of corticosteroid is to switch off multiple inflammatory genes that 
have been activated during the inflammatory process [58]. These genes encode for 
inflammatory cytokines, enzymes, receptors, proteins, chemokines and adhesion 
molecules.   
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The glucocorticoid receptor (GR) resides in the cytoplasm of almost every vertebrate 
mammalian cell. Cytoplasmic GRs are bound to molecular chaperone proteins such as 
heat shock protein -90 (hsp90) and FK-binding protein, thus protecting its receptor, 
and preventing its nuclear localisation.[61] Although only a single gene encodes the 
human GR, there are five different promoters, and the gene is translated into three 
messenger RNAs (mRNAs), each of which encodes two different proteins.  There are 
two isoforms of the glucocorticoid receptor; GRα and GRβ.  The GRα binds 
corticosteroids, whereas the GRβ binds to DNA and cannot be activated by 
corticosteroids. [58] Furthermore, GRβ has been shown to be transcriptionally inactive 
and is expressed at low levels compared to GRα. It has, however, been shown to block 
the effect of GRα and has been implicated in steroid resistance in asthma [62], 
although its functional relevance remains in question.  Hereafter, the abbreviation GR 
will relate specifically to the GRα, unless otherwise stated. 
Glucocorticoids are highly lipid soluble and readily cross the phospholipid cell 
membrane of the target cell. Once bound to GR, the activated complex effects its 
action via both genomic and non-genomic pathways. 
 
1.4.1.1.1 Genomic action of Glucocorticoids  
 
The activated GR-corticosteroid complex results in dissociation of the molecular 
chaperone proteins, thus unmasking the receptor nuclear localisation sites, and a 
resultant rapid transfer into the cell nucleus. Here it binds to DNA at specific 
sequences in the promoter region of corticosteroid-responsive genes known as 
glucocorticoid response elements (GRE) upon which, it affects gene transcription.  
Both positive and negative GREs exist, with activation of the former resulting in 
increased gene expression (trans-activation) and the latter decreased expression of 
genes (cis-repression) [63].   Genes which have been upregulated by activation of 
positive GREs encode a wide variety of proteins which exhibit anti-inflammatory 
effects. Such proteins include annexin 1 (lipocortin I), p11/calpactin binding protein, 
interleukin 10 (IL-10), secretory leukoprotease inhibitor 1 (SLPI), and Mitogen-
activated protein kinase phosphatase (MAPK phosphatase). Additionally, 
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corticosteroids switch on the synthesis of proteins that affect inflammatory signal 
transduction pathways i.e. glucocorticoid-induced leucine zipper protein (GILZ), which 
inhibits both the pro inflammatory transcription factors NF-kB and AP-1. [64]  
 
1.4.1.1.2 Non genomic action of glucocorticoids 
 
The activated GR complex may indirectly inhibit inflammation through the interaction 
with transcription factors but without directly binding to DNA (non-genomic). NF-kB 
requires engagement of co activation molecules such as cyclic AMP response element 
binding protein (CRBP) which is dependant in the acetylation of their intrinsic histone.  
The nuclear GR complex may interfere with CBP histone acetylation, thereby indirectly 
inhibiting NF-kB expression. [58] 
 
 Corticosteroids in the pharmacotherapy of PVR 1.4.2
 
The following sections include excerpts from a published book chapter (Banerjee et al, 
2014 [65] ) 
Corticosteroids emerged as the first pharmacological agent to be employed as an 
adjunctive agent to target the scarring response. Their anti-inflammatory and anti-
proliferative properties together with activity in blood-ocular-barrier breakdown 
reduction target key components of the PVR process.   A variety of modes of 
corticosteroid administration have been investigated; systemic (oral), periocular and 
intraocular (by direct injection or via the infusate).  
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 Preclinical Evidence 1.4.2.1
 
The effects of glucocorticoids on cellular proliferation both in vitro and in vivo have 
been widely described in non -ocular experimental cell systems [66]. Exploiting the 
anti-proliferative properties of corticosteroids served the basis of many experimental 
and early clinical cancer studies prior to the introduction of modern chemotherapeutic 
agents.  
 
In the context of the vitreoretinal scarring response, an intravitreal injection of 
corticosteroid was first reported to significantly reduce experimental PVR in rabbits by 
Tano et al in 1980.  In this animal model, tractional retinal detachment (TRD) in rabbits 
was significantly reduced from 57% to 24% and from 84% to 34% after a single 
injection of 1mg dexamethasone or triamcinolone acetonide, respectively [67, 68].  
This effect was later confirmed using 2mg of intravitreal triamcinolone acetonide 
(IVTA) in an experimental rabbit model of PVR, where the rate of TRD was reduced 
from 90% to 56% [69].  
Peri-ocular administration of methylprednisolone (10mg) was shown to reduce 
experimental complicated RD from 87% to 14%, also showing a reduction in cellular 
proliferation within the vitreous microenvironment [70].  More recently, this anti-
proliferative effect has been confirmed by a significant reduction in human retinal 
pigment epithelial cell proliferation in vitro following a dose-dependent treatment of 
unpreserved triamcinolone acetonide [71].  
 
An experimental rabbit model published in 2007 investigated the retinal toxicity of 
commercially available Kenalog® (triamcinolone acetonide). Albini et al compared dark 
-adapted electroretinography of 10 rabbit eyes injected with 4mg/0.1ml of IVTA with 
the fellow eyes serving as controls. At 2 and 12 weeks post injection, they found no 
discernible difference in the electroretinograms of either group. Histological analysis of 
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sacrificed animals showed no abnormality in the retinal architecture and the absence 
of intraretinal gliosis confirmed by immunohistochemistry. 
 
The effect of the IVTA (2mg/ml) on the intraretinal glial proliferative response was 
investigated in an experimental retinal detachment model in rabbits. At day 3, eyes 
treated with intraviteal triamcinolone showed a significant reduction in the absolute 
number of proliferating glial cells compared to controls. Cellular proliferation was 
measured using the thymidine analogue 5-bromo-2’deooxyuridine (BrdU). The BrdU 
positive cell count was 21 (+/- 2 SEM) cells/mm in control eyes compared to 7(+/-  1.5 
SEM) in IVTA –treated eyes.  
Figure 1.5:  Modification of Intraretinal Glial Proliferation with Triamcinolone Acetonide 
 
Figure 1.5 Reproduced with permission granted by D Charteris. OS, outer 
segments of photoreceptors, INL, inner nuclear layer, GCL, ganglion cell 
layer (A) normal rabbit retina showing Muller cells staining positive for anti-
Vimentin (green) and microglia positive for anti-isolectin B4 (blue). (B) and 
(C)  Day 3 post experimental retinal detachment in rabbit model.  (B) 
proliferating Muller glial cells are demonstrated staining positive for anti- 
BrdU (red) in the inner nuclear layer. (C) eye treated with 2mg/0.05ml of 
triamcinolone on detachment induction shows reduction in absolute 
number of anti-BrdU +ve proliferating glial cells  (mean of 21 cells/mm 
retina controls to 7 cells/mm retina in IVTA eyes) 
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An experimental study investigating the use of the slow-release dexamethasone 
implant, Ozurdex®, was recently described in a rabbit PVR model [72]. Interestingly, 
Kuo et al found no difference in the expression of a marker of reactive gliosis, glial 
fibrillary activated protein (GFAP), at day 7 or 14 between treated and untreated eyes. 
The clinical severity of PVR appeared comparable between the two groups. However, a 
significant reduction in the expression of TNFα (an inflammatory cytokine) was 
observed in the steroid group along with a trend towards lower expression of IL-6.  Kuo 
et al acknowledged limitations of their animal PVR model in that the rapid induction of 
vitreoretinal fibrosis was not reflective of the indolent process clinically. Furthermore, 
sub-therapeutic concentrations of the corticosteroid at the investigated time-point 
may have limited its effectiveness. 
 
 Clinical Evidence 1.4.2.2
 
The clinical application of corticosteroids as adjuncts to vitreoretinal surgery was first 
reported by Koerner et al in 1982. They concluded that effect of oral prednisolone on 
postoperative retinal fibrosis did not match that of experimental intravitreal 
triamcinolone [73]. An infusate containing dexamethasone showed a trend towards a 
reduction in PVR re-proliferation and a reduction in hypotony, but did not achieve 
statistical significance. A reduction in blood-ocular-barrier breakdown (as measured by 
laser-flare photometry) was reported using subconjunctival dexamethasone (10mg) 5-
6 hours prior to scleral buckle surgery [74].  
Jonas et al opened the door to the clinical investigation of intravitreal triamcinolone 
(IVTA)  in 2000 when they reported  its potential benefit through a reduction in 
postoperative intraocular inflammation, without demonstrable toxicity [75] . IVTA has 
become the most widely investigated adjunctive corticosteroid, clinically. Its safety 
profile has been subsequently confirmed although its benefit as a definitive 
therapeutic agent has yet to be consistently proven.  Reduction in blood ocular barrier 
breakdown [76] and a proposed benefit in established PVR have been reported [77-80] 
although these studies were either retrospective small or non-comparative.  
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A large multi-centre, prospective, quasi-randomised controlled trial investigating the 
use of varying doses of IVTA as an adjunctive surgical tool to aid vitreous visualization, 
showed a significant reduction in intraoperative complications [81] with fewer retinal 
breaks and intraoperative retinal detachments. However, 1 year follow up failed to 
show a statistical difference in visual acuity or reoperation rate [82]. The absence of 
any long-term positive effect may lie in its use as surgical tool rather than a 
therapeutic injection. It is likely that concentrations of corticosteroid remaining at the 
end of the procedure would have been sub-therapeutic, following its removal as part 
of the operative procedure.  
 
At the time of the submission of this thesis, a single prospective randomized controlled 
clinical trial investigating the use of triamcinolone acetonide in eyes with established 
PVR (Grade C) undergoing pars plana vitrectomy with silicone oil has been reported 
[83]. Seventy five eyes divided into two groups in a 1:1 treatment allocation ratio were 
investigated. The treatment group received 4mg of intravitreal triamcinolone into the 
oil-filled eye at the end of the procedure, whilst controls underwent standard care.  
There was no statistical difference in primary anatomical success at 6 months (84% in 
the adjunct group vs 78% in controls).  The investigated secondary outcomes (visual 
acuity, reoperation rate, PVR recurrence, macula pucker, IOP rise) also showed 
comparable results between the two groups. The authors acknowledge that a positive 
treatment effect may have been masked by a higher than expected primary success 
rate in the control group. This, together with inadequate numbers and no obvious 
sample size justification may have resulted in an underpowered study.  
 
More recently, Koerner et al have published earlier work on the use of systemic oral 
prednisolone [84] and its effect on cellophane maculopathy in 220 consecutive eyes 
undergoing scleral buckle surgery for primary RRD. They reported significantly fewer 
cases of cellophane maculopathy in the steroid group 27%, 24% and 20% compared 
with 42%, 47% and 39% in the control group at 1, 3 and 6 months, respectively. They 
concluded that oral corticosteroids may have a prophylactic effect against the early 
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stages of PVR, but affirmed the need for larger RCTs to confirm whether the observed 
effect could be extended to advanced PVR. 
Local corticosteroid administration is usually preferable over systemic use, as it 
achieves significantly higher intraocular concentrations [85] and avoids the unwanted 
systemic side effects.   
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 Non-steroidal anti-inflammatory drugs in the pharmacotherapy of 1.4.3
PVR 
 
Non-steroidal agents, like corticosteroids, are of therapeutic value in vitreoretinal 
scarring through their anti-inflammatory properties and subsequent reduction in blood 
ocular barrier breakdown. They have been less widely investigated than 
corticosteroids due to their reduced potency and have most commonly been adopted 
in combination with other agents.  
 
 Pre-clinical Evidence 1.4.3.1
 
Meclofenamate and indomethacin were first shown to inhibit RPE cellular proliferation 
in cell culture in 1984 [86], but were not subsequently investigated as single 
therapeutic agents, presumably due to their inability to compete with corticosteroids 
as realistic treatment options. However, in combination with 5-FU in a sustained-
release preparation, a significant reduction in both the presence and severity of post-
traumatic experimental PVR in rabbits was reported [87].  
 
 Clinical Evidence  1.4.3.2
 
Topical indomethacin in combination with routine peroperative corticosteroids was 
found to significantly reduce blood-aqueous barrier breakdown in patients undergoing 
extracapsular cataract surgery [88] as well as decrease postoperative inflammation 
[89]. No clinical trials have investigated the use of non-steroidal anti-inflammatories in 
patients with PVR. 
For completion, a brief outline of other therapeutic agents which have been 
investigated in the modification of PVR. They will be described in sequence followed by 
the preclinical and clinical evidence which supports their use.  
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 Fluoropyrimidines 1.4.4
  
The fluoropyrimidines are a family of antimetabolites which modify protein synthesis 
and are more commonly used as a chemotherapeutic agent in solid tumours of the 
gastrointestinal tract. They act by (a) binding to and inhibiting the enzyme thymidylate 
synthetase, and (b) causing coding errors in protein translation through RNA 
incorporation.  
 
 Preclinical Evidence 1.4.4.1
 
5 Fluorouracil (5-FU) was first reported to reduce experimental traction retinal 
detachment (TRD) in non vitrectomised rabbit eyes in 1982. The  TRD rate of 73.6% in 
control animals was reduced to 31.5% following a single intravitreal injection of 5-FU 
[90]. This effect was later replicated in vitrectomised eyes with repeated daily 
intraocular injections 0.5mg for 7 days [91]. A sustained-release preparation containing 
1mg of 5-FU, reduced TRD rates from 89% in controls to 11% in an experimental 
animal PVR model [92]. Co-drug preparations containing 5-FU and either 
dexamethasone or triamcinolone have also been shown to reduce the severity and 
progression of experimental PVR in non-vitrectomised rabbits [93, 94].  
 Clinical Evidence 1.4.4.2
 
A prospective non-comparative pilot study of 22 patients with established PVR were 
treated intraoperatively with additional intraocular and periocular 5-FU. Sixty per cent 
achieved final reattachment at 6 months. The therapy was considered to be well-
tolerated, non-toxic, and superior to reported standard care at the time [95].  This was 
subsequently confirmed in a prospective randomized controlled trial using 10mg of 
intravitreal 5-FU on completion of vitrectomy surgery [96]. Although a trend towards 
better vision in the treatment group was observed, the macula re-attachment rate was 
also lower compared to controls (60% vs 77%).   
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More recently, 5-FU has been investigated in combination with low molecular weight 
heparin (LMWH) in three prospective randomised controlled clinical trials [11, 97, 98] 
which will be outlined later in this chapter.  
 
 Daunorubicin 1.4.5
 
Daunorubicin, or daunomycin, is a chemotherapeutic agent of the anthracycline family 
previously used in combination therapy to treat haematological malignancies. It 
inhibits cellular proliferation by inhibiting DNA replication.   
 
 Preclinical Evidence 1.4.5.1
 
Daunomycin was shown to reduce dermal fibroblast proliferation when it was first 
tried intravitreally in experimental PVR in 1983 [99]. After initial concerns regarding its 
narrow safety margin [100], it later showed promise as a potential non-toxic and 
therapeutic adjunct [101-105]. In a staggered regimen with intravitreal triamcinolone, 
it has been shown to reduce experimental TRD in rabbits, with the staggered 
combination found to be superior to monotherapy. However, human multi-drug 
resistant cells have been found in excised premacular membranes, in eyes treated with 
daunomycin, thereby questioning its role as  clinical adjunctive agent[106].  More 
recently, doxorubicin (a close relative to daunorubicin) has been shown to attenuate 
the intraretinal glial cell response and reduce the severity of experimental PVR [107]. It 
may form the basis of future studies, either as a single agent, or in combination 
therapy.  
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 Clinical Evidence 1.4.5.2
 
The safety profile of intravitreal daunorubicin was first shown when administered as a 
7.5µg/ml intravitreal 10 minute infusion in 15 post-traumatic eyes with PVR, prior to 
silicone oil injection [108]. A larger non-comparative study of 68 eyes with advanced 
PVR reported an eventual anatomic success rate of 73% at 18 months [109].  
 A multicentre, prospective, randomized, controlled clinical trial study of 286 eyes with 
PVR grade C2 or greater undergoing vitrectomy and silicone oil exchange randomised 
patients to treatment with or without a 10 minute intraoperative infusion of 
daunorubicin (7.5 µg/mL). Primary anatomical success, was achieved in 62.7 % of 
patients in the treatment group compared to 54.1% in controls. Its primary outcome 
marginally failed to reach significance (P = 0.07). The trial did demonstrate a 
statistically significant reduction in the number of required reoperations within one 
year (P = 0.005) [110]. Further small-scale studies have since suggested a benefit [111] 
but it has not gained widespread acceptance. 
 
 Retinoids 1.4.6
 
Retinoids are vitamin A compounds and have important roles in regulating the cell 
proliferation and differentiation of multiple cell types throughout the body by 
mediating gene transcription. They are inhibitors cellular proliferation and may modify 
ECM and cell-mediated contraction.  
 Preclinical Evidence 1.4.6.1
 
Human RPE cell proliferation was significantly reduced when grown in the presence of 
1microM of retinoic acid[112].  This inhibitory effect on cell proliferation was 
subsequently confirmed [113], in addition to a reduction in cell-mediated contraction.   
Sustained drug delivery systems containing all-trans retinoic acid, have been shown to 
reduce experimental PVR from 100% to 36% in rabbit models [114] but an associated 
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foreign body reaction was reported. Doses of 605 micrograms and 1070 micrograms 
have since been found to be therapeutic and non-toxic [115, 116]. In an experimental 
PVR model in rabbits using silicone oil and heavy silicone oil, all-trans retinoic acid 
significantly reduced the severity of TRDs [117]. This was later confirmed with 13-cis-
retinoic acid [118]. Both isomers of retinoic acid were shown to reduce proliferation of 
PVR membrane-derived human RPE cells [119].  
More recently, all-trans retinoic acid has been shown to significantly inhibit RPE cell 
extracellular matrix production (particularly laminin beta-1) and thereby reduce cell 
mediated collagen contractility [120]. It may therefore offer a unique advantage as a 
single therapeutic agent with activity against multiple components in the PVR process. 
  
 Clinical Evidence 1.4.6.2
 
A small retrospective study compared the outcomes of 10 patients undergoing surgery 
for PVR with a control group of equal number. Adjunct patients received 40mg of oral 
13-cis-retinoic acid twice daily for 4 weeks postoperatively. A reduction in PVR 
recurrence was observed , with anatomical success in  9 out of 10 patients at 8 months 
compared with 4 out 10 in the control group (p=0.061) at 9 months [121].  
A prospective RCT of 35 patients with PVR compared 16 patients receiving 20mg of 
oral 13-cis-retinoic acid twice daily postoperatively for 8 weeks 19 control patients 
[122]. Both anatomical and visual outcomes were superior in the treatment arm 
compared with the control arm, with reported final anatomical success rates of 93.8% 
and 63.2% (p=0.047), respectively. 56.3% of adjunct patients achieved ambulatory 
vision compared to 10.5% in the control arm (p=0.009). Additionally, fewer patients in 
the treatment group developed macula pucker (18.8%) compared with the control 
group (78.9%) (p=0.001).  Despite this positive treatment effect, retinoic acid has not 
yet been universally adopted clinically which may be due to concerns regarding 
systemic side effects of the treatment. 
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 Immunotoxins 1.4.7
 
Immunotoxins are chimeric proteins consisting of a modified antibody (or antibody 
fragment) attached to a biological toxin fragment with its natural binding domain 
removed. The cell-specific antibody binds to its target thereby allowing intracellular 
incorporation of the toxin and a resultant cytotoxic effect.  Actively dividing RPE cells 
have been shown to abundantly express transferrin receptors and are thus targets for 
anti-proliferative therapy [123, 124].   
 
 Preclinical Evidence 1.4.7.1
 
Transferrin ricin-A (Tfr-rRA) is an immunotoxin comprised of an antibody to the RPE 
transferrin receptor which is linked with the A chain of ricin. Ricin is a potent toxin. It 
has been shown to significantly inhibit both RPE cell [125-127] and fibroblast 
proliferation [127, 128].  In an experimental PVR rabbit model, 10% of eyes developed 
TRDs when treated with an intravitreal injection of 2000ng of Tfr-rRA compared with 
78% of controls [129].   
VEGF receptors expressed by RPE cells have also been targeted using a combination of 
VEGF 165 and the diphtheria toxin (DT390-VEGF165). RPE cell survival was reduced 
when co cultured with this molecule in a dose-dependent response [130].  
At the time of submitting this thesis there have been no clinical studies conducted to 
investigate the use of immunotoxins as therapies for PVR. 
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 Colchicine 1.4.8
  
Colchicine is a natural product sourced from the autumn crocus plant (Colchicum 
autumnale). It may have been employed to treat rheumatism as early as 1500 BC in 
Ancient Egypt. Today, it remains an alternative therapeutic agent in the treatment of 
gout, although its narrow therapeutic window limits its use. Colchicine prevents cell 
proliferation by inhibiting microtubule polymerization with a resultant inhibition of 
mitosis.  
 Preclinical Evidence 1.4.8.1
 
In 1985, colchicine was first shown to inhibit fibroblast growth in an experimental 
model in vitro [131] and later shown to be a potent  inhibitor of RPE cell chemotaxis 
[132]. Its anti-proliferative effects were subsequently confirmed in cell culture animal 
models, where inhibition of  RPE cell proliferation and migration,  at concentrations 
well below levels of ocular toxicity was observed [133].  
Experimental TRDs in rabbits was reduced from 74% to 29.6% at 5 weeks in animals 
treated with oral colchicine [134].  It has also been shown to reduce RPE-cell-mediated 
collagen gel contraction when human RPE cells were treated with 0.01 – 1 microM of 
colchicine [135].  More recently, therapies where colchicine has been combined with 
both methylprednisolone and sodium diclofenac [136] or 5-FU [137], have shown a 
significant reduction in experimental TRD rate and an inhibition of human glial cell 
proliferation, respectively. 
 
 Clinical Evidence 1.4.8.2
 
A small prospective controlled study in patients with PVR secondary to trauma or 
proliferative vascular disease compared the use of oral colchicine (1.2mg daily) with 
placebo (Vitamin C 250mg daily). It was concluded that the safe therapeutic dose of 
colchicine does not inhibit PVR [138] and it has not since been clinically investigated.  
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 ECM Modifiers 1.4.9
 
Collagen (Types 1 and 3), fibronectin, and deposited fibrin form key components to the 
extracellular matrix found in PVR membranes. Drugs that affect their production, 
attachment or contraction may offer benefit in the pharmacotherapy of PVR.    
 Cis-hydroxyproline 1.4.9.1
  
Hydroxyproline is a major constituent of collagen stability, and its synthesis can be 
inhibited by a proline analogue, cis-4-hydroxyproline.  
1.4.9.1.1 Preclinical Evidence 
 
Cis-hydroxyproline was shown to inhibit bovine RPE cell proliferation, collagen 
synthesis, attachment, and migration in vitro, in a dose dependent manner [139]. 
More recently, two sustained-release scleral implants were investigated in an 
experimental PVR model. TRD rates were reduced from 89% in controls to 57% in 
treated animals at one month [140]. This adjunct has yet to be investigated clinically.  
 Matrix metalloproteinases 1.4.9.2
  
Turnover and remodelling of extracellular matrix is regulated by MMPs and their 
natural inhibitors, TIMPs. PVR membranes have been demonstrated to contain MMPs 
1,2,3 and 9 and TIMPs 1,2 and 3 [51, 141].  
1.4.9.2.1 Preclinical Evidence 
 
Prinomastat (AG3340) is a synthetic inhibitor of MMPs that has been shown to reduce 
PVR in an experimental rabbit model [142] and in post-traumatic rabbit eyes [143].  It 
has also been shown to reduce premacular membrane formation in rat eyes [144]. It 
has yet to undergo clinical investigation in patients with PVR. 
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 Heparin/Low Molecular Weight Heparin (LMWH) 1.4.9.3
  
Heparin has multiple cellular effects that can potentially inhibit PVR development. It 
inactivates thrombin by binding to anti-thrombin, promoting thrombin-antithrombin 
complex formation.  
1.4.9.3.1 Preclinical and Clinical Evidence  
 
 In preclinical studies heparin has been shown to reduce fibrin formation and interfere 
with cell-substrate adhesion by binding fibronectin It also binds fibrogenic growth 
factors FGF, EGF and PDGF (refer  section 1.3.2.5)  and inhibits RPE cell proliferation 
[145].  
 
A prospective RCT investigating the effect of heparin in the infusate on post-operative 
fibrin formation showed a positive effect using concentrations of 10 IU/ml, but a 
greater tendency to intraocular haemorrhage. Lower concentrations were ineffective 
at reducing fibrin formation [146].  Combined heparin and dexamethasone in the 
infusate suggested a trend towards a reduction in post-operative PVR in treated 
patients, but again higher reported rates of intraocular haemorrhage [147].  
 
The low molecular weight fragments of heparin (LMWH) have less effect on the 
coagulation cascade or platelet function than heparin and thus reduce the risk of 
haemorrhagic complications but produce a comparable antithrombotic effect [145]. 
Intraocular fibrin formation was markedly reduced using an infusate containing LMWH 
in vitrectomy/lensectomy surgery in rabbits [148].  
 
 
 
 
61 
 
 
 
  Combined 5 Fluorouracil and Low Molecular Weight Heparin 1.4.10
 
The combination of LMWH with 5-FU to modify PVR development in eyes undergoing 
vitrectomy surgery has been investigated in three large prospective RCTs [11, 97, 98].  
All three trials adopted a common adjunctive regimen as follows; an intraoperative 
vitrectomy infusion solution of Hartmann’s containing 5-FU at a concentration of 
200ug/ml and LMWH at a concentration of 5IU/ml for one hour. Plain Hartmann’s 
solution was used as a placebo in control patients.  
The three studies investigated eyes with (i) high risk retinal detachments undergoing 
vitrectomy and gas exchange [97], (ii) established PVR undergoing vitrectomy and with 
silicone oil [98] and (iii) unselected primary retinal detachments undergoing vitrectomy 
with gas [11].   
 
 High Risk Retinal Detachments 1.4.10.1
 
High risk cases were identified using a previously published regression formula based 
on PVR risk factors [149]. In 174 patients, PVR recurrence rates were significantly lower 
in the adjunct group (12.6%) compared to controls (26.4%) with fewer reoperations. 
Furthermore, visual outcome was better in adjunct patients who developed recurrent 
PVR.  
 Retinal Detachments with Established PVR 1.4.10.2
 
A total of 157 patients with established PVR (Grade C) undergoing vitrectomy surgery 
with silicone oil tamponade were randomized to receive the adjunctive combination or 
placebo in a 1:1 treatment allocation ratio. No benefit was found in primary 
anatomical success or in reported secondary outcome measures (complete or 
posterior retinal reattachment, visual acuity, hypotony, cataract, keratopathy). 
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 Unselected Primary Retinal Detachments 1.4.10.3
  
641 patients with unselected primary RDs undergoing vitrectomy with gas tamponade 
were studied in a 1:1 treatment to control allocation ratio. Primary anatomical success 
rates at 6 months were 82.3% and 86.8% in the adjunct and control groups, 
respectively. The proportion of patients who required reoperations due to PVR was 
7.0% in the treatment group, compared to 4.9% of controls.    Concerns of toxicity 
were reported in eyes with fovea-sparing retinal detachments and treated with the 
adjunctive regimen.  
 
1.5 Rationale behind need for further clinical trials of adjunctive 
therapy in the pharmacotherapy of PVR 
 
It is clear from the evidence outlined throughout section 1.4 that a multitude of 
therapeutic agents targeting various components of the PVR process have been 
identified as potential adjuncts in the pharmacotherapy of PVR.  Promising findings 
from laboratory and experimental work have yet to be consistently replicated 
clinically. This may in part be due to the inherent limitations of animal models of 
retinal detachment and PVR due to cross-species variation in retinal anatomy.  The 
rabbit model has been most frequently utilised, but, whilst (like humans) the rabbit 
retina is rod-dominant, it has no intraretinal vasculature,  with vessels on the surface 
of the posterior vitreous face serving as blood supply to the inner retina. Furthermore, 
it only serves as a useful short-term model of RD as the rabbit retina undergoes rapid 
degeneration following neurosensory detachment.   
Despite improvements in instrumentation and technique over the last twenty years of 
clinical practice, little progress has been made in terms of both visual and surgical 
outcomes, with the incidence of PVR remaining relatively static [48]. 
 
There therefore remains a clear need to identify an effective adjunctive therapy 
through the process of clinical trial investigation.    
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1.6 Clinical Trials; a history of evolution and regulatory milestones 
 
In order to determine whether a novel therapy or treatment paradigm offers 
additional advantages over the existing treatment, a comparison is usually necessary. 
When the experimentation involves human subjects, the scientist or clinician has a 
moral obligation to preserve the human rights and dignity of the subject. Regrettably, 
history has proven that this fundamental moral compass has been followed to varying 
degrees of consistency, sometimes with devastating consequences.  
Whether deviations from this path have occurred consciously or unwittingly, 
guidelines and frameworks have been instituted into practice.  These regulatory 
milestones were introduced to provide researchers guidance in prioritising the 
protection of subjects involved in clinical research whilst preserving the scientific 
integrity of the research goal.   
A brief overview of the evolution of clinical trials and events which triggered the 
implementation of key regulatory milestones will be discussed herein.  
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 Ancient Babylon to streptomycin; how we got here 1.6.1
 
It may be regarded that the first documented account of a clinical trial, albeit in 
rudimentary form, is in The Book of Daniel in The Bible [150]. King Nebuchadnezzar II 
following the siege of Jerusalem in 587 BC ordered the capture of a group of Hebrew 
boys who were to be trained for the purpose of serving in the King’s court in Babylon. 
They were instructed to be fed a rich diet of meat and wine akin to that of the palace. 
Daniel, one of the captured boys, refused the food as it had not been killed according 
to Jewish law and convinced his captor to allow himself and three others to follow a 
diet of pulses and water for a ten day trial period, citing a higher nutritional value of 
his preferred diet.   
 
After ten days, the four boys who had not followed the King’s decree were noted that 
‘their countenances appeared fairer and fatter in flesh than all the children which did 
eat the portion of the king's meat.’ The King allegedly switched those on meat and 
wine to the leguminous diet having observed the superior effect of those consuming 
the latter.  
 
 
In 1025, some 1500 years later, the Persian philosopher Ibn Sina (or Avicenna, as he 
has become more commonly known by the latinate form of his name), completed his 
encyclopaedic five books entitled the Canon of Medicine. In it, he outlined how new 
medicines should be effectively tested in seven principles. Three of these principles are 
highlighted in italics with their modern day relevance overleaf: 
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The time of action must be observed, so that essence and accident are 
not confused’ 
 
This suggests that the temporal relationship between administration 
and effect must be related 
 
 
The effect of the drug must be seen to occur constantly or in many 
cases, for if this did not happen, it was an accidental effect. 
 
This observation relates to the importance of adequate sample size 
and predefined outcome measures 
 
 
The experimentation must be done with the human body, for testing a 
drug on a lion or a horse might not prove anything about its effect on 
man 
 
This observation is an insightful reflection on the limitations of 
extrapolating the findings of preclinical studies and an affirmation of 
the need to perform clinical trials. 
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In 1537, the Renaissance military surgeon Ambroise Parè, unintentionally conducted 
the first clinical trial of a novel medicine. When supplies of the conventional treatment 
of boiling oil were limited, he chose to treat battlefield gunshot wounds with a 
combination of egg yolk, rose oil and turpentine. He noted the superior wound healing 
in those patients treated with the latter and reported his findings in ‘La Méthod de 
traicter les playes faites par les arquebuses et aultres bastons à feu (“The Method of 
Treating Wounds Made by Harquebuses and Other Guns”), in 1545.  
 
Furthermore, Dr James Lind is widely considered to be the first physician of the 
modern era to have conducted a controlled clinical trial.  He was appalled by the high 
mortality rate of sailors suffering from scurvy and whilst working on a British Naval 
ship, the Salisbury, he planned a comparative trial to offer a cure for the then 
untreatable illness. His vivid description of events covers the essential elements of a 
controlled trial.[151] 
On the 20th of May 1747, Lind described twelve patients whom he had selected as 
they were all suffering from scurvy, all with similar manifestations of the disease with 
one common diet. He divided the twelve into six pairs, with each pair ordered to  
supplement their diet with a different treatment as follows ‘ a quart of cyder a 
day...twenty-five drops of elixir vitriol three times a day … two spoonfuls of vinegar 
three times a day … sea-water… two oranges and one lemon  every day … and an 
electary recommended by a hospital surgeon ‘ .  The pair who had received the Vitamin 
C- rich oranges and lemons recovered within six days and were fit to return to duty. 
[152] 
Due to costs, Lind hesitated to recommend the use of citrus fruits in the treatment of 
scurvy despite the overwhelming observed treatment effect. Thus, the widespread 
recommendation of including lemon juice as a compulsory element of the seafarer’s 
diet was not made until 50 years later by the British Navy and was soon replaced by 
the more cost effective lime juice. [151] Lind’s report of his comparative trial is widely 
considered to be the precursor for modern clinical trials, in which he also included a 
systematic review of scurvy to date. 
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 Placebo 1.6.1.1
 
The next historical milestone was the introduction of placebo into the control arm in 
1863 by Austin Flint [153]. Previous studies had compared active treatment with the 
disease in its natural progression. Flint compared 13 patients in whom he had 
administered a placebo to ‘treat’ rheumatic fever with those on active therapy. He 
observed comparable outcomes in 12 out of the 13 patients. 
 
 Randomisation 1.6.1.2
 
There is debate as to when the concept of randomisation was first introduced into 
scientific trials in order to reduce treatment allocation bias.  Some propose that the 
study by Peirce and Jastrow in 1883 was the first example.  Blindfolded subjects were 
asked to discriminate a 1000 g weight from a 1001g or 1002g weight. The selected 
weight was dictated by the random drawing of a card from a specialized deck by the 
investigators.  However, others propose that R. A. Fisher was the first to employ 
randomization in a study setting with his agricultural experiment (crop variation) in 
1923. [154] 
 
Nevertheless, in 1931, J. Burns Amberson published the first use of randomization in a 
medical trial which had been conducted five years earlier in 24 patients with 
tuberculosis. Patients were allocated to either active treatment or control in a 1:1 
treatment allocation ratio which was determined by a coin toss. [154] 
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 Streptomycin Trial 1.6.1.3
 
In 1948 the landmark trial investigating the effect of streptomycin in the treatment of 
pulmonary tuberculosis was published by the Medical Research Council [155]. This 
multi-centre clinical trial is considered innovative as it provided a model of meticulous 
design and implementation with so many key elements influencing today’s protocol 
design. 
 
Aside from its systematic enrolment criteria and data collection methods which 
offered significant advantages over the ad hoc nature of other contemporary research, 
it was the statistical design which anchored its place in history. For the first time, the 
investigators were able control for bias which had previously limited the scientific 
integrity of clinical research thus far. 
 
Sir Austin Bradford Hill developed a randomisation scheme which replaced the 
preceding alternating sequence and was able to draw up a predetermined treatment 
allocation list which was distributed to the multiple study sites prior to recruitment. 
Furthermore, he introduced the concept of treatment allocation concealment to both 
the participants and the investigators. (I.e. double -masking).Additionally, objective 
outcome measures (X-rays) were assessed by masked assessors.  
 
The Streptomycin trial of 1948 has influenced trial design and methodology to such a 
degree that it continues to be justifiably referred to as ground breaking.  
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 Regulatory Legislation 1.6.2
 
 Nuremberg Code 1.6.2.1
In parallel to the emergence of novel clinical trial design and methodology which was 
highlighted in the Streptomycin Trial, the first set of research ethics principles were 
established in 1947 triggered by the abhorrent and inhumane experiments conducted 
on prisoners during the Second World War. The Nuremburg Code was a U.S led 
initiative which was created to provide an international set of principles by which the 
scientists and doctors of Nazi Germany could be tried against.  The code constituted 
ten key points which included the following: the necessity of voluntary informed 
consent in patients with legal capacity; preservation of participant safety; that human 
studies should only be conducted following strong pre-clinical evidence and in the 
absence of the availability of alternative methods; a proportionate risk: benefit ratio 
must exist and participants are free to discontinue their involvement at any point. 
[156] 
The Nuremberg Code remains the most important document in the history of medical 
research ethics as it has served as a framework for today’s principles which preserve 
the dignity and rights of individuals involved in human research. [156] 
 
 World Medical Authority 1.6.2.2
 
The ethical principles which were first set out in the Nuremberg Code were further 
developed by the World Medical Authority (WMA) in 1964 in the Declaration of 
Helsinki. This has undergone a series of revisions since its inception, with the most 
recent (seventh) in 2013.[157] The Declaration of Helsinki remains of pivotal 
importance to clinical trial conduct today, as it it provides the ethical foundation for 
ICH E6 (ICH GCP) (refer to section 1.6.2.4), the European Clinical Trial Directive 
(2001/20/EC) and GCP Directive (2005/28/EC) and national clinical research legislation. 
These directives will be discussed further in due course.   
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 European Community Pharmaceutical Directive 1.6.2.3
 
In the mid-1950s, there was an absence of guidelines for the development, production 
and marketing of medicinal products [158]. Licensing authorities were yet to exist and 
hence the drug Thalidomide (alpha-phthalimido-glutarimide) was introduced into the 
German market on 1st October 1957 as Contergan, and one year later in the U.K as 
Distarval. Although it was initially developed as an anticonvulsant, for which it had 
proven to be ineffective, it was marketed on the strength of its safety profile in 
overdose,  in that it only caused a prolonged sedation compared to the fatal side 
effects of its contemporaries[159]. Cruelly, the ill-fated indication in pregnancy to treat 
hyperemesis gravidarum (morning sickness) led to the tragic consequences of neonatal 
deformities [160-162] owing to its teratogenic effects unbeknown to expectant 
mothers.   
In response to the events which shook public health authorities and the general public, 
the first European Community Pharmaceutical Directive (65/65/EEC) was established 
in 1965. This aimed to address the system failures which had contributed to the 
Thalidomide disasters and ensure that a medicinal product was not marketed without 
prior authorisation[158].  
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 International Conference of Harmonisation 1.6.2.4
 
There then followed an emergence of multiple guidelines and legislations both 
nationally and globally, in order to report and evaluate the data on safety and efficacy 
of new medicinal products.    
However, as industry sought to develop global markets, the disparity in requirements 
from varying member states limited its expansion. A clear need for internationally 
standardised guidelines was apparent in order to avoid the duplication of time-
consuming and expensive test procedures whilst protecting the safety of clinical trial 
participants and ultimately the public.  
 
The International Conference of Harmonisation (ICH) was therefore established in 
1996 to provide an international ethical and scientific quality standard for the design, 
conduct, recording and reporting of clinical trials. These guidelines were to become 
known as the Guidelines for Good Clinical Practice (GCP). 
 
The ICH Guidelines for Good Clinical Practice (ICH E6) were formerly introduced in 
2001 as the Clinical Trials Directive (2001/20/EC) and the GCP Directive (2005/28/EC) 
in 2005. These European directives were subsequently adopted and enforced into UK 
law in 2004 (SI 2004/1031) and 2006 (SI 2006/1928), respectively.  
 
Compliance with this standard provides public assurance that the rights, safety and 
well-being of trial subjects are protected, consistent with the principles that have their 
origin in the Declaration of Helsinki. Furthermore it aims to ensure that clinical trial 
data are reliable, credible and of sound scientific value.  
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The ICH E6 document is divided into eight sections, the second of which outlines the 
core principles of GCP and is reproduced verbatim as follows [163] : 
1. Clinical trials should be conducted in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki, and that are consistent with GCP and the 
applicable regulatory requirement(s). 
2. Before a trial is initiated, foreseeable risks and inconveniences should be weighed 
against the anticipated benefit for the individual trial subject and society. A trial should 
be initiated and continued only if the anticipated benefits justify the risks.  
3. The rights, safety, and well-being of the trial subjects are the most important 
considerations and should prevail over interests of science and society.  
4. The available nonclinical and clinical information on an investigational product should 
be adequate to support the proposed clinical trial.  
5. Clinical trials should be scientifically sound, and described in a clear, detailed protocol.  
6. A trial should be conducted in compliance with the protocol that has received prior 
institutional review board (IRB)/independent ethics committee (IEC) 
approval/favourable opinion.  
7. The medical care given to, and medical decisions made on behalf of, subjects should 
always be the responsibility of a qualified physician or, when appropriate, of a qualified 
dentist.  
8. Each individual involved in conducting a trial should be qualified by education, training, 
and experience to perform his or her respective task(s).  
9. Freely given informed consent should be obtained from every subject prior to clinical 
trial participation.  
10. All clinical trial information should be recorded, handled, and stored in a way that allows 
its accurate reporting, interpretation and verification.  
11. The confidentiality of records that could identify subjects should be protected, respecting 
the privacy and confidentiality rules in accordance with the applicable regulatory 
requirement(s).  
12. Investigational products should be manufactured, handled, and stored in accordance 
with applicable good manufacturing practice (GMP). They should be used in accordance 
with the approved protocol.  
13. Systems with procedures that assure the quality of every aspect of the trial should be 
implemented.  
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 The Medicines and Healthcare products Regulatory Agency 1.6.2.5
 
The Medicines and Healthcare products Regulatory Agency (MHRA) is a government 
body established in 2003, which brought together the functions of the Medicines 
Control Agency (MCA) and the Medical Devices Agency. 
 
The principle remit of the MHRA is to ensure that medicines and medical devices work 
and are acceptably safe. They assess safety, quality and efficacy of medicines and 
devices both prior to granting a Market Authorisation or license for clinical use and 
through post marketing surveillance.  
They are the Competent Authority in the U.K for the regulation of clinical trials of 
medicines and devices, and therefore monitor compliance with statutory obligations 
through formal inspections [164].  
 
Understanding the importance of clinical trial governance and its regulatory 
framework has proved central to the focus of much of the work outlined in this thesis. 
 
  
74 
 
 
 
1.7 Thesis Aims 
 
The aim of this work was to identify strategies to improve outcomes in the 
management of eyes with proliferative vitreoretinopathy (PVR). Working with the 
team at the NIHR Biomedical Clinical Research Facility at Moorfields Eye Hospital, I 
primarily aimed to investigate the benefit of using local corticosteroids in the 
management of eyes at high risk and those with established PVR, in the clinical trial 
setting.  
I have also aimed to identify factors associated with limited visual recovery after 
successful retinal detachment repair for PVR.  Using optical coherence tomography 
(OCT), I aimed to investigate the outer retinal structure in the reattached retina, in  
addition to exploring OCT-derived objective markers of intraocular inflammation in this 
complex condition in which the inflammatory response is a key component.   
Finally, I aimed to explore the proof of principle that excised tissue in eyes with PVR 
harbour the capability of generating a population of Müller glia with stem cell 
characteristics.  
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2 Ocular Trauma  
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2.1 Ocular Trauma Epidemiology 
 
Ocular trauma is an important cause of visual impairment and blindness worldwide 
and a leading cause of blindness in young adult males. [165-169]  In 1977, there were 
almost one million people in the United States living with trauma-related visual 
impairment, with 40,000 to 60,000 additional new cases of trauma-related blindness 
each year. [170] Globally it has been estimated that 1.6 million people are blind as a 
result of ocular trauma with 2.3 million suffering bilateral low vision and up to 19 
million with unilateral blindness or low vision. [171] Ocular trauma is the commonest 
cause of unilateral blindness in the world today and in developing countries the high 
incidence of ocular trauma has extensive socio-economic costs. [171] In the UK, it 
was estimated that 5000 patients per year sustain eye injuries serious enough to 
require hospital admission and of these 250 will be permanently blinded in the injured 
eye [172].  
 
In Scotland, a one year prospective observational study using the British Ophthalmic 
Surveillance Unit (BOSU),  the incidence of serious ocular trauma (defined as that 
requiring hospital admission) is estimated  at 1.96 per 100,000 of the population [169] 
with one quarter (27.2%) suffering blinding injuries (VA < 6/60). In the Scottish working 
population, age-adjusted incidence ratio indicated a nine fold higher risk in males. 
Recent European studies report incidences of 2.4 and 3.2 per 100000 per year [173, 
174] for open-globe injuries (OGI) which suggests an annual incidence for the UK of 
between 1500 and 2000. 
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2.2 Ocular Trauma Classification 
 Classification by Mechanism 2.2.1
 
In 2002, Kuhn et al published an internationally standardised system for classifying 
ocular trauma such that injuries could be unambiguously described in order to 
facilitate the accurate interpretation of published results [175]. Figure 2.1 summarises 
the Birmingham Eye Trauma Terminology (BETT) system which was included in their 
original manuscript and will herein be used in the classification of ocular injuries 
throughout the remainder of the thesis. 
 
Figure 2.1:  Birmingham Eye Trauma Terminology (BETT) System 
 
Figure 2.1 Birmingham Eye Trauma Terminology System by Kuhn et al [175] 
and shows the division of ocular injury into open globe (OGI) and closed 
globe injuries. Bold bordered boxes indicate preferred terminology used in 
clinical practice.  Open globe lacerations can be further subdivided into 
penetrating, perforating and intraocular foreign body (IOFB) injuries. 
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Open globe injuries are those in which there is a full thickness injury to the eye wall 
and can be sub-divided into whether the injury was caused by a sharp (laceration) or 
blunt (rupture) appositional force.  The importance of the distinction lies in the 
nature and amplitude of the force applied to the globe in order to generate a full 
thickness wound.  
 
 Mechanisms of injury 2.2.1.1
 
In general, the globe has sustained a force of significantly higher amplitude to 
develop a rupture compared to a laceration. It is therefore not unsurprising that the 
intraocular tissues are often more extensively damaged in globe ruptures when 
compared to an injury caused by an intraocular foreign body (IOFB).  
 
The sequence of events culminating in globe rupture commences with globe 
deformation with significant antero/posterior shortening and a sudden rapid IOP 
rise.  The globe then ruptures at the weakest site.  If the eye has had previous 
surgery (typically with an extensive corneal wound from an extra capsular cataract 
extraction or penetrating keratoplasty) then this is an obvious site for the defect. If 
there is no history of previous surgery, the globe most commonly bursts in the 
weakest region i.e. circumferentially at the insertion of the recti muscles where the 
scleral wall is at its thinnest (Figure 2.2).   
 
Penetrating lacerations have a single entry wound, where perforating lacerations 
have an additional exit wound. In practice, there may be occasions when an 
intraocular foreign body is caused by a high velocity blunt object e.g. a pellet or 
bullet and it is therefore more accurate to describe these wounds as mixed rupture 
with IOFB.  
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Figure 2.2:  Mechanism of Globe Rupture 
 
 
 
D 
B A 
C 
Figure 2.2 illustrates the sequence of events culminating in globe 
rupture (A) Blunt object towards globe of sufficient velocity to cause 
globe deformation and antero-posterior shortening upon impact as 
seen in (B). (C) sudden rapid rise in IOP sufficient to rupture globe at 
weakest point (red line). (D) globe rupture occurs behind insertion of 
recti muscles where sclera is thinnest and may result in extrusion of 
intraocular content (images adapted from video animation donated 
by Mr P Sullivan, Moorfields Eye Hospital, with permission) 
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 Classification by site 2.2.2
 
In addition to classifying the injury by mechanism as mentioned above, open globe 
injuries can be further classified by site or extent. The eye can be divided into three 
zones from anterior to posterior with the boundaries dictated by ocular surface 
anatomical landmarks.  
Figure 2.3:  Schematic Eye Showing Injury Zones 
 
An injury that is entirely confined to the cornea or limbus is classified as a zone 1 
injury. Wounds that extend up to 5mm into the anterior sclera become zone 2. In 
practice the recti muscle insertions are used as an estimate of 5 mm and 
ophthalmologists commonly use this as a surface landmark to classify such injuries as 
zone 2 despite the more posterior positioning of superior and medial recti. Zone 3 
injuries are those which extend more than 5mm behind the limbus (i.e. behind the 
recti insertion). 
Full thickness injuries that involve zone 3 carry a worse visual prognosis than more 
anterior injuries as they more commonly involve retinal tissue [176]. 
 
      
Figure 2.3 demonstrates the 
surface anatomical landmarks to 
classify globe injury by site. An 
injury in zone 1 is entirely 
confined to the cornea or limbus. 
Zone 2 extends as far as the recti 
insertion. Injuries extending 
posteriorly to the recti insertions 
are classified as zone 3 injuries.  
81 
 
 
 
 Birmingham Ocular Trauma Score 2.2.3
 
In addition to classifying the mechanism, site and extent of open globe injuries a 
scoring system was developed as a validated tool as an indicator of final outcome. 
The Birmingham Ocular Trauma Score (OTS) includes a combination of the 
aforementioned characteristics in order to calculate a score as follows ([177]) . 
The initial presenting visual acuity is used as a starting raw point or score out of 100 
as indicated in the table below. 
 
Table 2.1:  Raw Point Designation for Ocular Trauma Score  
Visual Acuity Raw Point 
≥ 6/12 100 
6/60 – 6/15 90 
1/60 – 5/60  80 
CF/HM/PL 70 
NPL/Enucleation/Evisceration 60 
  Adapted from [177]. CF = counting fingers, HM = hand movements,  
  PL = perception of light, NPL = no perception of light 
 
 
Points are subsequently deducted from the raw point score depending on the 
presence of particular clinical features at presentation. Those associated with a 
worse visual prognosis are assigned a higher degree of importance (Table 2.2).  
 
 
 
 
82 
 
 
 
Table 2.2:  Deduction from Raw Point to calculate Ocular Trauma Score 
 
Clinical Feature Reduction of Raw Point 
Rupture - 23 
Endophthalmitis - 17 
Perforating Injury - 14 
Retinal Detachment - 11 
Relative Afferent Pupillary Defect 
(RAPD) 
- 10 
  Adapted from [177]. 
Therefore an open globe injury that presents with a visual acuity of 5/60 and is 
classified as a rupture with a retinal detachment and relative afferent pupillary 
defect would be assigned an Ocular Trauma Score (OTS) as follows:   
  80 (raw point) – 23 – 11 – 10 = 36   
Multiple studies have validated this system and found it a useful tool as a prognostic 
indicator of visual outcome in open globe injuries.  
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2.3 Posterior Segment Sequelae of Open Globe Injury 
 
 Retinal Detachment after Open Globe Injury 2.3.1
 
Eyes sustaining open globe injuries are at risk of severe visual loss through a variety of 
mechanisms. Stryjewski et al [176] recently published the largest retrospective review 
characterising the development of retinal detachment after open globe injuries. Data 
were available on 892 of 1036 OGIs over a twelve year period between 1999 and 2011 
at a single tertiary referral unit. They reported a crude overall incidence of RD in 29% 
of eyes (95 % confidence interval 26-32). Unsurprisingly, the incidence was significantly 
higher in Zone 3 injuries (60%, 95 % CI 53-67%) compared to Zone 1 injuries (9%, 95% 
CI 6-12%).   
 
Additional factors associated with retinal detachment determined on multiple variable 
regression analysis were the presence of vitreous haemorrhage (odds ratio [OR], 7.29; 
P<0.001) and poorer logarithm of the minimum angle of resolution (logMAR) visual 
acuity at the time of presentation after OGI (OR, 2.41 per integer increase in logMAR 
visual acuity; OR, 1.00-81.30; P<0.001). Interestingly, Kaplan-Meier analysis estimated 
that 27% (69/255) of eyes detached within 24 hours of primary open globe repair, 47% 
(119/255) detached within 1 week, and 72% (183/255) detached within 1 month.  
 
The authors developed a scoring tool (RD-OGI score) to predict the likelihood of RD 
development following an open globe injury. This is based on the three 
aforementioned clinical factors at the time of primary repair, namely presence or 
absence of vitreous haemorrhage, highest injury zone and logMAR VA. As this has only 
recently been published, it has yet to be validated as a useful tool in clinical practice.  
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 Proliferative Vitreoretinopathy after Open Globe Injury 2.3.2
 
Aside from the high incidence of retinal detachment after open globe trauma, eyes 
with a full thickness injury show an increased propensity to the development of 
proliferative vitreoretinopathy. It is unsurprising that the incidence of PVR varies 
depending on the mechanism of injury and therefore the degree of blood ocular 
barrier breakdown and release of secondary inflammatory cytokines.   
The largest report to date was published in 1997 by Cardillo et al [178] . Of 1654 eyes 
suffering severe ocular trauma over a three year period, 347 were classified as open 
globe injuries. The highest incidence of PVR was observed in perforating ocular 
trauma, where 43% (n=13/30, p<0.001) of eyes developed proliferative 
vitreoretinopathy. 21% (n=30/145) of eyes with globe ruptures, 15% (n=15/98) of 
penetrating injuries and 11% (6/54) eyes with an intraocular foreign body developed 
PVR in their series.  Other studies report a wide variety of PVR rates in open globe 
trauma. In a small non comparative study [179] where early (within 24 hours of injury) 
vitrectomy with silicone oil was performed,  only 2 out of 13 cases developed 
proliferative vitreoretinopathy.  
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2.4 The Adjuncts in Ocular Trauma (AOT) Trial 
 
 Rationale 2.4.1
 
Section 2.3 summarises why eyes sustaining open globe injuries are a group at high 
risk of severe visual impairment. Retinal detachment is common and multiple 
surgical interventions are often necessary [176, 180]. PVR is the commonest cause of 
recurrent retinal detachment and visual loss in eyes with open globe trauma. It is 
estimated to occur in 10-45% of all OGT. [172, 178, 179, 181-186]  
Although vitreoretinal surgical techniques have improved, outcomes remain 
unsatisfactory and that development of proliferative vitreoretinopathy (PVR) is the 
leading cause of this. [178, 179, 181, 182] 
Section 1.4.2 has outlined the experience of corticosteroid therapy in eyes with PVR. In 
particular, experimental work has suggested that triamcinolone acetonide can reduce 
the severity of PVR if administered intravitreally  [68, 187] and via periocular 
administration [70]. Laboratory work has also confirmed no demonstrable retinal 
toxicity of triamcinolone [188].  
A pilot study by Wickham et al has shown that triamcinolone is well tolerated in PVR 
cases undergoing vitrectomy and silicone oil exchange and that a combination of 
adjuncts targeting the inflammatory component of the PVR process may be a 
potential treatment to prevent PVR. [189]  
The Adjuncts in Ocular Trauma trial was thus developed to investigate the feasibility 
of conducting a prospective randomized controlled clinical trial in this demographic 
testing the aforementioned agents.    
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 Investigational Medicinal Products 2.4.2
 Triamcinolone Acetonide 2.4.2.1
 
Triamcinolone acetonide is a hydrophobic long-acting corticosteroid preparation 
which has been used off- label in clinical ophthalmic practice for many years. 
Ophthalmologists have experience of its periocular administration for over 50 years, 
with administration via the intraocular route adopted for over 30 years. It has been 
used to treat a variety of posterior segment ocular inflammatory pathology [190-193].   
Its use as an intraocular surgical adjunctive tool for visualisation of the posterior 
hyaloid during pars plana vitrectomy has been well established [194]. Additionally, 
intraocular triamcinolone has been found to reduce postoperative inflammation 
following vitrectomy surgery [76]. It has been investigated specifically to determine its 
effect on vitreoretinal scarring (PVR) with varying success [77, 78, 83]. 
It has an extremely well documented safety profile with the commonest significant 
side effect recorded as elevated intraocular pressure (IOP) [195]. It is particularly 
useful in patients who have isolated ocular disease especially unilateral, providing an 
anti-inflammatory and anti-proliferative efficacy equal to or greater than that 
achieved with systemic administration while avoiding the unwanted systemic side 
effects of steroid use. Its effects may last up to 3 months [196] which covers the key 
active developmental stage of PVR, which occurs over about 6 to 8 weeks following 
ocular injury.  
Various preparations of triamcinolone are available in the United Kingdom. Kenalog® 
(Squibb and sons) is the most widely used but continues to be used outside the terms 
of its licensed indication. Unpreserved preparations which are licensed for 
intraocular therapeutic use include Trivaris™ (Allergan, Incorporated) and 
Triescence® (Alcon, Incorporated) are now available in the U.K. but were not 
available at the time of study set up. Kenalog® was used as the primary IMP is this 
clinical trial.  
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 Flurbiprofen 2.4.2.2
 
Flurbiprofen is an oral non-steroidal anti-inflammatory drug most commonly used to 
treat musculoskeletal disorders including rheumatoid disease, osteoarthritis and 
bursitis, but in ophthalmic practice is commonly used to treat scleritis. The rationale 
for its use in this study stems from evidence suggesting that non-steroidal anti-
inflammatory medications given peri-operatively may limit the degree of blood-retinal 
barrier breakdown and have been shown to inhibit cellular proliferation in vitro. [86, 
88, 89]. Furthermore, combining corticosteroids and non-steroidal anti-inflammatories 
has been shown to have a synergistic effect in reducing blood-ocular barrier 
breakdown.  [89]  
 
 Prednisolone Acetate 1% 2.4.2.3
 
Prednisolone acetate 1% is an eye drop suspension used commonly in the treatment of 
steroid-responsive inflammatory conditions of the eye. It remains the most potent 
topical steroid treatment licensed for use in the U.K.  
 
 Purpose of the AOT trial 2.4.3
 
The primary purpose of this study was to determine the feasibility of conducting a 
prospective randomised controlled clinical trial using the aforementioned IMPs in this 
disease population. We aimed to acquire data in order to power a definitive study. 
Additionally, we aimed to investigate the treatment effect and toxicity of intensive 
anti-inflammatory agents.   
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 Primary Objective 2.4.3.1
 
To determine whether adjunctive use of anti-inflammatory agents in eyes requiring 
vitrectomy following open globe trauma has an effect on anatomic reapposition of the 
remaining retina to the retinal pigment epithelium in the absence of an internal 
tamponade agent at 6 months post-surgery. This study aimed to provide sufficient 
data to power a definitive future study.  
 
 Secondary Objectives:  2.4.3.2
 
To determine whether adjunctive use of anti-inflammatory agents in eyes requiring 
vitrectomy following open globe trauma has an effect on: 
i. Visual acuity at 6 months (as measured on an ETDRS Chart) 
ii. Number of procedures required to achieve retinal reattachment 
iii. Presence and grade of postoperative proliferative vitreoretinopathy according 
to the Retina Society classification on proliferative vitreoretinopathy (1991) 
iv. Persistent submacular fluid found by Optical Coherence Tomography in the 
presence of retinal reattachment 
v. Further secondary objectives include providing information regarding: rate of 
recruitment, case mix of ocular trauma and patient loss to follow-up rates 
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 Methods/design 2.4.4
 
This was a phase 2, single-masked, single-centre, pilot, randomised, controlled clinical 
trial involving 40 patients. Participants were randomised into either the adjunct group 
(standard care with additional per-operative anti-inflammatory adjuncts) or control 
group (standard care with no additional treatment). Both groups received the standard 
surgical treatment appropriate for their eye condition and routine preoperative and 
postoperative treatment and care, differing only in the addition of supplementary anti-
inflammatory agents in the treatment group. The study protocol has been published in 
Trials, an open access journal [197].  
 
 Study Setup 2.4.4.1
 
2.4.4.1.1 Funding 
An unrestricted grant was obtained from the Ministry of Defence via Qinetic (Ref No. 
RAO 24/5/59) by the chief investigator , Professor David Charteris (DGC) and Mr 
Malcolm Woodcock, a co-investigator .  The funding agency had no role in the 
management of the trial or results dissemination, but requested the provision of 
quarterly study reports per annum. Upon submission of the final study report, the final 
payment of the grant was made. 
 
2.4.4.1.2 Regulatory Authority Approvals 
 
Prior to participant recruitment: Moorfields Research Management Committee (RMC) 
approval was obtained, a favourable opinion from the Research and Ethics Committee 
for Wales was received (07/MRE09/60) and the study was granted a clinical trials 
authorisation by the MHRA. The trial was registered on the European Clinical Trials 
Database (EudraCT No: 2007-005138-35). The study was conducted in accordance with 
the International Conference on Harmonisation for Good Clinical Practice, as set out in 
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the European Union Clinical Trials Directive (2001) and associated UK Regulations 
(2004). The study complied at all times with the Declaration of Helsinki (2000). 
Moorfields Eye Hospital was the study sponsor and took overall responsibility of trial 
management.  The regulatory authority approvals were obtained by DGC.  
 
2.4.4.1.3 Case Report Form Design 
 
Paper case report forms were designed by DGC but modified by me to ensure the 
efficient capture of the required dataset (Appendix 1). The study database was 
designed by the research department applications managers at Moorfields Eye 
Hospital, Richard Seeberan and Shaun Kirupairatnam. Prior to green light approval, 
dummy data were entered into the study database in order to test its design.  
 
 Eligibility of Participants 2.4.4.2
 
Inclusion Criteria 
x All patients with an open globe injury requiring vitrectomy, either following 
open globe injury (OGI) or as the primary procedure itself 
(OGI has previously been defined in section 2.2.1). In the event of bilateral injury, the 
worst injured eye (at the investigators discretion) was to be included in the study.  
Exclusion Criteria 
x Age < 18 or > 80 years of age 
x Pre-existing Glaucoma 
x Previous vitrectomy surgery to the affected eye 
x Pregnant or breastfeeding females 
x Previous known adverse reaction to any of the IMPs 
x Inability to attend regular follow up or give informed consent 
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 Study Interventions 2.4.4.3
 
2.4.4.3.1  Adjunct Group 
 
Pre-operative Treatment 
x Guttae Prednisolone forte 2 hourly for up to one week replaced any topical 
ant-inflammatory agents which the patient was already using, and all other 
ocular treatment  was continued 
 
Per-operative Treatment  
x 4mg/0.1ml of triamcinolone acetonide was injected into the vitreous cavity 
following closure of the scleral ports at the end of procedure 
x 40mg/1ml of triamcinolone acetonide was given as a posterior subtenons 
injection prior to suturing the conjunctiva 
x Standard subconjunctival antibiotic injection at the surgeons’ discretion 
 
Post-operative Treatment 
x Guttae prednisolone forte hourly for 1 week followed by a tapering regimen 
for 3-26 weeks thereafter at the treating clinician’s discretion 
x 50mg flurbiprofen orally twice daily for 1 week 
x Routine topical antibiotics and mydriatics ( Guttae chloramphenicol 0.5% and 
Guttae cyclopentolate 1% -frequency and duration at surgeons’ discretion) 
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2.4.4.3.2 CONTROL GROUP 
 
Pre-operative 
x No additional treatment is given. Patients were instructed to continue with 
their current treatment, which may have already included topical anti-
inflammatory agents such as guttae dexamethasone, and topical antibiotics 
and mydriatics 
Peri-operative 
x Standard sub-conjunctival medications to include 4mg of betamethasone  and 
125mg cefuroxime (at operating surgeon’s discretion)  
Post-operative 
x Routine topical antibiotics (Guttae chloramphenicol 0.5%) topical steroids and 
topical mydriatic (Guttae dexamethasone 0.1% and Guttae cyclopentolate 1% 
- frequency and duration at operating surgeon’s discretion) 
 
 Schedule of assessments 2.4.4.4
 
2.4.4.4.1 Informed Consent  
 
Informed consent was taken by me or the chief investigator prior to any study-specific 
interventions were performed (Appendix 3). Adequate time was provided prior to 
signing of the consent form which in the majority of circumstances was greater than 24 
hours after issuing the participant information leaflet (PIL).  Where emergency surgery 
was required necessitating the enrolment within this time, we ensured that patients 
had been provided adequate time to reach their decision. This was documented in the 
source documents (hospital clinical notes).  
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2.4.4.4.2 Screening 
 
Screening assessments were carried out by me in order to confirm eligibility.  
2.4.4.4.3 Baseline Assessment 
 
Baseline assessments were performed by me within 2 weeks prior to the scheduled 
operation date. Data including: patient demographic; site, nature and extent of ocular 
injury; and a full slit lamp ophthalmic examination was included. Where posterior 
chamber assessment was directly possible, retinal attachment status, presence and 
Grade of PVR and spectral domain OCT of the macular was performed where possible. 
Where media opacity precluded a direct fundal assessment, B scan ultrasonography 
was used to document retinal attachment status, and parameters regarding grade of 
PVR and foveal thickness and volume were deemed unrecordable. 
 
2.4.4.4.4 Follow-up assessment schedule 
 
Post-operative study visits did not differ from the routine schedule for vitreoretinal 
procedures at the study site i.e. day 1, 10 days, 4-6 weeks, 3 months and 6 months. 
The time window allowed around these scheduled visits were as follows: Day 10 (+/- 
3 days), Week 4-6 (+/- 7 days) Months 3 and 6 (+/- 14 days). I performed >95% of 
clinical assessments. At each scheduled post-operative study visit, a full ophthalmic 
assessment was completed to include slit lamp biomicroscopy (+/- indirect binocular 
ophthalmoscopy when required) and parameters including ETDRS visual acuity, 
applanation tonometry, anterior segment assessment and retinal attachment status 
recorded. Spectralis domain optical coherence tomography was used to document 
the presence of subretinal fluid within the macular field.  
In patients in whom silicone oil was used as a tamponade agent, its routine removal 
was not considered a re-operation and routine subsequent follow up was followed 
until the patient returned to the study visit schedule.  Other vitreoretinal surgical 
interventions (excluding posterior epiretinal membrane peel) over the trial period 
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were considered reoperations and recorded as such. Postoperative visits related to 
reoperations, or any other attendances outside the study visit schedule, were 
recorded as ‘unscheduled visits’. CRFs identical in composition to the study 
scheduled visit CRF were completed and included in the data analysis on completion 
of the study.   
Following the final study visit at 6 months, participants were discharged back to the 
care of their General Practitioner. Participants requiring ongoing ophthalmic care 
continued to be followed up under their admitting consultant.   
 
 Randomisation 2.4.4.5
 
Upon enrolment into the trial, patients were randomised to either the adjunct group 
or control group from a non-stratified pre-randomised list of 40 study IDs held by the 
trials pharmacist. Participants were allocated to the lowest unused study ID. Out of 
hours (i.e. weekends and bank holidays), the next study ID in sequence was kept in a 
sealed envelope in a secure location on site when access to the trials pharmacist was 
limited.  
 
 Masking 2.4.4.6
 
This was a single masked study to the participants. Although the pre-operative and 
post-operative regimens differed, participants were not informed to which group 
they had been allocated. It was not possible to mask the investigator, as the primary 
IMP, intravitreal triamcinolone, can sometimes be visible on posterior chamber 
assessment. The operating surgeon was masked to the randomization of the 
participant, until the end of the procedure, to avoid any bias regarding surgical 
management.  
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 Outcome Measures 2.4.4.7
2.4.4.7.1 Primary Outcome Measure 
 
The primary outcome measure was anatomic reapposition of the remaining retina to 
the retinal pigment epithelium in the absence of an internal tamponade agent at 6 
months post primary vitrectomy surgery 
2.4.4.7.2 Secondary Outcome Measures 
 
Analysis of the following secondary outcomes at 6 months post primary vitrectomy 
surgery were performed:  
i. Best Corrected Visual acuity using (ETDRS Chart) 
ii. Number of procedures required to achieve retinal reattachment 
iii. Presence and grade of postoperative PVR [16] 
iv. Proportion of patients with persistent submacular fluid found by Optical 
Coherence Tomography in the presence of retinal reattachment.  
v. recruitment rate 
vi. retention rate  
vii. case mix of ocular trauma  
 
 Adverse Events and Safety Reporting 2.4.4.8
 
Safety reporting adhered to the sponsor’s standard operating procedures and means 
were in place to monitor, record and report adverse events in line with the MHRA 
guidelines.  An external Data Monitoring Committee was established and agreed to 
adhere to a trial-specific charter. They were scheduled to meet six to twelve monthly 
or on ad hoc basis with a remit of monitoring the safety of the trial participants.  
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Adverse events (AE) were recorded and classified in terms of severity, causality and 
seriousness. Expected adverse event included: cataract, raised intraocular pressure, 
hypotony, sterile hypopyon, retinal detachment, uveitis and further surgery.  
Unexpected adverse events included endophthalmitis and systemic illness. 
 
 Trial Size and duration 2.4.4.9
 
A power calculation to determine sample size was not performed as it was not 
required to meet the study objectives.  A total of 40 patients was deemed a feasible 
number over the study period and expected to provide sufficient data to power a 
definitive study. 
An internal audit of the incidence of open globe trauma at the study site provided 
data estimating an expected recruitment rate of 2.2 cases per month. This projected 
that the required recruitment target would be achieved within 18 months and 
completion of the trial within 24 months.  
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 Statistical Analysis 2.4.4.10
  
The statistical analysis plan was written in advance of the data analysis in conjunction 
with the trial statistician and was approved by the Trial Steering Committee and the 
Data Monitoring Committee. Data analysis adhered to the CONSORT guidelines for 
randomized controlled trials. The time taken to recruit patients is reported together 
with the number of patients who failed to provide outcome data.  Baseline 
characteristics of the two groups were compared to assess the adequacy of 
randomization.   
 
2.4.4.10.1 Primary Endpoint Analysis 
 
An odds ratio of patients in whom anatomical retinal attachment remained at 6 
months post primary vitrectomy between the 2 treatment groups was reported with 
95% confidence intervals. Since power is low, it must be acknowledged that this 
treatment effect may be imprecise.  
 
2.4.4.10.2 Secondary Endpoint analysis 
 
Secondary endpoint analyses comprised summary statistics for secondary outcomes 
by treatment group. 
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 Results 2.4.5
 Recruitment 2.4.5.1
 
The trial opened for recruitment on 12th September 2011 and the first patient was 
recruited on 22nd September 2011. The final patient was recruited on 3rd June 2013. 
During the first six months, the actual recruitment rate was well ahead of the 
projected target, but was followed by a marked plateau for a near equivalent period. 
The study completed recruitment approximately 10 weeks behind schedule. There did 
not appear to be a seasonal variation in available cases, and a retrospective review 
revealed one missed eligible case within the first six months and four missed eligible 
cases in the penultimate month. 
Figure 2.4:  Recruitment Line Graph  
 
 
 
 
 
 
 
 
 
Figure 2.4 demonstrates that, initially, recruitment rates were well ahead if 
target. However, owing to a four month plateau occurring in the mid study 
period, recruitment was completed 10 weeks behind the projected 
completion. Missed eligible cases in the final two months contributed to the 
delay in recruitment.  
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 Study Consort Flow Diagram 2.4.5.2
 
Figure 2.5 displays the consort flow diagram. Forty five patients suffering open globe 
injuries were identified as proceeding to pars plana vitrectomy surgery and screened 
for eligibility. One patient elected not to proceed with secondary vitrectomy surgery 
and four patients were ineligible due to pre-existing glaucoma (n=2) and aged over 
eighty years old (n=2). The remaining forty eligible patients elected to participate in 
the trial and were recruited within 21 months of the study commencing. There was a 
high enrolment rate (100%) once screened as eligible. This compares favourably to 
previously published studies where the median reported rate of enrolment was 90% 
[198].  
All patients in the adjunct group received their allocated intraocular, periocular and 
topical treatment as outlined in the treatment protocol. Oral flurbiprofen was 
omitted from the postoperative regimen in three out of the twenty patients in the 
adjunct group (15%) owing to medical contraindications to its use. This was in 
accordance with the study protocol. 
 Participant Retention 2.4.5.3
 
Thirty eight of the forty participants were retained in the study until the primary and 
secondary outcome assessment time-point at six months. One patient in the control 
group failed to attend for follow up visits after the 4-6 week assessment and was 
therefore excluded from the final analysis. One patient in the adjunct group attended 
for an additional visit at 4 months and was then subsequently lost to follow up. Their 
clinical condition was deemed stable and likely representative of the findings at 6 
months, and therefore, data collected at this time-point were used to populate the 6 
month visit CRF.  
Our study therefore achieved a 95% (38 out of 40) overall participant retention rate 
which compares favourably to reported rates of surgical clinical trials.[198]. This is an 
important finding in relation to designing the larger definitive RCT.  
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Figure 2.5:  AOT Trial Consort Flow Diagram 
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 Baseline Characteristics 2.4.5.4
 
Baseline demographics are summarized in Table 2.3 showing comparable mean age, 
gender and ethnicity. As expected and in keeping with previous reports [169, 172], 
there is a male preponderance.    
Table 2.3:  Baseline Demographic Characteristics 
  Adjunct Group (N=20) Control Group (N=20) 
Number of Patients 
(Eyes) 
20 20 
Male/Female 18/2 16/4 
Mean Age (yrs) 44 37 
Ethnicity: 
White 
Black 
Asian 
 
18 
1 
1 
 
14 
3 
3 
 
 
Ocular injury types according to the BETTS classification [175] were similar across the 
two groups, although there were two perforating injuries in the adjunct group, with 
none in the control group.  The incidence of IOFB injury was also higher in the 
adjunct group. (Table 2.4) 
Table 2.4:  Ocular Injury Classification 
  Adjunct Group (N=20) Control Group (N=20) 
Injury, col(%): 
 
Rupture 
Penetrating injury 
Perforating Injury 
IOFB 
                       
 
 5(25) 
7(35) 
2(10) 
6 (30) 
 
 
7(35) 
12(60) 
0 
1(3.3) 
Location of wound 
 
Corneal 
Scleral 
Corneal & Scleral 
 
 
4(20) 
8(40) 
8(40) 
 
 
6(30) 
8(40) 
6(30) 
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A relative afferent pupillary defect was present in 8 out of 20 patients (40%) in the adjunct 
group compared to 9 out of 20 (45%) in the control group. A clear crystalline lens was 
documented in only 7 patients (3 in the adjunct group and 4 in the control group). Over half 
of patients (21 of 40) showed signs of lens opacity and one quarter (25%) were rendered 
aphakic by the initial injury. Lens opacity and aphakia was comparable between the two 
groups at baseline.   Intraocular haemorrhage in the anterior segment was also relatively 
equally distributed, as a microscopic hyphaema was recorded in 7 out of 10 adjunct patients 
compared to 10 out of 20 patients in the control group. Severe anterior chamber 
haemorrhage (>25% hyphaema) was documented at baseline in 3 patients in the adjunct 
group and 4 in the control group.  
 
Table 2.5: Baseline Ocular Characteristics; anterior segment 
 Adjunct (N=20) Standard(N=20) 
Laterality (Left eye), col% 7(35) 12(60) 
RAPD  positive, col% 8(40) 9(45) 
VA, median(IQR) ETDRS  0(0-0) 0(0-0) 
IOP (mmHg), Median(IQR) 12(8-16) 11(5.5-15) 
Refraction, Median(IQR) 0(0-0) 0(0-0) 
Hyphaema, col(%) 
None 
Microscopic 
Organised 
 
7(35) 
7(35) 
6(30) 
 
4(20) 
10(50) 
6(30) 
Lens Status, col% 
Clear 
Cataract 
Aphakic 
Not possible 
 
3(15) 
12(60) 
5(25) 
0 
 
4(20) 
9(45) 
5(25) 
2(10) 
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Considering posterior segment characteristics at baseline, vitreous haemorrhage was 
universally present. This is unsurprising, as our cohort comprises eyes undergoing 
pars plana vitrectomy following an open globe injury. They are therefore subject to 
selection bias towards posterior segment pathology (i.e. vitreous haemorrhage or 
RD) by their inclusion in this study.  
 
Retinal detachment was present in 10 out 20 patients in the adjunct group and 11 
out of 20 in the control group (Table 2.6). Duration of RD was also similar between 
the two groups.  
 
Proliferative vitreoretinopathy (PVR) status was deemed to be more accurately 
assessed at the time of vitrectomy surgery, rather than at the slit-lamp baseline 
assessment. An intraoperative assessment is therefore not limited by media opacity 
and also controls for the potential 2 week time lag between slit-lamp biomicroscopic 
assessment and operative intervention. PVR of any grade was present at the time of 
the study vitrectomy in 7 patients in total (2 in the adjunct group and 5 in the control 
group). The presence of established PVR (Grade C) was present in both patients in 
the adjunct group and 4 out of the 5 patients in the control group. (Table 2.6) 
 
The median Birmingham Ocular Trauma Score was comparable across both groups 
and was calculated to be 53 (IQR 37-70) in the control group compared to 49 (IQR 43-
70) in the adjunct group.   
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Table 2.6:  Ocular Baseline Characteristics; posterior segment 
 Adjunct (N=20) Standard(N=20) 
Vitreous Haemorrhage, col% 
+ 
++ 
+++ 
NP 
 
2(10) 
12(60) 
3(15) 
3(15) 
 
3(15) 
8(40) 
3(15) 
6(30) 
Retinal detachment, col% 10(50) 11(55) 
Tractional RD, col% 2(10) 2(10) 
Duration of RD (median) IQR 15.5(8-21) 10(6-19) 
Macula Attached 0 0 
PVR Grade: 
B 
C 
 
0 
2(10) 
 
1(5) 
4(20) 
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 Surgical Techniques 2.4.5.5
 
The operative techniques during the primary study vitrectomy were comparable 
between the two groups (Table 2.7). Silicone oil was chosen as the primary tamponade 
agent in approximately one half of eyes in both groups. Eight eyes in both groups 
required surgical induction of a posterior vitreous detachment (PVD).  
 
Table 2.7:  Operative Techniques 
 Adjunct (n= 20) Control (n=19) 
Retinopexy  
Endolaser only 
Cryotherapy 
Cryotherapy and Endolaser 
None 
 
6 (30) 
4(20) 
7(35) 
3(15) 
 
5(26.3) 
2(15.8) 
8 (42.1) 
3(15.8) 
Intraocular tamponade 
SF6 
C3F8 
Oil (1000 cs) 
Oil (5000 cs) 
None 
 
3(15) 
1(5) 
11(55) 
0 
5(25) 
 
3(15.8) 
1(5.3) 
7(36.8) 
4(21.1) 
4(21.1) 
Additional Procedure 
Lensectomy 
Heavy Liquid 
Membrane Peel 
Drainage Retinotomy 
Posterior Vitreous Detachment 
Induction 
 
10(50) 
9(45) 
2(10) 
2(10) 
8(40) 
 
6(31.6) 
10(52.6) 
4(21.1) 
1(5.3) 
8(42.1) 
 
SF6 = Sulphur Hexafluride, C3F8 = perfluoropropane , cs = centistoke, PVD = posterior vitreous 
detachment (*Note that some patients had more than 1 procedure) 
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 Primary Outcome Measure 2.4.5.6
 
As previously mentioned, primary outcome data were available for 39 out of 40 
patients as one patient in the control group was lost to follow up after the 4-6 week 
visit.  
There was no observed difference in primary outcome between groups: 50% (n=10 of 
20) achieved anatomical success without internal tamponade at 6 months in the 
adjunct group, compared to 47.4% (n=9 of 19) in the control group, Odds Ratio 1.11, 
95% Confidence interval 0.316-3.904. (Table 2.8) 
Table 2.8:  Primary outcome result All patients Adjunct (N=20) Standard (N=19) Odds ratio(95%CI) Adjunct compare to standard Success 10 9  1.11(0.316-3.904) Failure 10 10 
Excluding early withdrawals Success 10 9  0.78(0.208-2.913) Failure 10 7 
 
The findings were unaffected by excluding early withdrawals.  
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 Visual Acuity 2.4.5.7
 
Considering visual acuity at six months following study vitrectomy: final median visual acuity 
was 31 ETDRS letters (IQR 12.6 - 47.5) in the adjunct group compared to 25 letters (IQR 0-65) 
in the control group. Three patients (15%) in the adjunct group could read no letters on the 
ETDRS chart at 6 months compared to eight patients (42.1%) in the control. Five patients in 
the control group read at least 55 letters compared to three patients who had received the 
adjunctive regimen (Table 2.9).   16 patients in the adjunct group (80%) gained at 10 letters 
or more compared to 10 patients (52.6%) in the control group.  
 
Table 2.9:  Final Visual Acuity and Change from Baseline 
 
VA at 6 months Adjunct(N=20) Control (N=19) 
0 Letters (%) 3(15) 8(42.1) 
≥ 55 Letters (%) 3(15) 5(26.3) 
VA change from baseline   
Gain 10 Letters (%) 16 (80) 10 (52.6) 
Gain 20 Letters (%) 13(65) 10(52.6) 
Gain 30 letters (%)  10(50) 8(42.1) 
Gain 40 Letters (%) 9(45) 6 (31.6) 
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Figure 2.6:  Box plot of Visual Acuity in ETDRS letters 
The visual acuity box plot (Figure 2.6) demonstrates that the median 
vision in the adjunct group initially lagged behind that in the control group 
at Day 10 but subsequently exceeded it by month 6. The proportion of 
patients with visual improvement in terms of number of letters gained is 
documented in table 4 with a greater proportion gaining 10, 20, 30 and 40 
ETDRS letters in the adjunct group compared to the control group. 
(central bar = median, box = interquartile range, whiskers =range)   
 
 
 
 
 
 
109 
 
 
 
 Number of operative procedures 2.4.5.8
 
There was no observed difference in the number of operations to achieve success (as 
defined in the primary outcome measure) with seven patients in each groups 
achieving success with a single operation, two patients in each group requiring two 
operations and one patient in the adjunct group undergoing three procedures to 
achieve stable reattachment at 6 months.  
 Persistent Subretinal Fluid 2.4.5.9
 
At 6 months, on OCT assessment, only one patient (standard group) was found to have 
persistent submacular fluid in the presence of an attached retina. 
 
 Prevalence of PVR 2.4.5.10
 
Table 2.10 highlights the prevalence of PVR Grade C at each time point, demonstrating 
a higher prevalence in the control group at day 10, week 4-6 and month 3. At 6 
months the prevalence of PVR becomes comparable (35% adjunct groups vs 26.3% 
control group).  
Table 2.10: Prevalence of PVR by time-point 
Timepoint  Adjunct(N=20) Control (N=19) 
Baseline 2(10%) 4(21%) 
Day 10 0 6(31.6) 
4-6 Weeks 2(10) 5(27.8) 
Month 3 3(15.8) 6(31.6) 
Month 6 7(35) 5(26.3) 
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 Missed Visits 2.4.5.11
 
Each trial patient was scheduled to attend for four postoperative study visits which 
corresponded to data entry points. There were only seven missed study visits 
throughout the trial, five of which relate to the two patients who were lost to follow 
up.  
  
 Adverse Events (AE)  2.4.5.12
 
There were a total of 97 adverse events (AE) throughout the study with 59 occurring 
in the adjunct group compared to 38 in the control group (Table 2.11). However, the 
proportion of patients suffering at least one AE was 90% (18 out of 20) in the adjunct 
groups compared to 80% 16 of 20 control patients.  There were no serious adverse 
reactions observed in either group. One serious adverse event occurred in one 
patient in the adjunct group which was not related to the IMP.  
The most frequently occurring AE in both groups was elevated IOP (>25mmHg), with 
15 episodes in the adjunct group compared to 11 in the standard group. A slightly 
higher proportion of patients in the adjunct group (n=7, (35%) suffered at least one 
episode of elevated IOP compared to five (25%) patients in the control group.   Figure 
2.7 demonstrates the box plot for IOP comparison by treatment group. There were 
more cases of postoperative uveitis in the control group (n=5) in comparison to the 
adjunct group (n=2). An equal number of patients (n=5) suffered at least one episode 
of hypotony (IOP <6mmHg) during the trial. There were no cases of postoperative 
endophthalmitis in either group.  
There were more single episodes of retinal detachment in the adjunct group 
compared to the control group (16 vs 8). However, multiple episodes occurred in a 
small number of patients (4 episodes in one patient and two episodes in two 
patients) in the adjunct group.  
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Table 2.11: Adverse Events by Treatment Allocation 
 Adjunct (N=20) Control (N=20) 
Raised IOP 15 11 
Retinal detachment 16 8 
Uveitis 2 5 
Further Surgery 15 6 
Hypotony 5 2 
Other ocular 1 2 
Rash/allergy/trauma 3 2 
Other Systemic Illness 2 2 
Total AE 59 38 
 
Figure 2.7: Box plot of Intraocular Pressure Variation over Time 
Figure 2.7 demonstrates the median IOP by treatment group over time. 
The greatest difference was observed at Day 10 post vitrectomy where 
median IOP was higher in the adjunct group (central white bars = median 
IOP, boxes = interquartile range, whiskers = range). 
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 Discussion 2.4.6
 
To date, there have been no prospective randomised controlled clinical trials in this 
disease group or patient population. The primary aim of this pilot study was to 
determine the feasibility of the conducting such a trial with a view to provide data to 
power a definitive RCT.  
 Recruitment and Retention  2.4.6.1
 
The study was projected to run for 24 months consisting of an 18 month recruitment 
period and 6 month final patient final follow up. We were able to recruit all 40 
participants within 21 months with a favourable eligibility to enrolment ratio of 
100%.   This in part may be attributable to the pragmatic design of the trial as follow-
up schedules and data entry points mirrored standard care. Furthermore, the natural 
history of both surgical and visual outcome is poor [180] in this disease group, and 
thus participants were eager to enrol, frequently adopting a ‘little to lose’ attitude, 
particularly given the well documented and tolerable side effect profiles of the IMPs. 
Participant retention rate was also favourable, losing only one patient to follow-up 
after their 4-6 week visit. This retention rate was higher than expected, with previous 
surgical trials at the study site reporting a 3-5% loss to follow up rate [11, 97, 98].  
 
 Anatomical Outcome  2.4.6.2
 
We observed no difference in anatomical outcome at 6 months with an approximate 
50% success rate in both groups. Similarly we did not observe a difference in the 
number of operations to achieve success. This is the first study to prospectively 
report anatomical success rates at 6 months in this disease group. Sheng et al 
retrospectively reviewed 90 eyes in elderly patients sustaining OGI [199]. 14 of 15 
eyes undergoing secondary PPV with silicone oil for RD achieved anatomical success. 
However, anatomical success included eyes with an intraocular tamponade in situ, 
and thus it is difficult to draw direct and meaningful comparisons. Taking our cohort 
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as a whole, we found 19 out of 39 patients (48.7%) undergoing vitrectomy surgery 
after open globe trauma maintained retinal attachment in the absence of internal 
tamponade at 6 months, with 14 out of 39 (35.9%) achieving primary anatomical 
success.  
Interestingly, the prevalence of postoperative PVR was higher at each time point up 
to month three in our control group. This could simply be reflective of a higher 
incidence of PVR at baseline in the control group (i.e. 5 patients in the control group 
compared to 2 patients in the adjunct group) , but could also be an indication of a 
trend towards a treatment effect of the IMP.  The prevalence of PVR at month six 
becomes comparable in both groups. Triamcinolone acetonide when administered as 
a 4mg/0.1ml Intravitreal injection has been shown to have a duration of effect of 
between 2 and 4 months[200]. It is possible that the postoperative vitreoretinal 
scarring response was delayed by the IMP administration, followed by resumption in 
proliferative activity with falling concentrations of corticosteroid after its clearance. 
In a rabbit model of two groups of 42 eyes, Chin et al [201] describe a reduced half-
life of triamcinolone in eyes which had previously undergone vitrectomy compared 
to non-vitrectomised eyes. Beer et al demonstrated this clinically, and noted 
increased clearance of a single IVTA injection upon aqueous sampling [196]. Spitzer 
et al describe findings of an in vitro study comparing modes of administration of 
Kenalog in an experimental oil-filled environment [202]. They suggested a depot 
effect of pre-mixing the corticosteroid with oil prior to injection compared to a single 
intra-oil administration. They also describe a potential toxic effect in the pre-retinal 
retro-oil sump of fluid. Due to the pragmatic design of our study we did not elect to 
premix the triamcinolone preparation. We did not observe any local toxic effects, 
although no formal electrodiagnostic tests were performed. Furthermore, a 
collection of corticosteroid in this retro oil fluid may in fact be the preferred 
distribution of any therapeutic agent targeting the PVR response.  Asaria et al [203]  
reported that silicone oil concentrates fibrogenic factors bFGF and Il-6 in this 
location.  
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 Casemix of Ocular Injuries 2.4.6.3
 
As expected, the nature and severity of the ocular injuries sustained varied markedly 
within the groups but fortunately not between the two groups. The median 
Birmingham Ocular Trauma Score [177] was 53 (IQR 37-70) in the control group 
compared to 49 (IQR 43-70) in the adjunct group. Given the sample size we accept 
that the sensitivity to detecting small differences between the groups is limited, 
which may be further confounded by the heterogeneity of the casemix. However, the 
adequacy of randomisation and comparison of characteristics at baseline showed no 
significant difference in covariates affecting outcome. 
 
 Visual Outcomes  2.4.6.4
 
The visual and anatomical outcome of eyes undergoing vitreoretinal surgery 
following open globe trauma remains poor. The largest retrospective review to date 
was by Andreoli et al. They reported outcomes of 848 eyes suffering open globe 
trauma, in which 245 (29%) eyes required vitreoretinal surgery. Despite comparable 
median baseline visual acuities of hand motions, the reported median final visual 
acuity was only 20/400 in those eyes requiring vitreoretinal surgery compared to 
20/40 in those that did not [180].  In our cohort, the median final visual acuities at 6 
months were 31 ETDRS letters (20/250) and 25 ETDRS letters (20/320) in the adjunct 
and control group, respectively. When considering improvement from baseline as 
displayed in Table 2.9, where 80% (n=16) gained 10 or more ETDRS letters compared 
to only 52% (n=10) in the control group, this difference becomes more clear.  We 
also noted fewer patients with very poor visual outcomes (Zero ETDRS letters) in the 
adjunct group compared to controls (15.0% vs 42.1%).  As this is an exploratory pilot 
study statistical comparisons have not been made, nonetheless the trend is 
interesting.   Covariates which could affect visual outcome such as severity of PVR, 
number of foveal-off detachments and the use of silicone oil were comparable 
between the two groups. 
115 
 
 
 
Additional clinical factors may affect visual outcome at 6 months. Although the 
presence of cataract at the final assessment was comparable between both groups, 
visually significant corneal scarring in those patients with injuries involving zone 1, 
was not included in the dataset at the final clinical assessment. Its presence in 
disproportionate numbers in either group could have either exaggerated or 
mitigated against any observed treatment effect.  Likewise, pre-existing ocular 
comorbidity (e.g. amblyopia or macula pathology) may also affect final visual 
outcome and should be recorded and adjusted for accordingly in future studies 
where vision is investigated as the primary outcome measure.  
 
 Adverse Events 2.4.6.5
 
As expected, the adverse event (AE) occurring most frequently in the adjunct group 
was elevated IOP, and accounts for a large number of the total AEs. Interestingly, this 
was the also the most common AE in the control group as well. A detailed review of 
corticosteroid related IOP rise will be discussed further in Chapter 3. Absolute AE 
numbers must be interpreted with caution as this gives limited information on AE 
occurrence in terms of proportion of patients with a particular AE.  
This is important when interpreting the AE data on retinal detachments. Prima facie 
review of the number of RDs may alarm the reader to note twice as many in the 
adjunct group (n= 16) compared to the control group (n=8). However, repeated events 
occurring in single patients may explain this disproportionate finding. Furthermore, 
one patient in the control group was lost at an early stage in the trial (after week four) 
and one patient did not undergo vitrectomy surgery, thereby reducing the overall ‘risk 
of exposure’ to this event.  
We did not observe any clear evidence of toxicity of triamcinolone although it is 
possible that the effects were masked in the context of the complex postoperative 
appearance in this patient demographic.  Concerns regarding the toxicity of IVTA and 
secondary endophthalmitis have been reported by numerous authors (summarized 
in [204])  and the preservative benzyl alcohol in Kenalog®  has been implicated in its 
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aetiology. However conclusions have commonly been drawn using higher doses in 
experimental studies of cultured RPE cells.  Oliveria et al compared Kenalog® to an 
unpreserved preparation of triamcinolone in rabbit eyes and  found higher mean 
vitreous concentrations  but without evidence of toxicity on electrophysiological and 
histological analysis [205].  
 
 Limitations 2.4.6.6
 
The study is limited as it is single masked and some of the outcome assessments are 
subjective. However, efforts were made to reduce investigator bias by:  1) masking the 
operating surgeon to the treatment allocation until the end of the surgical procedure  
and 2) being  explicit in definitions of clinical findings and adverse events  and defining 
rigid management protocols e.g. for IOP rise. An independent assessor of the primary 
outcome measure at 6 months was considered, but it was felt that there was 
insufficient evidence to suggest this to be necessary and added additional cost to a 
pragmatic exploratory pilot study.  Furthermore the numbers are small and so 
estimates of treatment effect may be imprecise.  
 
 Summary 2.4.7
 
This is the first randomised controlled clinical trial in this patient demographic and 
demonstrates that a prospective randomised controlled clinical trial in this disease 
group is feasible. Recruitment and retention rates are realistic. The use of intravitreal 
triamcinolone as a pharmacological adjunct at the time of primary vitrectomy 
following open globe trauma is safe and suggested a trend towards a better visual 
outcome in our cohort. An adequately powered definitive RCT is justified and the 
findings of this pilot study suggests that replacing an anatomical primary outcome in  
with visual outcome is a potential method of designing vitreoretinal surgical trials.  
The results of this study were recently published in the British Journal of 
Ophthalmology [206].  
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 Future and Ongoing work 2.4.8
 
 Public and patient involvement 2.4.8.1
 
INVOLVE is a national advisory group which was first established in 1996 and is funded 
by the National Institute for Health Research (NIHR). Its role is to support active public 
involvement in NHS, public health and social care research. It seeks to maximise 
opportunities for public involvement in research and to ensure that researchers, 
research commissioners, research funders and the public have access to the support 
and guidance that they need. 
 
In March 2012, it published a three year strategy plan in which it highlighted four key 
objectives [4]: 
x to lead on public involvement across the National Institute for Health Research 
by encouraging and facilitating a coordinated approach for promoting and 
developing involvement in NHS, public health and social care research 
x to build and share the evidence base  
x to develop capacity and capability for public involvement in research 
x to influence research policy and practice 
 
 
The Adjunct in Ocular Trauma trial met its research objectives. It confirmed that a 
randomized controlled clinical trial was feasible in patients suffering open globe 
trauma and it generated a robust outcome data set.   
Despite no obvious difference in anatomical outcomes, we observed an interesting 
trend towards a positive treatment effect in terms of improvement in vision from 
baseline.  
We met with patients who had participated in the trial to involve them in the design of 
the definitive large scale RCT. We asked whether they felt that vision or anatomical 
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success should be investigated as the primary outcome. There was unanimous 
agreement that vision was the more appropriate. 
In collaboration with the affiliated Clinical Trials Unit at Kings College London, we were 
able to secure a research grant from the National Institute of Health Research (NIHR) 
via the Health Technology Assessment (HTA) funding stream to fund the definitive 
large scale RCT ;  the Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Trial.   
 
 
 PPI in development of ASCOT  2.4.8.2
 
One patient who had exited the study reviewed the study protocol submission and 
contributed extensively to its design. This patient was a retired physician and clinical 
trialist whose professional remit included the review of study protocols and his input 
from both a professional and patient’s perspective was valued greatly.  
The AOT pilot study had a lay person who sat on the trial steering committee and 
agreed in principle to sit on the steering committee. She reviewed the participant 
information leaflet to help ensure its clarity and accessibility to the lay person. 
Patient input greatly contributed towards the decision to change the primary outcome 
measure to a measure of visual acuity, as it was unanimously considered to be most 
important to them. 
 
Patients were asked to rate the severity of their injury in terms of impact on their life. 
Five patients attending follow up were asked to rate their eye injury and compare it to 
either an illness or another bodily injury. All patients rated their eye injury as more 
severe than a recoverable life threatening illness such as cancer. Three patients 
equated their injury to loss of a digit or limb, whilst one rated their eye injury to be 
more severe.   
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The majority of patients who suffer an open globe injury are healthy males from the 
working population [169]. The research team asked the patients in the current pilot 
who were in full time employment to estimate the number of days they have taken off 
work as a result of their eye injury. We obtained data from 18 of 20 working patients 
and found that the median length of time away from employment was 60 days with a 
range between 7 and 330 days.   
 
 Lessons learned from pilot and modifications to definitive trial 2.4.8.3
 
As discussed in section 2.4.8.1, a greater emphasis has been placed on PPI during 
protocol and project development of the ASCOT study. This has resulted in a shift of 
focus away from investigating anatomical success as a primary outcome, and 
concentrated on vision. Furthermore, we have collaborated with the Health Economics 
Department at Bangor University and included quality of life parameters in the 
secondary outcome measures of the definitive study. 
 
Figure 2.5 (AOT consort) confirms that all participants randomised to receive 
adjunctive therapy received the primary IMP, triamcinolone, but that flurbiprofen was 
omitted in 3 out of 20 patients (15%). We therefore agreed to omit flurbiprofen from 
the adjunctive regimen in the ASCOT study. We have also simplified the pre and 
postoperative topical regimen to reflect standard care in both groups. 
The lessons learned regarding safety reporting are detailed further in Chapter 3 where 
their relevance sits more naturally in the discussion regarding the competent authority 
sponsor inspection. Adverse events occurred uniformly across both groups without 
evidence of serious adverse reaction.  We have therefore adopted a risk-adapted 
approach to the ASCOT study and modified our safety reporting to reflect this. This 
aims to deliver a pragmatic trial, reflective of clinical practice in a multicentre trial 
setting. A brief overview of the ASCOT trial is herein described.  
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 Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Trial.   2.4.8.4
 
The ASCOT trial is a phase 3 prospective, multi-centre double-masked randomised 
controlled trial in eyes undergoing vitreoretinal surgery for open globe trauma. It aims 
to compare the effect of using adjunctive intraocular and periocular steroid 
(triamcinolone acetonide) versus standard treatment in this disease group.  There are 
26 study sites of varying size throughout the U.K. The primary study site is based at 
Moorfields Eye Hospital NHS Foundation Trust of which I have been appointed as site 
Principal Investigator (PI).  
 
The trial incorporates a two-stage internal pilot study to verify recruitment and 
retention rates. In total 300 patients will be recruited and randomly allocated to two 
treatment arms.   Both groups will receive standard surgical treatment and routine 
preoperative and postoperative treatment and care. The treatment arm will receive 
additional preoperative steroid combination (triamcinolone acetonide) consisting of 
4mg/0.1ml into the vitreous cavity and 40mg/1ml subtenons. The additional IMPS 
(flurbiprofen and Guttae Prednisolone) included in the AOT trial have been omitted in 
the ASCOT study.  Participants and primary outcome assessors will be masked to 
treatment allocation. In keeping the pragmatic study design it aims to mirror standard 
NHS care and thus postoperative examinations will not differ from the schedule 
followed for vitreoretinal cases and participants will be followed up for 6 months post-
surgery. The primary outcome will be corrected visual acuity measured in ETDRS letter 
score at 6 months.  Removal of silicone oil, when used, (combined with cataract 
extraction + IOL implantation when applicable) will be planned for 3-5 months 
following study vitrectomy surgery.  
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2.4.8.4.1 Sample size calculation and primary outcome choice 
 
Aside from study feasibility, a key aim of the AOT trial was to provide data to power 
the definitive study. I have therefore chosen to include a section on this in this thesis. 
It must be acknowledged that the calculations were performed primarily by Victoria 
Cornelius and Jessica Lo from the medical statistics department at Kings CTU.  I was, 
however, involved in the choice of statistical method and acquisition of published data 
in order to complete the process. A summary is herein included: 
Whilst the AOT trial investigated an anatomical primary outcome, we chose to replace 
this with a primary outcome of visual acuity. As discussed above, this was influenced 
by patient involvement during protocol development, in addition to directives initiated 
by the funding body, the NIHR. 
Published data indicate that at six months, the distribution of best corrected visual 
acuity (BCVA) using the ETDRS letter score will be skewed in this patient population 
[180]. This is in line with results from the AOT pilot which confirms that the majority of 
participants had a baseline visual acuity of zero (35/40). Additionally, the shape of the 
distribution of VA at six month differs between the active and control arm.  Both of 
these factors impact the choice of suitable methods for analysis and thus an 
appropriate approach to calculate the sample size.  
The mean difference observed in VA between arms in the AOT study was 3.1 (32.9 – 
29.8) with a pooled standard deviation of 28.9. This summary statistic which showed a 
small average difference between arms may not have fully reflected the true benefit 
that participants received. Sixteen of 20 patients (80%)   versus 11 (55%) gained a 
meaningful improvement in VA of 10 letters or more in the active versus control group, 
respectively (Refer to Table 2.9). It was therefore thought to be important to assess 
both the mean change and the difference in proportion of participants with a clinically 
meaningful difference in outcome between arms. As a consequence a dual approach 
to evaluating the primary outcome was taken as recommended by Peacock et al [207]. 
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The two cut-offs for statistical significance are each set at 2.5% to provide a test of the 
composite null hypothesis that the active treatment is no different from control with 
overall significance of 5% If either the mean difference or the difference in proportions 
is significant using this cut-off, the composite hypothesis is rejected and it is concluded 
that the active treatment is superior to control. With 140 per group and using the cut-
off for significance of 2.5% we will have 90% power to detect a 20% increase (55% to 
75%) in participants who have a meaningful minimum improvement in VA of at least 
10. Similarly, with 140 per group and using a 2.5% significance level we would also be 
able to detect a mean difference of 10 letters with 80% power assuming a standard 
deviation of 28.  
Previous trials run at the primary study site and involving tertiary teaching hospitals 
maintained a  >95% participant retention rate at six month follow up which was 
confirmed in the AOT trial  [11, 97, 98, 206]). As this is a multi-centre trial including 
non-specialist centres a lower retention rate may be anticipated. Therefore allowing 
for a 7% dropout rate we will aim to recruit 300 participants to the trial.  
A change of 10 letters is widely accepted to be a clinically meaningful in research 
studies of eye disease [11, 73, 77, 78, 97, 98, 110, 146, 147, 208].  
 
2.4.8.4.2 ASCOT Study Status 
 
At the time of submission of this thesis 21 of 26 sites have gained R and D approval, 
with 20 sites granted green-light status and open for recruitment. The primary study 
site at Moorfields Eye Hospital opened for recruitment in December 2014. Projected 
recruitment rates based on the findings of the AOT trial, estimated recruiting three 
patients per two month period.  
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3 Slow-release dexamethasone preparation in the 
clinical management of eyes with proliferative 
vitreoretinopathy 
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3.1 Background 
 
As previously outlined in Chapter 1, proliferative vitreoretinopathy (PVR) is the most 
common cause of late anatomic failure in retinal detachment surgery and is generally 
regarded as having an incidence of 5-11% of all rhegmatogenous retinal 
detachments[12].  PVR may be considered a maladapted wound healing response in 
specialised tissue. The formation and contraction of fibrocellular membranes on both 
retinal surfaces and posterior hyaloid face can distort normal retinal architecture with 
visually detrimental sequelae.  
PVR represents a difficult vitreoretinal surgical challenge and despite the 
improvements instrumentation and technique, surgical failure is common. Multiple 
procedures are frequently required to eventually achieve final retinal attachment with 
poor visual results and unsatisfactory binocular visual outcomes [13, 54, 208]. 
Additionally,  PVR management is costly in patient time and healthcare resources 
[208]. 
Numerous adjunctive medications have been previously trialled clinically [11, 95, 97, 
98, 110, 121, 138, 209], yet no effective and safe adjunct has gained widespread 
acceptance to improve surgical and visual outcomes. There is a clear need to develop 
further strategies to improve the outcome in eyes with PVR. A prospective randomised 
controlled clinical trial investigating the proposed benefit of a novel pharmacological 
adjunct is justified. 
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 Rationale 3.1.1
 
The scientific rationale behind the use of corticosteroids in this disease process has 
already been outlined in Chapter 1. . Both preclinical and clinical evidence have been 
so far described.  Further elaboration will now follow rationalising the choice of 
pharmacological adjunct which was adopted in this large prospective clinical trial. The 
duration of action of triamcinolone acetonide may be reduced in vitrectomised eyes, 
and may offer an explanation as to why it has not emerged as a definitive adjunct.  
The adoption of a longer acting sustained-release preparation may offer additional 
advantages.  
Dexamethasone has a potency which is five times greater than triamcinolone [210] , 
and being more hydrophilic, allows for higher vitreous concentrations [211].  
However, its clinical utility had previously been limited by its short half-life of three 
hours [212] and therefore prompted the development of a slow release drug delivery 
system.  
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 Investigational Medicinal Product 3.1.2
 
Ozurdex® is a biodegradable intravitreal implant containing 700 micrograms of 
unpreserved dexamethasone in a slow-release preparation. The implant itself is 
approximately 6mm in length and 0.46mm in diameter, contained in a disposable 
injection applicator. The implant is made of a solid biodegradable polymer (Novadur™, 
Allergan, Irvine, CA, USA). The byproducts of its degradation are glycolic acid and lactic 
acid, which are subsequently converted to carbon dioxide and water [210].  It has 
emerged as an alternative therapeutic agent to triamcinolone acetonide and first 
obtained a market authorization for ophthalmic use in 2010.  
 
Figure 3.1:  Slow-release dexamethasone (Ozurdex) 
 
Figure 3.1:  Slow-release dexamethasone (Ozurdex) , the rod-shaped 
implant is supplied preloaded in a disposable injection device (image 
supplied courtesy of Allergan Inc. 
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 Pharmacokinetics of slow-release dexamethasone implant 3.1.2.1
 
Chang-Lin et al [213] described in detail the pharmacokinetic and pharmacodynamic 
properties of the slow-release dexamethasone implant (Ozurdex®) in an experimental 
in vivo study of 37 male monkeys (macaca fascicularis). Thirty four macaques were 
injected bilaterally with the 700ug implant and three primates were used as controls. 
Pharmacokinetic data were determined from plasma, vitreous and retinal samples 
harvested from day 7 to day 270. Levels of dexamethasone were quantified using 
liquid chromatography-tandem mass spectrometry. Pharmacodynamics of the 
released drug were assessed using the expression of dexamethasone-sensitive gene 
cytochrome P450 3A8 (CYP3A8) as a marker of biological activity. 
 
Dexamethasone concentration in the retina and vitreous humor were characterised by 
two distinct phases which corresponded to the observed fragmentation of the implant. 
The first phase consisted of initially high drug concentrations observed at day 7 and 
peaked at day 60 with a Cmax of 1110 +/- 284 ng/g and 213 +/-49 ng/mL in the retina 
and vitreous, respectively. There then followed a second phase of sustained lower 
concentration observed up to day 210 in the retina and day 180 in the vitreous. 
Thereafter, concentrations of dexamethasone were below the level of quantification 
(BLQ) in either tissue. Plasma levels were detected up to day 60 (Cmax = 1.11 +/- 
0.11ng/mL) and thereafter were undetectable.  
 
The pharmacodynamic profile mirrored the aforementioned pharmacokinetic 
properties. CY3A8 expression exhibited a similar dual-phase pattern , with a three-fold 
increase observed up to month 2 (day 60) followed by a lower but consistently 
elevated  level of gene expression up to month 6 (day 180), which subsequently 
returned to control levels thereafter.  
 
Chang-Lin et al likened this dual-phase pattern to the regimen employed with the 
administration of systemic corticosteroids i.e. an initial short phase of high 
corticosteroid concentration after pulsed intravenous methyl prednisolone, followed 
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by the lower doses achieved with subsequent oral prednisolone. This regimen, has 
been shown to induce T cell apoptosis [214, 215], and may therefore be advantageous 
to manage conditions in which T lymphocytes are contributory, as in PVR (refer section 
1.3.2) 
 
They went on to compare their findings to previously reported data on alternative 
modes of dexamethasone administration. They concluded that the slow-release 
preparation achieved higher and more stable posterior chamber levels of 
dexamethasone compared to subconjunctival, periocular, topical, or oral 
administration.  (Table 3.1)  
 
Table 3.1: Comparison of vitreous concentration achieved by mode of administration 
Mode of 
Administration 
Dose of Dex 
(mg) 
Mean Cmax 
(min, max)  
Time after last 
administration (units) 
    
Topical† [216] 0.55 1.1 (BLQ, 1.6) 21-128(minutes) 
Oral[217] 7.5 5.2 (1.7, 23.4) 4-10 (hours)  
Peribulbar [218] 0.5 13 (4.4, 208)  4-8 (hours)  
Subconjunctival 
[219] 
2.5 72.5 (NR)  3 (hours) 
Intravitreal [220] 0.4 67.4 (13.9, 392) 60-73 (hours)  
Ozurdex  0.7 213 (125, 252)  7-60 (days) 
Dex, dexamethasone, BLQ, below the limit of quantitation; NR, not reported. † 
Cumulative dose of 10–11 drops of 0.1% DEX administered over 15 hours. 
 
They concluded that the controlled release of dexamethasone into the vitreous 
allowed for lower and less frequent doses to be delivered directly towards the target 
tissue, thereby avoiding the unwanted side effects of systemic corticosteroid use, or 
the need for repeated injections.  
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 Licensed indications of Ozurdex ® 3.1.2.2
 
In July 2010, the slow-release dexamethasone implant, Ozurdex, was first granted a 
market authorization in the U.K for the following indications: 
x the treatment of adult patients with macula oedema following retinal vein 
occlusion (either branch or central) [221] 
x the treatment of adult patients with inflammation of the posterior segment of 
the eye presenting as non-infectious uveitis [222] 
 
Four years later, in July 2014, the European Union’s Committee for Medicinal 
Products for Human Use (CHMP) recommended extending the market authorization 
for Ozurdex to include: 
x the treatment of adult patients with vision loss due to diabetic macular 
oedema (DMO) who are considered insufficiently responsive to, or unsuitable 
for non-corticosteroid therapy 
 
 
A summary of the findings of the three studies which support the current licensed 
indications of Ozurdex® will follow.  
 
 
 
 
 
 
 
130 
 
 
 
3.1.2.2.1 GENEVA Study  
 
The GENEVA study [221] was a phase III prospective randomized controlled clinical 
trial of pooled data comparing the visual outcome of patients suffering macular 
oedema secondary to either branch or central retinal vein occlusion. A total of 1267 
patients were allocated to one of three treatment groups; 427 eyes received a single 
700ug dexamethasone implant  (Ozurdex®), 414 eyes received a 350ug slow release 
dexamethasone implant and  426 control eyes were administered a sham injection. 
Approximately two thirds of patients had suffered a branch retinal vein occlusion 
with the remaining third of patients, eyes with a CRVO.  Presenting BCVA was 
between 20/50 and 20/200 secondary to intraretinal oedema of ≥300 μm in the 
central 1 mm macular subfield. Macular oedema was required to be present for at 
least 6 weeks and up to 9 months for CRVO patients and up to 12 months for patients 
with BRVO. The primary outcome measure was time to achieve a best corrected 
visual acuity (BCVA) of ≥15 ETDRS letters.   The authors reported a higher proportion 
of patients achieving the primary outcome at all timepoints from day 30 to day 90.  
 
Table 3.2:  Summary of Primary Outcome Findings of GENEVA Study 
  
Visit 
OZURDEX® Sham 
N = 427 N = 426 
Day 30  21.3 % * 7.5%  
Day 60  29.3% * 11.3%  
Day 90  21.8% * 13.1%  
Day 180  21.5%  17.6%  
Proportion of patients (pooled ITT population) with ≥ 15 letters improvement from 
baseline best corrected visual acuity in the study eye (* denotes significant 
difference, p<0.001) 
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Additionally, secondary outcome findings reported fewer patients losing ≥ 15 ETDRS 
letters in the treatment group compared to the sham group. Furthermore, the mean 
reduction in central macular thickness was 207.9um in the Ozurdex group compared 
to 95um in patients who received the sham injection a day 90 (p=< 0.001). However, 
this lost statistical significance by day 180.  The second phase of the trial was open-
label and eyes were eligible for first or re-treatment. Eligibility required a BCVA of 
<84 letters or retinal thickness of >250 microns.  Those receiving their second 
implant continued to respond better than those with delayed treatment.  The 
incidence of raised IOP was greater in the Ozurdex group compared to the sham 
group, with 3.2% of patients recording an IOP of >35mmHg at month 2. Rates of 
cataract were low, but higher in the Ozurdex (7%) compared to 4% in the sham 
group. A detailed discussion regarding raised IOP and cataract will follow later in this 
chapter in section 3.2.7.6.  
 
3.1.2.2.2 HURON Study 
 
The HURON study provided the clinical evidence leading to the market authorization 
of Ozurdex in the treatment of non-infectious intermediate and posterior uveitis 
[222]. This was a phase 3, multicentre, randomized controlled clinical trial of 229 
patients divided into three equal groups. Eyes received either the 700ug Ozurdex 
implant, 350ug implant or sham injection. The primary outcome was the proportion 
of eyes with a vitreous haze score of zero at week 8. Secondary outcome measures 
included time to vitreous haze resolution, reduction in haze and BCVA improvement. 
The proportion of eyes treated with Ozurdex achieving the primary outcome (47%) 
was significantly greater than with sham (12%). The effect was maintained up to 
week 26. Secondary outcome measures (BCVA and vitreous haze improvement, 
reduction in rescue treatment) showed similar treatment effects. 
Elevated IOP (>25mmHg) was observed in 19 of 76 (25%) patients who received 
Ozurdex compared to 5 patients (6.7%) in the sham group.  
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3.1.2.2.3 The MEAD study  
 
The MEAD study [223] reported findings on the efficacy and safety of Ozurdex® in 
eyes with DMO. It comprised two parallel randomized, multi-centre, masked phase III 
clinical trials of 1048 patients with DMO. A  BCVA of 20/50 to 20/200 and OCT-
measured CMT of ⩾300 μm was a requirement for trial entry. The patients were 
randomized in a 1:1:1 treatment allocation ration as in the GENEVA and HURON trials 
and prospectively followed for 3 years. Re-treatments were restricted to 6 monthly 
intervals. The primary outcome measure was the proportion of eyes gaining 15 ETDRS 
letters from baseline to study exit. Secondary outcome measures included a 
comparison in mean reduction in central foveal thickness (CFT) from baseline.  
A significantly higher proportion of eyes in the Ozurdex® group (22.2%) achieved the 
primary outcome compared to 12 % in the sham group (p = 0.018). The mean 
reduction in CFT from baseline, was also greater in the treatment groups (−111.6 μm) 
compared to sham (−41.9 μm; p < 0.001).   However, treatment efficacy in the steroid 
group appeared to be lost prior to the 6 month retreatment interval. Furthermore, 
study retention was poor, with over one third of patients in the steroid treatment 
groups and over half in the sham group exiting the study early [224].  
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 Slow-release dexamethasone (Ozurdex®) in vitrectomised eyes 3.1.3
 
The three aforementioned studies provide evidence to support the use of the slow 
release dexamethasone implant for its licensed indications. However, no comment has 
been made regarding its use in eyes which have previously undergone vitrectomy. A 
review of pre-clinical and clinical evidence covering this topic will follow.  
 
 Preclinical Evidence 3.1.3.1
 
The clinical effectiveness of using pharmacological agents in eyes which have 
previously undergone vitrectomy surgery has been questioned as the 
pharmacokinetics may be altered in this environment. Increased drug clearance in 
vitrectomised eyes injected with anti-vascular endothelial growth factors (anti-VEGF) 
[225], triamcinolone [201, 226], 5’ FU [227] and amphotericin[228] have all been 
previously reported.   
Chang-lin et al published a second report in 2010 comparing the pharmacokinetics of 
the Ozurdex® implant in vitrectomised and non-vitrectomised experimental eyes 
[229]. Twenty five rabbits underwent vitrectomy surgery in one eye, with the fellow 
non-vitrectomised eye serving as a control. An implant was injected bilaterally and 
the drug release profile of dexamethasone was measured in the vitreous humor and 
retina, at weekly intervals from day 2 to 31 using their previously described methods 
[213].  They found no significant difference in the concentrations of dexamethasone 
in either tissue at any timepoint (p> 0.05). The maximum concentration of 
dexamethasone in non-vitrectomised versus vitrectomised eyes was 4110 ng/mL at 
day 15 compared to 3670 ng/mL at day 22 in the retina, respectively. For vitreous 
humor, the maximum concentration was 791ng/mL versus 731 ng/mL at day 22. They 
concluded that the pharmacokinetic profile of Ozurdex® was similar in the two 
posterior chamber environments.  
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 Clinical Evidence   3.1.3.2
 
The CHAMPLAIN Study was a multicentre, prospective, non-controlled, open-label 
study investigating the safety and efficacy of Ozurdex® in vitrectomised  eyes with 
DMO [230]. Patients with a central retinal thickness ≥ 275 μm on OCT, and BCVA from 
24 letters to 70 letters were eligible. Fifty five of 56 patients received a single 
treatment of Ozurdex at baseline and were followed for 6 months. Primary outcome 
measure was mean reduction in central macular thickness (CMT) at 6 months. 
Secondary outcomes included BCVA improvement and safety data.  
A significant reduction in CMT was noted at week 8 (-155.9µm) and persisted to month 
6 (-39 µm). A corresponding improvement in vision of 6 and 3 letters was noted at 
both timepoints, respectively. 
At least one episode of raised IOP (>25mmHg) was noted in 16% of patients, the 
prevalence peaking at week 8 and reducing to zero upon study completion. Cataract 
progression was observed in 17% (2 of 12) phakic patients. The authors concluded that 
treatment with the slow-release dexamethasone implant in this population led a 
statistically and clinically significant improvement in DMO and vision, with an 
acceptable safety profile.   
 
Furthermore, other authors have reported on vitrectomised eyes where the slow-
release preparation has successfully treated refractory macular oedema secondary to 
uveitis, vascular occlusions, and post vitrectomy for retained lens fragments  [231-
233].  
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 Ozurdex® and Silicone Oil 3.1.4
 
The pharmacokinetics of Ozurdex® has been described, exhibiting a dual-phase 
response of initially high concentrations of dexamethasone in the first two months, 
followed by a period of lower concentrations sustained for up to 6 months post 
injection [213]. Furthermore, vitrectomy has not been shown to significantly affect 
the drug release profile [229].  Nevertheless, the proposed clinical trial in which 
Ozurdex is to be used as pharmacological adjunct, eyes have not only undergone 
vitrectomy surgery, but will also be filled with an intraocular tamponade of silicone 
oil. 
As there is no published data on using Ozurdex® in this intraocular environment, the 
manufacturing company (Allergan, Inc.) were contacted to provide further 
information. An overview of unpublished data of an in vitro study conducted by 
Allergan is herein described [234].  
 
The study investigated the drug-release profile of dexamethasone from the Ozurdex 
implant in a saline/silicone oil medium and compared it to a control. Three 
experimental groups were investigated as follows: the first two groups each had six 
replicates of a forty milliliter (ml) medium containing 30 ml of 0.9% saline and 10ml 
silicone oil, the third group (control) consisted of a saline only medium, although the 
volume was not reported. Groups 1 and 2 differed in the manner in which the 
implant was introduced to the medium. In group 1, termed DSO, the implant was 
added to the glass vial prior to adding the saline and then silicone oil media. In group 
2, termed SOD, the sequence of vial fill was saline, followed by silicone oil, followed 
by the ‘placing’ of the Ozurdex implant over the oil layer.   Dexamethasone 
concentrations were measured in both the saline layer and the silicone oil layer and 
sampling was performed weekly for 28 days.  
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The calculation to estimate the percentage of dexamethasone released was as follows: 
                Concentration of dexamethasone released (μg/ml)x30 ml saline 
% Dex = ------------------------------------------------------------------------------------ x 100% 
                 Calculated amount of dexamethasone in Ozurdex 
 
 
 
Figure 3.2:  Drug release profile of dexamethasone in different media 
 
Figure 3.2 (DDS = saline only, DSO = implant, then saline then oil, SOD = saline, then 
oil, ‘placed’ implant). Line graph shows that the average percentage of 
dexamethasone released in saline for all three groups did not differ significantly. In 
group 2 (SOD) the drug release in saline from Day 1 to Day 21 is slower compared 
to control and group 1, however, by day 28 the drug release is comparable.  (Figure 
is reproduced unaltered directly from the correspondence provided by Allergan, 
U.K  with permission requested  [234])  
 
137 
 
 
 
The investigators concluded that the in vitro release profiles of dexamethasone in 
saline in the presence of silicone oil (groups 1 and 2)  versus the saline  alone (control) 
are similar. 
 
Additionally, the concentration of dexamethasone release from Ozurdex in the silicone 
oil layer was calculated. The silicone oil reportedly used in these experiments was a 
polydimethyl siloxane and has only trace solubility of dexamethasone (0.90 μg/mL). 
Dexamethasone concentrations were measured in the silicone oil layer extracted from 
both groups 1 and 2 on day 28 and showed only trace amounts (<2.5ug/mL) for all 
samples tested. This is as expected given the lipophobic properties of dexamethasone.  
 
 
Caution must be exercised when extrapolating this in vitro data to in vivo.  Firstly, the 
data is unpublished and the experimental methodology is incompletely described. 
Secondly, the proportion of silicone oil/saline medium does not accurately reflect that 
of clinical practice. In fact, upon completion of vitrectomy surgery and vitreous cavity 
air or fluid oil exchange, the surgeon aims to fill the cavity with silicone oil as 
completely as possible. The resultant oil/aqueous ratio is therefore more usually 
90:10, respectively, which starkly contrasts the 10:30 ratio which was investigated in 
vitro.  
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3.2 A slow- release dexamethasone implant in proliferative 
vitreoretinopathy; a prospective randomised controlled clinical 
trial  
 
 Purpose 3.2.1
 
The aim of this study was to determine whether an adjunctive slow release 
dexamethasone implant given at the time of vitrectomy surgery and repeated at oil 
removal could improve the anatomical and visual outcomes in eyes with established 
proliferative vitreoretinopathy 
 
 Primary Objective  3.2.2
 
To test the hypothesis that adjunctive Ozurdex®, given at the time of surgery, can 
improve the anatomical outcome of vitreoretinal surgery for established PVR i.e. stable 
retinal reattachment with removal of silicone oil without additional vitreoretinal 
surgical intervention at 6 months 
 
 Secondary Objectives 3.2.3
 
To determine whether adjunctive Ozurdex®, given at the time of surgery has an effect 
on the following at 6 and 12 months following primary study vitrectomy: 
 
i) visual acuity (median and ETDRS of 55 letters or better)  
ii) macula oedema and thickness (SD - OCT analysis) 
iii) development of overt PVR recurrence at any timepoint  
iv) complete retinal reattachment 
v) posterior (post equatorial) retinal reattachment  
vi) tractional retinal detachment  
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vii) hypotony/raised IOP 
viii) macula pucker/epiretinal membrane 
ix) cataract  
x) Quality of Life  
 
 
 Methods/design 3.2.4
 
This was a phase III participant masked randomised control study involving 140 
patients undergoing vitrectomy surgery with silicone oil for a retinal detachment with 
established PVR. Participants were randomised into two equal groups (adjunct and 
control arm) following satisfaction of the inclusion/exclusion criteria. Both groups 
received the standard surgical treatment appropriate for their eye condition and 
routine preoperative and postoperative treatment and care, differing only in the 
addition of supplementary Ozurdex® in the adjunct group. The study protocol has been 
published in Trials, an open access journal [235].  
 
 Study Set up 3.2.4.1
 
3.2.4.1.1 Funding 
 
An unrestricted grant was obtained from Allergan,  Ireland by Professor Charteris .  The 
funding agency had no role in the protocol design, management or results 
dissemination of the trial.  
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3.2.4.1.2 Regulatory authority approval 
 
The process of gaining all regulatory authority approvals was led by me. Moorfields 
Research Management Committee (RMC) approval was obtained as sponsor of the 
trial. A favourable opinion from the National Research and Ethics Service 
Committee London - Central was received (11/LO/1685) and the study was 
granted a clinical trials authorisation by the MHRA. The trial was registered on the 
European Clinical Trials Database (EudraCT No 2011-004498-96).  
 
The study was conducted in accordance with the International Conference on 
Harmonisation for Good Clinical Practice, as set out in the European Union Clinical 
Trials Directive (2001) and associated UK Regulations (2004). The study complied 
at all times with the Declaration of Helsinki (2000). Patients provided written 
informed consent before entering the trial. An independent Data Monitoring 
Committee (DMC) and Trial Steering Committee (TSC) provided study oversight 
throughout the duration of the trial. 
 
3.2.4.1.3 Case Report Form Design 
 
A project data guide was provided by the research department applications team at 
Moorfields Eye Hospital (MEH) in order to develop a case report form (CRF) which 
adhered to the sponsor’s standard operating procedures.  Paper case report forms 
(CRF) were developed by me to ensure the efficient capture of the required dataset 
(Appendix 4). The study database was designed and programmed by the applications 
team at MEH. Prior to green light approval, dummy data were entered into the study 
database in order to test its design.  
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 Eligibility of Participants 3.2.4.2
 
3.2.4.2.1 Inclusion Criteria 
 
Patients with established PVR (grade C) [16] following rhegmatogenous 
retinal detachment requiring surgery with planned silicone oil tamponade.  
3.2.4.2.2 Exclusion Criteria 
 
1. Individuals less than 18 years old 
2. History of Open Globe Injury 
3. A diagnosis of ocular hypertension on 2 or more pressure lowering 
medications or a definite diagnosis of glaucoma if in the opinion of a glaucoma 
specialist, the patient is at high risk of visual damage from raised IOP 
4. Uncontrolled uveitis  
5. Previous steroid induced glaucoma 
6. Proliferative Diabetic Retinopathy or vasculopathy 
7. Pregnant or Breastfeeding females (Females of child bearing potential must 
have had a negative pregnancy test within 7 days of commencing the trial and 
agree to adequate contraception throughout the duration of the trial) 
8. Previous known adverse reaction to the IMP 
9. Suspected ocular/periocular infection (e.g. Herpes Simplex Virus, Varicella 
Zoster Virus, mycobacterial, fungal disease) 
10. Aphakia or patients in whom a lensectomy is planned at time of surgery 
11. Pre-existing Anterior Chamber Intraocular Lens 
12. Inability to give informed consent 
13. Unwilling to accept randomization and attend follow-up 
 
 
There were no restrictions on the number of previous vitreoretinal procedures.    
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 Study Interventions 3.2.4.3
  
Both groups underwent the standard intraoperative procedure appropriate for 
their clinical condition.  Consultants or senior fellows (2nd year fellowship) 
performed the operative procedures. 
 
This involved a standard 3 port pars plana vitrectomy (or gel trimming if the eye 
was previously vitrectomised) and internal identification of retinal breaks; peeling 
of anterior and posterior epiretinal membranes and removal of subretinal 
membrane  was performed as required; relief of traction by retinectomy or 
placement of a scleral buckle was performed at the operating surgeons discretion; 
retinopexy to retinal breaks and retinectomy edge by cryotherapy or laser; 
intraocular tamponade using 1300 or 5000 centistoke  silicone oil.  
Removal of silicone oil (combined with cataract extraction + IOL implantation 
when applicable) was planned for four to five months after the study vitrectomy. 
360 degree prophylactic barrier laser was performed prior to oil removal at the 
treating clinicians’ discretion.  
 
3.2.4.3.1 Adjunct group  
 
Upon confirmation of successful retinal reattachment and completion of silicone 
oil exchange, the operating surgeon was asked to clinically grade the level of PVR 
using the standardized classification system in current practice [16]. Thereafter, 
the surgeon was asked to inject a 0.7mg slow release dexamethasone implant 
through the final open sclerotomy port prior to suturing (Figure 3.3). 
Slit-lamp and/or indirect biomicroscopy was performed the following day to 
confirm the position of the implant.  
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Figure 3.3: Intra-operative Injection of Steroid Implant 
 
Figure 3.3 Sequence of still photographs highlighting injection of slow-
release dexamethasone implant A) retina attached and eye is oil filled, note 
multiple white blanches of the retina where the retinectomy edge has 
undergone laser retinopexy, B) bevel of preloaded injector is  introduced 
through sclerotomy and is visible in the operating field as C) bevel is 
directed towards bare RPE, anterior to retinectomy edge D) the release 
button on body of applicator is depressed and rod-shaped implant is visible 
emerging from tip of injector, E) implant travels within oil bubble until 
impedance and begins to sink deeper into the eye F) injector is removed 
and implant sinks towards retina to rest on retinal surface 
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A similar procedure was followed for the second implant administration at the time 
of oil removal. Upon confirmation that the retina remained attached following 
removal of oil, the surgeon was again asked to confirm the retinal status and the 
presence or absence of PVR. As a variety of techniques were used to remove silicone 
oil, particularly if combined cataract surgery was performed, the implant was either 
injected through a sclerotomy port (if used) or via the conventional method of 
delivery [236].   
 
3.2.4.3.2 Control Group 
 
Following successful retinal reattachment, completion of silicone oil exchange and 
grading the level of PVR, the surgeon was informed that no adjunctive medication 
was required and the final sclerotomy port was sutured. 
 
 Modifications to Study Intervention 3.2.4.4
 
If a patient was rendered aphakic as part of the operative procedure and had been 
randomised to receive the IMP, the study treatment was not given, but the patient 
still followed up as part of the study. Reports of migration of the implant into the 
anterior chamber in unicameral eyes, with secondary corneal decompensation 
necessitated this safety precaution [237, 238].  
 
Additionally, restrictions were placed on proceeding with the second implant 
injection depending on preoperative IOP. This is detailed in section 3.2.4.6 in the 
algorithm for managing IOP.  
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 Schedule of assessments 3.2.4.5
3.2.4.5.1 Informed Consent 
 
Informed consent was taken by me or the chief investigator prior to performing any 
study-specific interventions and after administration of the PIL. Occasionally, 
emergency surgery was required necessitating trial enrolment within a 24 hour period. 
In these circumstances, we ensured that patients had been provided adequate time to 
reach their decision. This was documented in the source documents (hospital clinical 
notes). 
3.2.4.5.2 Screening 
 
A screening assessment was performed to confirm that eligibility criteria were met 
prior to enrolment in the trial. 
 
3.2.4.5.3 Baseline Assessment 
 
Baseline assessments were performed within one week of the scheduled study 
vitrectomy date. This included: patient demographics, past ocular history, logMAR 
visual acuity (ETDRS method), slit lamp/indirect ophthalmic examination (anterior and 
posterior segment assessment, lens status, extent of retinal detachment, grade of PVR 
[16]) , spectral domain OCT-guided foveal thickness , and quality of life questionnaires.  
 
3.2.4.5.4 Follow up assessments 
 
Postoperative study visits did not differ from the routine schedule for vitreoretinal 
procedures at the study site for the first 6 months i.e. day 1, day 10, week 4, 3 
months and 6 months.  Further assessments were scheduled for 9 and 12 months post 
initial surgery. The time window allowed around these scheduled visits were as 
follows: Day 10 (+/- 3 days), Day 30 (+/- 7 days) Months 3, 6, 9 and 12 (+/- 14 days). 
At each scheduled postoperative study visit, a full ophthalmic assessment was 
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completed which included slit lamp biomicroscopy (+/- indirect binocular 
ophthalmoscopy when required) and parameters including ETDRS visual acuity, 
Goldman applanation tonometry, anterior segment assessment and retinal 
attachment status were recorded. 
 
3.2.4.5.5 Visual Acuity Assessment 
 
As discussed, visual acuity was measured at baseline and subsequent study visits using 
the standardised ETDRS method by Margaret Zvobgo (Research Sister) or a delegated 
substitute. In our study, this consisted of a best spherical corrected vision where 
patients were assessed reading letters on an ETDRS Letter Chart at four and/or one 
metre to obtain an ETDRS letter score.  
More specifically, If 20 or more letters are read correctly at 4 metres, then the visual 
acuity score is equal to the number of letters read correctly (N)  + 30. If one or more 
but fewer than 20 letters were read at 4 metres, then the visual acuity score is equal to 
the number of letters read correctly at 4 metres plus the number of letters read 
correctly at one metre in the first six lines. If no letters were correctly read, the ability 
to count fingers (CF), identify hand movements (HM) or perceive light  (PL) was 
assessed.   
 
3.2.4.5.6 Optical Coherence Tomography 
 
Spectral-domain optical coherence tomography was performed by delegated was 
used to record central foveal thickness adopting a trial- specific scanning sequence as 
follows: 
The Heidelberg Spectralis HRA-OCT Model was used in all patients. 
The resolution mode was set to high speed, with a central internal fixation target and 
the enhanced depth imaging mode (EDI) switched off. 
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A sequence of 25 horizontal sections that covered an area 20o X 20o (5.6x 5.6mm) 
was recorded with a distance of approximately 200µm between each individual 
section. Ten frames (ART 10) were acquired for each B scan location to reduce noise 
and improve quality. The final OCT image dimensions were 512 X 496 pixels.  
Imaging technicians, trained on the scanning protocol acquired the OCT scans. 
Quantitative measurements were obtained using automated algorithms incorporated 
into the Heidelberg Software. The presence or absence of cystoid macular oedema 
and macular pucker were OCT-derived dichotomous variables. Where OCT scanning 
was not possible (e.g. due to media opacity) a clinical judgement was made.  
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3.2.4.5.7 Additional Visits and Reoperations 
 
An additional study visit to assess the IOP was included into the protocol schedule at 
day 60 postoperatively following both the study vitrectomy and the removal of oil 
procedure.  ETDRS visual acuity and applanation tonometry was recorded and entered 
in to the CRF for data capture. 
 
All reoperations were recorded as adverse events and again study specific CRFs were 
completed for data capture. Silicone oil removal was not considered a reoperation 
and routine subsequent follow up ensued until the patient returned to the study visit 
schedule.  Other vitreoretinal interventions (with the exception of isolated retinal 
laser and macula epiretinal membrane peel) over the trial period were considered 
reoperations and recorded as such.  
Postoperative visits related to reoperations, or other attendances outside the study 
visit schedule, were recorded as ‘unscheduled visits’. CRFs identical in composition to 
the study scheduled visit CRF were completed and included in the data analysis on 
completion of the study.   
 
Following the final study visit at 12 months, participants were discharged back to the 
care of their General Practitioner. Participants requiring ongoing ophthalmic care 
continued follow up under their admitting consultant or under the care of a more 
appropriate specialist consultant as required. 
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 Management of intraocular pressure (IOP)  3.2.4.6
 
Management of raised IOP adhered to the following explicit protocol, which was 
approved by an external glaucoma specialist and is summarised in below: 
Table 3.3:  Management of elevated intraocular pressure (IOP)  
Intraocular 
Pressure (IOP) 
(mmHg) 
Treatment Follow up 
≤ 25 None As per protocol schedule 
>25 but <30 Single Topical Ocular Hypotensive Within 6 weeks  * 
≥30 but <35 Dual Topical Ocular Hypotensive Within 6 weeks 
≥35 PO Acetazolamide 500mg and dual 
therapy given Stat 
(Recheck IOP within 2 hours) 
After 2 hours: 
1. IOP <35 – PO Diamox 
250mg SR bd 5 days + 
dual topical therapy F/U 1 
week  
2. IOP  ≥ 35 – same day 
glaucoma service input  
and/or consultant VR 
input 
 
* If IOP has not responded to single therapy or only partially responded, 
then a substitute agent will be tried, or an additional agent added, 
respectively. 
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Patients were referred to the glaucoma service if: 
1. IOP remained >25mmHg on dual therapy 
2. Long term IOP management was required (i.e.  >2 consecutive months of IOP 
lowering agents required  in the absence of an internal tamponade agent) 
3. the investigators deemed it in the patient’s interest 
 
In the event where a patient’s IOP was >25mmHg at the time of listing for removal of 
oil procedure then additional topical ocular hypotensive agents was started/or added 
and their surgery postponed by up to 4 weeks until the IOP is ≤ 25mmHg. Where the 
IOP remained >25mmHg or if systemic ocular hypotensive agents was required to 
control the IOP, then patients in the adjunct group had their second injection 
omitted. This was recorded and will be discussed in the results.   
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 Recruitment  3.2.4.7
 
Recruitment into the trial commenced following documented REC, Regulatory and 
Local Trust R&D approval. All 140 participants were identified and recruited from 
outpatients and emergency referrals at Moorfields Eye Hospital. The study research 
nurse (MZ) frequently identified individuals with potential eligibility but study 
enrolment and informed consent was performed by me in approximately 95% of cases.  
 
 Randomisation  3.2.4.8
 
After informed consent, patients were allocated to either the treatment arm or control 
arm. The randomisation list was generated using permuted blocks of varying sizes and 
was generated by a senior data manager independent to the trial team.  The list of 140 
study IDs was held by the trials pharmacist, and following recruitment into the trial, 
participants were allocated to the lowest unused study ID. Out of hours (i.e. weekends 
and bank holidays), the next study ID in sequence was kept in a sealed envelope in a 
secure location on site when access to the trials pharmacist was limited.  
 
 Masking 3.2.4.9
 
Participants were masked to their treatment allocation until their completion of the 
study and confirmation of masking status was assessed after the study vitrectomy, at 
month 6 and upon trial exit.  The operating surgeon was masked until the end of the 
procedure just prior to sclerotomy closure, to avoid any bias regarding surgical 
management. It was not possible to actively mask the investigators as the IMP was 
visible on posterior chamber assessment until its degradation. A placebo vehicle was 
not used as a comparator as it was deemed unethical due to lack of safety data, and 
scientifically justified by comparing the treatment group to standard care.   
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 Outcome Measures 3.2.4.10
3.2.4.10.1 Primary 
 
Stable anatomic reapposition of the retina to the retinal pigment epithelium in the 
absence of an internal tamponade agent at 6 months post study vitrectomy without 
additional vitreoretinal intervention 
3.2.4.10.2 Secondary  
 
Secondary outcomes were assessed at 6 and 12 months following primary study 
vitrectomy:  
i) visual acuity (a comparison of the median visual acuity and the 
proportion of patients in each group achieving a VA of 55 ETDRS 
letters or better) 
ii) macula oedema and thickness (OCT analysis) i.e. the proportion of 
patients in each group with a central A1 macula subfield measure of 
>300um   
iii) the proportion of patients in each group who develop overt PVR 
recurrence 
iv) the proportion of patients in each group achieving complete retinal 
reattachment  
v) the proportion of patients in each group achieving stable posterior 
(post equatorial) retinal reattachment  
vi) the proportion of patients in each group with a tractional retinal 
detachment  
vii) the proportion of patients in each group who suffer hypotony (defined 
as IOP <6mmHg and/or raised IOP (defined as >25mmHg) at any time 
point during the study period 
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viii) the proportion  of patients in each group who develop the presence of 
macula pucker/epiretinal membrane and/or require macula ERM 
surgery at any time point during the study 
ix) the proportion of patients in each group who require cataract surgery 
at any time point during the study 
x) Quality of Life assessment – a comparison in the median/mean  scores 
of both SF36 and VFQ between both groups and the proportion of 
patients with severe depression  
 
 Adverse Events and Safety Reporting 3.2.4.11
 
Safety reporting adhered to the sponsor’s standard operating procedures and 
measures were in place to monitor, record and report adverse events (AE) in line with 
the MHRA guidelines.  AEs were assessed for severity, causality, expectedness and 
seriousness. An external Data Monitoring Committee was established with an agreed 
charter to which to adhere. They met six to twelve monthly or on an ad hoc basis as 
required.  
For the purposes of this trial we determined the following adverse events as expected 
occurrences: a) cataract, b) raised IOP, c) hypotony, d) sterile hypopyon, e) retinal 
detachment, f) uveitis, g) further surgery, h) glaucoma. i) headache, j) migraine, k) 
vitreous opacities, l) tractional maculopathy 
More specifically, the recording of severity of Raised IOP was as follows:  
Mild: > 25mmHg <35mmHg; Moderate: ≥ 35mmHg; severe: any interventional invasive 
procedure (e.g. surgery/laser) required to control the elevated IOP acutely or long 
term, during the study period 
Unexpected adverse events included: a)endophthalmitis, b)systemic illness c)ocular 
vascular occlusion d) other 
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 Trial Size and time-scale 3.2.4.12
 
The sample size calculation was performed by the study site senior medical 
statistician as follows: 
based on the results of the primary outcome measure from a trial of the same 
patient group carried out in the study centre [97] 66 patients per study arm are 
required for a study power of 85% to detect, at the 5% level, a 50% improvement 
in success of the adjunctive regimen (reducing failure from 49% to 24%).  A 50% 
reduction in failure would represent a marked clinical benefit and would be likely 
to be adopted on a large scale by vitreoretinal surgeons.  Given a 5% loss to follow 
up and protocol violations (previous similar studies at Moorfields had rates of 3-
5% loss to follow up /protocol violation [11, 97, 98], this gives a study total of 140 
patients to be randomised.  
The trial was funded for 36 months allowing a 24 month recruitment period and 12 
month follow up. The projected recruitment rate was therefore 5.83 patients per 
month.  
 
 Data entry 3.2.4.13
 
Greater than 95% of all paper CRFs were completed by me as the primary clinical 
assessor throughout the trial duration. The remainder were completed by the chief 
investigator or research nurse. The accuracy of source document reflection was 
checked by the study research nurse prior to data entry. A second check was 
performed at the final visit of each patient by both me and the research nurse. A 
delegated authorised individual (research nurse) entered the data onto the trial 
database created by the R&D applications team. Data entry was carried out within 1 
week of CRF completion.  
When all patients had completed their follow-up, an R&D data officer performed 
double data entry of a random sample of all study data of 10% of the sample size. 
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Additionally, double data entry was performed for 100% of primary outcome data of 
all patients in the study.  
The first and second data entries were compared for completion and consistency 
checks were performed according to the sponsor’s SOPs. The error rate was calculated 
and errors were corrected as necessary with completion of investigator site file notes 
where appropriate. 
 
 
 Statistical analyses 3.2.4.14
 
3.2.4.14.1 Principle  
 
All statistical methods presented in this thesis were performed by me using IBM SPSS 
Version 22.0.  With approval from the internal data monitoring committee, the 
sponsor formally granted release of the locked data set for my personal use in this 
thesis. Results of the primary outcome and 6 month secondary analysis are herein 
included.  
As this study was a clinical trial of investigational medicinal product (CTIMP), a formal 
statistical analysis plan (SAP) was written in advance of the data analysis by the trial 
statistician (Ms Ana Qartilho, supervised by Dr Catey Bunce). The SAP was reviewed 
and approved by both myself and the chief investigator and subsequently the Trial 
Steering Committee. For the purposes of the primary research paper and study 
report data, concurrent analysis was performed by the trial statistician. The findings 
of the primary outcome measure analysis were compared to my findings and were 
identical, thus verifying my statistical methods. 
 
The outcome analysis was by intention to treat (ITT) in order to retain the validity 
of the randomisation process.  The trial ITT population comprised all randomised 
patients regardless of eligibility (inclusion/exclusion) error, post-randomisation 
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withdrawal and whether the correct study treatments were received, or other 
interventions received. All statistical tests use a 2-sided p-value of <0.05 for 
significance, unless otherwise specified. All confidence intervals presented are 
95% and two-sided. 
 
A CONSORT flow diagram was constructed in accordance with 2010 CONSORT 
Guidelines to report recruitment, randomisation and follow-up summarised by 
treatment arm.  
 
Baseline characteristics of the two groups were compared to assess the adequacy of 
randomization. Summary measures of each group are presented as mean and 
standard deviation (SD) for continuous (approximately) normally distributed variables, 
medians and interquartile ranges for non-normally distributed variables, and 
frequencies and percentages for categorical variables. 
 
 
3.2.4.14.2 Primary Endpoint Analysis 
 
 
The proportion of patients satisfying the primary outcome (section 3.2.4.10.1) was 
reported by treatment group with 95% confidence intervals computed by the 
exact binomial method.  A binary logistic regression model (including terms for 
baseline PVR grade) was used to estimate the treatment effect as an odds ratio 
reported with 95 % confidence intervals.  
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3.2.4.14.3 Secondary Endpoint analysis 
 
Summary statistics of each group are presented as mean and standard deviation 
(SD) for continuous (approximately) normally distributed variables, medians and 
interquartile ranges for non-normally distributed variables, and frequencies and 
percentages for categorical variables.  Assessment of normality was made by 
plotting frequency distributions and confirmed using the Shapiro-Wilk test,  
Analysis of covariance (ANCOVA) was used to explore change from baseline in 
continuous variables (e.g. visual acuity, intraocular pressure, and quality of life 
parameters) by treatment group [239]. In all circumstances where this was used, 
prior to testing, it was confirmed that the required assumptions were met to fit 
the model (i.e. frequency distributions were approximately normal and 
homogeneity of regression of baseline variables were satisfied)  
Mann-Whitney U test or unpaired t-test/ANOVA was used to compare continuous 
outcome variables where baseline data were limited (e.g. foveal thickness and 
macular volume).  
Binary categorical outcome variables (e.g. presence of CMO, proportion of eyes with 
complete retinal reattachment)   were compared using the Chi-Squared test with 
Yates correction where >80% of observed frequencies were >5.  Fishers Exact test 
was used where this condition was not met.  
 
As statistical comparisons of secondary outcomes are the result of post hoc analyses, 
it must be acknowledged that any observed estimates of treatment effect may be 
imprecise.  
 
Any deviations from these statistical methods will be further described and justified 
in the relevant section, as appropriate. 
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 Results 3.2.5
 Recruitment 3.2.5.1
 
Patient recruitment opened on 2nd February 2012 with the first patient recruited on 
6th February 2012. The study closed at the final visit of the final patient in February 
2015, 2 weeks outside the original projected timeframe.  
Figure 3.4:  Recruitment Line Graph 
Figure 3.4 displays the recruitment line graph of projected target recruitment 
(red line) compared to actual cumulative rate. Rates of recruitment initially 
exceeded projected targets from February to December 2012. The study team 
met the 50% recruitment milestone of 70 patients by January 2013. Thereafter, 
recruitment rates fell just below target rates with recruitment completed 2 
weeks after the scheduled close of recruitment in February 2014.   
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 Study Consort Flow Chart and Study Retention 3.2.5.2
 
One hundred and ninety two patients were assessed for eligibility of which 29 were 
ineligible and excluded. Of the remaining 163 eligible patients, 20 patients declined 
to participate in the study. Three further patients enrolled in the study but were not 
randomized as silicone oil was not used. The remaining one hundred and forty 
eligible patients elected to participate in the trial and were recruited within 24.5 
months of the study commencing. 
Two patients in the adjunct group did not receive their first (and also second) 
Ozurdex implant. One patient was rendered aphakic at the time of the primary study 
vitrectomy.  One patient was randomized prior to the surgeon’s decision to use a gas 
tamponade and thereby became ineligible for study inclusion.  
In addition to these two patients, two patients did not receive their second implant 
due to preoperative IOP restrictions as per the study protocol. 
One patient in the adjunct group did not attend the primary assessment outcome 
visit and one patient in the control group was lost to follow up after month 3. 
 
Three further patients (one adjunct and two controls) failed to complete the study at 
the 12 month secondary outcome assessment point. Two of these (either group) 
were lost to follow up. The remaining control patient was withdrawn by the study 
team after the 6 month outcome assessment as his treating clinician requested an 
injection of intraocular steroid injection thereby potentially confounding or 
mitigating against any potential treatment effect of the IMP. 
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Figure 3.5:  Consort Flow Diagram for Ozurdex in PVR Study 
 
Figure 3.5 outlines the consort flow diagram. It is evident in this study that there is 
a high enrolment rate (89%) once screened as eligible. This is comparable to 
previously published studies where the median reported rate of enrolment was 
90% [198].  One patient was withdrawn from the study by the trial team as he 
required a treatment of intravitreal corticosteroid to treat refractory cystoid 
macula oedema.  This may have confounded any treatment effect of the IMP or 
negated his suitability to remain in the control group. 
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 Baseline Characteristics 3.2.5.3
 
Baseline demographic and non-ocular characteristics are summarized in table 1 showing 
comparable gender, mean age, and ethnicity, with a Caucasian sexagenarian male 
preponderance in both groups.  
 
Table 3.4:  Non ocular Baseline Characteristics of the two treatment groups 
 Adjunct Group  (N=70) Control Group (N=70) 
Number of Patients (Eyes), n 70 (70) 70 (70) 
Male/Female, n (%) 46 (65.7) / 24 (34.3) 40 (57) / 30 (43) 
Mean Age in yrs,(SD) 60.6 (14.3) 61.6 (13.9) 
Ethnicity: 
White, n (%) 
Black, n (%) 
Asian, n (%) 
Other, n (%) 
 
53 (75.7) 
6 (8.6) 
10 (14.3) 
1 (1.4) 
 
57 (81.4) 
4 (5.7) 
6 (8.6) 
3 (4.3) 
Scores for: 
VFQ 25, median (IQR) 
Missing, n (%) 
 
SF 36, median (IQR) 
Missing, n (%) 
 
66 (50, 77) 
1 (1.4) 
 
63 (45, 75) 
1 (1.4) 
 
65 (55, 76) 
3 (4.3) 
 
72 (52, 84) 
3 (4.3) 
 
VFQ 25 = visual functioning 25 point questionnaire, SF 36 = social functioning 36 
point questionnaire, IQR interquartile range 
 
 
 
 
 
 
162 
 
 
 
The median refractive status in both groups was emmetropia. Approximately one 
third of eyes in each group (n=22 vs n=20, adjunct vs control, respectively) had not 
undergone previous vitreoretinal surgery, with the majority of the remaining two 
thirds of patients having suffered failed vitrectomy surgery with gas tamponade. Four 
patients in both groups had previously undergone failed scleral buckling procedures. 
Ten patients in the adjunct group were noted to have ocular co-morbidity limiting 
visual outcome compared to three control patients.  
Table 3.5:  Past Ocular History of the two study groups 
 Adjunct Group 
(N=70)  
Control Group 
(N=70) 
Laterality (Left eye) 36 (51.4) 38 (54.3) 
Refraction (SE) median (IQR) 
Missing 
-.6 (-5, 0) 
9 (12.9) 
0 (-2.63, 0) 
13 (18.6) 
Previous VR Surgery: 
None, n(%) 
V/Gas, n(%) 
V/Oil, (n%) 
V/B, n(%) 
C/B, n(%) 
Median mac off episodes (IQR) 
 
22 (31.4) 
36 (51.4) 
11 (15.7) 
0 
4 (5.7) 
2 (1, 2) 
 
20 (28.6) 
36 (51.4) 
11 (15.7) 
1 (1.4) 
4 (5.7) 
2 (1, 2) 
Co-existing ocular pathology: 
Macular Pathology n (%) 
Amblyopia, n(%) 
Corneal Scar, n(%) 
Other, n(%) 
 
3 (4.3)  
5 (7.1) 
0 
2 (2.9) 
 
2 (2.9) 
0 
1 
0 
SE = spherical equivalent, V/Gas = vitrectomy/gas, V/oil = vitrectomy/oil, V/B = 
vitrectomy/buckle, C/B = cryotherapy/buckle, OHT = Ocular hypertension, mac off 
episodes = know episodes fovea-involving retinal detachments  
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A summary of baseline ocular characteristics are displayed in Table 3.6.  The median 
presenting visual acuity was zero ETDRS letters (i.e. ≤ Counting Fingers) in both 
groups, and mean intra-ocular pressure readings were 11.9mmHg and 13.3mmHg in 
the adjunct and control group, respectively. Baseline markers of inflammation and 
blood ocular barrier breakdown (anterior chamber cells, vitreous haemorrhage and 
RPE cells) were comparable between the two groups.  
Thirty seven (52.9%) of the adjunct group patients were pseudophakic compared to 
thirty four (48.6%) control patients. Of the remainder, the majority showed signs of 
lens opacity with approximately ten percent of patients in each group with no 
cataract.  
 
Table 3.6:  Baseline Ocular Characteristics (Non Retinal) 
 Adjunct Group (N=70) Control Group (N=70) 
ETDRS VA, median (IQR) 0 (0, 22) 0 (0, 31) 
IOP, mean (SD) 11.9 (4.9) 13.3 (5.1) 
*AC inflammation (cell count):  
None (0), n (%) 
Mild (1+), n (%) 
Moderate (2+), n (%) 
Severe (3+, 4+), n (%) 
 
38 (54.3) 
30 (42.9) 
1 (1.4) 
1 (1.4) 
 
33 (47.1) 
29 (41.4) 
8 (11.4) 
0 
Lens Status: 
Clear, n (%) 
PCIOL, n (%) 
Cataract, n (%) 
 
8 (11.4) 
37 (52.9) 
25 (35.7) 
 
7 (10) 
34 (48.6) 
29 (41.4) 
Vitreous Haemorrhage: 
Absent, n (%) 
Present n (%) 
 
66 (94.3) 
4 (5.7) 
 
67 (95.7) 
3 (4.3) 
BCVA = Best Corrected Visual Acuity, IOP= Intraocular Pressure, AC = anterior chamber, 
PCIOL = posterior chamber intraocular lens, ACIOL = anterior chamber intraocular 
lens.* AC inflammation cell count according to SUN classification [240]   
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A summary of baseline retinal status is displayed in Table 3.7. The fovea was detached in 
60 of 70 eyes (85.7%) in the adjunct group and in 57 eyes (81.4%) in the control group. The 
median duration of retinal detachment was 28 and 25 days in the adjunct and control 
group, respectively. The median extent of retinal detachment was comparable, with 
eight clock hours of RD recorded in the adjunct group and nine in the control arm. 
Duration of RD, number of breaks and cumulative size of breaks at baseline and/or 
primary surgery (in eyes with previous RD repair) were similar across both groups.  
The median grades of anterior and posterior PVR (as assessed intraoperatively) were 
comparable between the two groups. Baseline foveal thickness and macular volume 
was unavailable for the majority of patients (117 of 140, 83.6%) and was therefore 
not included in the final analysis.  
 
Table 3.7:  Baseline Retinal Characteristics 
 Treatment Group 
(N=70) 
Control Group 
(N=70) 
Summed Duration of RD, median 
(IQR) 
Not Possible, n (%) 
28 (7, 45) 
 
17 (24) 
25 (11, 52) 
 
21 (30) 
Clock hours of RD 
(Primary/Baseline), median (IQR) 
Not Possible, n (%) 
6 (5, 10) / 8 (6, 11) 
 
7 (10) / 24 (34) 
6.5 (5, 11) / 9 (6, 12) 
 
8 (11) / 24 (34) 
Macular status: 
Attached, n (%) 
Detached, n (%) 
Bisected, n (%) 
 
10 (14.3) 
60 (85.7) 
0 
 
13 (18.6) 
56 (80) 
1 (1.4) 
PVR Grade*: 
CP, median (IQR) 
CA, median (IQR) 
 
3 (2, 4) 
4 (3, 6) 
 
4 (2, 6) 
4 (4, 6) 
RD = Retinal Detachment, PVR = Proliferative vitreoretinopathy, CP = posterior 
Grade C, CA = anterior Grade C *Measured at operation   
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 Operative Techniques 3.2.5.4
 
Table 3.8 outlines the operative techniques employed during the primary study 
vitrectomy. These appear well balanced as 38 (54.3%) adjunct patients and 39 
(55.7%) control patients underwent a retinectomy at the time of their primary study 
vitrectomy. 
 
Table 3.8: Operative Techniques during Study Vitrectomy 
 Adjunct Group 
(n=70) 
Control Group 
(N=70) 
Lensectomy 
 
1 1 
PVD Induction 
 
5 4 
PFCL n(%) 
 
40 (57) 44(63) 
Retinectomy n(%) 38(54) 39(56) 
 
PVR Membrane Peel n(%) 42 (60) 38 (54) 
 
Segmental Buckle, n 1 2 
 
Retinopexy 
    Endolaser n(%) 
    Cryotherapy n(%) 
 
56(80) 
43(61) 
 
58(83) 
48(69) 
PVD = Posterior Vitreous Detachment, PFCL = Perfluorocarbon 
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 Primary Outcome Result 3.2.5.5
 
Primary outcome data were available for 69 out of 70 patients in each group.   One 
patient in the control group was lost to follow up after month 3 and one patient in the 
adjunct group was prematurely withdrawn as they had failed primary surgery and no 
month 6 data were collected. It was subsequently agreed by both the TSC and DMC 
that they remain in the study and month 12 data were collected.   
 
Table 3.9: Primary Outcome Result (Available ITT analysis)  
 Adjunct Group  
(N=69) 
Control Group 
(N=69) 
Effect Estimate 
Odds Ratio(95% CI) 
Proportion of patients 
satisfying primary 
outcome measure, % 
(95% CI) 
 
49 (37, 62) 
 
46 (34, 59) 
 
0.89 (0.46, 1.74) 
 
There was no observed difference in primary outcome between the two groups 
(Table 4): 49.3% of patients (n= 34 of 69) in the adjunct group achieved a stable 
retinal reattachment with silicone oil removal without additional vitreoretinal 
surgical intervention at 6 months, compared to 46.3% (n=32 of 69) in the control 
group. (Odds Ratio 0.89, 95% Confidence interval 0.46 – 1.74, p= 0.733 Chi Squared). 
Best case and worse case imputation analysis did not affect the primary outcome 
findings. Sub-group analysis stratifying by severity of PVR (Grade CP or CA > 4) did 
not show any statistically significant difference in primary outcome achievement.  
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 Visual Outcomes 3.2.5.6
 
3.2.5.6.1 Vision by predefined secondary outcome 
 
 At six months following study vitrectomy (Table 3.10) mean visual acuity was 38.3 
ETDRS letters (standard deviation 23.7) in the adjunct group compared to 40.2 letters 
(standard deviation 21.1) in the control group (p=0.898, ANCOVA) . This mean visual 
acuity approximates to a LogMAR visual acuity of 0.9 and a Snellen Equivalent of 6/48. 
Similarly, change from baseline showed no significant difference in the two 
treatment groups.  A sensitivity analysis excluding eyes with pre-existing ocular co-
morbidity limiting visual outcome (10 eyes excluded in adjunct group, 3 in control 
group) was performed and did not significantly affect the findings. The proportion of 
eyes achieving a visual acuity ≥ 55 ETDRS letters was also comparable, with 21 of 69 
eyes (30.4%) in the adjunct group achieving this vision or better, compared to 17 of 
69 eyes (24.6%) in the control group.  
Table 3.10: Visual Outcome at 6 months 
 Adjunct Group 
(N=69) 
Control Group 
(N=69) 
Effect Estimate 
(95% CI)  
ETDRS BCVA, mean (SD) 
- At 6 months 
- Change from baseline at 6 
months* 
 
38.3 (23.7) 
24.5 (28.6) 
 
40.2 (21.1) 
23.1 (26) 
 
- 
1.1 (-6.3, 8.4) 
Proportion of patients achieving 
ETDRS VA ≥ 55, n (%) 
21 (30) 17 (25)  
Sensitivity Analysis  
ETDRS BCVA, mean (SD) 
- At 6 months 
- Change from baseline at 6 
months* 
(N=59) 
 
41.60 (23.1) 
26.4 (29.3) 
(N=66) 
 
41 (20.9) 
23.2 (26.4) 
 
 
- 
-1.2 (-8.8, 6.4) 
* Adjusted for respective baseline, BCVA = Best Corrected Visual Acuity, 
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 Exploratory analysis of visual outcome in eyes without limited visual 3.2.5.7
potential  
 
Further exploratory analysis of the subgroup included in the aforementioned 
sensitivity analysis (i.e. 125 eyes with no known pre-existing ocular morbidity limiting 
vision) was performed comparing: a) visual acuity at each study visit and b) VA change 
from baseline (proportion gaining/losing letters)  
 
3.2.5.7.1 Visual outcomes by time-point 
 
The mean visual acuity adjusted for baseline was calculated and statistical comparisons 
made (ANCOVA). Confirmation that the required assumptions for the model were met 
(i.e. approximately parametric distributions and homogeneity of regression was 
present across baseline variables by treatment group).    
 
The adjusted mean VA in the adjunct group was higher than the control group at all 
timepoints from Day 10 until month 6 when the values become comparable. The 
adjusted mean VA in the adjunct group at Day 60 post primary vitrectomy was 44.6 
letters (95% confidence interval 40.2 to 49.1) compared to 37.9 letters (95% CI 33.7 to 
42.2) in the control group. This was statistically significant. (p = 0.034 ANCOVA). Table 
3.11 displays the adjusted mean vision in each group (with 95% CI) at each scheduled 
study visit up to month 6. 
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Table 3.11:  Adjusted Mean Visual Acuity over Study Period 
Study Visit Adjunct (n=59 ) Control (n=66) p value 
Baseline 15 
(9.3 to 21.1) 
17 
(11.9 to 23.0) 
0.575 
Day 10  39 
(34.3 to 43.6) 
34 
(29.8 to 38.6) 
0.149 
Week 4  43 
(37.9 to 47.7) 
36 
(31.7 to 41.1) 
0.063 
Day 60 45 
(40.2 to 49.1) 
38 
(33.7 to 42.2) 
0.034 
Month 3 44 
(39.4 to 49.0) 
38 
(33.9 to 42.8) 
0.079 
Month 6 41 
(36.4 to 47.4) 
42 
(35.5 to 45.9) 
0.099 
Adjusted mean VA to nearest integer (95% Confidence Interval) ANCOVA p value, 
with prior confirmation that assumptions for model are met 
 Figure 3.6:  Mean Visual Acuity by Group over Study Period 
Figure 2.1 displays the adjusted mean VA by treatment group over the 6 
month study period. VA was higher in the adjunct group at all timepoints 
from day 10 but becomes comparable at month 6; * denotes statistical 
significance at Day 60 (95% CI displayed in Table 3.11  above) 
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Figure 3.7:  Box plots of Visual Acuity at Day 60 and Month 6   
 
Figure 3.7 displays the visual acuity distribution of both groups at Day 60 
and month 6 in sub group analysis of 125 eyes (59 adjunct, 65 control). The 
adjusted mean VA was higher in the adjunct group at Day 60 where the 
mean VA is 45 letters compared to 38 letters in the control group. The 
vision returns to comparable levels at the primary outcome endpoint at 
month 6. (central bar = median, box = interquartile range, whiskers = 
range) 
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3.2.5.7.2 Visual Outcome by proportion of letters gained or lost 
 
Visual outcome was categorised into proportion of eyes gaining or losing letters when 
measured at six months in comparison to baseline. As previously reported, median 
baseline vision was Zero ETDRS letters in both groups. 
Table 3.12: The proportion of eyes gaining letters from baseline 
ETDRS LETTERS 
GAINED 
ADJUNCT  (n= 59) CONTROL (n=66) 
GAINED ≥ 10 letters 
 
42 (70.0) 48 (72.7) 
GAINED ≥20 letters 
 
38 (63.3) 42 (63.6) 
GAINED ≥ 30 letters 
 
31 (51.7) 36 (54.5) 
GAINED ≥ 40 letters 
 
21 (35.0) 24 (36.4) 
GAINED ≥ 50 letters 
 
16 (26.6) 10 (15.2) 
GAINED ≥ 60 letters 
 
9 (15.0) 3 (4.5) 
Data expressed as n of 59 (%) in adjunct group and n of 66 (%) control group  
The proportion of eyes gaining 10, 20, 30 and 40 ETDRS letters from baseline visual 
acuity is comparable between the two groups (Table 3.12). However, the proportion of 
patients gaining 60 or more letters is 15.0% (n=9) in the adjunct group compared to 
only 4.5% (n=3) in the control group.  
Eleven patients (18.3%) in the adjunct group lost vision compared to nine (13.6%) in 
the control group. The proportion of patients suffering mild visual loss (≤ 10 letters) 
was 3.3% (n=2) in the adjunct group compared to 6.1% (n=4) in the control group. 
Severe visual loss (≥ 20 letters) was more common in the adjunct group (10%, n=6) 
compared to controls (4.5%, n=3). 
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 Secondary Anatomical Outcomes 3.2.5.8
 
At 6 months, the proportion of patients achieving complete retinal reattachment or a 
stable posterior retinal reattachment was comparable between the two treatment 
groups (Table 3.13). Similarly, the proportion of patients with a tractional retinal 
detachment at 6 months was also comparable. The rate of overt PVR recurrence 
(defined as the presence of postoperative PVR at any time-point up to 6 months post 
study vitrectomy) was 58.0% (n= 40) in the adjunct group and 59.4% (n=41) in the 
control group.  
There was no observed difference in the number of operations to achieve primary 
success (as defined in the primary outcome measure); however, 11 patients (15.9%) 
underwent more than one operation to achieve success in the control group 
compared to 3 patients (4.4%) in the adjunct group.  
 
Table 3.13: Secondary anatomical outcomes 
 Adjunct Group 
(N=69) 
Control Group 
(N=69) 
Effect Estimate 
Odds Ratio 
(95% CI)  
Overt PVR recurrence*, n (%) 40 (57) 41 (59)  
Complete retinal 
reattachment **, n (%) 
37 (53.6) 43 (62.3) 0.699,(0.36 – 
1.38, p= 0.301)  
Stable posterior retinal 
reattachment ** n (%) 
46 (66.7) 48 (69.6)  
TRD **, n (%) 15 (22) 13 (19)  
Number of procedures to 
achieve attachment, n (%) 
0 
1 
2 
 
 
41 (59.4) 
25 (36.2) 
3 (4.4) 
 
 
37 (53.6) 
21 (30.4) 
11 (16) 
 
* Between the primary study vitrectomy and 6 months, ** without silicone oil in situ 
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 Macular Findings 3.2.5.9
 
Each parameter will be reported sequentially to elaborate further but in brief the 
proportion of eyes with macular oedema in the adjunct group was 42.6% (n=29) 
compared to 65.2% (n=45), (p= 0.007, Chi Squared). Similarly, the proportion of eyes 
with a foveal thickness >300µm in the A1 macular subfield was lower in the adjunct 
group (n=30, 47.6 %) compared to the control group (n=42, 67.6%) (p= 0.036), Chi 
Squared). The median foveal thickness was lower in the adjunct group (297µm and 
8.85mm3) compared to the control group (365µm and 9.23 mm3).  
 
Table 3.14:  Summary of Macular Findings at Month 6 
 Adjunct Group 
(N=69) 
Control Group 
(N=69) 
Effect Estimate 
Odds Ratio 
(95% CI, p value)  
* CMO present  29 (42.6) 45 (67.2) 0.36  
(0.17 to 0.78, p= 0.007) 
** FT > 300 µm, n (%) 
Missing, n (%) 
30 (47.6) 
6 (9) 
42 (67.7) 
7 (10) 
0.43  
(0.20 to 0.95, p=0.036) 
FT, median (IQR) 
- At 6 months 
Missing, n (%) 
 
297 (255, 380) 
6 (9) 
 
365 (284, 455) 
7 (10) 
 
(P=0.053) 
 
    
Macula pucker/ERM †, 
n (%) 
40 (57) 41 (58.6)  
ERM surgery†, n (%) 33 (47) 31 (44.3)  
* % expressed as proportion of available cases (68 eyes in adjunct group 67 eyes control group), ** % 
expressed as proportion of available cases (63 eyes adjunct group, 62 eyes control) †  % expressed as 
proportion of n=70  
 
 
 
174 
 
 
 
3.2.5.9.1 Cystoid macular oedema  
 
The presence of cystoid macula oedema was defined as either intraretinal cystic spaces 
visible on spectralis OCT and/or the characteristic clinical appearance on fundal 
assessment by slit-lamp biomicroscopy.   Outcome data for this variable was available 
in 67 eyes in the control group and 68 eyes in the adjunct group. An assessment of the 
presence of CMO either clinically or by SD-OCT was not possible in two patients in the 
control group and one in the adjunct group due to media opacity. One patient was lost 
to follow-up in the standard group and one adjunct patient was prematurely 
withdrawn from the study prior to this data collection point. 
At 6 months post study vitrectomy, cystoid macula oedema was present in 67.1% 
(n=45) of patients in the standard group compared to 42.6% (n= 29) in the adjunct 
group (Odds Ratio 0.36, 95%CI 0.17 to 0.78, p= 0.007 Chi Squared with Yates 
correction). This observed difference was statistically significant (Table 3.14).  
3.2.5.9.1.1 Exploratory Cystoid Macular Oedema and Visual Acuity 
 
At month 6 there was no difference in mean visual acuity by treatment group (38.3 vs 
40.2 ETDRS letters adjunct vs control).However, a statistically significant difference 
was found between rates of CMO by treatment group. 
Therefore, a comparison was made between the visual outcomes achieved by 
treatment group depending on the presence or absence of CMO at 6 months. This was 
performed on the 123 of 125 eyes after excluding the 13 eyes with limited visual 
recovery and 2 eyes where CMO data was missing (refer section3.2.5.6.1) 
In the standard group, at 6 months, the adjusted mean VA in eyes with CMO (n=44) 
was 38.5 letters compared 50.4 letters in those without (n=20) (95% CI 33.2 to 43.8 vs 
42.4 to 58.4, no CMO vs CMO, respectively, p=0.017 ANCOVA).  
In the adjunct group, at 6 months, the adjusted mean VA in eyes with CMO (n=25) was 
30.1 letters compared to 51.2 letters in those without (n=34). (95% CI 22.0 to 38.2 vs 
37.1 to 51.9 no CMO vs CMO, respectively, p=<0.001 ANCOVA).  
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3.2.5.9.2 Foveal thickness 
 
Spectral Domain – OCT derived values for central foveal thickness (FT) were recorded 
for patients at all visits where possible, and a comparison at the 6 month time-point 
was made. As baseline parameters were unavailable in the majority of patients a 
comparison between the changes in foveal thickness from baseline was not indicated. 
Therefore, cross sectional comparisons were made between the two groups at 6 
months.  
OCT-derived data was available for 62 of 70 patients in the control group and 63 of 70 
patients in the adjunct group.  Reason for missing data was most commonly poor 
quality image acquisition due to either media opacity or poor central fixation.   
In the control group, the median FT was 365.0 um with an interquartile range of 
168.5um. The median FT in the adjunct group was 296.5um with an interquartile range 
of 107.75um. Mann Whitney U test for unpaired non-parametric data marginally failed 
to achieve statistical significance. (p=0.054) 
 
A comparison between the proportion of eyes in whom the central A1 macular 
subfield was >300um was investigated as a predetermined secondary outcome.  In the 
control group, 42 of 62 eyes (67.7%) were found to have a central foveal thickness of 
>300um, compared to 30 of 63 (47.6%) of those in the adjunct group. Binomial logistic 
regression determined an odds ratio of 0.43 (95 % CI 0.20 to 0.95, p=0.036). This 
achieved statistical significance using the Chi squared test with Yates correction (p= 
0.036).  
 
3.2.5.9.3 Macular pucker formation and surgery  
 
Forty patients (57.1%) in the adjunct group and 41 patients (58.6%) in the control 
group developed macular ERM at any time-point up to 6 months, with comparable 
rates of macular pucker surgery between the two groups.  
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 Cataract  3.2.5.10
 
The proportion of phakic patients in the adjunct group who underwent cataract 
surgery during the six months after the study intervention was 75.8% (n=25 of 33), in 
the adjunct group compared to the 86.1% in the control group (n=31 of 36). The 
definition of cataract as an adverse event has been described and the significance of 
this will be discussed further in section 3.2.9.  
 
 Quality of Life Parameters 3.2.5.11
 
The Social Functioning 36 (SF-36) questionnaire and National Eye Institute Visual 
Functioning Questionnaire (NEI-VFQ 25) were validated tools used to assess quality of 
life (QAL) of participants in the trial.  The aforementioned questionnaires were 
administered to all participants at baseline and again at the primary endpoint, 6 
months post study vitrectomy. Additionally, a simple three question screening tool for 
depression was used with flags for active symptoms of severe depression included, to 
prompt further action as required.  
 
There was no statistical difference between the mean VFQ 25 score or SF6 score at 6 
months between the two groups, when controlling for baseline scores (p=0.995 and 
p=0.158, respectively,  Mann Whitney U ).  
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 Intraocular Pressure Outcomes – Elevated IOP 3.2.5.12
 
A higher proportion of patients in the adjunct group (45.7%, n=32) experienced at least 
one episode of elevated IOP (>25mmHg) at any time-point up to 6 month post study 
vitrectomy compared to the control group (31.4%, n=22), although this was not 
statistically significant (p=0.135, Chi Squared). Furthermore, there was no statistical 
difference in the comparison of estimated means between the two groups at the 6 
month time-point. (p= 0.282, ANCOVA).   
 
Figure 3.8:  Box plot of Intraocular Pressure at Month 6 
At 6 months the mean IOP was 15.8mmHg (SD of 9.53) in the control group 
compared to   16.7mmHg (SD of 8.40) in the adjunct group (Figure 3.8). 
There was no statistical difference in the comparison of estimated means 
between the two groups at this 6 month time-point. (p= 0.282, ANCOVA 
test) (centre line = median, box = interquartile range, whiskers = range) 
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Figure 3.9 displays the IOP fluctuation over time throughout the first 6 month study 
period. The mean IOP at baseline was 13.3mmHg (standard deviation 5.13) in the 
control group and 11.9mmHg (standard deviation 4.92) in the adjunct group. Mean IOP 
peaked at Day 10 post study vitrectomy in both groups (20.3mmHg vs 21.9mmHg; 
control vs adjunct, respectively) and was at its lowest  at the Day 1 post removal of oil 
time-point (12.7mmHg vs 11.0mmHg; control vs adjunct, respectively). At 6 months 
the mean IOP was 15.8mmHg (SD of 9.53) in the control group compared to   
16.7mmHg (SD of 8.40) in the adjunct group.  
 
Figure 3.9:  Line graph of Mean IOP by Treatment group 
 
Figure 3.9. Line graph of mean IOP fluctuation. No statistical differences 
were found on comparison of means between the groups for the following 
timepoints; day 1(p=0.056), day 10 (p=0.22), week 4(0.377), month 3 
(p=0.38), day 1 post ROSO (p= 0.31) or Month 6.   Mean IOP at day 60 post 
study vitrectomy and day 60 post removal of oil were significantly higher in 
the adjunct group compared to the control group (* indicates statistically 
significant difference) 
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Figure 3.10:  Boxplots of Adjusted Mean IOP Day 60 after study vitrectomy and oil removal 
 
Figure 3.10 displays the box plots of distribution of IOP 60 days after the 
primary study vitrectomy time-point (when 1st Ozurdex implant was 
injected in adjunct group) and Day 60 following removal of silicone oil 
(ROSO)   Estimated means at Day 60 are 13.3mmHg , 95%CI 12.0-14.9 vs 
15.6mmHg, 95%  CI 14.2-17.1 (p=0.036) , day 60 post ROSO estimated 
means are 16.8 (95% CI 14.1 - 19.4) in controls vs  a21.6 (95% CI 18.8-
24.3)in adjunct group (p= 0.015). (central bar = median, box = interquartile 
range, whiskers = range) 
 
No patients were using ocular hypotensive agents at the time of their primary study 
vitrectomy. In total, there were 81 episodes of elevated IOP in the adjunct group 
compared to 70 episodes in the control group.  Of these, 42 vs 60 events were mild, 23 
vs 17 events were moderate and 5 vs 4 events were severe, in the control vs adjunct 
group, respectively.  
 
An equal number of patients (42 of 70, 60.0%) per group required treatment with at 
least one ocular hypotensive agent at any time-point during the 6 month period.  More 
patients in the control group (18 of 69 (26.1%)) remained on ocular hypotensive 
therapy at month 6, compared to 8 of 69 (11.6%) in the adjunct group.  Fewer patients 
in the adjunct group (5 of 70) had an episode of elevated IOP which required 
treatment with a systemic ocular hypotensive agent, than in the control group (8 of 
70). 5 patients in the control group required laser or surgical intervention to control 
the IOP compared to 4 in the adjunct group.  
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 Intraocular Pressure Outcomes - Hypotony 3.2.5.13
 
Rates of hypotony (defined as an IOP <6mmHg) were comparable across the two 
groups with 14 patients (20.0%) suffering at least one episode in the adjunct group 
compared to 17 patients (24.3%) in the control group.  Just under one half (48%) of all 
episodes of hypotony were recorded at Day 1 post removal of oil. 
 Adverse Events 3.2.6
 
There were a total of 595 reported adverse events (AE) and 17 serious adverse events 
(SAE). No serious adverse reactions (SAR) or suspected unexpected adverse reactions 
(SUSAR) were reported over the study period. The proportion of patients suffering at 
least one AE was similar between the two groups; 66 of 70 (94.3%) adjunct patients 
and 63 of 70 (90%) control patients.  
 Non Serious Adverse Events 3.2.6.1
 Adjunct Group (N=70) Control Group (N=70) 
Total number of AEs, n (%)  285 (96.6)  310 (97.8)  
Number of expected AEs:   
Cataract, n (%) 0 (0)  1 (0.42) 
Raised IOP, n (%) 85(39.2)  75 (31.4) 
Hypotony, n (%) 27 (12.4)  31 (13) 
Sterile Hypopyon, n (%) 0 (0)  1 (0.4) 
Retinal Detachment, n (%) 45 (20.7)  51 (21.3) 
Uveitis, n (%) 10 (4.6)  24 (10) 
Further Surgery, n (%) 41 (18.9)  51 (21.3) 
Glaucoma, n (%) 3 (1.4) 2 (0.8) 
Headache, n (%) 5 (2.3) 1 (0.4) 
Migraine, n (%) 1 (0.5) 2 (0.8) 
Vitreous Opacities, n (%) 0 (0) 0 (0) 
Tractional Maculopathy, n (%) 0 (0) 0 (0) 
Number of unexpected AEs   
Systemic Illness, n (%) 15 (22) 18 (25.4) 
Ocular Vascular Occlusion, n 
(%) 
3 (4.4) 3 (4) 
Raised Blood Pressure, n (%) 6 (8.8) 6 (8.5) 
Bombe, n (%) 6 (8.8) 6 (8.5) 
Fellow Eye RD Surgery*, n (%) 
Number of patients, n (%) 
2 (2.9) 
1 (1.5) 
1 (1.4) 
1 (1.6) 
Other (Ocular), n (%) 10 (14.7)  17 (23.9) 
Other (Non-Ocular), n (%) 26 (38.2) / 0 (0) 20 (28.2) 
(Percentage calculated in relation to total number of AE/SAE in each group – Overall 595) 
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 Serious Adverse Events 3.2.6.2
 
SAEs were similarly distributed between the two groups, with none deemed to be related to 
the study IMP.  
 
 Adjunct Group (N=70) Control Group (N=70) 
Total number of patients with at 
least one SAE, n (%) 
7 (10) 6 (8.6) 
Total number SAEs, n (%) 
(Percentage calculated in relation 
to total number of AE/SAE in each 
group – Overall 595 / 17) 
 10  7  
Number of unexpected SAEs   
Systemic Illness, n (%) 9 (90) 4 (57) 
Other (Ocular), n (%) 1(10) 0 (0) 
Other (Non-Ocular), n (%) 0 (0) 3 (42.9) 
 
There was one ocular SAE in the adjunct group as one patient was admitted for a 
corneal suture –related abscess with suspected secondary endophthalmitis. The event 
was deemed unlikely related to the IMP and closed.  
 
 
 
 Nested studies prompted by observed ocular adverse events 3.2.6.3
 
Throughout the trial, a number of unexpected events were observed. These formed 
the basis of valuable learning points on a personal level, and in the wider field, which 
were deemed significant for publication. Two selected clinical observations will herein 
be described as nested studies which arose during the study period.  Thereafter, the 
main discussion of the trial findings will follow. These nested studies have also 
generated findings which will be included in the overall discussion of this chapter 
(section 3.2.7.2.2).  
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3.2.6.3.1 Nested Study 1; neurotrophic corneal ulceration after PVR surgery 
  
Five study participants suffered an AE deemed related to the surgical repair and not 
related to the IMP.   These events had not been previously reported in the literature 
and hence were successfully published as a series in JAMA Ophthalmology [241]. They 
will be briefly described as a case series in sequence followed by a short discussion, 
given their relevance to this thesis.  Four were control patients and one had received 
the adjunctive therapy.   
 
3.2.6.3.2 Case 1 
 
A 68 year-old South Asian male developed a central epithelial defect with a secondary 
infective crystalline keratopathy 6 weeks after his study vitrectomy. He was treated 
with an intensive topical regimen using a fluoroquinolone. Corneal anaesthesia was 
documented 4 weeks later and a differential diagnosis of herpetic keratitis considered 
with additional topical and systemic anti-viral therapy instituted. After a negative viral 
PCR and a lack of treatment response, he was switched to intensive topical lubricants. 
A botulinum toxin- induced ptosis aided resolution at 6 months, but with 20% central 
corneal thinning and marked stromal scarring.   
 
3.2.6.3.3 Case 2 
 
A 58 year old Caucasian male with dense strabismic amblyopia developed a 
neuropathic ulcer eight weeks post ROSO and presented to his local ophthalmic unit 
(Figure 3.11 C).  He was treated with systemic antivirals, in addition to topical 
antibiotics and infrequent lubricants. One week later, upon review at MEH, systemic 
therapy was discontinued and resolution was achieved at three weeks with intensive 
lubricants, with residual central stromal scarring and 30% thinning.  
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3.2.6.3.4 Case 3 
A 72 year-old Caucasian female required augmented barrier endolaser at the time of 
silicone oil removal.  Ten weeks later she developed a neurotrophic corneal ulcer. 
Resolution was achieved after three weeks of prophylactic topical antibiotics and 
intensive topical ocular lubricants, with resultant mild stromal thinning and residual 
scarring in the visual axis.  
 
3.2.6.3.5 Case 4 
A 58 year-old Caucasian female developed a painless paracentral corneal epithelial 
defect (Figure 3.11 A) and fixed dilated pupil was noted five weeks post study 
vitrectomy. Complete resolution was achieved after three weeks with combined 
topical antibiotics and intensive topical ocular lubricants.  
 
3.2.6.3.6 Case 5 
 
After three failed previous procedures, a 53 year old Caucasian female presented with 
a painless reduction in vision ten weeks post study vitrectomy and was diagnosed with 
a neurotrophic ulcer. Complete resolution was achieved with four weeks of 
prophylactic topical antibiotics, intensive lubricants and a switch to an unpreserved 
topical steroid.   
All five eyes were treated with standard Argon (532nm) endolaser settings (200-250 
mW, 0.2s and 0.2s). Fundus examination showed marked confluent chorioretinal 
scarring at 3 and 9 o' clock in each case (Figure 3.11 B and D). We concluded that 
confluent intraoperative endolaser at these sites compromised long ciliary nerve 
function, with resultant corneal anaesthesia and ulceration. Concurrent short ciliary 
nerve damage may have occurred in case 4 which also had mydriasis.  No other clinical 
signs suggested a lesion elsewhere in the trigeminal nerve, nor a polyneuropathy.  
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Figure 3.11:  Composite of neurotrophic keratitis after retinal detachment surgery with PVR 
 
 
Figure 3.11. Composite images of AP slit lamp photographs (A) and (C) with 
corresponding fundus images of cases 4 and 2 with corresponding fundus 
images. White arrows indicate corneal ulceration; purple arrows indicate 
confluent laser scars at site of long ciliary nerves. We observed a more 
favourable outcome with a prompt diagnosis compared to when alternative 
causes were initially misdiagnosed. 
 
 
 
 
185 
 
 
 
3.2.6.3.7 Discussion of events; nested study 1 
 
As neurotrophic keratopathy following transcleral cyclodiode laser is well known [242] 
treatment in the regions of the long ciliary nerves is avoided.  Retinal surgeons are not 
afforded the same luxury as ‘treatment-immune sites’ as confluent retinopexy may be 
required for sustained retinal reattachment.  Retinal laser-induced internal 
ophthalmoplegia has been reported in diabetic patients following diode 
photocoagulation [243] and corneal sensitivity reduction after argon retinal laser 
[244]; the former thought to be short ciliary nerve damage and the latter damage to 
the long ciliary nerves.   
We noted a more favourable outcome with early diagnosis (cases 3, 4 and 5). Where 
alternative underlying causes were initially entertained (cases 1 and 2), the outcome 
appears to have been less favourable.  
This first reported series highlighted the importance of remaining mindful of the long 
ciliary nerves intraoperatively and where possible avoiding heavy confluent treatment 
at these sites, without compromising adequate retinopexy.  It stressed the importance 
of prompt recognition and treatment of corneal anaesthesia in order to minimise the 
risk of ulceration and visual loss.  
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 Nested study 2; implant position in silicone oil 3.2.6.4
 
3.2.6.4.1 Background 
 
The pharmacokinetics of Ozurdex in vitrectomised eyes in both animal and human 
models has been previously discussed. (section 3.1.2.1) The unpublished in vitro 
studies of its pharmacokinetics in the immiscible mixture of saline and silicone oil by 
the product’s manufacturer have also been previously outlined.  
However, the clinical experience of the slow release dexamethasone implant in 
silicone oil-filled eyes remains limited. In particular, implant behaviour in this atypical 
intraocular environment has not been described. 
In 2013,  a case report of a trapped implant in the macula region of an oil-filled eye 
reported an associated epiretinal membrane formation and advised either its prompt 
surgical removal or an attempt to displace the implant through posturing[245].  We 
had not observed any similar adverse sequelae despite frequently noting the implant 
positioned behind the oil bubble postoperatively. We therefore reported a different 
experience of this which was published in response [246].  
An internal safety review of trial patients who had received the implant was conducted 
in order to determine the incidence of trapped implants and elaborate further on any 
associated adverse effects of such an occurrence at the request of the sponsor.  
As the trial remained in active recruitment at the time of the 2013 publication, a 
retrospective review of available cases (n=55) was performed and submitted to the 
sponsor. However, a complete review of all sixty eight eyes of sixty eight patients in 
whom the IMP had been administered, was performed upon study closure and is 
herein included in this thesis. 
As previously described, the Ozurdex® implant was injected through an open 
sclerotomy port prior to closure in the oil-filled eye of sixty eight patients included in 
the treatment arm of this study. The implant injection procedure was carried out 
according to study protocol in all cases. A descriptive study of implant position from 
the time of intraoperative injection until dissolution is herein described.   
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3.2.6.4.2 Method 
 
Implant position was observed by slit lamp fundal examination at specific time-points 
and recorded in the medical notes contemporaneously; day one, day 10, 1 month and 
3 months, post-operatively.  A retrospective review of its position in relation to the 
retinal surface was performed and subsequently categorised into one of three zones 
(Figure 1): any part of the implant within the temporal arcade or abutting the optic 
disc (zone1); outside zone 1, but posterior to the equator (zone 2); anterior to the 
equator (zone 3). Spectralis domain optical coherence tomography was attempted at 
all visits in accordance with the study protocol.  
 
Figure 3.12:  Schematic Representation of Zones of Implant Position 
 
Figure 3.12 shows a schematic representation categorising the implant 
position in relation to the retinal surface. An implant in zone 1 was within 
the arcade or abutting the optic disc. Zone 2 implants were within the 
equator but outside zone 1. Zone 3 implants were anterior to the equator    
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Baseline demographics and ocular characteristics were recorded. More specifically, the 
following ocular characteristics were considered to be potentially clinically relevant 
and hence were also recorded: the preoperative presence of epiretinal membrane, 
history of macular ERM/ILM peel or intraoperative peel, pre-existing or intraoperative 
vitreous haemorrhage, intraoperative use of perfluorocarbon (PFCL). Day 1 IOP was 
used as a surrogate marker for oil fill.  
 
 Univariate logistic regression was used to identify factors that might be predictive of 
immediate and final implant position. Since none of the independent variables were 
significant in univariate models, we did not proceed to a multiple variable regression 
analysis.   
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3.2.6.4.3 Results: 
 
3.2.6.4.3.1 Baseline Characteristics 
 
Sixty eight eyes of sixty eight patients were eligible for the inclusion in this nested 
study. The mean age at the time of surgery was 60 years and 4 months (standard 
deviation 14.3). Fifty one (75.0%) patients were Caucasian, ten (14.7%) south Asian 
and six (8.8%) African/Caribbean. There was an equal distribution of laterality. 
Premorbid refractive status was known in 64 of the 68 patients. Of these, 
approximately one half (51.6%) of eyes were within one dioptre of emmetropia in 
terms of spherical equivalent. Seven eyes (10.9%) had refractive error (spherical 
equivalent) of ≥ 6 dioptres.  Surgery for primary PVR (i.e. no previous retinal 
detachment surgery) was performed in 20 patients (29.4%), with 27 (39.7%) patients 
having previously undergone one operation and the remaining 21 patients two or 
more previous operations (median number of previous operations is 1 range 0-3). 
There were an equal number of phakic and pseudophakic patients at the time of 
surgery when the implant was injected. Forty patients (58.8%) underwent an 
intraoperative macular peel (either ERM alone or combined ILM/ERM peel) with an 
additional six patients having previously undergone macular peeling surgery. 
Perfluorocarbon was used as in intraoperative surgical tool in 40 of the 68 eyes 
(58.8%). Vitreous haemorrhage was present in four eyes and the median grade of 
posterior PVR was CP 2 (range 0-12, IQR CP 0-3).   
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3.2.6.4.3.2 Implant Behaviour Intraoperatively 
 
No formal assessment of implant trajectory or velocity was conducted for the purposes 
of this study. Some groups have investigated the velocity of the implant in varying 
media, comparing its speed in saline and in vitreous [247-249] . Reported rates vary 
from 0.8m/s to 1.2 m/s in saline, with velocity reduced in vitreous due to increased 
impedance.  There have not been any reports in the literature to date investigating 
these parameters in the oil-filled eye.  
We encouraged the operating surgeon to visualise the tip of the injector such that it 
could be angled towards the mid-vitreous cavity, thereby allowing the longest 
intraocular path and theoretically reduce the risk of resultant local tissue trauma. The 
procedure for injecting the implant has been described in Section 3.2.4.3.1 and 
visualised in Figure 3.3. 
In reality, the distance that the implant travelled within the silicone oil bubble was 
relatively short. The viscosity of silicone oil is greater than saline and vitreous (which is 
99% water) and hence impedance greater.  We anecdotally found that the implant 
consistently halted a very short distance from the tip of the applicator. Thereafter, due 
to its increased density and lipid insolubility, it ‘sank’ to the most dependant part of 
the eye (usually the posterior pole in the supine patient). No further attempts to 
visualise the implant were made until the next day slit lamp postoperative assessment 
at day 1.  
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3.2.6.4.3.3 Postoperative Findings 
 
3.2.6.4.3.3.1 Exceptions to the Zone Category 
 
Two implants were situated in positions outside Zones 1 to 3 at Day 1 as follows:  
Case 1: 
A pseudophakic, 53 year-old Caucasian female underwent the study vitrectomy 
following a failed previous primary repair.  At Day 1, the steroid implant was trapped 
behind the posterior chamber intraocular lens/bag complex and anterior to the 
silicone oil bubble. The implant position was unchanged at a routine ten day 
postoperative visit (Figure 3.13). The implant was confirmed to have spontaneously 
dislocated to the vitreous base at one month post injection (zone 3) after the patient 
had reported its disappearance from the pupillary axis ten days earlier. No adverse 
effect was noted. The patient had a routine removal of oil procedure four months 
postoperatively and was subsequently discharged from the vitreoretinal service with 
an attached retina at twelve months. [250] 
Figure 3.13:  Retro-IOL implant 
Figure 3.13 (A) AP colour photograph (B) retro-illuminated image showing 
the implant is trapped behind the IOL and anterior to the oil bubble. The 
patient reported that the ‘white line’ she had noticed in the pupil had 
disappeared 10 days prior to her 4 week postoperative review.  
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Case 2: 
A second implant was similarly noted to be trapped behind the crystalline lens at Day 
10, where it remained until its eventual resorption at 3 months. This patient 
underwent uneventful cataract surgery, at month three with no obvious adverse 
effects noted on the adjacent posterior capsule. There was gradual increase in nuclear 
sclerosis of the lens but no evidence clinically of increased localised lens opacity in 
proximity to where the implant had been anomalously situated.  
 
Figure 3.14:  Retro-lenticular Implant 
 
Figure 3.14 shows the sequence of AP photographs from Day 10(A) Week 4 
(B) and Month 3(C) post implant injection. The implant can be seen to 
change morphology and shorten until its eventual resorption by month 3.   
 
 
 
Considering the remaining sixty six implants; at day one approximately one half 
(47.1%) (n=32) of implants were positioned in the vitreous base (zone 3), with the 
remaining implants near equally divided between zones 1 and 2, (n=18 and n=16, 
respectively). No implants situated in the vitreous base at day one changed location 
throughout the follow up period.   
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3.2.6.4.3.3.2 Zone 1 Implants at Day 1 
 
Considering the eighteen implants which were situated within the posterior pole (zone 
1) at day one; by day ten, eight of these implants had spontaneously relocated to the 
vitreous base, with all but three of the remainder in zone 3 by day 30. This suggests 
that the overall incidence of trapped premacular implants in oil-filled eyes is 4.41%. 
Interestingly, one of the eighteen implants was noted to ‘travel’ from zone 1 at day 1, 
to zone 2 at day 10 and eventually relocate to zone 3 by day 30. The three implants 
which remained ‘trapped’ at the posterior pole will be discussed further in due course.  
 
Figure 3.15:  Premacular dexamethasone implant 
Figure 3.15 (A) colour fundus photograph of premacular dexamethasone 
implant at day 1. (B) Corresponding SD-OCT scan shows hyper-reflective 
signal from implant edge of image) and masking of reflectance of deeper 
tissue (C) by day 10 the implant has spontaneously relocated to the vitreous 
base, without any observed adverse effect    
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3.2.6.4.3.3.3 Zone 2 Implants at Day 1 
 
Of the sixteen implants which were located outside the posterior pole, but within the 
equator (zone 2) the majority (n=10) had spontaneously relocated to zone 3 by day 10, 
with four further implants moving by day 30. Two implants remained ‘trapped’ in zone 
2 throughout the follow up period. One of these implants became trapped anterior to 
the edge of a retinectomy against bare retinal pigment epithelium, without any 
adverse effect on outcome. The second remained ‘caught’ superior to the arcade 
(Figure 3.16 and Figure 3.17) again without any observed adverse effect on the adjacent 
tissue clinically.    
Figure 3.16:  An Implant Trapped in Zone 2 
Figure 3.16(A) Fundus photograph showing the dexamethasone implant 
trapped in zone 2. (B) the implant is changing morphology as it degrades (C) 
fragmentation of the implant by month 3  
 
Figure 3.17:  SD-OCT image of Trapped Implant in Zone 2 
Figure 3.17 SD-OCT image of degraded implant at month 3 post injection. 
White arrow indicates hyper-reflective signal which may be the posterior 
meniscus of the oil bubble, or a fine epiretinal membrane.  
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3.2.6.4.3.4 Trapped Zone 1 Implants 
 
The three patients in whom the implant remained trapped in zone 1 throughout the 
follow up period will be discussed in further detail herein. 
Case 1 
A 59 year-old Caucasian male at day 1 post study vitrectomy the dexamethasone 
implant was noted to be situated on the posterior pole with no obvious adverse effect. 
The eye was densely amblyopic with a posterior staphyloma and marked myopic 
macular atrophy. The implant remained visibly in situ at the day 10 and week 6 
postoperative reviews. Figure 3.18.  By month 3 the implant showed signs of 
dissolution with fragmentation into three segments. SD – OCT over the implant 
showed a transmission defect, and masking of the underlying reflectivity of the retina 
deep to it. No adverse effect on the adjacent retinal tissue was noted. Oil was retained 
long-term due to the high risk of retinal re-detachment.  
Figure 3.18:  Implant trapped in Zone 1 (Case 1) 
 
Figure 3.18 (A) 6 weeks and (B) 3 months post injection, the implant can be 
seen to degrade and fragment over the atrophic retinal tissue. (C) SD –OCT 
shows hyper-reflective signal from implant and transmission defect 
‘masking’ reflectance from deeper tissue    
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Case 2 
A 68 year old Caucasian male underwent a 3PPPV, peel of posterior membranes with 
the aid of perfluorocarbon (PFCL) liquid , a 270 degree retinectomy and silicone oil 
tamponade for a recurrent RD with severe PVR (Grade CP 12 [16].  At Day 1 the 
implant was positioned in Zone 1 and imaged at day 10 trapped behind the oil 
meniscus and adjacent to a retained subretinal bubble of PFCL. Oil was retained due to 
the high risk of recurrent RD associated with its removal.  
Figure 3.19:  Composite SD-OCT of trapped premacular implant 
 
Figure 3.19 Left column show sequence through fovea and right sequence 
include implant until dispersion by 6 months. Note hyper-reflectance 
adjacent to the superior border of the implant edge which may represent 
local epiretinal membrane formation (white arrow). Also note left sequence 
highlights partial restoration of outer retinal architecture over 6 months.  
 
 
197 
 
 
 
Case 3 
A 66 year old Caucasian male underwent his study PPV with ERM/ILM peel for a 
recurrent PVR (CP3). A large posterior break was adjacent to the macular hole which 
was treated intraoperatively.  At day 10, the inferior edge of the trapped implant was 
situated over the treated break site (Figure 3.20).  By day 30, an inferior macular 
branch vein occlusion was noted. The event was reported to the sponsor and the 
MHRA notified via the yellow card system. Combined removal of oil, PRP was 
performed with removal of the adherent trapped implant/ERM complex 
intraoperatively.   
Figure 3.20:  Composite trapped premacular implant at Day 10 
 
Figure 3.20 displays trapped implant Day 10 (A) coloured fundus 
photograph (B) autofluorescent image showing hypoflourescence at site of 
previous retinal break and surrounding inferior third of implant (C) SD OCT 
image . An inferior macular branch vein occlusion was noted at day 30. At 
the time of oil removal, the implant was firmly adherent to retina with 
associated epiretinal membrane 
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3.2.6.4.4 Discussion of implant position; nested study 2 
 
Although, the appearance of the implant on the posterior pole may initially appear 
alarming, our series suggests that this is in fact a common event and occurred in over 
one quarter of cases (18 of 68). The overall incidence of trapped premacular implants 
was 4.4% (n=3 of 68).  
Most implants (approximately 50%) were observed in the vitreous base by day one, 
and no change in position was noted thereafter.    
 
Epiretinal membrane was noted in 2 of the 3 trapped premacular implants. Attributing 
causality to ERM formation is difficult in this population as membrane formation is a 
manifestation of the disease process itself. However, its presence may offer some 
insight into the negative findings relating to anatomical outcomes in this trial.  
The concentration of dexamethasone may be expected to be higher, locally, 
surrounding the trapped implant. The formation of local ERM may indicate that the 
slow release preparation has insufficient therapeutic activity to modify the 
vitreoretinal scarring response. It is also possible that the release profile of the 
preparation was affected and thereby altering the pharmacokinetics. 
Conversely, it is possible that the severity and extent of ERM may have actually been 
attenuated by the implants presence. The alternative sequelae of redetachment under 
oil may have ensued in its absence. 
 
A BRVO was noted in case 3 which may have been caused by the mechanical 
obstruction of a macular branch vein. Again, attributing causality is difficult as ocular 
vascular occlusions occurred in other eyes in the study in both groups.  
This nested study provided interesting results of the behaviour of the implant in this 
atypical environment. The findings associated with the trapped IMPs may offer insight 
into the therapeutic activity of the preparation on the PVR process.  
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 Discussion  3.2.7
 
This is the first randomised clinical trial to investigate the use of a sustained release 
corticosteroid preparation as an adjunct in the treatment of established proliferative 
vitreoretinopathy. 
 Recruitment and Retention 3.2.7.1
 
Recruitment rates were initially well ahead of target but reduced from month nine 
until month 13.  This reflects the period with the maximum number of active study 
participants. Since my role involved both recruitment and the clinical management of 
all 140 study participants throughout the trial, a reduction in recruitment may have 
been an inevitable consequence. This could be anticipated in future studies and 
strategies to cover this ‘bulge’ in work load implemented accordingly.   
Nevertheless, as participants completed the study the ‘resource strain’ may have been 
alleviated, allowing us the opportunity to complete recruitment close to target.  
We observed a high eligibility to enrolment ratio which again may be in part explained 
by the pragmatic trial design. Study follow-up visits reflected clinical practice thereby 
nullifying the ‘burden’ of additional visits which some studies adopt. Furthermore, the 
natural history of standard care carries a poor prognosis. Patients who were eligible for 
the study had frequently suffered multiple failed procedures, as shown in section 
2.4.5.4, with two thirds of patients having had at least one previous operation. 
Offering the opportunity to receive a potentially beneficial intervention with a well-
documented side effect profile was usually received positively.  
 
Study retention was also favourable with primary outcome data available for 138 out 
140 participants.  
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 Anatomical Outcome Discussion 3.2.7.2
 
For the purposes of this thesis, anatomical outcomes will refer to surgical success 
(primary outcomes and retinal reattachment rates), overt PVR recurrence and 
epiretinal membrane formation. Visual outcomes and cystoid macular oedema will be 
discussed in parallel, due to their close relationship in this disease population. 
3.2.7.2.1 Primary Anatomical Outcome 
 
The primary outcome was a comparison between the proportion of eyes in which 
stable retinal reattachment was achieved in the absence of internal tamponade 
without additional vitreoretinal intervention. (i.e. primary success with oil removal by 
month six post study vitrectomy). Reported anatomical outcomes in the surgery for 
established PVR vary considerably.  
 
We found no difference in this outcome measure. Approximately one half of patients 
achieved primary success in both groups (49.3% vs 43.3%, adjunct vs control), which 
is similar to previously published rates in RCTs adopting a comparable primary 
outcome measure [98, 122].   
 
In a study comparing the effect of 4mg of intravitreal triamcinolone, Ahmadieh et al 
[83] published an overall primary success rate of 81.3% in eyes with Grade C PVR 
undergoing vitrectomy surgery with an encircling scleral buckle. They observed no 
difference in primary or secondary outcomes between the adjunct and control arms. 
This rate of retinal attachment is markedly higher than other reported series, and has 
yet to be replicated. Cheema et al reported an eventual anatomical success rate of 
87.5% (21 of 24eyes) at 12 months [78]. Drawing direct comparisons is difficult as 
their study was retrospective and non-comparative. Furthermore, disparate 
definitions of success may explain their high anatomical success rate. Eyes with 
silicone oil in situ were included in their definition of success with only 4 of the 21 
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‘successful cases’ undergoing oil removal.  We observed an eventual anatomical 
success rate of 66.7% vs 69.6% at 6 months, in the adjunct and control group 
respectively. However, if eyes with retained oil are included, our ‘success’ rate 
increases to 93% (64 of 69) in both groups.    
 
The Silicone Oil Study reported visual and anatomical outcomes on eyes with 
established PVR. The first report compared silicone oil with sulphur hexafluoride 
(SF6) in eyes with primary PVR and found the former superior [251]. Macula 
attachment was more common in eyes managed with SO (80%) compared to SF 6 
(60%). In the second report, SO was compared to perfluoropropane (C3F8) in both 
primary and secondary PVR. Final anatomical rates were similar (73% vs 64%, 
respectively). Criteria for success included eyes with retained silicone oil. Our study 
outcomes compare favourably to the Silicone Oil Study Report.  
 
As discussed in Chapter 1, the current grading of PVR has served to standardise 
terminology, but remains limited in some respects. The extent of PVR is classified in 
only one circumferential axis,  and thus linear bands of membrane (particularly) 
subretinal, may be apportioned the same PVR grade as extensive posterior retinal 
sheets of membrane. This may offer an explanation as to why the sensitivity analysis 
adjusting for baseline PVR grade failed to show differences in outcome in either group.  
The heterogeneous nature of the population may have limited our ability to detect 
small differences between the two groups. As the study design was pragmatic and 
aimed to reflect clinical practice this is an inevitable consequence.  
 
The study was powered to improve failure rates from 49% to 24%. The primary 
outcome measure was set to reflect a clinically valid treatment effect. This was not 
achieved and hence a shift of focus towards potential treatment effects in secondary 
outcome measures will be discussed.   
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3.2.7.2.2 Secondary Anatomical Outcome Findings  
 
If we consider secondary outcomes indicative of the effect of the IMP on the 
proliferative component of the PVR process, we found no discernible differences 
between the two groups. A comparable proportion of patients achieved complete or 
posterior retinal reattachment and the proportion of eyes with a tractional RD or 
macular pucker was also similar between the two study groups. Furthermore, rates 
of overt PVR recurrence were similar across both groups (58.0% vs 59.4%, adjunct vs 
control). Our lack of treatment effect on the anatomical outcomes in this study 
reflect the findings of Kuo et al [72] in their experimental study of the same 
preparation. However, the significant reduction in inflammatory cytokine expression 
may explain our proposed positive treatment effect in reduction in cystoid macular 
oedema rates. This will be discussed further in due course.   
 
We did note that fewer patients in the adjunct group (n=3) required two or more 
operations to achieve attachment compared to the control group (n=11). However, 
as this was not investigated as a secondary outcome and numbers are small, we did 
not test for statistical significance, and caution must therefore be advised when 
interpreting this difference.    
 
Epiretinal membrane formation rates were comparable across both groups.  
Observations from the second nested study (section 3.2.6.4) may have provided insight 
into the local therapeutic action of the IMP when trapped. OCT guided visualisation of 
the sequelae longitudinally, revealed progressive ERM formation adjacent to and 
involving the trapped implant. This may suggest that the IMP is ineffective at 
modifying the local scarring response or may simply be an indication that the balance 
of activity remained in favour of the PVR process.  
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Taking these secondary findings in conjunction with results of the primary outcome 
measure, we can conclude that a slow –release dexamethasone implant does not 
improve the anatomical success rates in eyes with established PVR.  
 
 Visual Outcomes 3.2.7.3
 
As visual acuity was investigated as a secondary outcome, it is important to 
acknowledge that any observed estimates of treatment effect may be imprecise. 
Where statistical comparisons have been made, these findings are being reported as 
exploratory.  
 
Previous studies investigating the effects of pharmacological adjuncts in eyes with 
established PVR have also primarily investigated anatomical outcomes at either 6 or 12 
months post-surgery. However, reported secondary visual outcomes range 
considerably from 1.2 logMAR to 2.69 logMAR [83, 98, 122].  The visual outcomes in 
both groups in our cohort compare favourably with the aforementioned previously 
published data. Chang et al reported on outcomes in eyes with primary PVR [122] 
whereas Charteris et al [98] included eyes with both primary and secondary PVR, and 
thus is likely more akin to our dataset. Ahmadieh et al [83]reported a best corrected 
visual acuity of 1.2 LogMAR in eyes receiving IVTA compared to 1.4LogMAR  in control 
eyes at 6 months.  
 
The mean VA in the adjunct group was 38.3 ETDRS letters (standard deviation 23.7) 
compared to 40.2 letters (standard deviation 21.1) in the control group. This equates 
to LogMAR VAs of 0.96 and 0.90, and approximates to a Snellen VA of 20/160. 
Similarly, the proportion of eyes achieving a visual acuity ≥ 55 ETDRS letters (> 20/80) 
was also comparable (30.4% vs 24.6%, adjunct vs control) 
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The overall favourable visual outcome in our cohort as a whole (as there is little 
difference between the groups) may be indicative of a general improvement in surgical 
technique but a paucity of corroboratory contemporary data limits our ability to 
confidently draw this conclusion.  
 
If we consider the change in vision from baseline we did not observe any difference 
between the two groups gaining 10,20,30,40 or 50 letters. However, when 
considering the comparison between the proportion of eyes gaining 60 letters or 
more, the observed difference is more apparent. This comparison may show a trend 
towards a treatment effect of the adjunct.      
 
On exploratory sub analysis of eyes without limited visual potential at baseline, we 
found that the vision was consistently higher in the adjunct group compared to the 
control group until month 6 when the results become comparable. In fact the mean 
difference in 7 letters at Day 60 (45 letters vs 38 letters, adjunct vs control) achieved 
statistical significance. Although this difference may be of marginal clinical significance, 
it is an interesting finding.   
 
Further discussion regarding visual outcomes in relation to cystoid macular oedema 
will follow the discussion regarding macular findings.  
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 Macular Findings 3.2.7.4
 
As discussed in 3.1.2.2, the slow release dexamethasone implant is licensed for use in 
the treatment of macular oedema secondary to retinal vein occlusion and diabetes. Its 
therapeutic effect in vitrectomised eyes has also been discussed. 
 
Estimates of the incidence of postoperative cystoid macular oedema following retinal 
detachment repair are difficult to reliably interpret from the literature. Previous 
estimates range from <1% in eyes without PVR [11] to 66% in PVR eyes with limited 
visual recovery [252]. Clinical assessment of the presence of CMO is likely to 
underestimate its incidence. OCT has a higher sensitivity of detecting subtle 
anatomical macular changes which may not be apparent on fundal examination. In a 
recent study of  587 eyes with primary RD treated with either small gauge vitrectomy 
alone (n=461) or combined vitrectomy and scleral buckle (n= 126), the OCT guided 
incidence of CMO was 31.2% vs 48.4% (n= 144 and 61, respectively).[253]   
 
The pathophysiology of CMO is complex involving a variety of processes. Blood-retinal 
barrier breakdown and increased vascular permeability underlie its development. 
Inflammatory cytokines and growth factors (interleukin (IL-1), tumour necrosis factor 
(TNF)-alpha, and vascular endothelial growth factor (VEGF)) are released by activated 
leucocytes which have migrated into the extracellular space and further increase 
vascular permeability. The inflammatory process is thereby amplified.  Expansion of 
extracellular spaces with resultant fluid accumulation, overwhelm homeostatic fluid 
balance mechanisms thereby leading to retinal thickening and commonly visual loss 
[254].   
 
It is reasonable to presume that the incidence of CMO may be higher in eyes with 
proliferative vitreoretinopathy as the circulating levels of inflammatory cytokines in 
the vitreous and retinal microenvironment are high [255-258]. Benson et al[252] -
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reported a 66% incidence of CMO in 35 eyes with proliferative vitreoretinopathy 3 
months after successful retinal reattachment surgery. This figure is comparable to the 
observed rate of 67.1% in our control group.  
 
It is accepted that CMO is a cause of visual loss. Despite finding significant differences 
in rates of CMO at 6 months we did not find any difference in visual acuity at the same 
time-point. When adjusting for eyes with limited visual potential at baseline, the 
similarity in visual outcome was unaffected. 
Furthermore, if we take CMO as the independent variable, and subsequently compare 
the visual outcome in eyes with and without this pathology, we do observe a 
meaningful difference (3.2.5.9.1.1). This difference is apparent in the cohort as a whole 
and also when sub-analysed by treatment group.  
Therefore the following conclusions can be made from the findings of our study. CMO 
is associated with poorer vision in eyes with PVR.  A reduced rate of CMO at 6 months 
is observed in eyes treated with a slow release dexamethasone implant.  One may 
therefore question why we did not observe a treatment effect of the adjunct.  
 
Firstly, since the study was powered to detect a difference in anatomical outcome, it is 
likely that we have insufficient power to detect a difference in visual acuity between 
the two groups. 
If we refer to Figure 3.7, we note that the adjusted mean VA at Day 60 is significantly 
higher in the adjunct group (45 letters) compared to the control group (38 letters). As 
this study visit was scheduled primarily to monitor IOP, an OCT scan was not routinely 
performed and we did not collect data on the presence of CMO at this time point.  
Pharmacokinetic and clinical studies (section 3.1.2.1), consistently describe a maximal 
treatment effect at 2 months post injection, which support our findings.   
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Secondly, the strength of the association between CMO and vision may not have been 
sufficient for us to observe an effect in this study.  
Finally, it is reasonable to assume that there are factors other than CMO which 
contribute to visual loss in eyes with PVR and this warrants further investigation. This 
will be discussed further in Chapter4. 
 
It would be interesting to determine whether the difference in rate of cystoid macular 
oedema is sustained during the second 6 month period or whether the observed 
effects are transient. As the intraocular concentration of corticosteroid decreases and 
the effect of the implant diminishes, the rates of CMO may return to similar levels 
between the two treatment groups.   
 
 
 Quality of Life Analysis 3.2.7.5
 
We did not observe any differences in either of the two quality of life (QAL) 
parameters which were used in the study. Further analysis of the subgroups may 
suggest differences in sub groups of the QAL questionnaires, but this lies outside the 
scope of this thesis.  
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 Intraocular Pressure Findings 3.2.7.6
 
3.2.7.6.1 Elevated IOP following vitrectomy with Silicone Oil  
 
Estimates of the incidence of raised intraocular pressure (IOP) after pars plana 
vitrectomy with silicone oil are difficult to reliably interpret from the literature. 
Disparate definitions of diagnostic criteria for raised intraocular pressure and glaucoma 
contribute to the wide variation in reported rates to date [259].  Additionally, the 
incidence of ocular hypertension and/or glaucoma has often been further sub-
categorised in relation to the timing of silicone oil injection. Thus the researcher is not 
only required to infer rates from inconsistently defined outcome variables, but also 
must attempt to draw comparisons from conclusions drawn from temporally disparate 
events. 
 
The earliest comprehensive report of IOP-related complications following the injection 
of silicone oil was described in 1993 in the Silicone Oil Study Report 4[260]. In 241 eyes 
with established (Grade C) PVR randomised to either intraocular perfluoropropane gas 
or silicone oil tamponade , the  incidence of chronically elevated IOP was significantly 
higher in those treated with oil (2% vs 8%, respectively). Criteria for the 
aforementioned complication included two consecutive or three independent 
postoperative IOP measurements of >25mmHg using applanation tonometry. Six years 
later, Henderer et al [261] reported a 21% incidence of prolonged elevated IOP in 532 
eyes undergoing vitrectomy surgery with silicone oil. Prolonged elevated IOP was 
defined as an IOP requiring operative intervention at any time-point, or an IOP of 
greater than 25mmHg at or beyond month 6 post oil injection. Concurrently, Honavar 
et al [262] published findings of a retrospective study of 150 eyes undergoing 
vitrectomy surgery with silicone oil injection for complicated retinal detachments due 
to PVR, proliferative diabetic retinopathy and trauma. Glaucoma was defined as an IOP 
of ≥24mmHg, which was ≥10mmHg higher than baseline, and sustained for ≥ 6 weeks. 
Glaucoma was found to occur in 40% (n=60) of eyes and directly attributable to 
silicone oil in 70% of cases. Although approximately three quarters of eyes were 
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controlled with medication alone (30%), medication and removal of oil (25%) and  
filtration/aqueous shunt surgery/cycloablative procedures (17%), refractory 
‘glaucoma’ remained in 28% of eyes. Emulsification of silicone oil was found to be 
predictive of poorer IOP control.  
However, Jonas et al [263] subsequently reported a 7.1% incidence of glaucomatous 
optic neuropathy  in 198 eyes treated with 5000centistoke silicone oil. This was in spite 
of finding a 20% rate of IOP rise (defined as at least one episode of >21mmHg) and 
20.2% oil emulsification rate. Contrasting findings may be explained in part by the 
disparate diagnostic criteria, but also the shorter follow up period in the latter.  
More recent studies report incidences of postoperative elevated IOP ranging from 11% 
to 30% [264-266], although a trend towards adopting a lower threshold of 21mmHg is 
apparent.   
3.2.7.6.2 Corticosteroids and elevated IOP   
 
Aside from the reported increased risk of IOP rise secondary to silicone oil injection, 
the potential steroid-induced response from the dexamethasone implant may confer 
an additional risk of IOP elevation. 
The mechanism of steroid induced IOP rise is incompletely understood. It can occur 
following a variety of modes of administration, although it is more commonly 
associated with the use of potent topical corticosteroid use such as prednisolone and 
dexamethasone. [267] It was first reported in 1950 by Mclean et al [268] following the 
systemic administration of adrenocorticotrophin hormone (ACTH), and later with local 
cortisone injection[269].  The physiological diurnal variations in IOP correlate closely 
with plasma cortisol levels,  and this variation is lost following adrenal gland removal 
[270].  
It is generally accepted that the mechanism of induced rise in IOP is at the level of the 
trabecular meshwork and believed that corticosteroids induce an outflow obstruction 
through an inhibition of extracellular matrix degradation and accumulation of 
muccopolysaccarides [271-274].  
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3.2.7.6.3 Slow-release dexamethasone and elevated IOP  
 
Published clinical studies investigating the use of Ozurdex have defined post injection 
elevated intraocular pressure as an IOP ≥ 25mmHg.  The reported incidence of raised 
IOP following the injection of Ozurdex has ranged from 24.0% in non-vitrectomised 
eyes with venous occlusion [221]  to 36% in vitrectomised eyes with diabetic macular 
oedema [230].  In our study, the incidence of at least one episode of IOP rise by month 
6 was 45.7% (n=32) in the adjunct group compared to 31.4% (n=22) in the control 
group.  
 
As mentioned previously, it is difficult to draw direct comparisons between previously 
published data on Ozurdex-induced elevated IOP and our group. Aside from variations 
in diagnostic criteria, there are multiple additional potential factors which may 
contribute to ocular hypertension in this complex patient population i.e. post-pars 
plana vitrectomy alone, silicone oil tamponade, postoperative uveitis and the 
concurrent use of topical corticosteroids. Haller et al’s  [221] incidence of 24% IOP rise 
can be quite confidently attributed to a steroid response induced by the administration 
of Ozurdex, whereas we cannot directly draw that conclusion. If we consider our 
control group, the observed incidence in IOP rise of 31.4% is comparable to previous 
reports.  
 
 
The mean intraocular pressure peaked at day 10 post study vitrectomy in both groups 
and was not found to be statistically significant. However, mean IOP was significantly 
higher in the adjunct group at Day 60 post study vitrectomy and Day 60 post removal 
of oil.  As the implant was injected on two occasions in the adjunct group (i.e. study 
vitrectomy, and removal of oil procedure) it is highly likely that this difference can be 
confidently attributed to an Ozurdex-induced steroid response. This is further 
corroborated by previous studies in which the maximum IOP rise occurred at a similar 
time-point [14, 221, 230].   Interestingly this difference is most marked at Day 60 post 
ROSO when there is no intraocular tamponade, perhaps suggesting that the presence 
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of silicone oil affects the pharmacokinetic profile of the release of dexamethasone and 
thereby may have attenuated any steroid response.   
 
Although, in total, there were more IOP adverse events in the adjunct group (81 
events) compared to control group (70 events), and a larger proportion of patients 
suffered at least one IOP rise in the adjunct group (45.7%) compared to the standard 
group (31.4%), the majority were classified as mild events (i.e. IOP >25mmHg but 
<35mmHg).  Interestingly, the proportion of mild rises in IOP was 74.1% (n=60 of 81 
events) in the adjunct group compared to 60% (42 of 70 events). The proportion of 
moderate or severe IOP rises were lower in the adjunct group as follows; 17 of the 81 
events (21.0%) were classified as moderate compared to   23 of 70 events (32.9%) in 
the control group (Chi squared 2.11, p=0.143); 4 of 81 events (4.9%) in the adjunct 
group were classified as severe compared to 5 of 70 (7.1%) in the control group.   
 
One might have expected a greater difference in the incidence of IOP rises in the 
treatment group compared to the standard group. However, the interplay of factors 
which may either induce an elevated IOP, mitigate against a pressure rise or even 
predispose to hypotony makes interpretation of these results complex. Factors which 
may induce an IOP rise may at least in part be offset by surgical interventions that 
predispose to hypotony. A large proportion of patients underwent a retinectomy 
either prior to entering into the trial, during their primary study vitrectomy or at 
reoperations following recurrent retinal detachment. These eyes, by consequence, 
have an increased surface area of exposed retinal pigment epithelium and therefore a 
subsequent increase in aqueous outflow via the uveoscleral path through the choroid. 
49 of the 70 eyes (70.0%) in the control group had undergone a retinectomy and 45 of 
70(64.2%) in the adjunct group.  Furthermore, severe anterior PVR can reduce aqueous 
production through cyclitic membrane formation and secondary ciliary body 
detachment [275] Although no formal imaging assessment of ciliary body status was 
performed for the purposes of this study, it is likely that this may help to explain why 
silicone oil was retained in a proportion of eyes where there was insufficient IOP to 
allow its removal. 
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The intraocular pressure may either be reduced, unchanged or elevated in the 
inflamed eye. The former may be secondary to reduced outflow from a secondary 
trabeculitis and the latter owing to a  reduced aqueous production as the secretory 
ciliary epithelium function may be impaired [275]. 
 
We noted a lower incidence of postoperative uveitis in the adjunct group (10 patients 
14.3%) compared to the control group 23 patients (32.9%). Relating this to IOP 
variations may be complicated, but again may be indicative of a treatment effect of the 
adjunct.  
 
 
 Hypotony 3.2.7.7
 
Rates of hypotony (defined as an IOP <6mmHg) were comparable across the two 
groups with 14 patients (20.0%) suffering at least one episode in the adjunct group 
compared to 17 patients (24.3%) in the control group.  Just under one half (48%) of all 
episodes of hypotony were recorded at Day 1 post removal of oil. 
 
Hypotony post ROSO is a widely reported event. Kim et al [276] retrospectively 
reviewed 89 consecutive eyes treated with silicone oil following vitrectomy for 
complicated retinal detachment. They reported an incidence of 39.3% of transient 
hypotony post silicone oil removal. A binary logistic regression model found axial 
length to be a predictor of postoperative hypotony with an Odds Ratio of 1.385 
(p=0.023). Interestingly, preoperative IOP, severity of PVR, number and type of 
previous operations and duration of tamponade were not found to be predictive of 
post ROSO hypotony. In our study, silicone oil was removed in 111 of 140 eyes. 
Postoperative hypotony occurred in 27 of 111 eyes (24.3%) of eyes, but recovered in 
the majority.  
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 Conclusion 3.2.8
 
This study suggests that adjunctive slow-release dexamethasone does not improve 
anatomical outcomes in eyes with PVR. We observed a reduction in CMO in the 
treatment group. Exploratory sub-analysis may suggest a corresponding improvement 
in vision at the point of peak intraocular corticosteroid concentration at Day 60.  
 
The primary research paper is currently under review by Moorfields Research 
Management Committee, awaiting approval for submission for publication.   
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 Lessons Learned  3.2.9
 
 MHRA Inspection 3.2.9.1
 
On December 17th 2013, the Ozurdex in PVR Study team received electronic 
confirmation that Moorfields Eye Hospital as Sponsor of non-commercial clinical trials 
of investigational medicinal products (CTIMPs) would undergo a routine GCP 
inspection by the MHRA. Four CTIMPs were chosen to undergo study specific 
inspections, three of which were investigating the same medicinal product, Ozurdex ®.  
All three of these trials were actively recruiting participants. The inspection was 
scheduled to take place between 11th and 13th of March 2014, allowing a three month 
period of preparation.  
 
3.2.9.1.1 MHRA regulatory process; inspections 
 
Current clinical trial regulations make MHRA inspection a statutory requirement 
(2001/20/EC Article 15 (1) (2) and 2005/28/EC Article 21-30.) This mandates the 
inspection of trial sites, manufacturing sites of investigational medicinal products 
(IMPs), laboratories used for sample analyses (where appropriate) and Sponsor 
premises. The aim is to monitor compliance with the provision of Good Clinical Practice 
(GCP) and Good Manufacturing Practice (GMP).  
More specifically the 2001/20/EC European Union Clinical Trials Directive defines an 
Inspection as follows: 
 ‘An act by a Competent Authority (CA) of conducting an official review of documents, 
facilities, records, quality assurance arrangements and any other resources that are 
deemed by the CA to be related to the clinical trial and that may be located at the site 
of the trial, at the sponsor’s and or contract research organisations (CRO) facilities, or 
at other establishments which the CA sees fit to inspect’ 
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There are three types of Inspection: 
• Routine inspections: inspections of the systems and procedures used to conduct 
clinical research in the UK 
• Triggered inspections: ad hoc inspections triggered as a result of MHRA 
licensing requests or reports received on suspected violations of legislation 
relating to the conduct of clinical trials.  
• Committee for Medicinal Products for Human Use (CHMP) requested 
inspections resulting from central MA submissions: The EMEA (The European 
Medicines Agency) co-ordinates these inspections, which are conducted by 
inspectors from the EU Member States.  
 
Routine inspections can be further subdivided into: 
- Systems Inspection (either Sponsor or CRO)  -in order to evaluate the quality 
assurance and quality control systems established by the organisation  
 
- Specific Clinical Trial Inspection – in order to verify that the trial has been/is 
being conducted appropriately such that the data generated is documented 
and reported in compliance with a) the study protocol b) according to GCP 
principles and c) according to sponsor procedures 
 
 
The MHRA provide a notice period of approximately 12 weeks to the organisation, and 
thereafter detail a list of requested information in a dossier. The MHRA must then be 
in receipt of the requested information within 28 days of notice being served. The 
MHRA may then confirm the date of the inspection and will provide an outline plan 
four weeks in advance of the upcoming inspection. 
 
216 
 
 
 
The draft inspection plan outlines the timetable of events and follows a relatively 
standard format. This includes an opening meeting during which the scope of the 
inspection is set and the inspectors are introduced. The plan also highlights the 
processes which are to be assessed by session allocation, and the relevant personnel 
who are invited to interview. Finally a ‘close out’ meeting is held during which the 
preliminary findings of the inspection are discussed.    
 
This process was followed for the routine sponsor inspection at Moorfields Eye 
Hospital in March 2014. The inspection plan confirmed that the Ozurdex in PVR study 
was selected for a trial-specific inspection and that key members of the study team 
were invited to interview.  As the research fellow coordinating and running the trial, I 
was invited to interview by the MHRA and sat in loco PI in his absence. I therefore led 
the study team both through the process of inspection preparation and during the 
formal structured interview.  An outline of my role during this process will be discussed 
herein: 
 
 
 Inspection Preparation  3.2.9.2
 
The intricacies and minutia which constituted twelve weeks of intense preparation for 
this major event are well beyond the scope of this thesis. However, key aspects which 
were identified during the preparation process will be highlighted. They are valuable 
learning points which I will take forward in my continued development as a clinical 
trialist and have already incorporated these into projects which have grown out of this 
research. 
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3.2.9.2.1 In Search of the Perfect Protocol 
 
All clinical trials begin with the development of a clinical protocol. This document 
describes in detail how the trial will be conducted and states the rationale, objective, 
design, methodology, statistical considerations and organisation of the study. It should 
ensure the safety of trial subjects and protect the scientific integrity of the trial.  There 
are a number of useful templates available and prior to the MHRA Inspection, the 
Sponsor (MEH) instituted a standard operating procedure (SOP) outlining the required 
processes during study setup. These included a protocol template to facilitate 
investigators in protocol development. These processes were not yet in place during 
the development of the Ozurdex in PVR Study protocol and thus the MHRA inspectors 
were unable to review our study against these SOPs. This will be discussed in further 
detail in due course. 
 
By definition, in order to gain ethical approval and be granted an authorisation to 
conduct a clinical trial by the relevant regulatory authorities, the protocol must be 
written in advance of commencing the trial. During the active phase of the trial it may 
become necessary to modify the study design particularly if new safety information 
arises. 
3.2.9.2.2 Protocol Deficiencies Identified in the Inspection Preparation 
 
During the inspection preparation process, a review of adverse events was conducted 
in a trial management group meeting and it was noted that ‘cataract’ as an expected 
adverse event had not been recorded as having occurred in any patients at the point of 
review, some 18 months into the trial. As the research fellow clinically managing these 
patients I had confirmed that this was indeed the case. The pharmacovigilance officer 
had previously contacted the study team five months earlier informing us that a 
collective SUSAR had been submitted to the MHRA following the increased rate of 
cataract formation in eyes treated with Ozurdex. This was noted in a CTIMP using the 
same medicinal product but in a different patient population at the study site. Upon 
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receipt of this mail, a response was drafted on behalf of the study team stating that 
the team’s definition of cataract as an adverse event was study-specific. 
 
 As cataract formation is an expected consequence of vitrectomy surgery and that 
cataract surgery at the time of oil removal is considered routine, the study team 
considered the unexpected rapid progression of cataract as an adverse event and that 
clarifying this as a minor amendment to protocol could be done should the sponsor 
require it.  This was acknowledged by the pharmacovigilance officer and the study 
team did not receive any further instruction from the Sponsor. 
 
Upon further review by the Sponsor’s quality assurance (QA) advisors prior to the 
inspection, it was identified that the study team’s definition of cataract as an adverse 
event was not explicitly stated in the protocol. Furthermore, cataract surgery requires 
an admission to hospital (albeit as a daycase admission) and therefore satisfies the 
criteria for seriousness. An adverse event is any untoward occurrence in a subject 
participating in the trial irrespective of the relationship to the IMP. Therefore, as a 
proportion of patients entered the trial without evidence of cataract at the baseline 
assessment and had subsequently undergone cataract surgery, according to the then 
working study protocol, these patients had by definition suffered serious adverse 
events (SAE).  These SAEs had not been reported to the sponsor.  
Upon discussion with the sponsor, it was agreed that a substantial amendment be 
submitted clarifying the definition of cataract in the context of the Ozurdex in PVR 
Study and a file note was created explaining the course of events which had led to the 
oversight. 
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 MHRA Inspection Findings 3.2.9.3
 
Although the study team were commended on our efforts throughout the MHRA 
Inspection by both the Sponsor and the MHRA, reference to the lack of clarity in the 
protocol was raised as a significant finding. Whilst it was acknowledged by the 
Inspectors that the safety of patients in the trial had not been compromised, we had 
contravened regulation by effectively instituting a substantial protocol amendment 
without gaining regulatory authority approval.  
A corrective and preventative action plan was submitted in response to the finding 
acknowledging the oversight and the introduction of a revised CTIMP protocol 
template to ensure that safety sections were addressed more concisely and included 
rationale for risk adapted recording and reporting of AEs for future trials. 
 
The ASCOT study (refer section2.4.8) was one of the first clinical trials to follow the 
new protocol development process. This risk adapted approach was adopted in the 
writing of the study protocol and I shall continue to use the knowledge I gained 
throughout the inspection process in future RCTs.  
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4 Identification of prognostic factors for visual 
outcome  
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4.1 Background 
 
The visual outcome in patients undergoing surgery for PVR is dependent on numerous 
factors. Amongst them, cystoid macular oedema is a key finding in eyes with limited 
recovery [252]. The presence of CMO may be considered a surrogate marker of 
inflammation. The study findings outlined in Chapter 3 suggested a lower rate of 
cystoid macular oedema at the primary end point in eyes treated with the 
corticosteroid implant. We also demonstrated that eyes with CMO see worse than 
those without.  
Although CMO is associated with poorer vision, we did not observe a corresponding 
treatment effect in terms of visual outcome at this time point. We did, however, 
observe a more favourable visual outcome at two months post injection. As the study 
was not powered to detect this difference, the strength of the association of CMO and 
vision was not sufficient to observe this potential treatment effect, and additional 
factors may contribute to visual loss. These require further investigation.  
 
 
4.2 Aims 
 
In this Chapter, I aimed to use spectral domain -optical coherence tomography for two 
purposes. Firstly, I aimed to identify features on the OCT which may correlate to visual 
recovery following successful repair of RDs with PVR. These findings may serve to 
identify neuroprotective and regenerative targets for future studies.  
Secondly, I aimed to assess the use of OCT as an objective measure of vitreous 
inflammation in eyes with PVR. This may serve to define clearer and achievable 
endpoints in PVR trials, where modifying the inflammatory process may be key to 
managing the condition.  
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4.3 Photoreceptors 
 
The human eye contains two types of photoreceptors; rods and cones. They constitute 
the outermost layer of the neurosensory retina. There are approximately 115 million 
rods and 6.5 million cones in the eye. The density of each cell type varies in different 
regions of the retina, with cone density increasing towards to the macula where the 
fovea is exclusively cones (150 000 mm2).  The peripheral retina is dominated by rods 
(30 000 per mm2) [3].  
 
Rod photoreceptors sense contrast, motion and brightness, whereas cones are 
responsible for fine vision, spatial resolution and colour perception.  Both cell types 
share common anatomical features, being long narrow cells with an inner and outer 
segment joined by a connecting stalk of modified cilium. The shape of their outer 
segments differ as their name suggests, with rods adopting a cylindrical shape 
compared to the conical outer segments of cones.  
 
The nucleus of the cell body (ONL)  is ‘separated’ from the inner segments by an 
external limiting membrane (ELM) and project axons  through the outer plexiform 
layer to form synaptic terminals. Here they synapse with bipolar and interneurons. 
These cone and rode synaptic terminals are termed pedicles and spherules, 
respectively [3].  
 
The cone photoreceptor inner and outer segment anatomy and physiology will be 
discussed in further detail due to its reported significance on central visual function 
after retinal detachment repair. 
 
Three types of cone photoreceptor cells exist in humans and are referred to as blue, 
green and red according to their relative light wavelength sensitivity i.e. short, medium 
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and long wavelength, respectively.  The conical outer segments are shorter than rods 
(6um at the base and 1.5um at the apex) and contain the visual pigments known as 
opsins. Cone opsins can be further divided in to photopsin I, II and III depending on the 
aforementioned cell type in which they are found. These pigments are arranged in 
discs which are stacked throughout the length of the outer segments and 
communicate freely with the interphotreceptor proteoglycan matrix.  The villous 
melanin-containing apical processes of the RPE surround the outer segments.  
 
The cone inner segments consist of an inner half known as the myoid region and an 
outer ellipsoid   region. The inner segments are metabolically and synthetically active. 
The myoid region contains numerous organelles including smooth endoplasmic 
reticulum, Golgi bodies, ribosomes, microtubules and glycogen. The ellipsoid region is 
densely packed with elongated mitochondria arranged in parallel. The ellipsoid region 
communicates with the outer segment via a modified cilium which serves as a conduit 
for metabolites and lipids [3].  
 
4.4 Phototransduction 
 
The perception of light is mediated by opsins, which are found in the photoreceptor 
outer segments. These G proteins (opsins) are bound to a vitamin A-derived 
chromophore, 11 cis-retinal. Upon absorption of a photon of light, the 
phototransduction cascade is commenced by the cis-trans isomerisation of these 
transmembrane proteins.  The eventual hydrolysis of cGMP following the transducin-
induced activation of phosphodiesterase, results in a 100-fold amplification at every 
stage. Closure of Na+ channels is achieved by falling levels of cGAMP with resultant 
photoreceptor hyperpolarisation [277]. This results in the subsequent depolarisation of 
ON bi-polar cells and progression of the neuronal impulse along the visual pathway.  
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4.5 Visualising Photoreceptors – Optical Coherence Tomography 
(OCT) 
 
Relatively recent advances in imaging modalities have served to allow us to visualise 
the retinal microstructure in vivo. Comparisons between normal and abnormal have 
further helped us to understand the pathological basis of some ocular disease and 
relate these findings to clinical outcomes.  
 
Optical Coherence Tomography (OCT) is a non-invasive technique which uses light in 
the near-infrared spectrum to create high resolution cross sectional and 3 dimensional 
images of the retina which are thought to correlate well with retinal histology. 
 
 Optical Coherence Tomography – principle 4.5.1
 
 
OCT uses light of 810nm wavelength emitted from a super luminescent diode which is 
split by a partially reflective mirror into a measuring beam and a reference beam.  The 
measuring beam is directed into the eye and reflected to variable extents by 
succeeding ocular interfaces (e.g. retinal layers, RPE and choroid). The reference beam 
is directed to a reference mirror whose position is adjusted to synchronise with the 
returning measuring beam which has reflected from the retinal surface. This results in 
constructive interference.  Deeper structures reflect the measuring beam out of phase 
with the reference beam and produce variable degrees of destructive interference. 
This interference is measured by a photodetector and processed into a signal which 
can be displayed as an image. The signal amplitude determines the brightness of the 
image with highly reflective surfaces seen as brighter lines. 
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Figure 4.1:  Schematic Diagram of OCT Principle 
Figure 4.1 Schematic diagram displaying principle of OCT. 810nm light 
emitted from super luminescent diode is split by a partially reflective mirror 
into a measuring beam and a reference beam.  Reference beam is 
synchronised with reflected beam resulting in interference which is 
measured by a photodetector and processed into a signal which can be 
displayed as an image 
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 Optical Coherence Tomography – Evolution of Identifying Normal 4.5.2
Retinal Anatomy 
 
In 1991, Huang et al published the first report of the clinical application of OCT to 
visualise the human retina [278]. A time domain system was employed and was able to 
resolve to a level of 17um, requiring three minutes to acquire an image of 150 A-scans. 
Its application was limited to cadaveric tissue and described a hyperreflective zone 
indicative of a signal from the retinal nerve layer and an outer retinal hyporeflective 
zone. A second hyper-reflective region distinct from the retina was described and 
thought to be generated from the retinal pigment epithelium. Two years later a system 
that could be used in vivo was described by Swanson et al [279] corroborating the 
anatomical correlates of the two hyper-reflective zones.  
As acquisition speed increased and axial resolution further improved over the 
following six years, the retinal structure was viewed in greater detail. Scans were able 
to resolve images of varying levels of reflectivity such that more retinal layers could be 
distinguished [280-282]. In 2001, ten years after OCT first emerged as a clinical imaging 
tool,  Drexler et al [283]reported on ultra-high resolution OCT which represented a 
major advance in ophthalmic imaging. Where previously OCT systems achieved an axial 
resolution of between 10-15um, ultra high resolution OCT was capable of an axial 
resolution of 3um in the human retina. Images generated from this system displayed 3 
hyper-reflective bands in the outer retinal region attributed to the photoreceptor 
outer segments, the RPE and the choriocapillaris.  
Four hyper-reflective bands were subsequently reported in 2003 by Zawadzki et al 
[284] in that  an additional inner band representative of the external limiting 
membrane was described. The outermost band was attributed to a signal from 
Verhoff’s membrane, representing the structures where the RPE are joined by tight 
junctions. The second and third lines were assigned to the modified cilium (the 
junction between the inner and outer segments of the photoreceptor), and the RPE, 
respectively.  
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 SD-OCT subsequently gained rapid widespread popularity as a clinical tool for disease 
diagnosis and management. Its obvious merits as a modality to visualize the human 
retina almost at a cellular level resulted in a raft of publications describing retinal 
anatomy in a plethora of disease processes. However, concern existed that 
inconsistencies both between and within groups raised doubts to the accuracy of the 
anatomical correlates to which the image bands of varying reflectivity had been 
attributed [285]. For example, internal to the first outer retinal hyper-reflective band, 
the outer nuclear and outer plexiform layers are seen on the OCT scan as regions of 
low reflectivity of markedly different thicknesses. This does not correlate well to 
histological measurements where the two layers are comparable [286]. 
 
Owing to these concerns,  and in an attempt to standardise terminology and 
nomenclature, in 2014 an international panel of imaging and retinal specialists 
published a report proposing a lexicon for anatomical landmarks of the normal human 
retina as seen on spectral-domain optical coherence tomography [287].  Figure is 
reproduced directly from the original publication unaltered and demonstrates the 
relevant nomenclature.  
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Figure 4.2:  Proposed Lexcicon for International Nomenclature of Normal Retinal Image on SD-OCT 
 
Figure 4.2 Reproduced from Staurenghi et al [287] with permission granted 
from Elsevier. Note particularly the hyporeflective zone 8.1 (outer nuclear 
layer), the hyper-reflective band labelled (9) representing the external 
limiting membrane with band 11 representing the ellipsoid zone (formerly 
the IS/OS junction)  
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 What happens to photoreceptors after retinal detachment and 4.5.3
reattachment? 
 
Experimental models of retinal detachment and subsequent reattachment have shown 
that the retinal response to neurosensory separation from the RPE is complex.  Animal 
models based on histological findings have shown that the degenerative process 
occurs progressively inwards from outer retinal structures towards the inner layers. 
Initially, the apical processes of the RPE undergo morphological changes within a few 
hours of RRD [288].  Thereafter, the photoreceptor outer segments shorten with 
subsequent progressive disruption of the inner segments (IS) and IS mitochondria 
following prolonged duration of detachment.  
Apoptosis of photoreceptors has also been described in histological specimens of 
enucleated eyes following traumatic RDs [289].   Photoreceptor apoptosis has been 
shown to be induced following retinal detachment in several animal and human 
studies. Apoptosis has been identified within hours of neurosensory detachment, 
peaking at day 2 and subsequently dropping after one week. [290-292] 
 
Additionally, complex cellular responses including neuronal synapse remodelling and 
Müller cell proliferation have also been described.[292, 293] Cellular signalling 
mechanisms to modify the apoptotic response have been investigated to identify 
targets for limiting photoreceptor loss and improve visual outcome [290, 294]. 
 
Upon subsequent retinal reattachment, the recovery process may therefore require 
regrowth and reconfiguration of the photoreceptor inner and/or outer segments [295-
299], in addition to reorganisation of the cone interdigitation zone CIZ [295, 296].   
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 OCT findings after successful Retinal Detachment Repair 4.5.4
 
With earlier generation OCT models (Stratus, Carl Zeiss, Meditec, Germany), persistent 
submacular fluid was reported as a potential cause of incomplete visual recovery 
following successful RD surgery with vitrectomy and gas tamponade [300, 301] . In 
2002, Wolfensberger et al [300] observed persistent subretinal fluid (PRF) at the fovea 
in 11 of 16 eyes at 1 month, eight of which persisted at month 6. In one case they 
found this still present 12 months postoperatively. Benson et al [301] reported on a 
larger series of 100 eyes and found 15% had evidence of PRF subfoveally at 6 weeks. 
Eyes with this abnormal finding were followed for up to 18 months with sequential 
OCT assessments observing a 53% prevalence at month 6.  These findings were both 
replicated [302] and refuted [303] in fovea-off retinal detachments repaired with 
scleral buckling and the clinical significance of PRF remains uncertain.  
 
In 2008, Smith et al [304] reported on the superiority of fourier domain OCT over 
stratus OCT in this context. Unsurprisingly, due to the superior image resolution, the 
sensitivity in detecting outer retinal abnormalities post RD repair was significantly 
higher using the former OCT model.  They found photoreceptor disruption in 13 of 17 
eyes (76%) imaged with FD -OCT compared to a 12% detection rate (2 of 17 eyes) using 
the Stratus OCT. Interestingly, the incidence of PRF detection was 12% using both 
models.   
 
More recently, several groups have focussed on outer retinal abnormalities visualised 
using SD OCT in eyes postoperatively, and correlated their findings to visual outcomes 
[305-312]. Both qualitative changes in outer retinal band integrity and quantitative 
measures of outer retinal band width have been investigated with varying degrees of 
reproducibility. To date, no such studies have been performed in eyes complicated 
with PVR.  
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The Ozurdex in PVR study showed no difference in anatomical outcomes between the 
two treatment groups (3.2.5.5). There was, however, a difference in rates of cystoid 
macular oedema at 6 months. CMO was present in 66.2% of eyes in the control arm at 
this time-point. Benson et al [252] observed similar rates of CMO in eyes with poor 
visual outcome after RD surgery for PVR.  A lower incidence (42%) of CMO was noted 
in eyes which had received the dexamethasone implant in the Ozurdex in PVR study, 
yet, despite this difference, we did not observe a corresponding better visual outcome 
in this group at this time-point.  
There is, therefore, a clear need to further investigate the cause of limited visual 
recovery in these eyes which have achieved anatomical success and restoration of 
‘normal’ foveal contour. 
 
 OCT Findings in Retinal Detachment 4.5.5
 
Where previously, descriptions of the RPE and neurosensory response to RRD have 
relied upon experimental models and/or histological analyses, the advent of OCT has 
allowed in vivo analysis of this process. In 2000, Hagimura et al [313] were the first 
group to report on the pathological changes in the detached neurosensory retina using 
OCT. Preoperatively,  in 25 eyes with fovea-involving RDs, they found a ‘normal’ foveal 
structure in 40% (10 of25) with evidence of intraretinal separation in 28% (n=7) and 
undulation of the separated outer retina in 32% of eyes. More recently, two groups 
have compared the detached maculae in RRD with acute central serous 
chorioretinopathy (CSR) using SD-OCT [314, 315].  Both conditions result in 
neurosensory detachment, but the eyes achieve consistently better vision upon 
reattachment in latter.  Nakanishi et al [314] reported similar undulations in the 
photoreceptor layer in 47% (7 of15) eyes with dropout of the photoreceptor inner and 
outer segment layers in 6 of 15 (40%) of eyes suffering RRD. These changes were not 
seen in eyes with CSR and they thus postulated that this finding may be involved in 
incomplete recovery of vision after RRD repair.    
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 Visual outcomes after successful retinal detachment repair 4.5.6
 
Despite anatomical success following surgery for fovea-involving rhegmatogenous 
retinal detachment, suboptimal visual outcomes occur, in eyes which appear normal 
clinically. In the absence of factors which would obviously explain reduced 
postoperative visual acuity, e.g. pre-existing macular pathology, amblyopia, 
postoperative media opacity, recent studies have correlated outer retinal 
abnormalities as seen on SD –OCT with poor visual outcome [305, 312]. These findings 
may offer insight into therapeutic targets for neuroprotective or regenerative 
strategies. 
 
 Hypothesis 4.5.7
 
In eyes that have undergone RD surgery with PVR, there are changes in the outer 
retina which can be visualised using Spectral Domain Optical Coherence Tomography 
(SD-OCT) and can be correlated to visual recovery at 6 months post repair.  
 
 Methods/Design 4.5.8
 
This was an observational, non-comparative, cross sectional study of eyes with a 
normal foveal contour as imaged using SD-OCT at 6 months post study vitrectomy in 
the Ozurdex in PVR Study.   
Of the 140 patients who underwent vitrectomy surgery 138 patients were managed 
with silicone oil.  In six patients, an OCT scan was not performed either due to non-
attendance (lost to follow up) or fundus obscuring media opacity. A further 7 eyes had 
neurosensory retinal detachments present. Seventy four eyes with CMO and 5 eyes 
with a history or presence of a full thickness macular hole were also excluded. 
Retained Silicone oil and marked myopic foveal atrophy excluded a further four eyes.   
Of the remaining 42 eyes, a further 15 eyes were excluded due to co-existing ocular 
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pathology limiting visual outcome e.g. amblyopia, macular degeneration, visually 
significant media opacity. Four eyes were fovea-sparing at the time of their study 
vitrectomy and were also excluded. 
Therefore, a total of 22 eyes with fovea-involving RDs complicated with PVR and 
anatomical success at 6 months were included in the study. This group of 22 eyes 
comprised twice as many adjunct patients (n=15) as control patients (n=7).  
 
 OCT scanning protocol 4.5.8.1
 
The OCT scanning protocol sequence has been outlined in the study protocol section 3.2.4.5.5. 
 
 Interpretation of OCT Scan 4.5.8.2
  
Scans were viewed on an HP ProDisplay P201 monitor (20 inches) with a resolution of 
1600 x 900. The B scan displaying the deepest foveal excavation was chosen for 
analysis. The International Nomenclature for OCT (IN-OCT) Consensus was used as the 
reference for identification of anatomical layers and zones as proposed by Staurenghi 
et al [287].  For the purposes of this study the following binary variables were 
identified as either present or absent, a) discontinuity of zone 9 (the External Limiting 
Membrane (ELM)), b) discontinuity of zone 11 (the ellipsoid zone of the 
photoreceptors), c) the presence of discrete hyper-reflectancies in zone 8 (the outer 
nuclear layer) and d) abnormal hypo-reflectancies in zone 12 (the outer segments of 
the photoreceptors). Four continuous variables were investigated as follows: a) foveal 
thickness, b) macular volume, c) outer nuclear layer thickness (zone 8) and d) 
photoreceptor outer segment thickness (zone 12). Both foveal thickness and macular 
volume measurements were obtained using automated segmentation algorithms 
incorporated into the Heidelberg software. ONL and PROS thickness required manual 
segmentation using the measuring calliper setting.  
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Figure 4.3:  External Limiting Membrane Disruption and Photoreceptor Outer Segment Abnormalities on SD-OCT 
 
 
Figure 4.3 (A) and (B) Example of discontinuity/disruption of the external 
limiting membrane (ELM) (white arrow) and photoreceptor outer segment 
abnormal reflectancies (blue arrow). (C) and (D) show the abnormal 
reflections under higher magnification (scale bar 200µm) 
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Figure 4.4:  Outer Nuclear Layer and Ellipsoid Layer Abnormalities on SD-OCT 
 
 
Figure 4.4 (A) Blue arrow indicates discrete hyper-reflective lesions in the 
outer nuclear layer (ONL) (B) red arrow indicates discontinuity of the 
ellipsoid layer 
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Figure 4.5:  Technique for Manual Segmentation of Outer Retinal Layers. 
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 Statistical Analysis 4.5.9
 
IBM SPSS version 22 was used for the analysis. Univariate linear regression analysis 
was performed for all of the aforementioned independent variables using ETDRS visual 
acuity at 6 months post study vitrectomy as the continuous dependent variable. 
Additionally, preoperative visual acuity and baseline grade of PVR (highest recorded 
grade intraoperatively at the time of study vitrectomy) were also included as 
independent variables. Forward stepwise multiple regression analysis was then 
performed for all continuous and binary independent variables significant where p < 
0.05. The final model fitted contained variables significant where p< 0.05. Analysis of 
variance (ANOVA) was used to compare mean postoperative visual acuities by variable.  
 
 Results 4.5.10
 
Twenty two eyes of 22 patients were analysed. There were an equal number of male 
and female patients with a right eye preponderance (59.1%).  Median baseline visual 
acuity was zero ETDRS letters. The median best corrected final visual acuity was 63 
ETDRS letters and median grade of PVR at presentation was grade 3.  Discrete hyper-
reflectant changes in ONL were found in 11 eyes (50.0%).  Discontinuity of the ELM 
was observed in 6 eyes (27.3%). The ellipsoid layer was disrupted in 15 of the 22 eyes 
(68.2%) of eyes. Detecting abnormal hyporeflectancy in the photoreceptor outer 
segment (PROS) layer was challenging and deemed unreliable in 8 eyes. It was thought 
to be present in 12 of the remaining 14 eyes (85.7%). The mean PROS thickness was 
28.5 µm.  Mean central foveal thickness (FT) was 260 µm (SD 38.5) and mean macular 
volume (MV) was 8.33mm3(SD 1.13). The mean thickness of the outer nuclear layer 
(ONL) was 96.2 µm (SD 26.7).   
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Table 4.1:  Patient Demographics and Postoperative SD-OCT findings 
No Sex Eye Final  
VA  
Base 
VA 
PVR 
Grade  
ONL 
abnorm  
ELM 
(disrupt) 
Ellipsoid  
(disrupt) 
PROS 
changes 
FT 
µm 
MV 
mm3 
ONL 
µm 
PROS 
µm 
1 F OD 44 0 4 + + + + 220 7.93 66 26 
2 F OS 51 59 4 - - - - 254 9.06 87 27 
3 F OS 41 0 2 + + + NP 194 6.98 58 12 
4 M OD 71 15 2 + - + + 312 5.92 117 29 
5 M OS 70 15 3 - - + NP 303 9.49 125 23 
6 M OD 36 0 4 + + + NP 220 8.6 64 23 
7 F OS 77 0 3 - - - + 259 8.84 118 32 
8 M OS 35 7 3 + - - NP 232 8.5 66 28 
9 F OD 78 44 4 - - - + 215 7.69 82 28 
10 F OS 63 53 3 - - + NP 314 8.9 119 NP 
11 M OD 63 0 4 - - - + 297 8.34 153 29 
12 F OD 65 39 4 + - + NP 222 7.52 87 23 
13 M OD 63 21 3 + - + + 236 8.74 76 32 
14 M OD 74 0 2 - - - - 293 8.4 128 39 
15 M OD 70 40 2 - - + + 243 5.09 79 33 
16 F OD 74 0 4 + - + + 231 8.65 102 23 
17 M OS 36 0 4 + + + NP 284 8.8 77 30 
18 M OD 58 0 6 + + + + 316 9.99 90 21 
19 F OS 74 11 6 - - - + 310 9.58 136 34 
20 F OD 65 0 5 - - + NP 291 8.6 116 37 
21 F OS 60 0 3 + - + + 237 8.32 97 46 
22 M OD 51 53 2 - + + + 239 9.3 74 25 
 
VA =Visual Acuity in ETDRS letters, Base = baseline, PVR = proliferative 
vitreoretinopathy,  ONL abnorm = Outer nuclear layer hyperreflectancies, 
PROS changes = photoreceptor outer segment hyporeflectancy, FT = foveal 
thickness, MV = macular volume, ONL = outer nuclear layer, PROS = 
photoreceptor outer segments 
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Table 4.2:  Linear Regression Analysis 
Independent 
Variable 
R squared coefficient Standard 
error 
T score P 
value 
95 % 
Confidence 
Interval 
       
Baseline VA 0.026 0.107 0.147 0.730 0.474 -0.20 to 0.41 
Baseline PVR 
Grade 
0.000 0.222 2.655 0.083 0.935 -5.32 to 5.76 
ONL changes 0.256 -13.909 5.304 -2.622 0.016 -24.98 to -2.85 
ELM 
Disruption 
0.484 -21.479 4.959 -4.332 0.000 -31.82 to -11.14 
Ellipsoid 
Disruption 
0.053 -6.771 6.425 -1.054 0.304 -20.17 to 6.63 
PROS change 0.178 11.650 5.598 2.081 0.05 -0.03 to 23.33 
Foveal 
Thickness 
0.115 0.125 0.082 1.529 0.144 -0.05 to 0.30 
Macular 
Volume 
0.014 -1.432 2.810 -0.509 0.617 -7.34 to 4.47 
ONL thickness 0.451 0.356 0.088 4.051 0.001 0.17 to 0.54 
PROS 
Thickness 
0.128 0.716 0.428 1.670 0.111 -0.18 to 1.61 
 
 
Table 4.3:  Multiple Variable Regression Model 
Independent 
Variable 
R squared coefficient Standard 
error 
t P value 95 % 
Confidence 
Interval 
       
ELM 
Disruption 
0.479 -17.636 2.460 -3.32 0.006 -29.21 to -6.06 
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The mean visual acuity in eyes with an intact ELM at six months was 65.8 +/- 2.7 ETDRS letters 
compared to 44.3 +/- 3.6 ETDRS letters in eyes with evidence of ELM disruption (p<0.001). 
(Figure 4.6) 
 
 
 
 
Figure 4.6:  Blox plot of  Visual Acuity Depending on Integrity of ELM 
 
Figure 4.6 demonstrates that in eyes with successful PVR retinal 
detachment repair, achieve a better visual outcome (mean 65.8 , standard 
deviation 2.5) where the external limiting membrane is preserved 
compared to eyes where there is evidence of disruption of this band (44.3 
letters +/- 3.6). (central bar = median, box = interquartile range, whiskers = 
range) 
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 Discussion 4.5.11
 
Despite successful anatomical reapposition of the neurosensory retina to the RPE, the 
visual outcome in eyes which have suffered foveal detachments remains unpredictable 
and sometimes unsatisfactory. Numerous studies have correlated several factors 
predictive of final visual acuity including preoperative VA [316], height [316, 317] and 
duration of detachment [316, 318].  Improvements in imaging modalities have 
facilitated the detailed visualisation of retinal microstructure such that the resolution 
achieved nears histological clarity. Several authors have used OCT to correlate 
postoperative retinal appearance with visual outcome. 
 
In our series, we did not find persistent subfoveal fluid present at 6 months in any of 
the eyes which were imaged. This may indicate that eyes without PVR reattach in a 
different manner to eyes where PVR is present. This pertinent negative finding, further 
questions the clinical significance of PRF as an indicator of limited visual recovery. Its 
previously observed presence may, in fact, have simply co-existed with more subtle 
outer retinal changes which were then yet to be defined due to limitations in imaging 
resolution. 
In 2009, Wakabayashi et al [311] reported the significance of the combined 
discontinuity of the ELM band and the ellipsoid layer (then referred to as the inner 
segment (IS) and outer segment (OS) junction), in relation to postoperative visual 
outcome. Their cohort of 53 eyes consisted of 15 fovea- sparing and 38 fovea-involving 
RDs. Two thirds underwent pars plana vitrectomy with the remaining third managed 
successfully with scleral buckle surgery.   Photoreceptor layer abnormalities were only 
observed in the fovea-involving sub group. No photoreceptor layer abnormality was 
observed in 15 of the 38 eyes (39.5%). Ellipsoid layer disruption with an intact ELM was 
noted in 14 of the 38 eyes (36.8%). Disruption of the ELM was always noted in 
conjunction with ellipsoid layer discontinuity, and was present in 9 eyes (23.7%).   The 
mean best corrected visual acuity was significantly lower (p<0.001) in the group with 
ELM disruption 0.6LogMAR +/- 0.32 compared to eyes with an isolated ellipsoid layer 
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abnormality (0.34+/- 0.15) and those without any detectable photoreceptor 
abnormality (LogMAR -0.03+/-0.10). This mirrors our findings in eyes with PVR where 
the ELM integrity was the only variable significant on the multiple variable regression 
model. We also found a statistically significant difference (p<0.001) on comparison of 
mean post op VA in eyes with and without ELM disruption (44.3 +/- 3.6 ETDRS letters 
vs 65.8+/- 2.7 ETDRS letters respectively).  However, it must be acknowledged that as 
the inclusion required a preserved foveal contour, we may have selected scans of eyes 
with PVR representative of less severe foveal pathology. Extrapolating this finding 
more broadly may therefore be limited.  
 
Wakabayashi et al [311] found recovery of the ellipsoid layer in approximately two 
thirds of eyes with preserved ELM integrity but no evidence of reorganisation of either 
the ellipsoid layer or ELM in eyes where the latter had been affected. Their findings 
supported the histological evidence that the process of neurosensory retinal 
degeneration occurs progressively inwards. They also concluded that involvement of 
the external limiting membrane may be indicative of irreversible damage to the 
photoreceptor cell bodies and Muller cell cone and that it may be predictive of 
restoration of photoreceptor microstructure after RD repair.  
 
In 2010, three groups published their findings [307, 309, 319], two of which 
concentrated only on the integrity of the IS/OS junction (ellipsoid layer) [309, 319]. 
Both Sheth et al [309] and Shimoda et al [319] correlated discontinuity in the ellipsoid 
layer with limited postoperative visual recovery, but the absence of comment on the 
integrity of the ELM makes it difficult to draw direct comparisons to our study. In 
addition to SD-OCT, Lai et al [307] introduced microperimetry and fundus 
autofluorescence findings in their correlation with visual outcome. Again drawing 
direct comparison with our findings is difficult due to differing methodology, 
particularly as our dependant variable remained continuous where Lai et al 
dichotomised visual outcome into optimal, > 0.52LogMAR (6/18  Snellen equivalent)  
and suboptimal ≤ 0.52LogMAR. Individual abnormalities in any of the outer retinal 
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bands (ELM, ellipsoid and cone interdigitation zone) were significantly associated with 
suboptimal postoperative visual outcome. They also noted that the areas of decreased 
microperimetric sensitivity corresponded well with both the ultrastructural OCT 
changes and abnormal FAF.  
 
In 2012, in addition to the aforementioned binary qualitative outer retinal OCT 
findings, three groups introduced quantitative measures [305, 308, 312] as potential 
correlates to visual recovery.   Kim et al [312] found the ONL thickness in reattached 
retina to be significantly thinner than that in the unaffected retina of the same eye, 
when measured equidistant from the foveal centre. The significance of the ONL 
thickness in relation to visual outcome was reported by Gharbiya et al [308] in their 
study of 23 fovea-involving primary RDs. They report a mean post ONL thickness of 
105µm +/- 25.2, which is similar to our findings (96.2 µm +/- 26.7).   Although ONL was 
significant in univariate regression, it subsequently lost significance in our multiple 
regression model. Delolme et al [305] did not find a significant correlation of ONL 
thickness and final VA. However, unlike our findings, they reported the significance of 
the PROS thickness. This will be discussed further subsequently when commenting on 
limitations of our study. Interestingly, Delolme et al found no difference in visual acuity 
between those with ellipsoid layer disruption and preserved ELM and those with 
disrupted ellipsoid layer with ELM disruption 
The anatomical significance of the ELM and its potential significance to visual recovery 
will be further expanded in section 4.6.4 
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4.5.11.1.1 Limitations 
 
Although the numbers included in this study are small they are comparable to 
published studies of similar design.  The sample is a heterogenous group, particularly 
in terms of number of previous procedures and number of times the fovea was 
detached but is reflective of an unselected group of eyes with attached retinae and 
preserved contour at 6 months post intervention. Furthermore, in this study, all 
comparisons are made to published findings on eyes without PVR.  
 
Despite this, the inclusion criteria were still relatively restrictive so as to exclude 
alternative causes of visual loss. Furthermore it was necessary to eliminate variables 
such as CMO and ERM which could have contributed to changes in retinal layer 
thickness and are an obvious cause of visual impairment. The process of scan selection 
could therefore be questioned, as it is likely to favour those eyes with better vision. 
However, it could be argued that focussing on this group of eyes may be of specific 
importance, especially if by improving the modifiable secondary causes of visual loss 
(e.g CMO) we are able to maximise the number of eyes with ‘normal’ foveal contour.  
The cross sectional study design does not give an indication of change over time and 
this could be further analysed in future studies. 
The manual segmentation of photoreceptor outer segment (PROS) layer was 
challenging. Although the inner border (the outer limit of the ellipsoid layer) was 
usually well defined, the outer border was less easily visualised (Figure 4.5). Further 
potential inaccuracies may occur when there is ellipsoid layer discontinuity and the 
reliability of this measurement could be questioned.  
Additionally, the manual segmentation of ONL and PROS and the grading of qualitative 
measures are subjective. Repeat assessment of these images both by myself and an 
independent observer, may help to determine the test-retest variability and provide a 
measure of inter and intra observer agreement.  This may serve to validate my 
findings.  
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Finally, the reliability of hyperreflective outer band continuity as an indicator of tissue 
damage has been questioned.  The absence or fragmentation of the ELM, ellipsoid 
zone and the cone interdigitation zone have been reported as artefact in normal eyes 
[320].  The ability to visualise a band as a discrete structure is a function of multiple 
factors.  Amongst others, this includes the thickness of the flanking layers which 
border the band [319]. Fortunately, these quantitative values were measured in this 
study, but the reliability and reproducibility of the PROS measurements could be 
questioned. 
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4.6 Primary PVR and Primary Surgical Success 
 
Where the work conducted so far on PVR eyes with normal foveal contour post 
successful retinal detachment repair at 6 months has provided interesting results, it is 
limited in both the heterogeneity of the sample and the cross sectional design of the 
study. Information regarding recovery of band discontinuity and change in retinal layer 
thickness may further facilitate our understanding of the visual recovery process in 
these complex eyes.  
Therefore, in order to explore this recovery process over time in a homogenous group 
of eyes with PVR, a longitudinal study design is required. Eyes with primary PVR are 
those where no previous surgery has been performed. Furthermore, focussing on eyes 
where primary anatomical success has been achieved may further improve group 
homogeneity.  
 
 Aim and hypothesis 4.6.1
 
To correlate postoperative visual acuity with postoperative SD-OCT findings in eyes 
with primary PVR fovea-involving RDs achieving primary anatomical success. 
To explore whether outer retinal abnormalities as visualised using SD-OCT change over 
time and provisionally correlate this to visual outcome 
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 Methods 4.6.2
 
Of the 140 eyes in Ozurdex in PVR Study, 41 eyes presented with primary PVR. Twenty 
one eyes achieved primary anatomical success, two of which were fovea sparing and 
two treated with gas. Seven eyes with ocular co-morbidity limiting visual outcome 
were excluded (two eyes were amblyopic, two had macular degeneration, two had 
previous macular surgery and one patient there was a visually significant corneal scar). 
Longitudinal analysis of the remaining 10 eyes was performed and is herein described.  
The OCT scanning protocol and scan interpretation has previously been outlined in 
section 4.5.8.1.  
As the sample size is small, the results will be presented as a descriptive series from 
baseline to 12 months post retinal detachment repair. Statistical comparisons have not 
been made.  This sample of ten patients with primary PVR consisted of five patients 
who had received the adjunct and five control patients. This equal distribution 
occurred by chance and did not form the basis of the sample selection.   
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 Results  4.6.3
 
Table 4.4:  Summary of Ocular and Non-ocular Baseline Characteristics of the Patients 
No Sex Eye AGE  
(Yrs) 
Ethnicity Base 
VA 
ETDRS 
Letters 
Spher 
Equiv. 
Lens 
Status 
No.  of 
Breaks 
RD 
Ext. 
(hrs) 
RD dur.   
 
(days) 
PVR 
Grade 
1 M OS 63 Black 21 -0.25 PCIOL 2 8 365 3 
2 F OS 73 Caucasian 3 -0.75 PCIOL 4 12 18 2 
3 M OD 66 Caucasian 0 + 0.5 CLEAR 2 10 10 3 
4 M OD 65 Caucasian 15 NP PCIOL 2 7 18 4 
5 M OD 64 Caucasian 40 -3.75 NS+ 1 3 NP 1 
6 F OD 73 Caucasian 65 0.0 NS+ 1 4 21 2 
7 F OD 61 Caucasian 0 +1.25 PCIOL 1 9 5 4 
8 M OS 53 Caucasian 42 +0.25 CLEAR 1 8 NP 4 
9 F OS 77 Caucasian 0 -0.68 PCIOL 2 12 28 2 
10 F OS 85 Caucasian 0 NP PCIOL 1 8 90 3 
 
Spher Equiv. = spherical equivalent, No.of Breaks= number of breaks, RD ext 
(hrs) = extent of retinal detachment on clock hours, RD duration = duration 
of RD, PVR Grade = maximum recorded grade of PVR C (either posterior or 
anterior), NP = not possible/not recorded, PCIOL = posterior chamber 
intraocular lens, NS = nuclear sclerosis  
 
 Presenting features 4.6.3.1
 
The baseline characteristics are displayed in Table 4.4. demonstrating an equal sex 
distribution and a mean age of 68.4 years. Presenting visual acuity was poor in the 
majority of the ten cases, with 4 out of 10 patients unable to see any ETDRS letters. 
One patient (case 6) presented with a fovea bisecting retinal detachment and hence 
had a better presenting visual acuity. Six patients were pseudophakic; two had clear 
lenses and two early nuclear sclerotic cataracts. The median grade of PVR was Grade 
C3. The reported duration of RD ranged considerably, from 5 days to one year. In two 
patients the duration of RD was not recorded.  
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 Visual Outcome 4.6.3.2
 
Figure 4. displays the trend of visual recovery for each patient over the 12 month follow 
up period. The final visual outcome was good in most patients, with an observed 
median final vision of 72 ETDRS letters at 12 months (range 44 to 80 letters). In order 
to better graphically visualise the recovery of vision over time Figure 4. has been 
further separated into two sub figures, both containing 5 patients. From these images 
it is clearer to see that in the majority of cases the greatest visual improvement 
appears to occur between baseline and Day 10 post repair. Thereafter, there is further 
improvement up to month 3, with a plateau after month 6.  
Figure 4.7:  Line Graph of Visual Acuity Progression in Eyes with Primary PVR 
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Figure 4.8:  Two Line Graphs of Visual Recovery in Eyes with Primary PVR 
    
Figure 4.8 Two line graphs arbitrarily divided into two groups for clarity of 
display. In general, the greatest improvement occurs initially from baseline 
to Day 10, and up to month 6. Thereafter, the visual recovery appears 
relatively static between months 6 and 12.   
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 Description of Cases 4.6.3.3
 
Selected cases will be outlined sequentially, and where common features present, 
these will be elaborated further in the discussion. 
4.6.3.3.1 Patient 1 
 
Figure 4.9:  SD OCT Sequence of Patient 1 
 
Figure 4.9 . A 63 year old African male underwent a primary retinal 
detachment (RD) repair with silicone oil. Duration of the RD was estimated 
as one year. (A) to (F) demonstrate the sequential SD-OCT scans from day 
10 post repair with oil to month 12 (Scale Bar 200µm, numbers in upper 
right corner of each box of composite display the visual acuity in ETDRS 
letters). (A)  Day 10 post RD repair with oil shows marked disorganisation of 
the outer retina. Discrete hyperreflectancies (red arrow) are seen inner to 
the RPE layer but with no discernible resolution of the outer retinal bands 
representative of ELM and ellipsoid layers. VA is 9 ETDRS letters.  (B) and (C) 
Week 4 and Month 3 post-op showing mild recovery of vision but persistent 
outer retinal disorganisation (D) to (F) the oil has been removed but the 
vision remains poor; scans suggest possible partial reorganisation of the 
ONL but no recovery of the ELM or ellipsoid zone. 
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4.6.3.3.2 Patient 2 
 
Figure 4.10:  SD-OCT sequence of Patient 2 (a) 
 
Figure 4.10  76 year old pseudophakic Caucasian female presented with a 
primary PVR RD of 18 days duration.  She underwent a repair with oil. (A) to 
(D) demonstrate the sequential SD-OCT scans from day 10 post repair with 
oil to day 10 post oil removal at month 4 (Scale Bar 200µm, numbers in 
upper right corner of each box of composite display the visual acuity in 
ETDRS letters). (A) At day 10 post RD repair, the retina is attached with 
disorganisation of the outer retinal hyper-reflective bands, perhaps with 
evidence a residual subfoveal bleb of subretinal fluid. VA is 48 ETDRS 
letters. (B) By week 4, a hyper-reflective outer retinal band (white arrow) 
most likely representative of the ELM is visible but incomplete; VA remains 
poor at 41 ETDRS letters (yellow arrow shows hyper-reflective signal from 
posterior meniscus of oil bubble).   (C) By month 3 the VA is now 60 ETDRS 
letters with a distinct ELM (white arrow) but disrupted ellipsoid layer (red 
arrow). (D) Ten days post oil removal the changes observed in figure C are 
clearer and the vision is unchanged.   Note also the increased number and 
intensity of pixels in the vitreous (white star)   
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Figure 4.11:  SD-OCT sequence of Patient 2 (b) 
 
Figure 4.11 Figure (F) to (G) show sequential SD-OCT scans at months 6, 9 
and 12 of patient 2(scale bar 200µm). Note how the visual acuity remains 
static as the hyper-reflective band representing the ELM remains intact 
whilst the ellipsoid layer continuity improves (C) there are discrete hyper-
reflectant lesions in the outer nuclear layer (blue arrow), the ELM is 
continuous and there may be subtle disruptions in the ellipsoid layer. VA is 
69 letters at month 12 
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4.6.3.3.3 Patient  4 
 
Figure 4.12:  SD-OCT Sequence of Patient 4 
Figure 4.12 A 65 year old pseudophakic Caucasian male presented with a 
primary PVR RD (Grade CP4) of 18 days duration.  (A) to (G) demonstrate 
the sequential SD-OCT scans from day 10 post repair with oil to month 12 
(Scale Bar 200µm, numbers in upper right corner of each box of composite 
display the visual acuity in ETDRS letters). (A) and (B) demonstrate poor 
resolution of the ELM (white arrow) and ellipsoids layer (red arrow) with a 
barely discernible outer nuclear layer. ETDRS VA remains poor (yellow 
arrow indicates hyper-reflection from posterior oil meniscus).  (C) By month 
3, VA has improved to 63 letters as the ELM continuity is restored (white 
arrow) and ellipsoid layer is visible but discontinuous (D) the ellipsoid layer 
(red arrow) appears intact day 10 after oil removal but shows signs of 
discontinuity at month 6  in figure E .  (E) to (G) Months 6, 9 and 12 the VA 
remains stable with a continuous ELM (white arrows), ellipsoid layer with 
disruptions (red arrows) and hyper-reflective lesions in the ONL 
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4.6.3.3.4 Patient 5 
 
Figure 4.13:  SD-OCT Sequence of Patient 5 
 
Figure 4.13 A 63 Caucasian male with early nuclear sclerotic cataract 
underwent a primary PVR RD repair. (A) to (G) demonstrate the sequential 
SD-OCT scans from day 10 post repair with oil to month 12 (Scale Bar 
200µm, numbers in upper right corner of each box of composite display the 
visual acuity in ETDRS letters). (A) Day 10 post RD repair there is 
disorganisation of the outer retinal layers with no ELM band continuity, a 
disrupted ellipsoid zone and a bleb of subfoveal fluid (black region below 
red arrow); corresponding VA is poor at 38 ETDRS letters. (B) to (D) Week 4, 
Month 3 and Day 10 post combined cataract and oil removal, the vision has 
recovered as the ELM appears intact (white arrows) whilst there is 
persistent discontinuity of the ellipsoid layer (red arrows) and persistent 
subfoveal fluid.   (E)  to (G) At months 6,9 and 12 there is gradual recovery 
of the ellipsoid layer (red arrows) with preserved clarity of the ELM (white 
arrows) and discrete hyper-reflections(blue arrow)  in the ONL, the vision 
remains good and stable throughout 
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4.6.3.3.5 Patient  8 
 
 
Figure 4.14:  Preoperative SD-OCT of Patient 8 
 
Figure 4.14 A 53 year old Caucasian male presented with an RD of 8 days 
duration and linear bands of subretinal PVR (Grade 4). Figure shows 
preoperative SD-OCT of detached fovea (scale bar 200µm). Accurate 
identification of outer retinal layers is limited but hyper-reflective band 
(white arrow) may represent ELM, thick undulating hyper-reflective layer 
may represent combination of inner and outer segments of photoreceptors,  
discrete hyper-reflective signal below detached retina (orange arrow) 
corresponds to subretinal PVR membrane. Presenting VA was 42 ETDRS 
letters. 
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Figure 4.15:  SD-OCT Sequence of Patient 8 
 
 
(D) 10 days post combined cataract and oil removal an intraretinal cyst (maroon arrow) 
is visible in the ONL, and the SRM (orange arrow) remains unchanged (E) at month 6 
more cysts are visible within the inner layers of the retina (maroon arrow) , whilst there 
is preservation of the ELM and ellipsoid zone (red arrow) the vision remains stable (F) 
there are gross cystic changes throughout the retina at month 9 and the clarity of the 
ELM is reduced, the vision has worsened and note the increased intensity of pixels in the 
vitreous (white star) (G) at month 12 chronic intraretinal cysts persist, whilst the vision 
has improved along with clarity of the ELM (white arrow)  and ellipsoid layer (red 
arrow).    The SRM (orange arrow) appears unchanged.  
 
G 
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 Discussion 4.6.4
 
As expected, in comparison to baseline, vision improved upon successful reattachment 
of the retina. However, at day 10 post retinal reattachment, no evidence of outer 
retinal band restoration was observed in any of the eyes studied. Thereafter, by weeks 
4 to 6, reorganisation of the ELM becomes noticeable which appears to correlate with 
visual recovery and supports the findings from section 4.5.10.  In this series, ELM band 
resolution appears to occur either prior to, or concurrently with, ellipsoid layer 
restoration. This may suggest that the reorganisation of the photoreceptors post 
retinal reattachment occurs from inner regions, outwards.  
 
The OCT scans of three patients demonstrated the presence of residual subfoveal fluid 
at Day 10 post RD repair. In all three of these patients, discontinuity of the ellipsoid 
layer was present but with preservation of the external limiting membrane. The 
sequence of scans outlining the postoperative course in patient 5, suggest that visually 
recovery can occur independently of persistent subfoveal fluid resorption. This 
confirms findings reported by Seo et al [303] but conflicts with Ricker et al [302]. 
Drawing direct comparisons is limited by the small numbers in our series and the 
differing operative techniques, as both of the aforementioned groups report on 
findings after scleral buckling surgery. 
The significance of the integrity of the ELM requires further elaboration. Anatomically 
it represents the collective row of zonular adherentes connecting the apical processes 
of the Muller cells with the cell bodies of the photoreceptors [321, 322]. Wakabayashi 
et al postulated that ELM disruption represented an irreversible state of photoreceptor 
damage as complete restoration of the ellipsoid layer was not observed following ELM 
disruption. However, in this study we have observed poor ELM resolution at day 10 in 
most eyes, followed by subsequent reorganisation by week 4. Furthermore, we have 
noted that visual recovery can occur independently of complete ellipsoid layer 
restoration but that it does seem to correlate with ELM integrity in both the study of 
primary PVR eyes and in our cross sectional study. 
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The process of visual recovery in PVR eyes post RD is complex. Laboratory work from 
explanted peripheral human retinectomy specimens has demonstrated that most of 
the structural motifs necessary for visual recovery remain in place, even in advanced 
disease [45]. The pathological events in retinal detachment not complicated by PVR 
are therefore of central importance to understanding the reasons for the poor visual 
outcomes in PVR. Müller glia play a central role in the intraretinal remodelling 
response to retinal detachment.  Changes in Müller cell processes are seen within 24 
hours of experimental RD [323]. By day 3, the altered Müller cell processes which 
extend into the subretinal space, appear to do so through localised disruptions in the 
ELM. Those cells which extend into this region (rather than those which remain 
intraretinal)  may ultimately form multi-layered scars [324]. Müller cell processes 
within the sub retinal space appear to inhibit photoreceptor regeneration [293]. 
Furthermore, since glial extensions have been demonstrated in excised epiretinal and 
subretinal PVR membranes, our findings of ELM disruption as a correlate to limited 
visual recovery are supported.  
It could therefore be proposed that disruptions in the ELM which are visible on OCT, 
may not only represent more extensive damage to the photoreceptor cell bodies as 
previously thought [311], but may actually indicate that the equilibrium of the intra-
retinal glial response has been shifted from protective to destructive. Furthermore, it is 
possible that the aforementioned OCT studies on eyes without PVR where ELM was 
found to correlate to visual recovery, may actually be describing a subtle sub-clinical 
demonstration of PVR in its early stages.   
 
4.7 Summary  
 
We have noted both in the multiple regression analysis of our cross sectional study and 
anecdotally in the longitudinal analysis of eyes with primary PVR, that vision appears 
to correlate with ELM integrity and this is supported by laboratory reports. Should our 
findings be validated, differentiating the different aspects of features we have 
observed may be important in the design of future trials of new treatment.   
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4.8 Grading Intraocular Inflammation 
 
Analysis of intraocular inflammation may be performed clinically or using automated 
tools. The former is subjective. Its reliability may be observer dependent and thus may 
be inherently limited by subjectivity. Classification and standardisation of inflammation 
is important.  
Proliferative vitreoretinopathy is an inflammatory condition and the work in this thesis 
aims to identify strategies to improve outcomes in these patients. Establishing an 
objective marker of inflammatory activity may not only facilitate ‘real-life’ disease 
management of PVR but may prove critical in the context of future clinical research, 
where clearly defined endpoints are required.   
 
 Clinical analysis of intraocular inflammation 4.8.1
 
Clinical methods of classifying aspects of intraocular inflammation involve quantifying 
the following parameters in the anterior and posterior chambers: 
x anterior chamber cells 
x anterior chamber flare 
x vitreous haze  
The most widely employed system in clinical practice was initially described in 1959 by 
Hogan, Kimura and Thygeson when classifying inflammation in eyes with uveitis [325]. 
The number of anterior chamber cells visualised in a ‘wide beam with a narrow slit’ 
were summed and categorised into one of four categories (i.e. 1+, 2+. 3+ or 4+)  
reflecting increasing severity of disease activity. Descriptions of anterior chamber flare 
had rather less well-defined classification criteria. Its severity was graded depending of 
the clarity by which intraocular structures (i.e. iris/lens)  were visible [325].   
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Classification of vitreous haze was first formally described by Nussenblatt et al in 1985 
[326]. In their report, they describe a similar incremental categorical scoring system 
whereby the observer views the fundus through an indirect binocular 
ophthalmoscope. The viewed image is then compared to standard photographs with 
varying degree of fundal clarity and feature obscuration. The inflammatory activity in 
the vitreous therefore ranges from the greatest amount (4+) through lesser 
intermediate points (3+, 2+, 1 +, trace) to no evident vitreous haze at all (0).  
 
Where the optic nerve head is obscured the vitreous haze is graded as 4+. Where the 
optic nerve head is visible but with indistinct borders, the grade is 3+. A 2+ haze allows 
for better visualization of the retinal vessels, while 1 + permits a better definition of 
both the optic nerve head and the retinal vasculature [326] . The differences between 
trace vitreal haze and 0 are sometimes subtle. The trace eyes are those in which the 
nerve fibre layer striations cannot be visualized and there may be slight blurring of the 
optic disc margin.  
 
 
 
In 2005, the Standardization of Uveitis Nomenclature (SUN) Working group published 
guidelines on the reporting of clinical data in eyes with uveitis [240] . In addition to 
standardising diagnostic terminology and outcome measures, group members agreed 
a consensus of grading intraocular inflammation in terms of the three aforementioned 
parameters above. 
 
Table 4.5, Table 4.6, and Table 4.7 which follow display the SUN criteria for grading 
anterior chamber cells, anterior chamber flare and vitreous haze 
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Table 4.5:  SUN Working Group Grading Scheme for Anterior Chamber Cells 
Grade Number of Cells in Field* 
0 <1 
0.5 1-5 
1 6-15 
2 16-25 
3 26-50 
4 >50 
 * Field Size is 1mm by 1mm Slit Beam 
Table 4.6:  SUN Working Group Grading Scheme for Anterior Chamber Flare 
Grade Description 
0 None 
1+ Faint 
2+ Moderate (iris/lens details clear) 
3+ Marked (iris/lens details hazy)  
4+ Intense (fibrin/plastic aqueous) 
            
Table 4.7:  SUN Working Group Grading Scheme for Vitreous Haze 
Grade Description 
0 None 
0.5+ NFL striations not visible 
1+ Clarity of Retinal Vasculature and 
Optic Nerve Head 
2+ Retinal Vessels Visible 
3+ 
 
Visible Optic Nerve Head 
(indistinct borders) 
4+ Optic Nerve Head Obscured 
  NFL = Nerve Fibre Layer,  
The SUN classification of vitreous haze mirrors that reported by Nussenblatt et al [326] with 
the simple substitution of ‘trace’ with ‘0.5’, for consistency. 
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 Objective Measurement of Intraocular Inflammation 4.8.2
 
Although the SUN classification served to standardise nomenclature and facilitated the 
reproducible reporting of clinical signs, it remained subject to both inter and 
intraobserver variability [327]. Furthermore, it only provides a categorical incremental 
scale which at the lower end of disease severity is poorly discriminatory and lacks the 
sensitivity required in the clinical trial context [328, 329]. 
 Laser Flare-Cell Photometry 4.8.2.1
 
Efforts to provide objective measurements of anterior chamber inflammation using 
automated techniques have principally relied on laser flare-cell photometry [330].  This 
technique quantifies aqueous humor protein (flare) and cells using either a helium-
neon or diode laser that is projected into the anterior chamber [331, 332].   
For flare measurement, light is detected by a photomultiplier which scans across a 
fixed area over a fixed time period (0.3mm X 0.5mm over 0.5 seconds).  The average of 
two additional background readings above and below the fixed window are obtained. 
This is subtracted from the reading within the scanned window to provide the laser 
flare photometry measurement, which is expressed in photon units/msec [330].  
Aqueous cells are detected similarly by a laser scan through a fixed aqueous volume 
over a fixed time period (0.5mm X 0.6mmX 0.25mm over 0.5 seconds). Light reflected 
off an aqueous particle is recorded as a peak of light by the photomultiplier and 
counted as a single cell (provided it is of an intensity higher than a preset background 
threshold). A fixed cell index (or count) is thus generated [330].  
Laser flare-cell photometry has provided an objective measure of intraocular 
inflammation as determined by the degree of anterior chamber activity. It has been 
used to quantify intraocular inflammation various conditions involving both anterior 
and posterior segment pathology [333-337] .  It is a safe and non-invasive technique 
that may be a useful research tool which provides a more accurate and reproducible 
method for quantifying anterior chamber protein and cells than clinical observation 
alone. Its precise role in clinical practice has yet to be definitively determined. 
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 Objective Measures of Vitreous Inflammation Analysis; VITAN 4.8.2.2
 
Until recently, no objective measure of posterior inflammatory activity existed. Laser 
flare-cell photometry of the anterior chamber has been used as an indirect surrogate 
marker of posterior chamber inflammation but with obvious limitations.     
 
In 2014, Keane et al published a pilot study describing their development of an OCT-
derived signal of vitreous intensity in eyes with intermediate and posterior uveitis 
[338].  They describe an automated technique whereby the intensity of pixels 
calculated in a fixed compartment (the vitreous) can be summed to generate a mean 
OCT intensity. This is then expressed in arbitrary units as a ratio, in relation to the 
signal generated from the RPE (vit/RPE relative intensity ratio).  This objective measure 
was found to correlate well to clinical scores of vitreous haze in uveitic eyes with and 
without haze, and normal controls.  
A second report was published, the following year further validating the tool and 
described   improvements to the automation process [339]. Where the initial pilot 
study required manual segmentation of the OCT to define the borders of the relevant 
compartments (RPE and vitreous), a fully automated algorithm was developed in order 
to eliminate observer subjectivity completely. Furthermore, additional indices were 
introduced as objective markers of vitreous inflammation. 
 
I am grateful to Pearse Keane, Tariq Aslam and Alastair Denniston who have kindly 
provided me with the updated software (VITAN, vitreous) described in their recent 
publication in order to explore its role in the management of eyes with PVR.  
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 Aims and hypothesis 4.8.2.3
 
The aims of the subsequent study were to determine the use of VITAN as an objective 
measure of vitreous inflammation in eyes which have undergone surgery with PVR in 
the context of work in this thesis: 
As cystoid macular oedema is a well-defined primary endpoint, one might assume that 
the level of vitreous inflammation would be higher in eyes with this abnormality when 
compared to eyes without CMO. 
Furthermore, eyes treated with a slow-release dexamethasone implant may be 
expected to display lower levels of vitreous inflammation than eyes without adjunctive 
corticosteroid. 
 
Hypothesis: 
1) There is a difference in the objective markers of vitreous inflammation in eyes 
with and without CMO,  6 months after successful retinal detachment surgery 
for PVR 
2) Eyes treated with a slow-release dexamethasone implant have a lower ‘marker’ 
of vitreous inflammation after injection 
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 Methods 4.8.3
 
 Selection of subjects: 4.8.3.1
 
Of the 140 eyes in the Ozurdex in PVR Study, at 6 months post study vitrectomy, 
approximately one third retained silicone oil and hence were excluded. Forty five eyes 
with cystoid macular oedema and twenty seven eyes without CMO were included in 
the study. These eyes were not divided by treatment allocation, as the presence or 
absence of CMO was used as the dichotomising variable. Fifteen normal eyes served as 
controls.  
For comparison of the proposed treatment effect of corticosteroid vs non-
corticosteroid treated eyes, the time-point chosen for cross-sectional comparison was 
following the injection of the second Ozurdex® implant. At 10 days post combined 
silicone oil removal and implant injection, eyes were without internal tamponade. 
Furthermore, pharmacokinetic studies describe detectable differences in 
dexamethasone concentrations within the vitreous by day seven [213]. Twenty two 
eyes treated with Ozurdex and twenty four eyes without Ozurdex were compared. 
Fifteen normal eyes served as controls.  The control data were kindly donated by Tariq 
Aslam and was obtained from a bank of normal subjects. 
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 Application of VITAN 4.8.3.2
 
The OCT scanning protocol used has previously been described (Refer Section 
3.2.4.5.5). B scans with the deepest foveal excavation were manually chosen for 
analysis. In eyes with cystoid macular oedema, or where a foveal dip was not visible, 
local anatomical landmarks were used to determine the scan through the fovea. 
Images were exported in a 1:1 pixel format with maximum resolution and zero 
compression. All scans were then opened in Windows Live Photo Gallery and cropped 
to a fixed dimension of 506 X 489 pixels. 
 
VITAN is based upon the MATLAB image-processing platform (MathWorks, Natick, MA, 
USA), and was designed, developed, and coded to work with Heidelberg Spectralis OCT 
images [339]. MATLAB version R2015-b was used during this study. 
 
 
 Deriving objective measures of vitreous inflammation   4.8.3.3
 
The algorithm sequence was previously developed and validated by Keane et al. The 
process by which objective indices are obtained will be briefly outlined herein.  
The OCT scan is loaded into the software and a sequence of algorithms initiated in 
order to automatically segment the image into binary form consisting of retinal and 
pigment epithelial layers. This then allows the software to precisely construct a 
rectangle consisting entirely of vitreous tissue, just anterior to the macula. Its position 
is confirmed by the user, or can be manually adjusted as necessary. Thereafter, the 
analysis proceeds as described above (section) generating a mean intensity signal 
relative to that derived from the segmented RPE layer. This allows for variation in 
image gain (e.g media opacity).  Additional algorithms are derived using mathematical 
descriptions of texture relative to the RPE. Figure 4.16 displays this sequence.  
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Figure 4.16:  Sequence of Automatic Segmentation in Vitreous Analysis 
 
Figure 4.16 showing sequence of automated segmentation in order to 
automatically segment image to construct rectangle for analysis (A) initial B 
scan image uploaded into software (B) binary from of image following 
automatic segmentation (C) rectangle constructed consisting entirely of 
vitreous and sited anterior to macular. Mean intensity of pixels contained in 
this area is calculated 
 
 
 Data analysis and statistical methods 4.8.4
 
The two imaging process measures were a) the mean intensity adjusted for the RPE 
(MIA) and b) the texture intensity adjusted for RPE (TIA). These two objective indices 
were chosen as they are previously validated measures of vitreous inflammation. 
Statistical comparisons were made using the Kruskal Wallis H test and Mann Whitney 
U test for non-parametric data in IBM SPSS version 22.0.   
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 Results 4.8.5
 
 Accuracy of automated vitreous segmentation 4.8.5.1
 
A total of 133 scans were processed. Four scans were of insufficient quality for the 
software to initiate the algorithm sequence. The automated box placement was 
inaccurate in seven scans and required manually siting. Statistical analysis was 
performed both including and excluding these eyes.  
 
 Adjusted mean intensity (MIA) and texture intensity (TIA) values; 4.8.5.2
cystoid macula oedema 
 
The median MIA in eyes with cystoid macula oedema was 19.1, compared to 15.8 in 
eyes without.  This difference was not statistically significant. However, the median 
MIA of both groups were significantly higher than he MIA in normal controls (MIA = 
7.2, p=0.001). 
 
The median TIA in eyes with CMO (TIA = 5.07) was also similar to eyes without CMO 
(TIA = 4.63) but significantly higher (p=0.001) than normal controls (TIA = 1.12). Figure 
4.17 and Figure 4.18  display the box plots demonstrating the sample distributions for 
MIA and TIA by group.  
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Figure 4.17:  Boxplot of Mean Intensity Adjusted for RPE (MIA) Score in PVR Eyes; CMO comparison 
 
 
 
 
 
 
 
 
Figure 4.17 demonstrates the mean intensity adjusted for RPE (MIA) is 
comparable between eyes with and without CMO but significantly higher 
than normal controls (central bar = median, box = interquartile range, 
whiskers = range) 
 
 
Figure 4.18:  Boxplot of Texture Intensity Adjusted for RPE (TIA) Score in PVR Eyes; CMO comparison 
 
 
 
 
 
 
 
 
Figure 4.18 boxplot demonstrates the texture intensity adjusted for RPE 
(TIA) is comparable between eyes with and without CMO but significantly 
higher than normal controls (central bar = median, box = interquartile 
range, whiskers = range) 
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 Adjusted mean intensity (MIA) and texture intensity (TIA) values; day 4.8.5.3
10 post implant 
 
The median MIA in eyes day 10 post -implant was 21.50 compared to 19.41 in eyes 
that had not received the implant.  This difference was not statistically significant. 
However, again the median MIA of both groups were significantly higher than the MIA 
in normal controls (MIA = 7.23, p<0.0001). 
The median TIA in eyes treated with Ozurdex (4.58) was also similar to untreated eyes 
(5.23) but significantly higher (p=0.001) than normal controls (TIA = 1.12). Figure 4.19 
displays the box plots for MIA and TIA by group.  
 
Figure 4.19:  Boxplots of Adjusted Mean and Texture Intensity Scores Day 10 Postoperatively 
 
Figure 4.19  above demonstrates that  mean intensity adjusted for RPE 
(MIA) and texture adjusted for RPE (TIA)  are comparable between eyes 
treated and not treated with Ozurdex, but significantly higher than  normal 
controls ((central bar = median, box = interquartile range, whiskers = 
range) 
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 Discussion 4.8.6
 
This custom image analysis software (VITAN) has been so far validated as an objective 
tool to measure vitreous inflammation in eyes with uveitis [339]. Recently, the 1st 
generation automated tool adopting the vit/RPE index (which preceded VITAN) was 
shown to have comparable sensitivity between eyes irrespective of phakic status and 
previous vitrectomy [340].  
The VITAN software was user friendly and only failed to initiate the automated 
algorithm sequence in four scans out of 133. It correctly segmented the images in 
order to generate the rectangular box for analysis in all bar 7 eyes (5.3%). In these 
eyes, the rectangle was manually positioned which upon sensitivity analysis, did not 
affect the overall findings.    
Considering the two measures of inflammation, mean intensity adjusted for RPE (MIA) 
and texture intensity adjusted for RPE (TIA), we found no difference between the 
groups with and without CMO. However, there was a notable difference between 
these groups and the control population in both these indices.  
Figure 4.20 shows examples of images in each group with their corresponding intensity 
scores.  
Figure 4.20:  Example of Varying Vitreous Intensity Scores 
Figure 4.20 highlights examples of scans of eyes post PVR detachment 
surgery with and without cystoid macular oedema and normal controls. 
Their respective intensity scores are as follows (A) Eye showing CMO with a 
mean intensity adjusted for RPE (MIA) of 15.87 and texture intensity 
adjusted (TIA) score of 3.11, (B) No CMO where MIA is 11.89 and TIA is 1.99 
(C) normal control eye where MIA is 4.12 and TIA is  0.54 
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PVR is an inflammatory process, and surgical intervention is intrinsically perceived as 
an injury, thereby further contributing to the inflammatory response. It is therefore 
unsurprising that these eyes ‘score’ higher in markers of vitreous inflammatory activity 
compared to normal eyes. Drawing comparisons to Keane et al's publication, the MIA 
and TIA scores for both groups (CMO vs no CMO) are similar to those eyes which 
correlated to clinical scores of 2+ vitreous haze. Interestingly, the VITAN scores 
correlating to clinical vitreous haze scores of +1 and +2, are the least discriminatory of 
subgroup classification and may offer a reason as to why we did not observe a 
detectable difference between eyes with and without CMO.  
 
Additionally, the TIA was found to correlate marginally better than MIA with clinical 
grades of vitreous haze in the report by Keane et al. They describe the image texture 
as that referring to ‘spatial variation in pixel intensity [which] allows quantification of 
intuitive features such as roughness or bumpiness of the image’.  
At 10 days after removal of oil, eyes with a slow–release dexamethasone implant did 
not show a significantly lower MIA or TIA compared to eyes which had undergone 
standard care. However, both groups scored higher than normal eyes.  
Pharmacokinetic studies have shown a detectible rise in dexamethasone concentration 
by day 7 post injection [213], but this does not seem to correlate to reductions in 
objective markers of inflammation in eyes with the implant in situ in our cohort. As the 
peak in dexamethasone concentration and secondary therapeutic action of Ozurdex 
peaks by month 2, analysis at this time point may increase the chances of VITAN 
detecting a difference between the two groups.   
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 Study Strengths and Limitations 4.8.6.1
 
Observer bias is unlikely to be a significant limitation of this study as the process is 
near fully automated, with manual input required in only 5% of eyes. Masking of the 
primary assessor in eyes with and without CMO is not possible as it is visualised on the 
scan.  Nevertheless, as the primary assessor, I was not masked to the treatment 
allocation of eyes which had received the dexamethasone implant and this must be 
acknowledged.  
 
Our study has limitations which will be discussed in turn. Firstly, assumptions have 
been made that the clinical correlations of VITAN have already been validated and no 
further attempts were made to correlate our objective indices clinically. This was due 
to the retrospective design of this study. It is also important to note that the previously 
reported correlations of VITAN with clinical haze score were moderate [338], and 
discordances of agreement may reflect limitations of both.   
 
Additionally, only one foveal B scan was selected for analysis. VITAN generates 
intensity indices relative to the RPE in order to compensate for overall variability in 
image gain.  Nevertheless, to further account for this variability, analysing more than 
one B scan per eye and averaging the indices may be preferable. 
 
The cross-sectional design of the study may have also limited our ability to detect 
differences in both groups of interest, particularly in the comparison between eyes 
with and without adjunctive Ozurdex. A longitudinal study investigating the change in 
VITAN indices may increase the sensitivity of detecting differences in vitreous 
inflammation in eyes where the treatment effect varies over time. This may also 
overcome the limitations of inter-eye variability that may exist.  
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 Conclusion 4.8.7
 
PVR eyes have higher level of inflammation than normal and hence a higher likelihood 
of developing CMO and fibrogenic growth factors. The custom SD-OCT software VITAN 
may provide and objective measure of vitreous inflammation in eyes following surgery 
for PVR, but appears to lack the sensitivity required to discriminate between subtle 
differences at moderate levels of inflammation in our cohort. Further longitudinal 
studies in this population may be helpful to further develop the application of this 
objective tool. 
 
 Relevance of this work to thesis 4.8.8
 
The lack of observed treatment effect in the primary anatomical outcome of the 
Ozurdex in PVR study may in part be due to the optimistic nature of the primary 
endpoint. However, should VITAN prove to be a reliable discriminator of moderate or 
marked grades of inflammation, it may serve as an ancillary tool as an objective 
measure of disease activity in the clinical trial context. This may be of particular value 
in future PVR trials where modifying the inflammatory response and objectively 
assessing the level of blood ocular barrier breakdown is important.  
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5 Exploratory Investigation into Retinal 
Regenerative Strategies in Eyes with PVR 
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5.1 Müller Glial Cells 
 
Müller cells are the principal glial cells found in the vertebrate retina and can be 
considered analogous to oligodendrocytes in the central nervous system. Müller cells 
span the entire depth of the retina. Proximally, their expanded endfeet lie adjacent to 
the internal limiting membrane and abut the vitreous body, with their distal limit 
marked by tight junctions with photoreceptor inner segments, to form the external 
limiting membrane [341]. They are, therefore, able to ensheath or interact with all 
retinal neuronal somata and processes and form both an anatomical and functional 
link between all compartments within the retinal microenvironment from the vitreous 
body proximally, to the choroidal circulation via the RPE, distally [342]( Figure 5.1.) 
Figure 5.1:  Müller glial cell morphology 
Figure 5.1 Müller glial cell morphology (Adapted from [342]with permission) 
(A) Drawing of a Golgi-labelled rabbit Müller glial cell (B) Müller cells of a 
guinea-pig in slice selectively stained with Mitotracker orange (green), (C) 
artist’s impression of a human Müller cell (blue) enveloping various types of 
neurones (green) and interacting with retinal capillaries (cap, red) NFL = 
nerve fibre layer, GCL = ganglion cell layer, IPL = inner plexiform layer, INL = 
inner nuclear layer, OPL= outer plexiform layer, ONL =outer nuclear layer 
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 Role of Müller cells 5.1.1
 
The role of the Müller cell in the vertebrate retina is diverse and extensive, performing 
the functions that oligodendrocytes, astrocytes and ependymal cells effect in other 
regions of the central nervous system [343]. In addition to stabilising the complex 
retinal architecture and providing neuronal support, they have key roles in the 
buffering of K+ and water, free radical scavenging, neurotransmitter recycling and the 
regulation of retinal blood flow. Figure 5.2 and Table 5.1 summarise these key 
functions.      
Figure 5.2:  Müller cell interactions in healthy mature retina 
Figure 5.2 (Adapted from [342] with permission requested) Important 
Müller cell interactions in healthy mature retina (A) buffering of K+ ions and 
water (B) neurotransmitter recycling (C) retinal blood flow regulation and 
maintenance of BRB (D) free radical scavenging/GSH metabolism (Key CA = 
carbonic anhydrase, cyst = cysteine, GABA = gamma-aminobutyric acid, glut 
= glutamate, GS = glutamate synthetase, GSH = glutathion, LDH = lactate 
dehydrogenase, PK = pyruvate kinase, R ◦ = free radical molecule 
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 Müller glia as stem cells 5.1.2
 
Stem cell-based therapies to replace irreversibly damaged tissue has proved successful 
in the anterior segment where access is good and the target structure is relatively 
simple [344].  However, regenerating the complex multilayered neural retina has 
highlighted many problems which remain unsolved.   
Fish and amphibians regenerate neural retina throughout their life [345]. Compelling 
evidence for the ability of a population of Müller glial cells (MGC) to regenerate retinal 
neurons in the post-natal eye has been demonstrated in the adult zebra fish. In this 
species, Müller glia cells constitute the retinal stem cell niche and are able to 
regenerate the complex multilayered retina following full thickness injury. This ability 
for regeneration has been shown to be the result of Müller cell de-differentiation, re-
entry into the cell cycle and production of a progeny that subsequently differentiates 
into all types of retinal neurons [346]. Earlier studies showed that Müller cells were 
capable of regenerating chick [347] and rat retina [348, 349] in vitro in early postnatal 
life.  
The first report of successful isolation of an immortalised human Müller glial cell line 
(MIO-M1) was published in 2002 [350]. It was derived from the whole retina of a 
cadaveric specimen, from a 68 year old female donor. Since then, multiple cell lines 
have been generated from whole adult cadaveric retina and these, along with the 
MIO-M1 line, have subsequently been confirmed to exhibit neural stem cell 
characteristics [351]. Detailed characterisation of the distribution of these cells within 
the retina, have shown a higher population density towards the periphery [352].  More 
recently, human Müller glial cells (hMGC) have been shown to be a potential source of 
retinal ganglion cell precursors [353] and rod photoreceptors [354], the latter derived 
from MGCs retrieved from surgical adult explants.  
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Retinal diseases that lead to blindness are commonly associated with reactive Müller 
cell gliosis [355] and the release of inflammatory cytokines such as TGFβ, TNFα, IL-6 
and IL-1 [356-359]. Furthermore, there is growing evidence to support the hypothesis 
that the intraretinal Müller cell response may be the key player in the development of 
PVR. It may also be a major contributor to visual impairment in eyes with restoration 
of grossly normal anatomy following successful retinal re-attachment (refer Chapter 
4).  
 
Since Müller stem cells are present in the adult human eye and in vitro they can be 
induced to differentiate into neurons, it would be expected that after disease or 
injury, these cells would be able to regenerate damaged retina and restore function 
such as that seen in the zebrafish.  This prompts an investigation into why we observe 
a dwindling ability for the retina to regenerate following disease or injury as 
vertebrate evolution increases.  
Retinal progenitor and Müller glial cell proliferation in the developing rat retina can be 
inhibited by co-culture with dissociated adult rodent retinal cells. This effect has been 
attributed to TGFβ signalling [360]. In vivo inhibition of TGFβ signalling resulted in 
potentiation of the EGF mediated proliferation of Müller glia [360]. Taking into account 
the effect of inflammatory cytokines on retinal gliosis, it is reasonable to hypothesize 
that the interaction of pathways involved in neurogenesis and inflammation may affect 
the ability of Müller glial stem cells to endogenously regenerate the diseased retina.  
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5.2 Research Question and Hypothesis 
 
Since the human eye harbours stem cells with neurogenic ability, the isolation of these 
cells from peripheral biopsies of the retina during vitreoretinal surgery may provide a 
significant step towards developing cell based therapies for autologous 
transplantation. Furthermore, the stimulation of endogenous proliferation and neural 
differentiation to replace diseased neurons may be a preferable alternative to 
transplantation.  
It is necessary to gain a better understanding of the factors that regulate and 
negatively control the ability of resident stem cells to regenerate the diseased retina.  
This project aims to identify factors that inhibit the proliferation of resident Müller 
stem cells within the adult human retina. In addition, it will examine whether blocking 
specific TGF receptors may reverse the inhibitory effects of this cytokine, known to be 
prevalent in the microenvironment of gliotic retina.   
 
 
5.3 Objectives 
 
1. To examine the feasibility of obtaining Müller glial cells with stem cell characteristics 
(hMSC) from retinal biopsies of patients undergoing vitrectomy and retinectomy in 
eyes with proliferative vitreoretinopathy (PVR) 
2. To explore the role of TGFβ signalling on the growth and neural differentiation of 
hMSCs isolated from retinectomy specimens.  
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5.4 Methods 
 
 Acquisition of peripheral biopsies of adult donor human retina from 5.4.1
surgical retinectomy specimens  
 
The acquisition of human tissue for use in this study adhered to the tenets of the 
Declaration of Helsinki. Approval by the Research Management Committee at 
Moorfields Eye Hospital was gained and a favourable ethical opinion was granted by 
the National Research and Ethics Committee East Midlands - Derby.  Following 
informed consent, retinectomy specimens normally discarded following surgery, were 
collected (as indicated in Figure 5.3 and Figure 5.4) from patients undergoing retinal 
detachment surgery complicated by proliferative vitreoretinopathy (PVR). Samples 
were collected in DMEM, transferred to the laboratory and processed within four 
hours of retrieval. The specimens were obtained either 1) as small fragments removed 
from the eye through a sclerotomy port using surgical forceps and/or 2) aspirated 
directly from the aspiration line of the vitrector during cutting. Both types of 
specimens were transferred immediately after retrieval into DMEM before processing.  
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Figure 5.3:  Sequence of retinectomy retrieval using forceps 
Figure 5.3 (A) to (C) Linear endodiathermy is applied to detached retina for 
haemostasis at site of proposed retinotomy, (D) to (E) angled micro-scissors 
are introduced to create linear retinotomy and advanced to desired length , 
(F) ‘flap’ of retina approximately 3mm x 1mm is fashioned and left on 
pedicle, (G) to (H) end-gripping micro-forceps are used to grasp flap and 
detach from pedicle (I) explanted retinectomy specimen  to be transferred 
to eppendorf for processing 
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Figure 5.4:  Sequence of harvesting retinectomy specimen via cutter 
 
Figure 5.4 (A) Vitrectomy cutter is introduced into previous retinotom,  
adjacent to cut edge of site of retinectomy,  (B) to (D)  cutter is advanced 
along anterior edge of free ‘redundant’ retina whilst assistant gently 
aspirates syringe to retrieve sample in controlled fashion (care is taken such 
that the aspiration rate does not exceed the infusion to avoid the eye 
becoming hypotonous , (F) to (E) the residual anterior retina is removed, 
note the larger area of retinal tissue which is removed compared to small 
flap in Figure 5.3 
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 Primary Cell Culture from retinal explants 5.4.2
 
Cell isolation was performed as previously described [350] with slight modifications to 
increase cell yield.  Samples were received in serum-free DMEM with Penicillin and 
Streptomycin and centrifuged at 1400 rpm for 4 minutes. After discarding the 
supernatant, the tissue was re-suspended in 200μL TrypLE™ Express (1X) (#12604-013, 
Invitrogen) and incubated at 37ºC for 20 minutes. 500μL of DMEM with 10% foetal 
bovine serum was then added to inactivate the trypsin. Following 20-30 seconds of 
vigorous pipetting, the suspension was centrifuged at 1400rcf for 4 minutes. The 
supernatant was discarded and the pellet of cells resuspended in 2.4ml of media with 
10% foetal bovine serum and epidermal growth factor (EGF) at a final concentration of 
40ng/ml. Cell viability and initial cell counts were obtained after removing 24μL of this 
cell suspension and mixing with an equal volume of trypan blue. Cells were plated in 
central wells of a 24 well plate (4 well/sample) precoated with fibronectin (50 μg/ml; 
BD Bioscience, UK). The surrounding wells were filled with PBS in order maintain a 
moist environment.   Plates were examined and photographed using a phase contrast 
microscope at regular intervals. 
 
Cells were cultured for one week at 37°C in DMEM containing 10%FBS and 40ng/ml 
EGF with the medium replaced weekly thereafter. When cells reached confluence, 
they were detached using TrypLE™ Express (1X) (#12604-013, Invitrogen) for 3 min at 
37°C and resuspended in fresh medium before re-plating  in larger tissue culture 
plates.   
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 Modification to cell culture medium and addition of TGFβ	signalling	5.4.2.1
inhibition 
 
The aforementioned protocol was followed for the first ten explants, and subsequently 
modified as follows for six further specimens derived from the vitrectomy cutter. The 
primary cell culture medium of DMEM with 10% foetal bovine serum was substituted 
for DMEM/F12 (Invitrogen, Carlsbad, CA, USA, 
http://www.invitrogen.com/site/us/en/home.html) supplemented with 20 ng/ml bFGF 
,4 mg/ml heparin , 0.1 mg/ml apo-transferrin, 25 mg/ml insulin, 1 mg/ml putrescine, 
20 ng/ml progesterone,30 ng/ml sodium selenite, 1% BSA (Bovine Serum Albumin) (All 
Sigma-Aldrich, St. Louis, MO, USA, http://www.sigmaaldrich.com).  
 
Cell pellets were re-suspended in the above neural stem cell medium with 40ng/ml of 
EGF, and samples divided into two (with and without TGFβ inhibition) before plating as 
above.  
 
The following TGFβ inhibitory factors were added at the time of plating and at all 
subsequent media changes; TGF β RII – Fc  (0.5µg/ml), SB-431542 (3ng/ml), TGFβ1,2,3 
Ab (25µg/ml), (All R&D systems).  
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 Immunocytochemistry  5.4.2.2
 
Immunocytochemistry was performed on: a) cells isolated from 1 donor sample at 
days 1, 4 and 7 in culture and b) retinectomy samples (approximately 3mm by 1mm) 
following cryosectioning from six live donors. 
 
Cells were cultured on fibronectin-coated (50μg/ml) Lab-Tek glass chamber slides 
(Nunc, Inc, USA). After fixation with 4% paraformaldehyde in PBS, cells or cryosections 
of retinectomy specimens were blocked for 1 hour in 0.3% Triton-X in TBS, and 
incubated overnight at 4°C with primary antibodies diluted in the blocking solution. 
The following primary antibodies were used: Nestin (sc-21247; monoclonal; 1:100; 
Santa Cruz, USA. http://www.scbt.com/), SOX2 (AB5603; rabbit; 1:500; Merck 
Millipore, USA. http://www.millipore.com/), PAX6 (sc-11357; rabbit; 1:200; Santa Cruz, 
USA. http://www.scbt.com/), CRALBP (sc-28193; rabbit; 1:50; Santa Cruz, USA. 
http://www.scbt.com/), Vimentin (sc-5565; rabbit; 1:200; Santa Cruz, USA. 
http://www.scbt.com/) and GFAP (sc-9973; mouse; 1:200; Santa Cruz, USA. 
http://www.scbt.com/). Cells from the MIO – M1 cell line were used as positive 
controls.  Mouse and rabbit IgG isotypes matching test antibodies were used as 
negative controls. After incubation with primary antibodies, specimens were washed in 
TBS, and then incubated for 3 hours with Alexa-conjugated secondary antibodies 
(Invitrogen, UK) at room temperature. Slides were washed and counter-stained with 
2μg/ml 4’,6’-diamino-2-phenylindole (DAPI) for 2 minutes and mounted with 
Vectashield mounting medium (Vector Labs, USA). Fluorescent images were recorded 
using a Zeiss LSM 710 confocal microscope operating in multitrack mode for FITC, DAPI 
and TRITC fluorochromes.  
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5.5 Results 
 
 Isolation of Müller glia with stem cell characteristics from retinectomy 5.5.1
specimens 
 
Ten retinectomy specimens from nine patients were initially studied without TGFβ 
inhibition, and a further six specimens were treated with TGFβ inhibitory factors. The 
typical dimensions were 3mm x 1 mm when retrieved directly with forceps. (Figure 
5.3)  The area of tissue retrieved by the vitrectomy cutter was difficult to measure 
accurately but was likely to be larger than that achieved using forceps (Figure 5.4).   
 
After one week in culture, cells with the expected morphology of human hMSCs were 
observed in all processed samples, with higher yields achieved in samples derived from 
the cutter. They appeared bright when viewed under a phase objective and showed 
characteristic glial morphology. Considering the first ten samples, cells appeared to 
proliferate and form colonies by week 1. The majority, however, survived up to 8 
weeks and appeared to form neurospheres (Figure 5.5) Attempts to release cells from 
these spheres and encourage proliferation were unsuccessful.   
 
However, two cutter-derived samples appeared to proliferate and survived up to four 
passages and expansions into larger plates (Figure 5.6). Unfortunately, immortality was 
not achieved as eventually all cells were observed to adopt the morphology of 
terminally differentiated mature Müller glia with a characteristic flattened, enlarged 
and elongated cell morphology.  One sample derived an additional cell preparation 
exhibiting a different morphology to that expected of hMSCs. These cells appeared 
epithelial in appearance, although they were not formally characterised by 
immunocytochemical staining (Figure 5.7)  
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Figure 5.5:  Primary Cell Culture of Explants; colonies and neurospheres 
 
Figure 5.5 An example of cellular proliferation and colony formation by 
week 1 in a cutter derived sample. Note the characteristic morphology of 
hMGC and their bright appearance under a phase microscope.  Formation 
of neurospheres was observed by week 3 with surrounding colonies of 
hMGC, attempts to release cells from spheres through enzymatic disruption 
were unsuccessful at both 5 and 8 weeks with no further proliferative 
activity observed – (scale bar 100µm) 
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Figure 5.6:  Primary Cell Culture; proliferation to confluence 
 
 
Figure 5.6 An example of cellular proliferation and colony formation by 
week 1 in a cutter derived sample. Cells reached confluence by week 3 and 
were expanded into larger flasks. By 7-8 weeks, cells appear flattened and 
adopted a terminally differentiated morphology (scale bar 100µm)  
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Figure 5.7:  Primary Cell Culture; non hMGC morphology proliferative cells 
 
 
Figure 5.7  Cells of an epithelial morphology were isolated in addition to 
those with Müller glial stem cell morphology; at day 7 note how the wells 
contained extracellular pigment, at 3 weeks the cells appeared different in 
morphology to hMGC (bottom row) and appeared hexagonal, by 2 months 
very few cells with hexagonal morphology remained in culture (bottom 
row), whilst those presumed hMGC adopted a flattened and terminal 
morphology - scale bar 100µm 
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 Isolation of Müller glia with stem cell characteristics from retinectomy 5.5.2
specimens	with	TGFβ	inhibitory	factors 
 
Considering the final six samples with modified culture media and TGFβ inhibition; 
again after one week in culture cells appeared to initially proliferate and form colonies. 
There did not appear to be any apparent difference in the cell yield when comparing 
those with additional TGFβ inhibition, and no samples reached confluence nor 
progressed to expansion into larger plates.  Cells appeared to accumulate into 
neurospheres, and again attempts to release cells and encourage proliferation were 
unsuccessful. Eventually, they adopted the morphology of terminally differentiated 
mature Müller glia.  
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 Characterisation of Müller glia with stem cell characteristics in culture 5.5.3
from one donor sample 
 
 
Cells harvested by both forceps and cutter retrieval methods from one adult donor 
were stained for the neuroprogenitor marker, Nestin, and the marker, CRALBP, which 
is expressed by Müller glial cells.   Cells were removed from culture at day one, four 
and seven after primary plating. Figure 5.8 shows a cell staining positive for Nestin on 
day one. By day four a colony of cells were observed staining positive for both Nestin 
and CRALBP, and were noted to form a neurosphere at day seven (Figure 5.9).  
  
 
Figure 5.8:  Immunocytochemistry of cells in culture at day 1 
 
 
Figure 5.8 shows a single cell in culture at day 1 staining positive (green) for 
the neuroprogenitor marker Nestin. Central staining of nucleus (blue) with 
DAPI. The cell adopts the classic morphology of a human Müller glial cell 
with stem cell characteristics (hMSC). The cell did not stain positive for 
CRALBP.  
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Figure 5.9:  Immunocytochemistry of Cells in culture at Days 4 and 7 
 
Figure 5.9 Immunohistochemistry composite shows a colony of cells in 
culture at day 4 (top) and day 7 (bottom), At day 4 the cells form a colony 
and stain positive for the neuroprogenitor marker nestin (green) and the 
glial cell marker CRALBP (red). (Nuclei stain blue with DAPI). At day 7, the 
cells appear to form a sphere and stain positive for nestin and weakly for 
CRALBP  
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 Immunostaining of human retinectomy sections for neural progenitor 5.5.4
markers and cell specific proteins 
 
Retinectomy specimens from four adult donors were fixed in 4% PFA and stained for 
markers as mentioned above. The images shown in Figs 5.4.2, 5.4.3 and 5.4.4 are 
derived from cryosections of 15µm from one donor sample.  
 
Most retinal sections appeared dystrophic and thickened but preservation of the 
overall retinal architecture was observed, with 3 distinct nuclear layers visible (stained 
positive with DAPI).  In some sections, there appeared to be separation of the ganglion 
cell layer from the underlying outer retinal layers. This may represent trauma at the 
time of tissue retrieval, or damage during processing of the sample. Specimens stained 
positive for Nestin and CRALBP throughout the entire depth of the retina, with 
increased fluorescence observed at the inner retinal surface. Co -localisation was 
noted for both antibodies. Positive staining and co-localization was observed for GFAP 
and Vimentin. Non-specific staining was observed with PAX6 and samples did not show 
positivity for SOX 2.  Positive controls confirmed activity of the primary and secondary 
antibodies. 
 
Figure 5.10:  Immunocytochemistry; positive control 
Figure 5.10 Composite figure of positive control staining for primary and 
secondary antibodies of cells from MIO-M1 cell line  DAPI (blue nuclei), 
Nestin, SOX 2 and PAX 6 (green) and CRALBP (red) (Scale Bar 50µm) 
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Figure 5.11:  Immunohistochemistry of retinectomy specimen; nestin and CRALBP  
Figure 5.11 Immunostaining of retinectomy specimen as viewed under Zeiss 
710 confocal microscope stained for DAPI (blue), nestin (green) and CRALBP 
(red) ONL, outer nuclear layer, INL inner nuclear layer, RGC, retinal 
gangliom cell layer  (A) X10 magnification - Nestin and CRALBP were 
observed throughout the whole retinal thickness with co-localisation and 
greatest staining observed in inner retina (scale bar - 100µm (B) X40 
magnification showing a high powered view of regions of increased staining 
in the inner retina, images also display thickened and dystrophic retina 
(scale bar 50µm) 
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Figure 5.12:  Immunohistochemistry of retinectomy specimen; Vimentin and GFAP 
 
Figure 5.12 Immunostaining of retinectomy specimen as viewed under Zeiss 
710 confocal microscope stained with DAPI (blue) , vimentin (green) and 
GFAP (red) ONL, outer nuclear layer, INL, inner nuclear layer, RGC, retinal 
ganglion cell layer (A) X10 magnification showing a marked staining for 
GFAP, indicating reactive gliosis with co-localisation of vimentin, a Müller 
glial cell marker (scale bar - 100µm (B) X40 magnification showing a high 
powered view of regions of increased staining in the inner retina. Images 
again demonstrate thickened and dystrophic retina (scale bar 50µm) 
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Figure 5.13:  Immunohistochemistry of retinectomy specimen; PAX 6 
 
 
Figure 5.13 Immunostaining of retinectomy specimen as viewed under Zeiss 
710 confocal microscope stained with PAX 6 (green) and DAPI (blue). ONL, 
outer nuclear layer, INL, inner nuclear layer, GCL, ganglion cell layer (A) X10 
magnification – Non-specific staining observed in the inner retinal surface 
contrary to expected region of staining of this protein expressed in the 
nucleus (scale bar - 100µm (B) X40 Objective – higher powered images are 
inconclusive of positive staining for nuclei at inner nuclear layer (scale bar 
50µm) 
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5.6 Discussion 
 
Using established protocols, it was possible to isolate cells with the appropriate 
morphology of hMSCs which survived up to ten weeks in culture. However, only two of 
the sixteen specimens processed proliferated to reach confluence and were expanded 
into larger tissue culture plates. Successful hMSC culture from surgical specimens have 
reported initial cell counts of less than 106 yielding a 40% efficiency rate. This increases 
to 77% with higher cell counts (2 X 106) [354].  As the samples retrieved in this study 
are small fragmented pieces of tissue, it is difficult to achieve such high cell numbers. 
This may explain the lack of success in this study to date, and is consistent with the 
observed higher cell yield with cutter-derived samples when compared to those 
retrieved with forceps.  
 
 
When specimens were cultured with the addition of TGFβ inhibitory factors, there was 
no effect on increasing cell yield, with an apparent overall reduction in proliferation 
seen. No samples proliferated to confluence when treated with TGFβ inhibitory 
factors.  Previous reports in rodents describe a cytostatic effect of mature retinal 
neurons attributed to the effect of TGFβ signalling. Inhibition through a combination of 
TGFβRII – Fc protein and a pan TGFβ blocking antibody has been shown to enhance the 
ability of Müller glia to re-enter  the cell cycle in response to EGF [360]. The lack of 
effect observed in this study may be also explained by the low initial cell counts at the 
time of plate seeding. Additionally, the cocktail of inhibitory factors used included a 
small molecule inhibitor of TGFβRI (SB-431542). In effect, with the combined inhibition 
of TGFβRI and TGFβRII – Fc, the entire TGF pathway may have been inhibited, thereby 
resulting in an ‘excessive inhibition’ of proliferation per se, with a lack of selectivity.  
Therefore, selective inhibition of TGFRs may yield different effects on cell proliferation 
and it may benefit further investigation. 
 
 
All retinectomy samples were retrieved from eyes with proliferative vitreoretinopathy.  
Glial cell activation and reactive gliosis is a key feature in PVR, confirmed by the 
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marked staining for GFAP noted in the specimens in this study.  Since it is likely that a 
large proportion of the resident glial cell population had already become activated and 
terminally differentiated towards reactive gliosis, it is logical to assume that the 
population of cells with stem cell ability may have already been depleted in this tissue. 
This may explain the negative staining for SOX2 and the non-specific staining for PAX6.   
Nevertheless, the positive staining for the neuroprogenitor marker, Nestin, both in 
retrieved retinectomy specimens and in cells early in culture suggest that the 
population of Müller glia with stem cell characteristics may not be completely absent 
in this dystrophic tissue. 
 
 
As two samples initially showed signs of proliferation in which cell growth arrested at 
approximately seven to eight weeks was observed, future work may involve the study 
of local factors which inhibit proliferation at this stage. Sequential western blot 
analysis of the cells in culture, or proteomics of the culture media at specific time 
points may help to identify the changes in protein production which occur through an 
initial proliferative period, followed by a rapid cessation and terminal differentiation. 
 
 
A proportion of the retinectomy samples studied were derived from patients enrolled 
in the Ozurdex in PVR Study.  However, as the timing of sample retrieval was at the 
primary study vitrectomy, none of the eyes had undergone previous treatment with 
intravitreal corticosteroid.  Further work may involve repeating the 
immunohistochemical analysis performed in this study with the addition of western 
blot analysis. A comparison between the expression of markers of reactive gliosis, and 
markers of neurogenesis in eyes treated with and without prior glucocorticoid 
treatment may be valuable.  Whilst Kuo et al [72], in their rabbit model, observed 
neither a difference in the clinical manifestations of PVR severity, nor in GFAP 
expression in Ozurdex-treated eyes, it may be interesting to investigate this in human 
retinectomy specimens. 
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Similarly, it may then be interesting to reassess the feasibility of acquiring Müller glia 
with stem cell characteristics within the two treatment groups. It follows that if we 
were to find a reduction in reactive gliosis following the treatment of corticosteroid, 
we may benefit from a higher yield of cells with potential for immortality in the initial 
primary cell culture.   
 
Ideally, peripheral biopsies from human retina would be large enough to obtain 
sufficient primary cell counts and ‘healthy’ enough to harbour a significant population 
of Müller glia with stem cell characteristics. In practice, this is difficult to achieve as 
patients undergoing vitreoretinal surgery, have by definition, vitreoretinal disease. 
Higher yields may be obtained from anterior retinectomies from large giant retinal 
tears of recent onset, thereby achieving adequate initial cell counts from tissue where 
reactive gliosis is less marked.  
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6 General Discussions and Future Work 
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This work has aimed to identify and test strategies focussed on improving the visual 
and surgical outcomes in proliferative vitreoretinopathy. During the process there 
were significant challenges in the clinical and laboratory investigations and much was 
learned both about the condition and how to investigate it.  
 
6.1 Challenges 
 
As with any clinical and scientific research, logistical challenges have presented 
themselves, some of which have been unpredictable. The process of gaining regulatory 
body approval for a clinical trial of investigational medicinal product is both rigorous 
and humbling. Ethical review board submissions, re-submissions and meeting 
attendances can be daunting but satisfying upon gaining a favourable opinion.  
Obtaining an authorisation to conduct a clinical trial is a privilege. Whilst the process 
was complex and we were presented with unexpected new safety information shortly 
before submission, we were able to overcome these logistical challenges to gain 
authorisation within a self-imposed timescale. The novel learning experience 
throughout this process has already served me well for projects which have developed 
from work in this thesis, and will continue to do so in my future endeavours in clinical 
research. 
Proliferative vitreoretinopathy is as complex a condition to manage clinically as it is to 
understand scientifically. A substantial proportion of data collection for this work was 
generated from the clinical management of 40 patients with a history of ocular trauma 
and 140 patients with established PVR. Cumulatively, I have estimated that over both 
study periods, I personally performed between 3000 – 3500 outpatient attendances 
clinical assessments and was present at over 400 operative procedures. This 
significantly tested my skills of time management, and may explain why recruitment 
rates are compromised when study teams perform multiple roles. 
The challenges of preparing both oneself and one’s study team for the level of scrutiny 
of an MHRA inspection should not be underestimated. Whilst we prided ourselves in 
the high level of safe and effective clinical and pastoral care we provided to all our 
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study participants, the uncertainty of whether this would be evident when subjected 
to external critique was a source of stress. Furthermore, the timing of the inspection 
fell at a critical period during my research fellowship and added to the challenges 
which I was already facing at the time.  
Managing personal expectations of the success of laboratory work is another 
challenge. I have learned that despite one’s best efforts, primary cell culture is 
unpredictable, cryo-sectioning can be monotonous but therapeutic, and 
immunohistochemistry is an art.  
 
6.2 Successes 
 
In some ways, any of the aforementioned challenges could comfortably position 
themselves in this subsection of successes. In order to complete the work required to 
write this thesis, these challenges were overcome. The work in this thesis has 
answered many research questions by proving and disproving hypotheses.   
 
Ocular trauma is a blinding condition and has a propensity to vitreoretinal scarring. 
Whilst triamcinolone acetonide may not improve the anatomical outcomes in eyes 
undergoing vitreoretinal surgery following OGI, visual outcomes may be better in 
steroid-treated eyes. It could be argued that the AOT trial exceeded its study 
objectives. It confirmed the feasibility of an RCT in this disease group and provided 
sufficient data to power a large scale definitive study. Indeed, the findings of this trial 
were instrumental in the successful procurement of a £1000, 000 NIHR grant to 
conduct the study (ASCOT) of which the AOT trial was designed to test the feasibility.   
The ASCOT Study forms part of the ‘future work’ which has already begun and its 
findings may help to definitively clarify whether triamcinolone plays a significant role 
in the management of open globe trauma.  
Furthermore, as principal investigator at the primary ASCOT Study site and a co-
investigator in the trial management group, I have forged valuable collaborations with 
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the Clinical Trials Unit at Kings College London. Established collaborations with many of 
the other 25 site PIs in the U.K will also prove a valuable resource for my involvement 
in multi-centre studies in the future.  
 
The Ozurdex in PVR trial was the first study to investigate a slow-release 
dexamethasone implant in eyes with PVR. We successfully achieved our study aim by 
recruiting to time, maintaining retention of 99% of participants to the primary 
endpoint whilst securing a robust dataset. Despite a lack of efficacy in anatomical 
outcomes, in exploratory sub-analysis, we observed a potential treatment effect in 
terms of visual outcomes and rates of cystoid macular oedema. Further work 
investigating vision as a primary outcome measure may help to definitively answer the 
question.  Future studies may require a multi-centre approach to achieve the desired 
sample size to maintain power to detect a statistically and clinically meaningful 
difference.  
 
OCT guided analysis of the outer retina revealed the ELM as a correlate to visual 
recovery in eyes with PVR. This may add to the growing evidence that the intraretinal 
glial response plays a significantly larger role both in the development of PVR and as a 
vision limiting factor following successful RD repair. When published, this will be the 
first study to report these findings in this cohort. A larger study on a more 
homogenous group may help to validate our findings and serve to differentiate the 
different aspects of features we have observed. This may prove to be important in the 
design of future trials of new treatment.  
OCT-derived indices of objective measures of inflammation are higher in eyes with PVR 
when compared to normal controls. If the sensitivity of discriminating higher levels of 
vitreous inflammation is improved, these indices may prove to be useful tools in 
establishing well-defined endpoints in future PVR studies. 
The laboratory work outlined in this thesis constituted a small but important 
contribution to this endeavour. I was able to acquire skills in primary cell culture, cryo-
306 
 
 
 
sectioning of tissue and immunocytochemistry. We isolated cells early in culture 
staining positive for nestin, a marker of neurogenesis and CRALBP, a glial cell marker. 
This suggests that a resident population of Müller glial cells with stem cell 
characteristics may exist in anterior dystrophic tissue with advanced proliferative 
vitreoretinopathy. Further work in primary cell culture, identifying the changes in 
protein expression which occur through an initial proliferative period, followed by a 
rapid cessation and terminal differentiation may prove valuable.  
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6.3 Summary 
 
Studying disease in its advanced stage carries inherent disadvantages. The work in this 
thesis has suggested that it is difficult to modify the vitreoretinal scarring response 
sufficiently to improve anatomical outcome measures. For now, we may be better 
placed to improve the secondary causes of visual loss in eyes with PVR by focussing on 
vision as a primary outcome measure. This may be a plausible design for future 
vitreoretinal clinical trials in PVR. I hope to be a part of them.  
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8.1 Appendix 1: Adjuncts in Ocular Trauma Trial Case Report Form Pack 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
CHAD1024_ CRF_PACK_v4.7.pdf CONFIDENTIAL  Page 1 of 10 
Rev 4.7 – 05/02/2013 
 
Completing Case Report Forms (CRFs) 
 
This document has been created to provide guidelines about completing clinical trial case 
report forms at Moorfields Eye Hospital (MEH).  The information has been extracted from the 
revised MEH SOP documents that are being developed by the Research & Development 
department at Moorfields. 
 
1. The CRF must be completed as soon as possible after the patient has been assessed or during the assessment if the 
CRF is the source data. 
 
2. CRFs must be completed using a black ink ballpoint pen. 
 
3. If the CRF is printed on carbonless duplication paper, a suitable separator must be inserted under the form being 
completed. 
 
4. Data entry into the CRF must be complete as without omissions. If data are unavailable then ‘unknown’, ‘missing’, ‘tes t 
not done’ etc. should be inserted. The ambiguous phrase, ‘not available’ should be avoided. 
 
5. All entries into the CRF must be accurate, legible and verifiable with the source data in the medical records (unless the 
CRF is the source data). Data must not be invented – this is fraud. 
 
N.B. Whenever a subject has been seen by clinical staff for the purposes of a clinical trial, the time, date and reason 
for visit must always be entered into the subject’s corresponding hospital notes. Copies of trial investigations/results 
that are clinically significant or have an impact on the patient’s clinical care must also be filed in the medical notes.  
 
6. Any discrepancies between the CRF and the source data should be explained and the significance noted in the CRF 
and/or patient’s medical records. 
 
7. All CRF data derived from source documents must be transcribed exactly. This includes laboratory values, which 
unless otherwise agreed, should be entered without conversion from printed reports, even if, for multi-centre studies, 
the units of measurement differ from centre to centre. 
 
8. For laboratory values that fall outside the laboratory’s reference range or trial specific range or when a value shows a 
significant variation from one assessment to the next, this should be commented on and the significance noted in the 
CRF and/or patient’s medical records. 
 
9. The subject’s identity should remain confidential at all times and as such the trial subject must only be identified in the 
CRF using a trial number or code. 
 
10. Entries into the CRF must never be overwritten. 
 
11. Corrections to the CRF must be made as follows: 
 
x An incorrect entry must be deleted with a single line through the text allowing the incorrect entry to remain 
legible. Correction fluid must never be used and entries must not be obliterated. 
x The correct data must be entered. 
x The correction must be initialled and dated and an explanation given of the correction, if applicable. 
 
12. The CRF must be signed and dated where indicated, by the chief/principal investigator or designee (for example, 
research nurse at the end of an assessment) to assert that he/she believes the data is completed and correct. 
 
13. All CRFs must be faxed/scanned weekly to Moorfields 
 
Appendix Summary 
 
Appendix 2 
No. of Unscheduled Visit Forms 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 3 
No. of Protocol Deviation Forms 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 4  
No. of Concomitant Medication Forms Prior to trial 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 5 
No. of Concomitant Medication Forms During the trial 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 6 
Early Withdrawal Form Yes  F No  F  
Appendix 7  
No. of Adverse Events Forms 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
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Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
PATIENT & PRIMARY REPAIR ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Patient Details 
Study Eye  Right  F Left  F 
 
Gender Male  F Female  F 
 
Ethnic Origin Please complete Ethnic Categories Form 
Date of Birth (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Primary Repair Details 
Location of wound Corneal  F Scleral/Corneal  F Scleral  F

Anterior Vitrectomy Yes  F No  F 
 
Location of Foreign Body Yes  F No  F 
 
If Yes Specify  _____________________________________________________ 
Removal of Foreign Body Yes  F No  F 
 
Classification of Trauma 
Contusion  F Rupture  F Laceration  F
 Penetrating Injury  F Perforating Injury  F 
 
Date of Accident (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Date of Primary Repair (dd mm yyyy) __ __ / __ __ / __ __ __ __
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
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Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
BASELINE ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Baseline Exam  
 
Date of Exam (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
RAPD Yes  F No  F 
 
AC Flare  0  F +  F ++  F +++  F ++++  F NP  F 
 
AC Cells  0  F +  F ++  F +++  F ++++  F NP  F 
 
Hyphaema  0  F Microscopic  F <25%  F 25-50%  F 50-99%  F Total  F 
 
Iris (Choose one) Normal  F Incomplete  F Incarcerated  F NP  F
 
Lens (Choose one) Clear  F AC IOL  F Aphakic  F Cataract  F
PC IOL  F Traumatic Cataract  F NP  F 
 
Vit RPE Cells  0  F +  F ++  F +++  F ++++  F NP  F 
 
Vit Flare  0  F +  F ++  F +++  F ++++  F NP  F 
 
Vit Haemorrhage   0  F +  F ++  F +++  F NP  F 
 
Vit Foreign Body (Choose one) 
Intravitreal  F Intraretinal  F Intrascleral  F
Retrobulbar  F Incarceration  F Not Present  F 
 
Clinical Diagnosis of Endophthalmitis Yes  F No  F 
 
BCVA ETDRS  
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-70) __ __
Spherical Equivalent Dioptres 
(Range – -40-40) __ __ . __ __ NP  F  
Retinal Detachment 
(If yes please complete the following section) Yes  F No  F  
If Yes Specify 
Durations of RD (no. of days, Range 0-999 __ __ __ 
Extent (clock hours) __ __ NP  F 
 
Macula Involved Yes  F No  F NP  F 

Traction RD Yes  F No  F NP  F 
 
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading  
(See grading chart for further details)  A  F B  F C  F 
If grading C please specify  
(range 1-12) CA  F__ __ CP  F__ __ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macula Attachment Yes  F No  F NP  F 
Foveal Thickness (Range 0-999) __ __ __ µm NP  F 
Macular Volume (Range 0-100) __ __ . __ __ mm3 NP  F 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
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Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
OPERATION RECORD FORM Study Eye Data Only, all fields are mandatory 
Operation Details  
 
Date of Operation (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Surgeon Grade SPR  F Fellow  F Consultant  F

Anaesthetic Local  F General  F
 
Operative Techniques 
(Tick yes or no) 
Yes   No   Yes   No 
Phako FF Encircling Buckle  FF 
Vitrectomy FF Gas SF6  FF 
Lensectomy  FF Gas C2F6  FF 
Posterior Vit Detach Induced  FF Gas C3F8  FF 
Heavy Liquid  FF Oil (1000)  FF 
Membrane Peel  FF Oil (5000)  FF 
Drainage Retinotomy  FF Oil (Heavy)  FF 
Local Buckle  FF  

Relaxing Retinectomy Yes  F No  F 
 
If Yes Specify Degrees __ __ __° 
Retinopexy 
(Tick yes or no) 
Yes   No Yes   No 
Endolaser  FF Indirect Laser  FF 
 Cryotherapy  FF 
 
Complication Type 
(Tick yes or no) 
Yes   No Yes   No 
Entry Site Breaks  FF AC Haemorrhage  FF 
Choroidal Haemorrhage  FF Other Iatrogenic Breaks  FF 
Subretinal Haemorrhage  FF Lens Touch  FF 
Preretinal Haemorrhage  FF Deep Buckle Suture  FF 
Haemorrhage at Retinectomy  FF Failure to Reattach Retina  FF 

Complication Other Yes  F No  F
 
If Yes Specify 
 
________________________________________________________ 

________________________________________________________ 
 
________________________________________________________ 
Adjunct given Yes  F No  F 
 
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading  
(See grading chart for further details)  A  F B  F C  F 
If grading C please specify  
(range 1-12) CA  F__ __ CP  F__ __ 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
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Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
RE-OPERATION RECORD FORM Study Eye Data Only, all fields are mandatory 
Re-Operation Details  
 
Date of Operation (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Surgeon Grade SPR  F Fellow  F Consultant  F

Anaesthetic Local  F General  F
 
Operative Techniques 
(Tick yes or no) 
Yes   No   Yes   No 
Phako FF Encircling Buckle  FF 
Vitrectomy FF Gas SF6  FF 
Lensectomy  FF Gas C2F6  FF 
Posterior Vit Detach Induced  FF Gas C3F8  FF 
Heavy Liquid  FF Oil (1000)  FF 
Membrane Peel  FF Oil (5000)  FF 
Drainage Retinotomy  FF Oil (Heavy)  FF 
Local Buckle  FF  

Relaxing Retinectomy Yes  F No  F 
 
If Yes Specify Degrees __ __ __° 
Retinopexy 
(Tick yes or no) 
Yes   No Yes   No 
Endolaser  FF Indirect Laser  FF 
 Cryotherapy  FF 
 
Complication Type 
(Tick yes or no) 
Yes   No Yes   No 
Entry Site Breaks  FF AC Haemorrhage  FF 
Choroidal Haemorrhage  FF Other Iatrogenic Breaks  FF 
Subretinal Haemorrhage  FF Lens Touch  FF 
Preretinal Haemorrhage  FF Deep Buckle Suture  FF 
Haemorrhage at Retinectomy  FF Failure to Reattach Retina  FF 

Complication Other Yes  F No  F
 
If Yes Specify 
 
________________________________________________________ 

________________________________________________________ 
 
________________________________________________________ 
Adjunct given Yes  F No  F 
 
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading  
(See grading chart for further details)  A  F B  F C  F 
If grading C please specify  
(range 1-12) CA  F__ __ CP  F__ __ 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
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Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
10 DAY ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
BCVA ETDRS  
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-70) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF   Fibrin FFF Hyphaema FFF 
Oil (patent pi) FFF Oil (blocked pi) FFF Flat AC FFF
    Rubeosis FFF
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF Cataract (oil) FFF Cataract FFF 
AC IOL FFF PC IOL FFF Aphakic FFF
 
State of Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Detached FFF Oedema FFF 
  Pucker FFF FTMH FFF
 
State of Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Traction RD FFF RRD FFF 
Open Previous Break FFF Entry Site Breaks FFFOther New Breaks FFF
 
Other Procedures Since Initial Surgery 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out   FF __ __ / __ __ / __ __ __ __ Buckle   FF __ __ / __ __ / __ __ __ __ 
ICCE   FF __ __ / __ __ / __ __ __ __ Peel   FF __ __ / __ __ / __ __ __ __ 
E/C + IOL   FF __ __ / __ __ / __ __ __ __ Retinectomy   FF __ __ / __ __ / __ __ __ __ 
Phako + IOL   FF __ __ / __ __ / __ __ __ __ Laser   FF __ __ / __ __ / __ __ __ __ 
YAG PI   FF __ __ / __ __ / __ __ __ __ Surgical PI   FF __ __ / __ __ / __ __ __ __ 
Other   FF __ __ / __ __ / __ __ __ __   
 
        If Other Specify   __________________________________________________________________  
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading (See grading chart for further details)  A  F B  F C  F 
If grading C please specify (range 1-12) CA  F__ __ CP  F__ __ 
 
OCT Taken Yes  F No  F NP  F 
 
If Yes Specify 
OCT Macular SRF Yes  F No  F NP  F 
OCT Foveal Thickness (Range 0-999) __ __ __ µm NP  F 
OCT Macular Volume (Range 0-100) __ __ . __ __ mm3 NP  F 
 
Retina Re-Attached without further VR Intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of Additional VR Procedures Since First 
Vitrectomy apart from removal of oil __ __ N/A  F  
Any Adverse Events since their last study visit? (If yes complete separate  adverse event form) Yes  F No  F 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
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Rev 4.7 – 05/02/2013 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
4-6 WEEK ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
BCVA ETDRS  
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-70) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF   Fibrin FFF Hyphaema FFF 
Oil (patent pi) FFF Oil (blocked pi) FFF Flat AC FFF
    Rubeosis FFF
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF Cataract (oil) FFF Cataract FFF 
AC IOL FFF PC IOL FFF Aphakic FFF
 
State of Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Detached FFF Oedema FFF 
  Pucker FFF FTMH FFF
 
State of Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Traction RD FFF RRD FFF 
Open Previous Break FFF Entry Site Breaks FFFOther New Breaks FFF
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out   FF __ __ / __ __ / __ __ __ __ Buckle   FF __ __ / __ __ / __ __ __ __ 
ICCE   FF __ __ / __ __ / __ __ __ __ Peel   FF __ __ / __ __ / __ __ __ __ 
E/C + IOL   FF __ __ / __ __ / __ __ __ __ Retinectomy   FF __ __ / __ __ / __ __ __ __ 
Phako + IOL   FF __ __ / __ __ / __ __ __ __ Laser   FF __ __ / __ __ / __ __ __ __ 
YAG PI   FF __ __ / __ __ / __ __ __ __ Surgical PI   FF __ __ / __ __ / __ __ __ __ 
Other   FF __ __ / __ __ / __ __ __ __   
 
        If Other Specify   __________________________________________________________________  
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading (See grading chart for further details)  A  F B  F C  F 
If grading C please specify (range 1-12) CA  F__ __ CP  F__ __ 
 
OCT Taken Yes  F No  F NP  F 
 
If Yes Specify 
OCT Macular SRF Yes  F No  F NP  F 
OCT Foveal Thickness (Range 0-999) __ __ __ µm NP  F 
OCT Macular Volume (Range 0-100) __ __ . __ __ mm3 NP  F 
 
Retina Re-Attached without further VR Intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of Additional VR Procedures Since First 
Vitrectomy apart from removal of oil __ __ N/A  F  
Any Adverse Events since their last study visit? (If yes complete separate  adverse event form) Yes  F No  F 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
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Rev 4.7 – 05/02/2013 
Triamcinolone at Vitrectomy for Trauma – AOT 
Study Study No: __ __ __ __ 
3 MONTH ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
BCVA ETDRS  
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-70) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF   Fibrin FFF Hyphaema FFF 
Oil (patent pi) FFF Oil (blocked pi) FFF Flat AC FFF
    Rubeosis FFF
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF Cataract (oil) FFF Cataract FFF 
AC IOL FFF PC IOL FFF Aphakic FFF
 
State of Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Detached FFF Oedema FFF 
  Pucker FFF FTMH FFF
 
State of Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Traction RD FFF RRD FFF 
Open Previous Break FFF Entry Site Breaks FFFOther New Breaks FFF
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out   FF __ __ / __ __ / __ __ __ __ Buckle   FF __ __ / __ __ / __ __ __ __ 
ICCE   FF __ __ / __ __ / __ __ __ __ Peel   FF __ __ / __ __ / __ __ __ __ 
E/C + IOL   FF __ __ / __ __ / __ __ __ __ Retinectomy   FF __ __ / __ __ / __ __ __ __ 
Phako + IOL   FF __ __ / __ __ / __ __ __ __ Laser   FF __ __ / __ __ / __ __ __ __ 
YAG PI   FF __ __ / __ __ / __ __ __ __ Surgical PI   FF __ __ / __ __ / __ __ __ __ 
Other   FF __ __ / __ __ / __ __ __ __   
 
        If Other Specify   __________________________________________________________________  
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading (See grading chart for further details)  A  F B  F C  F 
If grading C please specify (range 1-12) CA  F__ __ CP  F__ __ 
 
OCT Taken Yes  F No  F NP  F 
 
If Yes Specify 
OCT Macular SRF Yes  F No  F NP  F 
OCT Foveal Thickness (Range 0-999) __ __ __ µm NP  F 
OCT Macular Volume (Range 0-100) __ __ . __ __ mm3 NP  F 
 
Retina Re-Attached without further VR Intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of Additional VR Procedures Since First 
Vitrectomy apart from removal of oil __ __ N/A  F  
Any Adverse Events since their last study visit? (If yes complete separate  adverse event form) Yes  F No  F 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
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Rev 4.7 – 05/02/2013 
 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
6 MONTH ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
BCVA ETDRS  
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-70) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF   Fibrin FFF Hyphaema FFF 
Oil (patent pi) FFF Oil (blocked pi) FFF Flat AC FFF
    Rubeosis FFF
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF Cataract (oil) FFF Cataract FFF 
AC IOL FFF PC IOL FFF Aphakic FFF
 
State of Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Detached FFF Oedema FFF 
  Pucker FFF FTMH FFF
 
State of Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Traction RD FFF RRD FFF 
Open Previous Break FFF Entry Site Breaks FFFOther New Breaks FFF
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out   FF __ __ / __ __ / __ __ __ __ Buckle   FF __ __ / __ __ / __ __ __ __ 
ICCE   FF __ __ / __ __ / __ __ __ __ Peel   FF __ __ / __ __ / __ __ __ __ 
E/C + IOL   FF __ __ / __ __ / __ __ __ __ Retinectomy   FF __ __ / __ __ / __ __ __ __ 
Phako + IOL   FF __ __ / __ __ / __ __ __ __ Laser   FF __ __ / __ __ / __ __ __ __ 
YAG PI   FF __ __ / __ __ / __ __ __ __ Surgical PI   FF __ __ / __ __ / __ __ __ __ 
Other   FF __ __ / __ __ / __ __ __ __   
 
        If Other Specify   __________________________________________________________________  
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading (See grading chart for further details)  A  F B  F C  F 
If grading C please specify (range 1-12) CA  F__ __ CP  F__ __ 
 
OCT Taken Yes  F No  F NP  F 
 
If Yes Specify 
OCT Macular SRF Yes  F No  F NP  F 
OCT Foveal Thickness (Range 0-999) __ __ __ µm NP  F 
OCT Macular Volume (Range 0-100) __ __ . __ __ mm3 NP  F 
 
Retina Re-Attached without further VR Intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of Additional VR Procedures Since First 
Vitrectomy apart from removal of oil __ __ N/A  F  
Any Adverse Events since their last study visit? (If yes complete separate  adverse event form) Yes  F No  F 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
CHAD1024_ CRF_PACK_v4.7.pdf CONFIDENTIAL  Page 10 of 10 
Rev 4.7 – 05/02/2013 
 
 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
ETHNIC CATEGORIES FORM Study Eye Data Only, all fields are mandatory 
 
These are the standard categories to be used for the collection of ethnic group information from 
1 April 2001. 
 
Ethnic Categories 
White British   F 
Irish  F 
Any other White background  F 
 
Mixed White and Black Caribbean F 
White and Black African  F 
White and Asian  F 
Any other mixed background   F 
 
Asian or Asian British Indian F 
Pakistani F 
Bangladeshi F 
Any other Asian background F 
 
Black or Black British Caribbean F 
African F 
Any other Black background F 
 
Other ethnic groups Chinese  F 
Any other ethnic group  F 
 
If Any Other Ethnic Group Specify  
 
___________________________________________ 
Not stated Not stated F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
CHAD1024_ CRF_PACK_v4.7.pdf CONFIDENTIAL   
Rev 4.7 – 05/02/2013 
 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
APPENDIX 1 - GRADING CHART All fields are mandatory 
 
PVR Grade Features 
A  Vitreous haze; vitreous pigment clumps; pigment clusters on inferior retina 
B Wrinkling of inner retinal surface; retinal stiffness; vessel tortousity; rolled and irregular edge of retinal break; decreased mobility of vitreous 
CA 1-12  Anterior to equator; focal, diffuse or circumferential full thickness folds; subretinal strands; anterior displacement; condensed viterous with strands 
CP 1-12 Posterior to equator; focal, diffuse or circumferential full-thickness folds; subretinal strands; anterior displacement; condensed vitreous with strands 
 
 
 
 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
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Rev 4.7 – 05/02/2013 
 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
APPENDIX 2 - UNSCHEDULED VISIT ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details   
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
BCVA ETDRS  
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-70) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF   Fibrin FFF Hyphaema FFF 
Oil (patent pi) FFF Oil (blocked pi) FFF Flat AC FFF
    Rubeosis FFF
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF Cataract (oil) FFF Cataract FFF 
AC IOL FFF PC IOL FFF Aphakic FFF
 
State of Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Detached FFF Oedema FFF 
  Pucker FFF FTMH FFF
 
State of Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Traction RD FFF RRD FFF 
Open Previous Break FFF Entry Site Breaks FFFOther New Breaks FFF
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out   FF __ __ / __ __ / __ __ __ __ Buckle   FF __ __ / __ __ / __ __ __ __ 
ICCE   FF __ __ / __ __ / __ __ __ __ Peel   FF __ __ / __ __ / __ __ __ __ 
E/C + IOL   FF __ __ / __ __ / __ __ __ __ Retinectomy   FF __ __ / __ __ / __ __ __ __ 
Phako + IOL   FF __ __ / __ __ / __ __ __ __ Laser   FF __ __ / __ __ / __ __ __ __ 
YAG PI   FF __ __ / __ __ / __ __ __ __ Surgical PI   FF __ __ / __ __ / __ __ __ __ 
Other   FF __ __ / __ __ / __ __ __ __   
 
        If Other Specify   __________________________________________________________________  
PVR Present Yes  F No  F NP  F 
 
If Yes Specify 
PVR Grading (See grading chart for further details)  A  F B  F C  F 
If grading C please specify (range 1-12) CA  F__ __ CP  F__ __ 
 
OCT Taken Yes  F No  F NP  F 
 
If Yes Specify 
OCT Macular SRF Yes  F No  F NP  F 
OCT Foveal Thickness (Range 0-999) __ __ __ µm NP  F 
OCT Macular Volume (Range 0-100) __ __ . __ __ mm3 NP  F 
 
Retina Re-Attached without further VR Intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of Additional VR Procedures Since First 
Vitrectomy apart from removal of oil __ __ N/A  F  
Any Adverse Events since their last study visit? (If yes complete separate  adverse event form) Yes  F No  F 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
 
CHAD1024_ CRF_PACK_v4.7.pdf CONFIDENTIAL   
Rev 4.7 – 05/02/2013 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
APPENDIX 3 - PROTOCOL DEVIATIONS FORM All fields are mandatory 
 
Deviation Details 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
Moorfields Eye Hospital, Case Report Form 
CHAD1024  
 
CHAD1024_ CRF_PACK_v4.7.pdf CONFIDENTIAL   
Rev 4.7 – 05/02/2013 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
APPENDIX 4 - CONCOMITANT MEDICATION FORM PRIOR TO TRIAL All fields are mandatory 
 
Name of Medication Total Dose  
per day 
Approximate  
Start Date  
of medication 
Stop Date (leave 
blank if continuing on 
the medication) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Comments 
 
 
Moorfields Eye Hospital, Case Report Form 
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CHAD1024_ CRF_PACK_v4.7.pdf CONFIDENTIAL   
Rev 4.7 – 05/02/2013 
Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
APPENDIX 5 - CONCOMITANT MEDICATION FORM DURING THE TRIAL All fields are mandatory 
 
Name of Medication Total Dose  
per day 
Approximate  
Start Date  
of medication 
Stop Date (leave 
blank if continuing on 
the medication) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
 
Comments 
 
 
Moorfields Eye Hospital, Case Report Form 
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Triamcinolone at Vitrectomy for Trauma – AOT Study Study No: __ __ __ __ 
APPENDIX 6 – EARLY STUDY WITHDRAWAL FORM All fields are mandatory 
Withdrawal Details 
Did the patient discontinue the  
trial prematurely? Yes  F No  F  
Date of premature  
Study Discontinuation (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Primary reason for discontinuation 
(tick one box only) 
Patient withdraws consent F 
 
 
If known, state reason:     
_____________________________________________ 
Patient is participating in another trial F 
Patient is non-compliant F 
Patient is pregnant F 
Patient is lost to follow up F 
Investigator feels that it is in the patients best interest due to adverse 
event F 
 
 
Related AE No:    
___________________________________________________ 
Other reason for discontinuation F 
 
 
If Other specify:    
___________________________________________________ 
 
Does the patient still agree to have 
their data collected and analysed 
as part of an intent to treat 
analysis? 
Yes  F No  F 
 
 
Comments 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
 
Office use only, data entry completed by: 
Print Name:    Date: 
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Triamcinolone at Vitrectomy for Trauma – AOT Study 
Adverse Event Pharmacovigilance Log Study No: __ __ __ __ 
 
Visit Number Visit Date Any Adverse Events since  
their last study visit 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
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Triamcinolone at Vitrectomy for Trauma – AOT Study  
APPENDIX 8 - ADVERSE EVENT FORM 
Site number: 
 
MEH/001 
Sponsor ID: 
 
CHAD1024 
Eudract Number: 
 
2007/005138/55 
Study Drug: 
 
Triamcinolone, Pred Forte, 
Froben 
Patient Initials: Visit Number: 
 
 
Adverse Event 
Ocular/Non-ocular 
Severity Study Drug 
Relationship 
Action Taken Regarding 
Study Treatment 
Outcome of AE Expected Serious 
 
L=event in left eye 
R=event in right eye 
B=event in both eyes 
N=Other non-ocular  event 
(code each prefix/ non event) 
 
1=Mild 
2=Moderate 
3=Severe       
 
1=Definitely  
2=Probably  
3=Possibly  
4=Unlikely 
5=Not Related 
6=Not 
Assessable 
 
1=None 
2=Discontinued 
permanently 
3=Discontinued temporarily 
4=Reduced dose 
5=Increased dose  
6=Delayed dose  
 
1=Resolved, No Sequel 
2=AE still present- no treatment 
3=AE still present- being treated 
4=Side effects present- not treated 
5=Side effects present- treated 
6=Death 
7=Unknown 
 
1=Yes 
2=No 
 
1=Yes 
2=No 
 
(If yes  
complete  
SAE form) 
 
 
 
Adverse Event 
 
Start Date 
 
Stop Date  
 
Severity 
 
Relationship to 
Study Treatment 
 
Action Taken 
with Study 
Treatment 
 
Outcome of 
AE 
 
Expected 
 
Serious 
(If yes 
complete 
SAE form) 
 
Initials 
1.  
 
 
         
2. 
 
 
         
3. 
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8.2 Appendix 2 Adjuncts in Ocular Trauma Trial GP Letter 
 
Dear Doctor 
 
This is to inform you that your patient: 
 
 
has been recruited into a new study at Moorfields Eye Hospital entitled: 
 
A pilot study of intraocular use of intensive anti-inflammatory; 
Triamcinolone Acetonide to prevent proliferative vitreoretinopathy 
(PVR) in eyes undergoing vitreoretinal surgery for open globe trauma 
(OGT) 
 
Please find enclosed a copy of the Participant Information Sheet. 
 
Your patient has given written consent to take part in this study.  They are 
of course free to withdraw at any time, without needing to give a reason.  
The study has been subject to a review by The Research Ethics Committee 
for Wales, who have given approval for the study to take place. 
 
If you require any further information or you feel that your patient is 
unsuitable to take part in this trial, please do not hesitate to contact us. 
 
 
Yours sincerely 
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8.3 Appendix 3 Adjuncts in Ocular Trauma Trial Consent Form 
 
CONSENT FORM 
 
Study Title:  A pilot study of intraocular use of intensive anti-
inflammatory; Triamcinolone Acetonide to prevent proliferative 
vitreoretinopathy (PVR) in eyes undergoing vitreoretinal surgery for 
open globe trauma (OGT) 
 
Researcher:  Mr D. G. Charteris 
        Please initial box 
 
1. I confirm that I have read and understand the information sheet dated   
July 2011 version number 1.5 for the above study and have had the  
opportunity to ask questions 
 
 
2. I understand that my participation is voluntary and that I am free to  
     withdraw at any time, without giving any reason, without my 
     medical care or legal rights being affected. 
 
 
3. I understand that sections of any of my medical notes may be looked   
          at by individuals from regulatory authorities where it is relevant to  
my taking part in research.  I give permission for these individuals 
to have access to my records 
 
4. I understand that my GP will be informed of my participation in this  
     research project and of any findings significant to my general health 
 
349 
 
 
 
 
5.  I agree to take part in the above study 
 
_________________________   _______  ________________ 
Name of patient    Date   Signature 
 
_________________________  ________  ________________ 
Name of person taking consent  Date   Signature 
(if different from researcher)   
 
_________________________   _______  ________________ 
Researcher     Date   Signature 
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Completing Case Report Forms (CRFs) 
 
This document has been created to provide guidelines about completing clinical trial case 
report forms at Moorfields Eye Hospital (MEH).  The information has been extracted from the 
revised MEH SOP documents that are being developed by the Research & Development 
department at Moorfields. 
 
1. The CRF must be completed as soon as possible after the patient has been assessed or during the assessment if the 
CRF is the source data. 
 
2. CRFs must be completed using a black ink ballpoint pen. 
 
3. If the CRF is printed on carbonless duplication paper, a suitable separator must be inserted under the form being 
completed. 
 
4. Data entry into the CRF must be complete as without omissions. If data are unavailable then ‘unknown’, ‘missing’, ‘tes t 
not done’ etc. should be inserted. The ambiguous phrase, ‘not available’ should be avoided. 
 
5. All entries into the CRF must be accurate, legible and verifiable with the source data in the medical records (unless the 
CRF is the source data). Data must not be invented – this is fraud. 
 
N.B. Whenever a subject has been seen by clinical staff for the purposes of a clinical trial, the time, date and reason 
for visit must always be entered into the subject’s corresponding hospital notes. Copies of trial investigations/results 
that are clinically significant or have an impact on the patient’s clinical care must also be filed in the medical notes.  
 
6. Any discrepancies between the CRF and the source data should be explained and the significance noted in the CRF 
and/or patient’s medical records. 
 
7. All CRF data derived from source documents must be transcribed exactly. This includes laboratory values, which 
unless otherwise agreed, should be entered without conversion from printed reports, even if, for multi-centre studies, 
the units of measurement differ from centre to centre. 
 
8. For laboratory values that fall outside the laboratory’s reference range or trial specific range or when a value shows a 
significant variation from one assessment to the next, this should be commented on and the significance noted in the 
CRF and/or patient’s medical records. 
 
9. The subject’s identity should remain confidential at all times and as such the trial subject must only be identified in the 
CRF using a trial number or code. 
 
10. Entries into the CRF must never be overwritten. 
 
11. Corrections to the CRF must be made as follows: 
 
x An incorrect entry must be deleted with a single line through the text allowing the incorrect entry to remain 
legible. Correction fluid must never be used and entries must not be obliterated. 
x The correct data must be entered. 
x The correction must be initialled and dated and an explanation given of the correction, if applicable. 
 
12. The CRF must be signed and dated where indicated, by the chief/principal investigator or designee (for example, 
research nurse at the end of an assessment) to assert that he/she believes the data is completed and correct. 
 
13. All CRFs must be faxed/scanned weekly to Moorfields 
 
Appendix Summary 
 
Appendix 2 
Patient Questionnaire Forms Completed Depression Screener  F SF36  F VFQ-25  F  
Appendix 3 
No. of Unscheduled Visit Forms 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 4 
No. of Protocol Deviation Forms 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 5  
No. of Concomitant Medication Forms Prior to trial 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 6 
No. of Concomitant Medication Forms During the trial 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
Appendix 7 
Early Withdrawal Form Yes  F No  F  
Appendix 8 
No. of Adverse Events Forms 0  F 1  F 2  F 3 F 4  F 5  F 6  F  
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Ozurdex in PVR Study Study No: __ __ __ 
PATIENT & BASELINE ASSESSMENT FORM (1/2) Study Eye Data Only, all fields are mandatory 
Patient Details 
Study Eye  Right  F Left  F 
 
Gender Male  F Female  F 
 
Ethnic Origin Please complete Ethnic Categories Form 
Date of Birth (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Baseline Exam  
 
Date of Exam (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
VFQ score (Range – 0-100)  __ __ __ 
SF36 score (Range – 0-100) __ __ __ 
Dysthmia/ Major Depression Yes  F No  F 
 
If yes are symptoms present? Yes  F No  F 
 
Spherical Equivalent Dioptres 
(Range – -30-30)  +/- __ __ . __ __ NP  F  
Past Ocular History 
Uveitis  Yes  F No  F 
Previous VR surgery  Yes  F No  F 
Stable glaucoma/OHT  Yes  F No  F 
Other (except cataract surgery)  Yes  F No  F 
 
If Other Specify  _______________________________________________________ 
If Previous VR Surgery Specify 
Yes   No (dd mm yyyy) 
V/Gas   FF __ __ / __ __ / __ __ __ __ 
V/Oil FF __ __ / __ __ / __ __ __ __ 
V/B   FF __ __ / __ __ / __ __ __ __ 
C/B FF __ __ / __ __ / __ __ __ __ 
Other FF __ __ / __ __ / __ __ __ __ 
 
If Other Specify  _______________________________________________________ 
Extent of Buckle (hrs 0-12) __ __ 
No’ of times Mac off __ __ 
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC Flare  0  F 1+  F 2+  F 3+  F 4+  F NP  F 
 
AC Cells  0  F 1+  F 2+  F 3+  F 4+  F NP  F 
 
Lens Status (Choose one)  Clear  F PC IOL  F Cataract  F
 Traumatic Cataract  F NP  F 
 
If Cataract, state LOCS II 
NS 0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC 0  F 1+  F 2+  F 3+  F 4+  F 
 
Vit Haemorrhage  0  F 1+  F 2+  F 3+  F 4+  F NP  F 
 
Vit RPE Cells  0  F 1+  F 2+  F 3+  F 4+  F NP  F 
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Ozurdex in PVR Study Study No: __ __ __ 
PATIENT & BASELINE ASSESSMENT FORM (2/2) Study Eye Data Only, all fields are mandatory 
 
Retinal Detachment 
(Please enter Primary if first Detachment or enter both 
Primary and Baseline if more than one Detachment ) 
 
     Primary     Baseline 
Number of Breaks __ __ __ NP  F __ __ __ NP  F 
Clock hours of Breaks __ __ __ NP  F __ __ __ NP  F 
Duration of RD __ __ __ NP  F __ __ __ NP  F 
Clock hours of RD __ __ __ NP  F __ __ __ NP  F 
 
Macula Attached Yes  F No  F Bisecting  F 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Grade (range 1-12)  CA  F__ __ CP  F__ __ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
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Ozurdex in PVR Study Study No: __ __ __ 
OPERATION RECORD FORM Study Eye Data Only, all fields are mandatory 
Operation Details  
 
Date of Operation (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Surgeon Grade SPR  F Fellow  F Consultant  F

Anaesthetic Local  F General  F
 
Operative Techniques 
(Tick yes or no) 
Yes   No   Yes   No 
Phako FF Drainage Retinotomy  FF 
Vitrectomy FF Encircling Buckle  FF 
Lensectomy  FF Oil (1300)  FF 
Posterior Vit Detach Induced  FF Oil (5500)  FF 
Heavy Liquid  FF  

Relaxing Retinectomy Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Peel Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Local Buckle Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Retinopexy 
(Tick yes or no) 
Yes   No Yes   No 
Endolaser  FF Indirect Laser  FF 
 Cryotherapy  FF 
 
Complication Type 
(Tick yes or no) 
Yes   No Yes   No 
Entry Site Breaks  FF AC Haemorrhage  FF 
Choroidal Haemorrhage  FF Other Iatrogenic Breaks  FF 
Subretinal Haemorrhage  FF Lens Touch  FF 
Preretinal Haemorrhage  FF Deep Buckle Suture  FF 
Haemorrhage at Retinectomy  FF  

Failure to Reattach Retina   Yes  F No  F
 
Complication Other Yes  F No  F
 
If Yes Specify 
 
 
________________________________________________________ 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12)  CA  F__ __ CP  F__ __ 
 
Adjunct given Yes  F No  F 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
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Ozurdex in PVR Study Study No: __ __ __ 
RE-OPERATION RECORD FORM Study Eye Data Only, all fields are mandatory 
Operation Details  
 
Date of Operation (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Surgeon Grade SPR  F Fellow  F Consultant  F

Anaesthetic Local  F General  F
 
Operative Techniques 
(Tick yes or no) 
Yes   No   Yes   No 
Phako FF Drainage Retinotomy  FF 
Vitrectomy FF Encircling Buckle  FF 
Lensectomy  FF Oil (1300)  FF 
Posterior Vit Detach Induced  FF Oil (5500)  FF 
Heavy Liquid  FF  

Relaxing Retinectomy Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Peel Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Local Buckle Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Retinopexy 
(Tick yes or no) 
Yes   No Yes   No 
Endolaser  FF Indirect Laser  FF 
 Cryotherapy  FF 
 
Complication Type 
(Tick yes or no) 
Yes   No Yes   No 
Entry Site Breaks  FF AC Haemorrhage  FF 
Choroidal Haemorrhage  FF Other Iatrogenic Breaks  FF 
Subretinal Haemorrhage  FF Lens Touch  FF 
Preretinal Haemorrhage  FF Deep Buckle Suture  FF 
Haemorrhage at Retinectomy  FF  

Failure to Reattach Retina   Yes  F No  F
 
Complication Other Yes  F No  F
 
If Yes Specify 
 
 
________________________________________________________ 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12)  CA  F__ __ CP  F__ __ 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
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Ozurdex in PVR Study Study No: __ __ __ 
REMOVAL OF SILICONE OIL PROCEDURE FORM (1/2) Study Eye Data Only, all fields are mandatory 
Removal of Silicone Oil Procedure  
 
Date of Operation (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Surgeon Grade SPR  F Fellow  F Consultant  F

Anaesthetic Local  F General  F
 
State of Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF
Traction RD FFF Entry Site Break FFF 
RRD FFF Other New Breaks FFF
  Visible Flat ERM FFF 
 
Macula Attached Yes  F No  F Bisecting  F 
 
Operative Techniques 
(Tick yes or no) 
Yes   No   Yes   No 
Cataract Extraction FF Light Shield Used  FF 

Relaxing Retinectomy Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Peel Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Local Buckle Yes  F No  F 
 
If Yes Specify Degrees (range 1-360) __ __ __° 
Retinopexy 
(Tick yes or no) 
Yes   No Yes   No 
Endolaser  FF Indirect Laser  FF 
 Cryotherapy  FF 
 
Infusion site   AC  F Pars Plana  F
 
IOL Yes  F No  F 
 
If Yes Specify AC IOL  F Sulcus  F BAG  F 
 
Evacuation Method   Automated  F Manual  F
 
Evacuation Site AC  F Pars Plana  F
 
Tamponade Yes  F No  F 
 
If Yes Specify Air  F SF6  F C3F8  F Oil 1300  F Oil 5500  F 
 
Complication Type 
(Tick yes or no) 
Yes   No Yes   No 
Entry Site Breaks  FF AC Haemorrhage  FF 
Choroidal Haemorrhage  FF Other Iatrogenic Breaks  FF 
Subretinal Haemorrhage  FF Lens Touch  FF 
Preretinal Haemorrhage  FF Deep Buckle Suture  FF 
Haemorrhage at Retinectomy  FF  

Failure to Reattach Retina   Yes  F No  F
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Ozurdex in PVR Study Study No: __ __ __ 
REMOVAL OF SILICONE OIL PROCEDURE FORM (1/2) Study Eye Data Only, all fields are mandatory 
 
 
Complication Other Yes  F No  F
 
If Yes Specify 
 
 
________________________________________________________ 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12)  CA  F__ __ CP  F__ __ 
 
Adjunct given Yes  F No  F 
 
Duration of Operation (range 0-240 mins) __ __ __ . __ mins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
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Ozurdex in PVR Study Study No: __ __ __ 
10 DAY ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF Oil (patent PI) FFF Corneal Oedema FFF
  Fibrin FFF Oil (blocked PI) FFF  
  Hyphaema FFF Rubeosis FFF  
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF PC IOL FFF Cataract FFF 
AC IOL FFF Aphakic FFF  
 
If Cataract, 
state  
LOCS II 
NS  0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC  0  F 1+  F 2+  F 3+  F 4+  F 
 
State of 
Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Oedema FFF FTMH FFF
Detached FFF Pucker FFF  
 
State of 
Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF Visible Flat ERM FFF 
Traction RD FFF Entry Site Break FFF  
RRD FFF Other New Breaks FFF  
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out    FF __ __ / __ __ / __ __ __ __ Buckle    FF __ __ / __ __ / __ __ __ __ 
ICCE    FF __ __ / __ __ / __ __ __ __ Peel    FF __ __ / __ __ / __ __ __ __ 
E/C + IOL    FF __ __ / __ __ / __ __ __ __ Retinectomy    FF __ __ / __ __ / __ __ __ __ 
Phako + IOL    FF __ __ / __ __ / __ __ __ __ Laser    FF __ __ / __ __ / __ __ __ __ 
YAG PI    FF __ __ / __ __ / __ __ __ __ Surgical PI    FF __ __ / __ __ / __ __ __ __ 
Other    FF __ __ / __ __ / __ __ __ __ If Other Specify   _____________________________ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12) CA F__ __ CP  F__ __
 
Hypotensive Agents Yes  F No  F
 
If Yes Specify 
Prostaglandin  F Topical CAI F Combigan F
B Blocker F Systemic CAI F Combined B Blocker +  
Prostaglandin 
F
Alpha Agonist F Cosopt F 
 
Retina Reattached without further VR surgical intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of additional VR procedures since first vitrectomy apart from ROSO __ __ 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
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Ozurdex in PVR Study Study No: __ __ __ 
4-6 WEEK ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF Oil (patent PI) FFF Corneal Oedema FFF
  Fibrin FFF Oil (blocked PI) FFF  
  Hyphaema FFF Rubeosis FFF  
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF PC IOL FFF Cataract FFF 
AC IOL FFF Aphakic FFF  
 
If Cataract, 
state  
LOCS II 
NS  0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC  0  F 1+  F 2+  F 3+  F 4+  F 
 
State of 
Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Oedema FFF FTMH FFF
Detached FFF Pucker FFF  
 
State of 
Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF Visible Flat ERM FFF 
Traction RD FFF Entry Site Break FFF  
RRD FFF Other New Breaks FFF  
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out    FF __ __ / __ __ / __ __ __ __ Buckle    FF __ __ / __ __ / __ __ __ __ 
ICCE    FF __ __ / __ __ / __ __ __ __ Peel    FF __ __ / __ __ / __ __ __ __ 
E/C + IOL    FF __ __ / __ __ / __ __ __ __ Retinectomy    FF __ __ / __ __ / __ __ __ __ 
Phako + IOL    FF __ __ / __ __ / __ __ __ __ Laser    FF __ __ / __ __ / __ __ __ __ 
YAG PI    FF __ __ / __ __ / __ __ __ __ Surgical PI    FF __ __ / __ __ / __ __ __ __ 
Other    FF __ __ / __ __ / __ __ __ __ If Other Specify   _____________________________ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12) CA F__ __ CP  F__ __
 
Hypotensive Agents Yes  F No  F
 
If Yes Specify 
Prostaglandin  F Topical CAI F Combigan F
B Blocker F Systemic CAI F Combined B Blocker +  
Prostaglandin 
F
Alpha Agonist F Cosopt F 
 
Retina Reattached without further VR surgical intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of additional VR procedures since first vitrectomy apart from ROSO __ __ 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
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Ozurdex in PVR Study Study No: __ __ __ 
3 MONTH ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF Oil (patent PI) FFF Corneal Oedema FFF
  Fibrin FFF Oil (blocked PI) FFF  
  Hyphaema FFF Rubeosis FFF  
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF PC IOL FFF Cataract FFF 
AC IOL FFF Aphakic FFF  
 
If Cataract, 
state  
LOCS II 
NS  0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC  0  F 1+  F 2+  F 3+  F 4+  F 
 
State of 
Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Oedema FFF FTMH FFF
Detached FFF Pucker FFF  
 
State of 
Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF Visible Flat ERM FFF 
Traction RD FFF Entry Site Break FFF  
RRD FFF Other New Breaks FFF  
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out    FF __ __ / __ __ / __ __ __ __ Buckle    FF __ __ / __ __ / __ __ __ __ 
ICCE    FF __ __ / __ __ / __ __ __ __ Peel    FF __ __ / __ __ / __ __ __ __ 
E/C + IOL    FF __ __ / __ __ / __ __ __ __ Retinectomy    FF __ __ / __ __ / __ __ __ __ 
Phako + IOL    FF __ __ / __ __ / __ __ __ __ Laser    FF __ __ / __ __ / __ __ __ __ 
YAG PI    FF __ __ / __ __ / __ __ __ __ Surgical PI    FF __ __ / __ __ / __ __ __ __ 
Other    FF __ __ / __ __ / __ __ __ __ If Other Specify   _____________________________ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12) CA F__ __ CP  F__ __
 
Hypotensive Agents Yes  F No  F
 
If Yes Specify 
Prostaglandin  F Topical CAI F Combigan F
B Blocker F Systemic CAI F Combined B Blocker +  
Prostaglandin 
F
Alpha Agonist F Cosopt F 
 
Retina Reattached without further VR surgical intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of additional VR procedures since first vitrectomy apart from ROSO __ __ 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
CHAD1030   
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Ozurdex in PVR Study Study No: __ __ __ 
6 MONTH ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
ETDRS VA (Range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF Oil (patent PI) FFF Corneal Oedema FFF
  Fibrin FFF Oil (blocked PI) FFF  
  Hyphaema FFF Rubeosis FFF  
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF PC IOL FFF Cataract FFF 
AC IOL FFF Aphakic FFF  
 
If Cataract, 
state  
LOCS II 
NS  0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC  0  F 1+  F 2+  F 3+  F 4+  F 
 
State of 
Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Oedema FFF FTMH FFF
Detached FFF Pucker FFF  
 
State of 
Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF Visible Flat ERM FFF 
Traction RD FFF Entry Site Break FFF  
RRD FFF Other New Breaks FFF  
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out    FF __ __ / __ __ / __ __ __ __ Buckle    FF __ __ / __ __ / __ __ __ __ 
ICCE    FF __ __ / __ __ / __ __ __ __ Peel    FF __ __ / __ __ / __ __ __ __ 
E/C + IOL    FF __ __ / __ __ / __ __ __ __ Retinectomy    FF __ __ / __ __ / __ __ __ __ 
Phako + IOL    FF __ __ / __ __ / __ __ __ __ Laser    FF __ __ / __ __ / __ __ __ __ 
YAG PI    FF __ __ / __ __ / __ __ __ __ Surgical PI    FF __ __ / __ __ / __ __ __ __ 
Other    FF __ __ / __ __ / __ __ __ __ If Other Specify   _____________________________ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Taken Yes  F No  F
 
If Yes Specify Grade (range 1-12) CA  F__ __ CP  F__ __
 
Hypotensive Agents Yes  F No  F
 
If Yes Specify 
Prostaglandin  F Topical CAI F Combigan F
B Blocker F Systemic CAI F Combined B Blocker +  
Prostaglandin 
F
Alpha Agonist F Cosopt F 
 
VFQ score (Range – 0-100)  __ __ __  
SF36 score (Range – 0-100) __ __ __  
Dysthmia/ Major Depression Yes  F No  F 
 
If yes are symptoms present? Yes  F No  F 
 
Retina Reattached without further VR surgical intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of additional VR procedures since first vitrectomy apart from ROSO __ __ 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
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Ozurdex in PVR Study Study No: __ __ __ 
9 MONTH ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF Oil (patent PI) FFF Corneal Oedema FFF
  Fibrin FFF Oil (blocked PI) FFF  
  Hyphaema FFF Rubeosis FFF  
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF PC IOL FFF Cataract FFF 
AC IOL FFF Aphakic FFF  
 
If Cataract, 
state  
LOCS II 
NS  0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC  0  F 1+  F 2+  F 3+  F 4+  F 
 
State of 
Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Oedema FFF FTMH FFF
Detached FFF Pucker FFF  
 
State of 
Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF Visible Flat ERM FFF 
Traction RD FFF Entry Site Break FFF  
RRD FFF Other New Breaks FFF  
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out    FF __ __ / __ __ / __ __ __ __ Buckle    FF __ __ / __ __ / __ __ __ __ 
ICCE    FF __ __ / __ __ / __ __ __ __ Peel    FF __ __ / __ __ / __ __ __ __ 
E/C + IOL    FF __ __ / __ __ / __ __ __ __ Retinectomy    FF __ __ / __ __ / __ __ __ __ 
Phako + IOL    FF __ __ / __ __ / __ __ __ __ Laser    FF __ __ / __ __ / __ __ __ __ 
YAG PI    FF __ __ / __ __ / __ __ __ __ Surgical PI    FF __ __ / __ __ / __ __ __ __ 
Other    FF __ __ / __ __ / __ __ __ __ If Other Specify   _____________________________ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12) CA F__ __ CP  F__ __
 
Hypotensive Agents Yes  F No  F
 
If Yes Specify 
Prostaglandin  F Topical CAI F Combigan F
B Blocker F Systemic CAI F Combined B Blocker +  
Prostaglandin 
F
Alpha Agonist F Cosopt F 
 
Retina Reattached without further VR surgical intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of additional VR procedures since first vitrectomy apart from ROSO __ __ 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
CHAD1030   
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Ozurdex in PVR Study Study No: __ __ __ 
12 MONTH ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
ETDRS VA (Range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF Oil (patent PI) FFF Corneal Oedema FFF
  Fibrin FFF Oil (blocked PI) FFF  
  Hyphaema FFF Rubeosis FFF  
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF PC IOL FFF Cataract FFF 
AC IOL FFF Aphakic FFF  
 
If Cataract, 
state  
LOCS II 
NS  0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC  0  F 1+  F 2+  F 3+  F 4+  F 
 
State of 
Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Oedema FFF FTMH FFF
Detached FFF Pucker FFF  
 
State of 
Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF Visible Flat ERM FFF 
Traction RD FFF Entry Site Break FFF  
RRD FFF Other New Breaks FFF  
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out    FF __ __ / __ __ / __ __ __ __ Buckle    FF __ __ / __ __ / __ __ __ __ 
ICCE    FF __ __ / __ __ / __ __ __ __ Peel    FF __ __ / __ __ / __ __ __ __ 
E/C + IOL    FF __ __ / __ __ / __ __ __ __ Retinectomy    FF __ __ / __ __ / __ __ __ __ 
Phako + IOL    FF __ __ / __ __ / __ __ __ __ Laser    FF __ __ / __ __ / __ __ __ __ 
YAG PI    FF __ __ / __ __ / __ __ __ __ Surgical PI    FF __ __ / __ __ / __ __ __ __ 
Other    FF __ __ / __ __ / __ __ __ __ If Other Specify   _____________________________ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Taken Yes  F No  F
 
If Yes Specify Grade (range 1-12) CA  F__ __ CP  F__ __
 
Hypotensive Agents Yes  F No  F
 
If Yes Specify 
Prostaglandin  F Topical CAI F Combigan F
B Blocker F Systemic CAI F Combined B Blocker +  
Prostaglandin 
F
Alpha Agonist F Cosopt F 
 
VFQ score (Range – 0-100)  __ __ __  
SF36 score (Range – 0-100) __ __ __  
Dysthmia/ Major Depression Yes  F No  F 
 
If yes are symptoms present? Yes  F No  F 
 
Retina Reattached without further VR surgical intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of additional VR procedures since first vitrectomy apart from ROSO __ __ 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
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Ozurdex in PVR Study Study No: __ __ __ 
INTERIM ASSESSMENT FORM  Study Eye Data Only, all fields are mandatory 
Day 1 Details (Post Op primary study vitrectomy)  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
IOP mmHG (Range – 0-80) __ __
If treatment group is implant in 
vitreous cavity? Yes  F No  F Adjunct not given  F  
Day 60 Details (Post primary study vitrectomy)  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
IOP mmHG (Range – 0-80) __ __
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
Day 1 Details (Post Op ROSO)  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
IOP mmHG (Range – 0-80) __ __
If treatment group is implant in 
vitreous cavity? Yes  F No  F Adjunct not given  F  
Day 60 Details (Post ROSO)  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
IOP mmHG (Range – 0-80) __ __
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
 
 
 
 
 
 
 
Comments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
 
Moorfields Eye Hospital, Case Report Form 
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Rev 2.2 – 26/01/2012 
Ozurdex in PVR Study Study No: __ __ __ 
ETHNIC CATEGORIES FORM Study Eye Data Only, all fields are mandatory 
 
These are the standard categories to be used for the collection of ethnic group information from 
1 April 2001. 
 
Ethnic Categories 
White British   F 
Irish  F 
Any other White background  F 
 
Mixed White and Black Caribbean F 
White and Black African  F 
White and Asian  F 
Any other mixed background   F 
 
Asian or Asian British Indian F 
Pakistani F 
Bangladeshi F 
Any other Asian background F 
 
Black or Black British Caribbean F 
African F 
Any other Black background F 
 
Other ethnic groups Chinese  F 
Any other ethnic group  F 
 
If Any Other Ethnic Group Specify  
 
___________________________________________ 
Not stated Not stated F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
CHAD1030   
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Rev 2.2 – 26/01/2012 
Ozurdex in PVR Study Study No: __ __ __ 
APPENDIX 1 - GRADING CHART All fields are mandatory 
 
PVR Grade Features 
A  Vitreous haze; vitreous pigment clumps; pigment clusters on inferior retina 
B Wrinkling of inner retinal surface; retinal stiffness; vessel tortousity; rolled and irregular edge of retinal break; decreased mobility of vitreous 
CA 1-12  Anterior to equator; focal, diffuse or circumferential full thickness folds; subretinal strands; anterior displacement; condensed viterous with strands 
CP 1-12 Posterior to equator; focal, diffuse or circumferential full-thickness folds; subretinal strands; anterior displacement; condensed vitreous with strands 
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Ozurdex in PVR Study Study No: __ __ __ 
Appendix 2 - Visual Function Questionnaire – 25 (1/5) Please answer all questions 
 
Part 1 – General Health and Vision  
 
1. In general, would you say your overall health is* (Tick one) 
Excellent ………………………………………………… 1  F 
Very Good ………………………………………………. 2  F 
Good …………………………………………………….. 3  F 
Fair ………………………………………………………. 4  F 
Poor ……………………………………………………… 5  F 
 
2. At the present time, would you say your eyesight 
using both eyes (with glasses or contact lenses, if 
you wear them) is excellent, good, fair, poor, or 
very poor or are you completely blind? 
 
(Tick one) 
Excellent ………………………………………………… 1  F 
Good …………………………………………………….. 2  F 
Fair ………………………………………………………. 3  F 
Poor ……………………………………………………… 4  F 
Very Poor ……………………………………………….. 5  F 
Completely Blind ……………………………………….. 6  F 
 
3. How much of the time do you worry about your 
eyesight? 
 
(Tick one) 
None of the time ……………………………………….. 1  F 
A little of the time ………………………………………. 2  F 
Some of the time ………………………………………. 3  F 
Most of the time ………………………………………... 4  F 
All of the time …………………………………………… 5  F 
 
4. How much pain or discomfort have you had in 
and around your eyes (for example, burning, 
itching, or aching)? Would you say it is: 
(Tick one) 
None …………………………………………………… 1  F 
Mild …………………………………………………….. 2  F 
Moderate ………………………………………………. 3  F 
Severe, or ……………………………………….......... 4  F 
Very severe ……………………………………………. 5  F 
 
* Skip Question 1 when the VFQ-25 is administered at the same time as the SF-36 or RAND 36-Item Health Survey 1.0 
 
The next questions are about how much difficulty, if any, you have doing certain activities wearing your 
glasses or contact lenses if you use them for that activity. 
 
Part 2 – Difficulty with activities (Read categories as needed)  
 
5. How much difficulty do you have reading 
ordinary print in newspapers? Would you say 
you have: 
 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………... 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
6. How much difficulty do you have doing work or 
hobbies that require you to see well up close, 
such as cooking, sewing, fixing things around the 
house, or using hand tools? Would you say: 
 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………... 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
Moorfields Eye Hospital, Case Report Form 
CHAD1030   
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Ozurdex in PVR Study Study No: __ __ __ 
Appendix 2 - Visual Function Questionnaire – 25 (2/5) Please answer all questions 
 
7. Because of your eyesight, how much difficulty do 
you have finding something on a crowded 
shelf? 
 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
8. How much difficulty do you have reading street 
signs or the names of stores? 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
9. Because of your eyesight, how much difficulty do 
you have going down steps, stairs, or curbs in 
dim light or at night? 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
10. Because of your eyesight, how much difficulty do 
you have noticing objects off to the side while 
you are walking along? 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
11. Because of your eyesight, how much difficulty do 
you have seeing how people react to things you 
say? 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
12. Because of your eyesight, how much difficulty do 
you have picking out and matching your own 
clothes? 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
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Appendix 2 - Visual Function Questionnaire – 25 (3/5) Please answer all questions 
 
13. Because of your eyesight, how much difficulty do 
you have visiting with people in their homes, at 
parties, or in restaurants? 
 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
14. Because of your eyesight, how much difficulty do 
you have going out to see movies, plays, or 
sports events? 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
15. Now, I’d like to ask about driving a car. Are you 
currently driving, at least once in a while? 
(Tick one) 
Yes (Skip to Q15c) …………………………….………. 1  F 
No ………………………………………………………… 2  F 
 
15a. IF NO, ASK: Have you never driven a car or have 
you given up driving? 
(Tick one) 
Never drove (Skip to Part 3, Q17) ……………………. 1  F 
No ………………………………………………………… 2  F 
 
15b. IF GAVE UP DRIVING: Was that mainly because 
of your eyesight, mainly for some other reason, 
or because of both your eyesight and other 
reasons? 
 
(Tick one) 
Mainly eyesight (Skip to Part 3, Q17) ……………….. 1  F 
Mainly other reason (Skip to Part 3, Q17) ………….. 2  F 
Both eyesight and other reason (Skip to Part 3, Q17) 3  F 
 
15c. IF CURRENTLY DRIVING: How much difficulty do 
you have driving during the daytime in familiar 
places? Would you say you have: 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
 
16. How much difficulty do you have driving at night? 
Would you say you have: 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
 
16a. How much difficulty do you have driving in 
difficult conditions, such as in bad weather, 
during rush hour, on the freeway, or in city 
traffic? Would you say you have: 
(Tick one) 
No difficulty at all …………………………………….… 1  F 
A little difficulty …………………………………………. 2  F 
Moderate difficulty ……………………………………… 3  F 
Extreme difficulty ………………………………………. 4  F 
Stopped doing this because of your eyesight ……… 5  F 
Stopped doing this for other reasons or not  
interested in doing this ………………………………… 6  F 
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Appendix 2 - Visual Function Questionnaire – 25 (4/5) Please answer all questions 
 
The next questions are about how things you do may be affected by your vision.  For each one, I’d like 
you to tell me if this is true for you all, most, some, a little, or none of the time. 
 
Part 3 – Responses to Vision Problems  
 
17. Do you accomplish less than you would like 
because of your vision? 
(Tick one) 
All of the time …………………………………….…….. 1  F 
Most of the time ………………………………………... 2  F 
Some of the time ……………………………………….. 3  F 
A little of the time ………………………………………. 4  F 
None of the time ……………………………………….. 5  F 
 
18. Are you limited in how long you can work or do 
other activities because of your vision? 
(Tick one) 
All of the time …………………………………….…….. 1  F 
Most of the time ………………………………………... 2  F 
Some of the time ……………………………………….. 3  F 
A little of the time ………………………………………. 4  F 
None of the time ……………………………………….. 5  F 
 
19. How much does pain or discomfort in or around 
your eyes, for example, burning, itching, or 
aching, keep you from doing what you’d like to be 
doing? Would you say: 
(Tick one) 
All of the time …………………………………….…….. 1  F 
Most of the time ………………………………………... 2  F 
Some of the time ……………………………………….. 3  F 
A little of the time ………………………………………. 4  F 
None of the time ……………………………………….. 5  F 
 
 
For each of the following statements, please tell me if it is definitely true, mostly true, mostly false, or 
definitely false for you or you are not sure. 
 
20. I stay home most of the time because of my 
eyesight: 
(Tick one) 
Definitely True …………………………………….…… 1  F 
Mostly True ………………………………………......... 2  F 
Not Sure ………………………………………………… 3  F 
Mostly False ……………………………………………. 4  F 
Definitely False ………………………………………… 5  F 
 
21. I feel frustrated a lot of the time because of my 
Eyesight: 
(Tick one) 
Definitely True …………………………………….…… 1  F 
Mostly True ………………………………………......... 2  F 
Not Sure ………………………………………………… 3  F 
Mostly False ……………………………………………. 4  F 
Definitely False ………………………………………… 5  F 
 
22. I have much less control over what I do, 
because of my eyesight: 
 
(Tick one) 
Definitely True …………………………………….…… 1  F 
Mostly True ………………………………………......... 2  F 
Not Sure ………………………………………………… 3  F 
Mostly False ……………………………………………. 4  F 
Definitely False ………………………………………… 5  F 
 
 
 
 
 
 
 
Moorfields Eye Hospital, Case Report Form 
CHAD1030   
 
CHAD1030_ CRF_PACK_v2.2.pdf CONFIDENTIAL  Page 5 of 9 
Rev 2.2 – 26/01/2012 
Ozurdex in PVR Study Study No: __ __ __ 
Appendix 2 - Visual Function Questionnaire – 25 (5/5) Please answer all questions 
 
23. Because of my eyesight, I have to rely too much 
on what other people tell me: 
(Tick one) 
Definitely True …………………………………….…… 1  F 
Mostly True ………………………………………......... 2  F 
Not Sure ………………………………………………… 3  F 
Mostly False ……………………………………………. 4  F 
Definitely False ………………………………………… 5  F 
 
24. I need a lot of help from others because of my 
Eyesight: 
(Tick one) 
Definitely True …………………………………….…… 1  F 
Mostly True ………………………………………......... 2  F 
Not Sure ………………………………………………… 3  F 
Mostly False ……………………………………………. 4  F 
Definitely False ………………………………………… 5  F 
 
25. I worry about doing things that will embarrass 
myself or others, because of my eyesight: 
(Tick one) 
Definitely True …………………………………….…… 1  F 
Mostly True ………………………………………......... 2  F 
Not Sure ………………………………………………… 3  F 
Mostly False ……………………………………………. 4  F 
Definitely False ………………………………………… 5  F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
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Appendix 2 - Health Survey – SF36 (1/3) Please answer all questions 
 
Health Survey  
 
1. In general, would you say your overall health is (Tick one) 
Excellent ………………………………………………… 1  F 
Very Good ………………………………………………. 2  F 
Good …………………………………………………….. 3  F 
Fair ………………………………………………………. 4  F 
Poor ……………………………………………………… 5  F 
 
2. Compared to ONE YEAR AGO, how would you 
rate your health in general NOW? 
(Tick one) 
MUCH BETTER than one year ago ………………….. 1  F 
Somewhat BETTER now than one year ago ……….. 2  F 
About the SAME as one year ago …………………… 3  F 
Somewhat WORSE now than one year ago ……….. 4  F 
MUCH WORSE now than one year ago ……………. 5  F 
 
 The following items are about activities you might do during a typical day.  Does your health now limit you in 
these activities?  If so, how much? 
Activities Yes 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
3. Vigorous activities, such as running, lifting heavy objects, participating in 
strenuous sports? 
1  F 2  F 3  F 
4. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, 
or playing golf? 
1  F 2  F 3  F 
5. Lifting or carrying groceries? 1  F 2  F 3  F 
6. Climbing several flights of stairs? 1  F 2  F 3  F 
7. Climbing one flight of stairs? 1  F 2  F 3  F 
8. Bending, kneeing or stooping? 1  F 2  F 3  F 
9. Walking more than a mile? 1  F 2  F 3  F 
10. Walking several blocks? 1  F 2  F 3  F 
11. Walking one block? 1  F 2  F 3  F 
12. Bathing or dressing yourself? 1  F 2  F 3  F 
 During the past 4 weeks, have you had any of the following problems with your work or other regular activities as 
a result of your physical health? 
 Yes No 
13. Cut down on the amount of time you spent on work or other activities? 1  F 2  F 
14. Accomplished less than you would like? 1  F 2  F 
15. Were limited in the kind of work or other activities? 1  F 2  F 
16. Had difficulty performing the work or other activities (for example it took extra effort)? 1  F 2  F 
 During the past 4 weeks, have you had any of the following problems with your work or other regular daily 
activities as a result of any emotional problems (such as feeling depressed or anxious)? 
 Yes No 
17. Cut down on the amount of time you spent on work or other activities? 1  F 2  F 
18. Accomplished less than you would like? 1  F 2  F 
19. Didn’t do work or other activities as carefully as usual? 1  F 2  F 
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Appendix 2 - Health Survey – SF36 (2/3) Please answer all questions 
 
20. During the past 4 weeks, to what extent has your 
physical health or emotional problems interfered 
with your normal social activities with family, 
friends, neighbours, or groups? 
 
(Tick one) 
Not at all ………………………………………………… 1  F 
Slightly ………………………………………………….. 2  F 
Moderately ……………………………………………… 3  F 
Quite a bit ………………………………………………. 4  F 
Extremely ……………………………………………….. 5  F 
 
21. How much bodily pain have you had during the 
past 4 weeks? 
(Tick one) 
None ……………………………………………………… 1  F 
Very Mild ………………………………………………… 2  F 
Mild ………………………………………………………. 3  F 
Moderate ………………………………………………… 4  F 
Severe …………………………………………………… 5  F 
Very Severe ……………………………………………..  
 
22. During the past 4 weeks, how much did pain 
interfere with your normal work (including both 
work outside the home and housework)? 
 
(Tick one) 
Not at all ………………………………………………… 1  F 
Slightly ………………………………………………….. 2  F 
Moderately ……………………………………………… 3  F 
Quite a bit ………………………………………………. 4  F 
Extremely ……………………………………………….. 5  F 
 
 These questions are about how you feel and how things have been with you during the past 4 weeks. For each 
question, please give the one answer that comes closest to the way you have been feeling. How much of the time 
during the past 4 week … 
 All of 
the 
time 
Most 
of the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
23. Did you feel full of pep? 1  F 2  F 3  F 4  F 5  F 6  F 
24. Have you been a very nervous person? 1  F 2  F 3  F 4  F 5  F 6  F 
25. Have you felt so down in the dumps that nothing 
could cheer you up? 
1  F 2  F 3  F 4  F 5  F 6  F 
26. Have you felt calm and peaceful? 1  F 2  F 3  F 4  F 5  F 6  F 
27. Did you have a lot of energy? 1  F 2  F 3  F 4  F 5  F 6  F 
28. Have you felt downhearted and blue? 1  F 2  F 3  F 4  F 5  F 6  F 
29. Do you feel worn out? 1  F 2  F 3  F 4  F 5  F 6  F 
30. Have you been a happy person? 1  F 2  F 3  F 4  F 5  F 6  F 
31. Did you feel tired? 1  F 2  F 3  F 4  F 5  F 6  F 
32. During the past 4 weeks, how much of the time 
has your physical health or emotional 
problems interfered with your social activities 
(like visiting with friends, relatives, etc.)? 
 
(Tick one) 
All of the time ………………………………………….. 1  F 
Most of the time ……………………………………….. 2  F 
Some of the time ……………………………………… 3  F 
A little of the time ……………………………………… 4  F 
None of the time ………………………………………. 5  F 
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Appendix 2 - Health Survey – SF36 (3/3) Please answer all questions 
 
 How TRUE or FALSE is each of the following statements for you? 
 Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
33. I seem to get sick a little easier than other 
people? 
1  F 2  F 3  F 4  F 5  F 
34. I am as healthy as anybody I know? 1  F 2  F 3  F 4  F 5  F 
35. I expect my health to get worse? 1  F 2  F 3  F 4  F 5  F 
36. My health is excellent? 1  F 2  F 3  F 4  F 5  F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
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Appendix 2 - Depression Screener (1/1) Please answer all questions 
 
Almost everyone has experienced times of feeling sad or depressed, like when suffering from a severe illness, when a 
person close to you has died, or if there are problems at work or in the family. The following questions are about such times. 
 
Patient Questionnaire  
 
1. Have you ever had 2 years or more in your life 
when you felt depressed or sad most days, even if 
you felt OK sometimes? 
 
(Tick one) 
Yes ………………………………………………………. 1  F 
No (Skip to Question 2) ………………………………..  2  F 
 
a. Did any period like that ever last 2 years without 
an interruption of 2 full months when you felt OK? 
(Tick one) 
Yes ………………………………………………………. 1  F 
No (Skip to Question 2) ………………………………..  2  F 
 
b. Did any of those long periods of feeling sad or 
depressed continue into the last 12 months? 
(Tick one) 
Yes ………………………………………………………. 1  F 
No …………………………………………………………  2  F 
 
2. In the last 12 months, have you had 2 weeks or longer when ...  
a. nearly every day you felt sad, empty or depressed 
for most of the day? 
 
(Tick one) 
Yes ………………………………………………………. 1  F 
No …………………………………………………………  2  F 
 
b. you lost interest in most things like work, hobbies, 
and other things you usually enjoyed? 
 
(Tick one) 
Yes ………………………………………………………. 1  F 
No …………………………………………………………  2  F 
 
3. In the last month did you have a period of 1 week or more when ...  
a. nearly every day you felt sad, empty or depressed 
for most of the day? 
 
(Tick one) 
Yes ………………………………………………………. 1  F 
No …………………………………………………………  2  F 
 
b. you lost interest in most things like work, hobbies, 
and other things you usually enjoyed? 
 
(Tick one) 
Yes ………………………………………………………. 1  F 
No …………………………………………………………  2  F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
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APPENDIX 3 - UNSCHEDULED VISIT ASSESSMENT FORM Study Eye Data Only, all fields are mandatory 
Examination Details  Missed Visit?  F 
 
Date of Visit (dd mm yyyy) __ __ / __ __ / __ __ __ __    
ETDRS VA 
(Enter no. of letters, range 0-100) __ __ __ 
If score ‘0’ please specify   CF  F HM  F PL  F NPL  F 
 
IOP mmHG (Range – 0-80) __ __
AC 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Uveiitis FFF Oil (patent PI) FFF Corneal Oedema FFF
  Fibrin FFF Oil (blocked PI) FFF  
  Hyphaema FFF Rubeosis FFF  
 
Lens 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Clear FFF PC IOL FFF Cataract FFF 
AC IOL FFF Aphakic FFF  
 
If Cataract, state  
LOCS II 
NS  0  F 1+  F 2+  F 3+  F 4+  F 
CLO 0  F 1+  F 2+  F 3+  F 4+  F 5+  F 
PSC  0  F 1+  F 2+  F 3+  F 4+  F 
 
State of Macula 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Attached FFF Oedema FFF FTMH FFF
Detached FFF Pucker FFF  
 
State of Retina 
(Tick yes or no) 
 Yes   No  NP  Yes   No  NP  Yes   No  NP 
Fully Attached FFF Open Previous Break FFF Visible Flat ERM FFF 
Traction RD FFF Entry Site Break FFF  
RRD FFF Other New Breaks FFF  
 
Other Procedures Since Last Visit 
Yes   No (dd mm yyyy) Yes   No (dd mm yyyy) 
Oil Out    FF __ __ / __ __ / __ __ __ __ Buckle    FF __ __ / __ __ / __ __ __ __ 
ICCE    FF __ __ / __ __ / __ __ __ __ Peel    FF __ __ / __ __ / __ __ __ __ 
E/C + IOL    FF __ __ / __ __ / __ __ __ __ Retinectomy    FF __ __ / __ __ / __ __ __ __ 
Phako + IOL    FF __ __ / __ __ / __ __ __ __ Laser    FF __ __ / __ __ / __ __ __ __ 
YAG PI    FF __ __ / __ __ / __ __ __ __ Surgical PI    FF __ __ / __ __ / __ __ __ __ 
Other    FF __ __ / __ __ / __ __ __ __ If Other Specify   _____________________________ 
 
OCT Yes  F No  F NP  F 
 
If Yes Specify 
Macular SRF Yes  F No  F
 
Foveal Thickness (Range 0-999)   __ __ __ µm NP  F 
Macular Volume (Range 0-100)   __ __ . __ __ mm3 NP  F 
 
PVR Present Yes  F No  F
 
If Yes Specify Grade (range 1-12) CA F__ __ CP  F__ __
 
Hypotensive Agents Yes  F No  F
 
If Yes Specify 
Prostaglandin  F Topical CAI F Combigan F
B Blocker F Systemic CAI F Combined B Blocker +  
Prostaglandin 
F
Alpha Agonist F Cosopt F 
 
Retina Reattached without further VR surgical intervention Yes  F No  F 
 
Silicone Oil In situ Yes  F No  F 
 
Number of additional VR procedures since first vitrectomy apart from ROSO __ __ 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
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APPENDIX 4 - PROTOCOL DEVIATIONS FORM All fields are mandatory 
 
Deviation Details 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
Deviation Date (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Type of Deviation 
 
 
___________________________________________ 
Any Outcomes or Actions 
 
 
___________________________________________ 
 
 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
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APPENDIX 5 - CONCOMITANT MEDICATION FORM PRIOR TO TRIAL All fields are mandatory 
 
Name of Medication Total Dose  
per day 
Approximate  
Start Date  
of medication 
Stop Date (leave 
blank if continuing on 
the medication) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Comments 
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APPENDIX 6 - CONCOMITANT MEDICATION FORM DURING THE TRIAL All fields are mandatory 
 
Name of Medication Total Dose  
per day 
Approximate  
Start Date  
of medication 
Stop Date (leave 
blank if continuing on 
the medication) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
 
Comments 
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APPENDIX 7 – EARLY STUDY WITHDRAWAL FORM All fields are mandatory 
Withdrawal Details 
Did the patient discontinue the  
trial prematurely? Yes  F No  F  
Date of premature  
Study Discontinuation (dd mm yyyy) __ __ / __ __ / __ __ __ __ 
Primary reason for discontinuation 
(tick one box only) 
Patient withdraws consent F 
 
 
If known, state reason:     
_____________________________________________ 
Patient is participating in another trial F 
Patient is non-compliant F 
Patient is pregnant F 
Patient is lost to follow up F 
Investigator feels that it is in the patients best interest due to adverse 
event F 
 
 
Related AE No:    
___________________________________________________ 
Other reason for discontinuation F 
 
 
If Other specify:    
___________________________________________________ 
 
Does the patient still agree to have 
their data collected and analysed 
as part of an intent to treat 
analysis? 
Yes  F No  F 
 
 
Comments 
 
 
 
I can confirm that I have completed this form in full and take full responsibility for any missing data. 
Signed:   Print:   Date:  
Office use only, data entry completed by: 
Print Name:     Date:  
Moorfields Eye Hospital, Case Report Form 
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Ozurdex in PVR Study Study No: __ __ __ 
APPENDIX 8 - ADVERSE EVENTS FORM All fields are mandatory 
 
Please enter details of adverse events below and use relevant codes where necessary. 
 
 
Expected / 
Unexpected 
(enter ‘E’ or ‘U’) 
Code Start Date Stop Date 
(enter ’C’ if 
continued) 
Severity Study Drug 
Relationship 
Action Taken 
Regarding 
Study Drug 
Outcome of 
Adverse Event 
Was this an 
SAE? 
Initials Date 
Recorded 
           
            
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
 
ADVERSE EVENT CODES 
 
Expected: 
1 = Cataract 
2 = Raised Intraocular Pressure 
3 = Hypotony 
4 = Sterile Hypopyon 
5 = Retinal Detachment 
6 = Uveitis 
7 = Further Surgery 
8 = Glaucoma 
9 = Headache 
10 = Migraine 
11 = Vitreous Opacities 
12 = Tractional Maculopathy 
 
Unexpected: 
13 = Endophthalmitis 
14 = Systemic Illness 
15 = Ocular Vascular Occlusion 
16 = Other 
 
Severity: 
1 = Not Severe 
2 = Moderate 
3 = Severe 
 
Study Drug Relationship: 
1 = Not Related 
2 = Possibly/Probably Related 
 
Action Taken Regarding Study Drug: 
1 = None 
2 = Discontinued Permanent 
3 = Discontinued Temporary 
4 = Reduced Dose 
5 = Increased Dose 
 
Was this an SAE? 
1 = Not Severe 
2 = SAE 
3 = SUSAR 
 
Outcome of Adverse Event: 
1 = Resolved without effects 
2 = Resolved with effects 
3 = On-going 
4 = Death 
5 = Unknown 
 
Moorfields Eye Hospital, Adverse Event Pharmacovigilance Pack 
CHAD1030 
CHAD1030_AE_PHARMA_PACK_v2.2.pdf CONFIDENTIAL   
Rev 2.2 – 11/02/2013 
 
Ozurdex in PVR Study 
Pharmacovigilance Adverse Event Log Study No: __ __ __ 
 
Visit Number Visit Date Any Adverse Events since  
their last study visit 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
 
__ __ / __ __ / __ __ __ __    (If yes complete separate  adverse event form) Yes  F No  F 
 
Moorfields Eye Hospital, Adverse Event Pharmacovigilance Pack 
CHAD1030 
CHAD1030_AE_PHARMA_PACK.v2.2.pdf CONFIDENTIAL   
Rev 2.2 – 11/02/2013 
 
 
 Date__ __ / __ __ / __ __ __ __    Study No: __ __ __ __ 
Ozurdex in PVR Study  
PHARMACOVIGILANCE ADVERSE EVENT FORM 
Site number: 
 
MEH/001 
Sponsor ID: 
 
CHAD1030 
Eudract Number: 
 
2011-004498-96 
Study Drug: 
 
Ozurdex 
 
Patient Initials: Visit Number: 
 
Adverse Event 
Ocular/Non-ocular 
Severity Study Drug 
Relationship 
Action Taken Regarding 
Study Treatment 
Outcome of AE Expected Serious 
 
L=event in left eye 
R=event in right eye 
B=event in both eyes 
N=Other non-ocular  event 
(code each prefix/ non event) 
 
1=Mild 
2=Moderate 
3=Severe       
 
1=Definitely  
2=Probably  
3=Possibly  
4=Unlikely 
5=Not Related 
6=Not 
Assessable 
 
1=None 
2=Discontinued 
permanently 
3=Discontinued temporarily 
4=Reduced dose 
5=Increased dose  
6=Delayed dose  
 
1=Resolved, No Sequel 
2=AE still present- no treatment 
3=AE still present- being treated 
4=Side effects present- not treated 
5=Side effects present- treated 
6=Death 
7=Unknown 
 
1=Yes 
2=No 
 
1=Yes 
2=No 
 
(If yes  
complete  
SAE form) 
 
 
 
Adverse Event 
 
Start Date 
 
Stop Date  
 
Severity 
 
Relationship to 
Study Treatment 
 
Action Taken 
with Study 
Treatment 
 
Outcome of 
AE 
 
Expected 
 
Serious 
(If yes 
complete 
SAE form) 
 
Initials 
1.  
 
 
         
2. 
 
 
         
3. 
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8.5 Appendix 5 Ozurdex in PVR Participant Information Leaflet 
 
PARTICIPANT INFORMATION SHEET 
(Version 3.2 – March 11th 2013)  
EXPLANATION TO PATIENT 
Title of Project : Ozurdex in proliferative vitreoretinopathy: a randomised controlled trial 
Researcher:  Mr. D.G. Charteris. 
 
You are being invited to take part in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you 
wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
 
What is the purpose of this study? 
The purpose of this study is to investigate the potential benefit of an additional anti-
inflammatory treatment to improve the outcome of surgery in eyes that have developed scar 
tissue on the surface of the retina (proliferative vitreoretinopathy, PVR). The retina is a thin 
layer which lines the inside of the eye.  It is sensitive to light (like the film in a camera) and is 
necessary for vision.  If a hole or holes develop in a retina it can become detached. Your retina 
has detached and has developed scar tissue (PVR) which increases your risk of it detaching 
again after surgery. This is because the scar tissue pulls on the retina preventing the holes from 
being repaired by the standard technique used in other retinal detachment patients. 
If the retina remains detached you will lose vision.  
The study is designed to investigate whether this anti-inflammatory medication is a feasible 
treatment to prevent this scarring response from recurring. 
The only treatment available is an operation which attempts to remove the scar tissue and close 
the holes, allowing the retina to reattach.  The success rate is limited because the scar tissue 
often returns, leading to re-detachment. 
Inflammation is the medical term used to describe the way in which the body reacts to injury. 
There is laboratory evidence that the formation of scar tissue might be prevented by using anti-
inflammatory medications around the time of surgery. This anti-inflammatory medication is 
currently used routinely on patients in other clinical settings however, we do not yet know 
whether this additional treatment would be helpful in your situation. If you chose to enter the 
study we will not ask you to take any other additional medications as the treatment is given at 
the time of surgery. 
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Why have I been chosen? 
You have been chosen because the retina in your eye has detached and has begun to develop 
scar tissue (PVR), and we are planning to carry out an operation to the back of your eye 
(vitreous gel and retina) to repair this. Initially we hope to study 140 patients with this 
condition.  
 
What will happen to me if I take part? 
The treatments are either the best available current therapy (standard treatment) or the study 
treatment. You will be randomly allocated to one of these treatments. Therefore you have a 50% 
chance of receiving the study treatment and 50% chance of receiving the standard treatment.  
Study Treatment: 
The operation will be the standard one for your particular type of retinal detachment.  At the 
time of surgery we will peel away areas of scar tissue and treat any retinal holes by ‘spot 
welding’ them back into place. In addition to the standard operation we plan to treat the eye at 
the time of surgery with an anti-inflammatory drug called OZURDEX. This drug will be 
administered as a local injection into the eyeball. This will be done whilst you are still under 
anaesthetic so you will not be aware of the additional treatment.  
Following the surgery you will be given the standard steroid, antibiotic and pupil dilating eye 
drops that are usually prescribed following this type of surgery.  
As is routine for patients undergoing surgery for retinal detachments with scar tissue, silicone 
oil is put into the eye at the time of the operation to help the retina stay in place. This is 
normally removed approximately 3-6 months later. We plan to treat the eye with another 
injection of Ozurdex at the time of this second procedure.  
Standard Treatment: 
The operation will be the standard one for your particular type of retinal detachment.  At the 
time of surgery we will peel away areas of scar tissue and treat any retinal holes by ‘spot 
welding’ them back into place. Following the surgery you will be given the standard steroid, 
antibiotic and pupil dilating eye drops that are usually prescribed following this type of surgery. 
As is routine for patients undergoing surgery for retinal detachments with scar tissue, silicone 
oil is put into the eye at the time of the operation to help the retina stay in place. This is 
normally removed approximately 3-6 months later. 
 
What will happen to me at each clinic visit? 
By participating in this study, you will be asked to visit the clinic for 1 additional visit lasting 
approximately 10-15 minutes in the first 6 months and we will continue to see you for 2 further 
appointments at 9 months and 12 months after the initial surgery. 
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At each visit, your vision will be checked and the doctor will examine your eye as usual with a 
microscope. You will also have a routine scan (OCT scan) of the back of your eye. This is 
completely painless and harmless and does not involve radiation.  
You will be asked to complete a short questionnaire at the beginning, middle and end of the 
trial. This will ask questions about how your eyesight affects your life and your mood. 
 
What are the drugs that are being tested? 
OZURDEX is a type of steroid that is commonly used in the treatment of inflammation in a 
number of eye conditions and in eyes that have suffered blood vessel blockages. It has been 
shown to be a safe and effective drug when administered into the eye. In this study the 
OZURDEX is being used outside the terms of its license. 
 
What are the side effects of taking part? 
The medicine that will be used is not new, and has been extensively used for other medical 
conditions.  Therefore we do not expect to discover unknown side effects.  
OZURDEX may cause the pressure in your eye to increase, however we can treat this with 
pressure lowering drops. The pressure usually returns to normal once the drug’s effect has 
stopped.  If the pressure in your eye remains increased above a certain level, your doctor will 
not give you the second injection of OZURDEX. 
If during the study there is strong evidence from other studies that the use of OZURDEX results 
in patients having a poorer outcome than conventional treatment we will stop the study. 
 
What are the possible benefits of taking part? 
We hope that the treatment will help you. However this cannot be guaranteed. The information 
we get from this study may help us to treat future patients with retinal detachment by improving 
the success rate of the surgery.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. This will not affect 
the standard of care you receive. If you do not wish to take part in this study you will not be at a 
disadvantage and will continue to receive normal clinical management. 
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What if I become pregnant whilst taking part in the study? 
We shall not ask you to take part in the study if you are pregnant or breast-feeding, and if you 
are a female of child-bearing age, we shall ask you to take a pregnancy test to confirm that you 
are not pregnant. We shall also ask you to agree to adequate contraception throughout the 
duration of the trial (12 months). 
If you do become pregnant during the trial, we shall refer you back to your GP to monitor your 
pregnancy routinely, as there is no evidence to suggest that the trial medication is harmful to 
you or your unborn baby. We will ask you to continue to be reviewed as part of the trial if you 
agree.   
 
What happens when the research study finishes? 
If you like, we can tell you which study group you were in. If you still require follow-up for 
your eye condition, this will be continued routinely in the out-patient department, and not as 
part of the study in the clinical trials unit.  
 
What will happen to the results of the study? 
We plan to publish the results of this study in a medical journal, and if you like, we can give 
you information about how to access this material. Please remember that as there are 140 
participants in the study, the process may take many years before this information is available. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds for a 
legal action but you may have to pay for it. Regardless of this, if you wish to complain about 
any aspect of the way you have been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms may be available to you. 
 
Who is organising and funding the research? 
This study is a commercially funded but investigator led trial. This means that the funding for 
the trial is being provided by Allergan Ltd (the pharmaceutical company which makes 
OZURDEX) but the organisation and clinical running of the trial is the responsibility of the 
investigating research team at Moorfields Eye Hospital.  
 
Will my taking part in this study be kept confidential? 
Information derived from the study will be treated as completely confidential.  Information will 
be stored in electronic and paper form and kept in a secure location.  All electronic data storage 
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will comply with the requirements of the data protection act. Your GP will be informed of your 
participation in this study. 
 
Who has reviewed the study? 
A full scientific protocol for this research has been approved by the National Research 
Ethics Committee London – Central. This study complies and at all times will comply with 
the Declaration of Helsinki1 as adopted at the 52nd WMA General Assembly, Edinburgh, 
October 2000 and with the Additional Protocol to the Convention on Human Rights and 
Biomedicine, concerning Biomedical Research, (Strasbourg 25.1.2005). Ask the Project 
Manager if you would like further details of the approval or to see a copy of the full 
protocol.  
 
Contact Numbers:   
Emergency Contact:          
 
 
You will be given a copy of this information sheet and the consent form, which you have 
signed, to keep. The original will be retained in your clinical notes.                                                                      
 
 
  
                                                          
1 World Medical Association (2000) Declaration of Helsinki. Ethical principles for medical research 
involving human subjects. 52nd World Medical Association General Assembly, Edinburgh, Scotland 
October 2000. 
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8.6 Appendix 6 Ozurdex in PVR Study GP Letter  
 
 
Dear Dr 
 
This is to inform you that your patient: 
 
 
 
has been recruited into a new study at Moorfields Eye Hospital entitled: 
 
Ozurdex in proliferative vitreoretinopathy: a randomised control trial  
 
Please find enclosed a copy of the Participant Information Sheet. 
 
Your patient has given written consent to take part in this study.  They are 
of course free to withdraw at any time, without needing to give a reason.  
The study has been subject to a review by The Research Ethics Committee 
London Central, who have given approval for the study to take place. 
 
If you require any further information or you feel that your patient is 
unsuitable to take part in this trial, please do not hesitate to contact us. 
 
 
Yours sincerely 
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8.7 Appendix 7 Ozurdex in PVR Consent Form 
 
CONSENT FORM 
 
Study Title:  Ozurdex in proliferative vitreoretinopathy: a randomised 
control trial 
 
Researcher:  Mr D. G. Charteris 
        Please initial box 
 
I confirm that I have read and understand the information sheet dated   
March 11th 2013 version number 3.2 for the above study and have  
had the opportunity to ask questions 
 
 
I understand that my participation is voluntary and that I am free to  
     withdraw at any time, without giving any reason, without my medical care or legal 
 rights being affected. 
 
 
I understand that sections of my medical notes may be looked   
          at by responsible individuals from Moorfields Eye Hospital or from regulatory 
 authorities where it is relevant to my taking part in research.  I give permission for 
 these individuals to have access to my records 
 
I understand that my GP will be informed of my participation in this  
     research project and of any findings significant to my general health 
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 I agree to take part in the above study 
 
 
_________________________   _______  ________________ 
Name of patient    Date   Signature 
 
_______________________  ________  ________________ 
Name of person taking consent  Date   Signature 
(if different from researcher)   
 
_________________________   _______  ________________ 
Researcher     Date   Signature 
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8.8 Appendix 8 Stem cell feasibility study - Participant Information 
Leaflet 
 
Investigation into the feasibility of harvesting Stem Cells from Adult Human Retina Tissue; 
The StRetTis Project 
 
Principal Investigator: Mr Philip Banerjee 
Co-Investigators: Mr Hari Jayaram, Dr Astrid Limb, Mr David Charteris 
 
We would like to invite you to take part in a research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you. One of our 
team will go through the information sheet with you and answer any questions you have.  
 
Talk to others about the study if you wish. 
 
Part 1 tells you the purpose of this study and what will happen to you if you take part. 
 
Part 2 gives you more detailed information about the conduct of the study. 
 
Ask us if there is anything that is not clear. 
 
You are being invited to take part in this research study because you are undergoing retinal 
surgery under the vitreoretinal service at Moorfields Eye Hospital. Before you decide to 
participate it is important for you to understand why the research is being done and what it will 
involve.  Please read the following information carefully. Talk to others about the study if you 
wish. 
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Part 1 
 
What is the purpose of the study? 
Stem cells (cells capable of dividing to produce numerous other cell types) are known to exist 
within the adult human retina. In the future, cells such as these may potentially be used to 
develop new treatments for individuals who have lost vision from retinal disease.  We know that 
it is possible to readily obtain such cells from large samples of retina and the aim of this study is 
to see if it is possible to obtain cells from very small samples of retina. 
 
Why have I been invited? 
You have been invited as you are due to undergo retinal surgery at Moorfields Eye Hospital. 
Your surgical procedure will involve the removal of very small amount of tissue from the outer 
retina which is usually discarded at the end of the procedure. 
 
Do I have to take part? 
It is up to you to decide to join the study. We will describe the study and go through this 
information sheet. If you agree to take part, we will then ask you to sign a consent form. You 
are free to withdraw at any time, without giving a reason. This would not affect the standard of 
care you receive. 
 
What will happen to me if I take part? 
We would ask you to consider donating the very small fragments of retinal tissue for use in the 
laboratory at the UCL Institute of Ophthalmology, which would be normally removed and 
discarded as part of the surgical treatment.  Other than this, there is no further involvement 
required on your part. 
 
Expenses and payments 
There will no expenses provided for this study, as no additional visits to the hospital are 
necessary. If you give your consent to donate a sample of retinal tissue, it will be treated as a 
gift, and as such you will be giving up all legal rights to the sample and will not be eligible for 
payment should the laboratory experiments lead to the development of new treatments in years 
to come. 
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What will I have to do? 
One of our team will go through the patient information sheet with you and answer any further 
questions you may have and obtain your consent. Other than this your operation will take place 
as normal, except that we shall collect the small samples of retina during the procedure that 
would normally be discarded. 
 
What are the possible disadvantages and risks of taking part? 
There are no specific risks to taking part in this study as we shall be collecting tissue that would 
normally be discarded. Your clinical team will have discussed the risks associated with the 
surgical procedure with you on a separate occasion before your operation. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you directly but the information we get from this study 
will help medical scientists to try to develop new treatments for retinal disease in the future. 
 
What happens when the research study stops? 
Your participation in this study will not affect your clinical care during the study or after its 
completion. The findings of the study will have an influence upon the development of future 
work towards new treatments for retinal disease. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, please read 
the additional information in Part 2 before making any decision. 
 
 
 
395 
 
 
 
Part 2 
 
What if relevant new information becomes available? 
Sometimes we get new information about the subject being studied. If this happens, your 
research doctor will tell you and discuss whether your participation is required in the study. 
However we would expect this to be very unlikely 
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at anytime without your clinical care being affected.  
 
What if there is a problem? 
In the event that something does go wrong and you are harmed during the research and this is 
due to someone‘s negligence then you may have grounds for a legal action for compensation 
against Moorfields Eye Hospital NHS Foundation Trust, but you may have to pay your legal 
costs. The normal National Health Service complaints mechanisms will still be available to you 
 
Will my taking part in this study be kept confidential? 
Your samples will be fully anonymised using a unique identification number and researchers 
will not be able to identify the donor. No identifiable data will be used or stored for the purpose 
of this study. 
 
What will happen to any samples I give? 
Your tissue sample will be immediately sent to the laboratory in the UCL Institute of 
Ophthalmology, where we will attempt to isolate stem cells. The process of cell isolation 
involves the use of enzymes to break down the tissue and therefore there will be no tissue 
remaining after processing. Any cells that are grown in culture will be studied in the laboratory, 
and will not be used for any experiments involving animals. Any cells that remain at the end of 
the study period will be destroyed. 
 
What will happen to the results of the research study? 
The results of the study will be published in a scientific journal or be presented at a conference. 
All data will be anonymous and none of the participants involved the study can be identified 
from any reports published. Should you wish to see the results of the study in the future, please 
contact the study doctor. 
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Who is organising and funding the research? 
This project is being sponsored by Moorfields Eye Hospital NHS Foundation Trust with support 
from the NIHR Biomedical Centre for Ophthalmology at Moorfields Eye Hospital and the UCL 
Institute of Ophthalmology. 
 
Who has reviewed the study? 
This study has been reviewed and given a favourable opinion by the National Research Ethics 
Service (NRES) committee, East Midlands. 
 
Further information and contact details 
For any further information, please contact the principal investigator, Mr Philip Banerjee, 
Vitreoretinal Research Fellow on 020 75662283 or Philip.Banerjee@moorfields.nhs.uk . If you 
have any concerns regarding the conduct of the study, please contact the Patient Advice and 
Liaison Service (PALS) on 0207 253 3411 extension 2325  
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8.9 Appendix 9 Stem cell feasibility study – Consent Form 
 
CONSENT FORM 
 
Study Title:  Investigation into the feasibility of harvesting Stem Cells 
from Human Retinal Tissue; The StRetTis Project  
 
Researcher:  Mr P J Banerjee     Please initial box 
 
1. I confirm that I have read and understand the information sheet dated   
17th February 2012 version number 1.2 for the above study and have had the 
opportunity to ask questions 
2. I agree to donate a sample of retinal tissue (that would otherwise be 
discarded) as a gift for research in the above project. I understand 
 how the sample will be collected and that giving a sample is voluntary. 
3. In giving this sample as a gift, I understand that I am giving up all  
legal rights with regards to its use, and will not be eligible for  
payment should the experiments lead to any new intellectual property.  
 
4. I understand that the sample I have given will be sent to a laboratory 
in the UCL Institute of Ophthalmology, as described in the patient information sheet 
5. I understand that relevant sections of my medical notes and data collected during the 
study, may be looked at by individuals from the sponsor of the study (Moorfields Eye 
Hospital NHS Foundation Trust) and the regulatory agencies, where it is relevant to my  
participation in this study. I give permission for these individuals to  have access to my 
records. 
 
_______________________   _______  ________________ 
Name of patient   Date   Signature 
________________________  ________  ________________ 
Name of person taking consent Date   Signature 
(if different from researcher)  
________________________   _______  ________________ 
Researcher     Date   Signature 
